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Drug encapsulation within nanocarriers provides a solution to the poor bioavailability and off-
site toxicities seen for poorly water soluble active agents. Nanocarriers formulated from 
biodegradable, biocompatible polyesters such as PLA and PCL are capable of being cleared 
from the body whilst functionalisation of the monomer species offers pathways for the tuning 
of polymer physicochemical properties to aid drug encapsulation. Here the application of 
substituted caprolactone monomers in MSA catalysed ROP produced a range of ε-CL-based 
polyesters of varying architecture with the ultimate goal of creating a range polymeric 
nanoparticles capable of encapsulating active metabolite 7-ethyl-10-hydroxycamptothecin, 
SN-38. 
Baeyer Villiger oxidation allowed the synthesis of 4 new ε-CL based monomers with 
increasing alkyl side chain lengths plus the additional bis-lactone monomer, 4,4’-bioxepanyl-
7,7’-dione, BOD. Henceforth capabilities of MSA-catalysed ROP in the construction of a 
variety of polymer architectures was explored avoiding traditional SnOct2 and mitigating the 
risk of residual metal in polymers bound for pharmacological use. PEG2/5K-OH macroinitiators 
were synthesised to complete the library of polymers taken forward for (co)nanoprecipitation 
studies. PCL polymers were initially used for more in depth studies producing stable aqueous 
nanoparticle dispersions with hydrodynamic diameters > 110 nm. Co-nanoprecipitation with 
amphiphilic PEG-b-PCL40 polymers showed a reduction in zeta potential with increasing PEG-
b-PCL40 content with both Mn for the hydrophilic PEG blocks. In view of these preliminary 
results, the full library of polymers were investigated and comparable nanoparticle 
characteristics such as size, PdI and zeta potential were achieved. Encapsulation ability of these 
systems was assessed with the introduction of guest molecules, such as oil red, docetaxel and 
SN-38 pentanoate, successfully producing stable nanoparticle dispersions at 2.43 wt% drug 
loading.  
Conversely failure to yield SN-38 encapsulating nanoparticles via co-nanoprecipitation led to 
the employment of thin film hydration. This allowed drug loadings from 2.43 wt% to 95 wt% 
to be achieved with increasing particle size of 45 to 240 nm. Supplementary studies allowed 
the characterisation of both the thin films and resulting dispersions as well as the determination 
of stability both in dry and hydrated states. Finally, preliminary pharmacological analysis, in 
vitro gave an important comparison to free SN-38 highlighting retardation of release and 
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1.1 Colorectal cancer 
Cancer, derived from the Greek word karkinos, describes the growth of many abnormal cells 
within the body resulting from disruption of their normal growth mechanism.1,2 This disruption 
occurs as a consequence of gene mutations, as cells divide during mitosis, or by 
deoxyribonucleic acid, DNA, damage from environmental factors. This leads to unregulated 
cell proliferation as the cells fail to respond to signals for both proliferation and apoptosis, 
resulting in a number of regulatory cell mechanisms being affected, and giving cancer cells 
different characteristics to those of normal cells.3 However uncontrolled cell growth can lead 
to both benign and malignant tumours of which only malignant tumours are commonly referred 
to as cancer. Benign tumours are non-invasive, remaining isolated to the location they formed 
in and are often susceptible to treatment by surgical intervention.3 On the other hand, 
malignancy describes the capability of a tumour to spread and invade a number of tissues 
throughout the body via the circulatory and lymphatic systems; a process known as metastasis.4 
This characteristic of cancers develops through a series of multiple mutations, which can 
accumulate over a number of years, making many cancers more prolific in the aging 
population.3  
The term colorectal cancer, CRC, refers to malignant tumours found in the early and/or late 
part of the bowel, colon (‘colo’) and/or the rectum (‘rectal’) respectively, and is often referred 
to as bowel cancer. Worldwide it is the third most common cancer after lung and breast cancer, 
estimated to account for 10.2 % of the 18.1 million new cases of cancer worldwide in 2018 for 
both sexes.5 It is also estimated to be the second leading form of cancer mortality with 9.2 % 
of all 9.6 million cancer-related death cases (both sexes) in 2018 being attributed to CRC.5 
These statistics are only set to increase with the CRC global burden predicted to increase by 
60 % by 2030, estimating 2.2 million new cases and 1.1 million deaths.6 The incidence and 
mortality rates of CRC are vastly affected by the socioeconomic status of various countries, 
with first world countries exhibiting higher incidence rates due to dietary and obesity factors; 
even so the mortality rates within these countries are also lower due to more advanced 
screening and treatment processes.6 
Although many developed countries have long standing screening processes to diagnose CRC, 
up to 25 % of patients have metastases at the time of diagnosis which in turn diminishes the 
prognosis for the patient in question.7–9 2.1 % of these patients have lung metastases, however 
the most common site for CRC metastasis is the liver due to the hepatic portal venous system 




treated with surgery and resection of the tumour, incurring a loss of part of the colon to prevent 
reoccurrence, additional chemotherapy and/or radiotherapy has been used to improve success 
rates.9,11,12 In contrast secondary tumours in metastasis sites are commonly more difficult to 
treat, with a 5 year survival rate being predicted for ~50 % of patients.13 Survival rates for 
hepatic metastasis are predicted by the operability of the tumour but only ~10-30 % of patients 
can undergo tumour resection.13 The prognosis for the other 70- 90 % of patients is bleak; if 
the tumour has developed in an inoperable location patients must first undergo systemic chemo- 
and/or radiotherapy. This is to hopefully decrease the tumour to a size where resection is safe 
to perform and achieve complete/partial remission,* however 70 % of these patients will 
typically develop reoccurrence.14 If this is unsuccessful, the last resort for these patients is 
palliative chemotherapy and care which aims to maintain an acceptable quality of life for the 
patient for the remainder of their lifetime (Figure 1.1).  
        
Figure 1.1 – Flow chart showing the treatment process for CRC and liver metastases. 
                                                          
* A term used to describe the decrease in growth of an active tumour. Complete remission refers to the 
disappearance of all signs and symptoms of the cancer although reoccurrence is still possible.199 Partial remission 




Consequently research to advance and improve chemotherapy treatments has been a major 
topic at the forefront of cancer research. The increased effectiveness of these types of 
treatments could increase the number of patients that either achieve complete remission or are 
able to undergo resection and extend the life expectancy for CRC sufferers. In addition, with 
the consideration of currently available treatments, the improvement of chemotherapy 
regimens has potential to improve patient wellbeing and quality of life whilst undergoing such 
treatments. 
1.2 Conventional chemotherapy 
Systemic chemotherapy is broadly used across all stages of CRC tumour development, often 
being used in combination with surgical interventions, and most commonly involves the anti-
metabolites fluorouracil, 5-FU and leucovorin, LV.14,15 These agents are often used in 
combination with other anti-cancer drugs, either irinotecan (US regimen FOLFIRI) or 
oxaliplatin (UK regimen FOLFOX).16–18 Nonetheless both irinotecan and oxaliplatin are linked 
to inimical side effects specific to the liver, for example diarrhoea and leukopenia, which 
severely impair the level of safe dose of these compounds.19,20 Although both of these anti-
cancer drugs have disadvantages that require additional research and improvement, our 
research will focus on irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin, 
SN-38, in particular. 
The camptothecin derivative irinotecan is a water soluble pro-drug that, when converted into 
its active metabolite, poorly water soluble SN-38, acts as a Topoisomerase I, TOP 1, inhibitor†. 
SN-38 is of the most potent TOP 1 inhibitors (100-1000 x more potent than irinotecan), and is 
classed as a TOP 1 poison due to its mechanism of action.21 Its main mechanism of inhibition 
of TOP 1 occurs by stabilising the TOP 1 cleavage complex after DNA strand scission by 
hydrophobic interactions with the DNA strands and hydrogen bonding to TOP 1 (Figure 1.2).22–
24 This modifies the enzymes ability to recognise cleavage sites preventing the re-ligation of 
TOP 1 and results in the definition of the cleavage complex as ‘suicide’ or ‘aborted’.21,25 This 
inhibition of DNA relaxation during the replication process leads to breaks in the DNA double 
strand and ultimately cell death.21,26,27 
                                                          
† Topoisomerases are universal enzymes that regulate the cleavage of the DNA backbone to release supercoils 
that are created during replication and transcription. This is done by cleavage of one strand of the DNA double 
helix followed by rotation, before re-ligation. This allows replication and transcription to continue without strands 




Figure 1.2 – Scheme representing the mechanism of action of SN-38 and TOP 1. (A) Binding of TOP 1 to a single DNA strand resulting in strand 
scission. (B) SN-38 binding via hydrogen bonding between SN-38 functional groups and TOP 1 amino acids. (C) Re-ligation of the DNA strand and release of 




Although these treatments have been common practice for treating liver CRC metastases, their 
effectiveness in achieving remission or preventing reoccurrence – as with the majority of 
chemotherapy regimens, regardless of cancer type - is limited by the adverse cumulative side 
effects from systemic chemotherapy and cancer cell mutations.10 The conversion of irinotecan 
into the active metabolite occurs in the liver via carboxylesterases, CES, which is followed by 
the deactivation of SN-38 to SN-38 glucuronide, SN-38G,‡ The SN-38G is excreted in urine 
and bile along with unconverted irinotecan and SN-38 (Figure 1.3) and the secretion of these 
compounds in bile has been shown to be a main contributor to the severe diarrhoea seen in 
most patients.19,28,29 
Figure 1.3 – Scheme representing the metabolism of A (irinotecan, pro-drug) to B (SN-38, 
active drug) to C (SN-38-glucuronide, inactive metabolite). i) Shows the side reaction of A to 
inactive metabolites via CYP3A4 enzyme. ii) Shows the side reaction of B to TOP 1 resulting in 
apoptosis. *UGT1A1 is polymorphic affecting the metabolism of B. 
Studies indicate that irinotecan and SN-38G can be converted back to the active SN-38 by 
bacterial β-glucuronidase as they pass through the intestines leading to increased cell apoptosis 
and consequentially severe colonic damage.19,29–31 In turn this damage, in combination with 
                                                          
‡ The conversion of SN-38 to SN-38G is mitigated by the polymorphic gene UGT1A1 producing UDP-
glucuronosyltransferases. However mutations in this gene, specifically UGT1A1*28 and UGT1A1*6, can affect 




increased mucus secretion and goblet cell mutation, leads to decreased absorption in the gut 
and therefore results in increased diarrhoea.19,28 Another limitation linked to irinotecan is poor 
drug metabolism, with only ca. 10 % of the administered dose being converted into the active 
metabolite SN-38 with a significant patient-patient variability in SN-38 exposure.32 
Consequently this has directed research to focus on delivery systems and interventions that 
tackle the problems on two fronts by mitigating side effects and increasing the drug efficacy 
by targeting tumour sites directly. The direct delivery of SN-38 to tumour sites, via systems 
such as nanocarriers, would avoid any patient-patient variability in dose. Additionally 
diminishing the presence of the active metabolite in the replication mechanisms of healthy cells 
would avoid triggered apoptosis of healthy cells, in turn alleviating some adverse side effects 
present from the current dosing regimens. Eventually the application of these delivery systems 
across the spectrum of all chemotherapy could prevent the unnecessary attack of healthy cells 
in most cases, which would contribute to a decrease in serious side effects seen with most 
chemotherapy treatments whilst increasing efficacy.  
1.3 Nano-medical interventions 
Nano-medical drug delivery systems have been prevalent in research in recent decades due to 
the advantages they offer to many treatment and diagnostic interventions of diseases including 
chemotherapy, HIV and malaria treatments.33–35 These systems arose from the necessity to find 
solutions for the direct delivery of highly toxic and/or poorly water soluble drugs to specific 
sites in the body, avoiding attack on healthy cells or tissues and increasing therapeutic effect. 
Direct delivery of the active agent using nanotechnology also facilitates increased efficacy, 
pharmacokinetics, lower doses and in some cases long acting formulations that are beneficial 
to both patients and industry.33,36–38 As the field of nanotechnology expands, drug molecules 
can now be incorporated within a range of materials and structural forms, for example, polymer 
hydrogels,39 solid lipid nanoparticles,40 solid drug nanoparticles,35,41 and inorganic 
nanoparticles,42,43 along with the encapsulation of drug molecules within the hydrophobic 
domain of stable aqueously dispersed polymeric nanoparticles.44,45 
These nanostructures are all of a size that is between 1-1000 nm although the exact definition 
of the nanoscale is disputed.46,47 Their components are chosen to be biocompatible and must 
be able to be cleared from the body to minimise any toxicity that could arise from the carrier 
itself. These constituents can often be adapted to include functionality that can increase 




nanoparticles often have a polyethylene glycol, PEG, ‘stealth’ corona that results in longer 
circulation times by avoiding the liver first pass metabolism and also increasing stability under 
biological conditions.38 Biodegradability is also being introduced into some polymeric 
nanoparticle systems with the use of polyesters such as poly(lactide-co-glycolide), PLGA, or 
poly(ε-caprolactone), PCL, which can be cleared from the body via the Krebs cycle.48 In 
addition, nanocarriers can be tailored to activate changes within a particular environment such 
as pH or chemical stimuli.49 This variety in nanoparticle features, component characteristics 
and domains capable of carrying drug molecules has led to a vast number of nanomedicines 
that are either already approved and used in the clinical setting or being tested within clinical 
trials, showing how successful this field is developing to be (Table 1.1). 
In addition to desirable properties of nanoparticle components, other advantages that are 
achieved by the use of nanoscale interventions can be derived from the ability to target a group 
of specific cells within the body. At this point nanomedical interventions can be split into two 
distinct groups based on their mechanism of targeting; either passive or active.50 Both groups 
involve the exploitation of a number of biological pathways to achieve their respective 
targeting and often involve specific characteristics or components of the nanocarriers that are 










Description Of Carrier 
(Drug(s)) 
Passive or Active 
Targeting 





Ovarian cancer; multiple myeloma; 
Karposi’s sarcoma; recurrent breast 
cancer 
Decreased free drug toxicity; improved 
site specific delivery 
51 
 Onivyde® Liposome (irinotecan) Passive 
Metastatic pancreatic ductal 
adenocarcinoma 
Improved survival when administered with 
5-FU and folinic acid. 
52 
 Thermodox® 
Thermal sensitive lipid 
functionalised liposome 
(doxorubicin) 
Passive Primary liver cancer 
Increased drug concentration in target 









More sustained release of drug overtime; 






Rectal, ovarian, tubal and peritoneal 
cancer 
Decrease in side effects; 





Active Triple negative breast cancer 




Hyaluronic acid functionalised 
PAMAM G4 
(cisplatin and doxorubicin) 
Active Breast cancer 




Biotin functionalised PEGylated 
PAMAM G4  
(paclitaxil) 
Active Lung cancer 




Transferrin cyclodextrin micelle 
(siRNA) 
Active Solid organ tumours; RRM2 gene 
Provides targeted delivery of functional 
siRNA (still to be fully assessed) 
58,59 
 AZD2811 Accurins; PEG-PLA  Passive 
Aurora kinase B inhibitor; acute 
myeloid leukaemia; colorectal 
carcinoma 
Improved site specific delivery; increased 
efficacy; decreased toxicity 
60,61 
 CriPec® 
PEG-ylated poly(lactate) micelle 
(docetaxel) 
Passive Ovarian cancer; solid tumours 
Preferential release in acidic conditions; 




Nanotherm™ Aminosilane-coated SPION 
Directly injected 
into the tumour 
Glioblastoma 
Local tissue hyperthermia – (non-) 
programmed cell death; increased survival 
by up to 12 months 
43,63 
 CYT-6091 
Human tumour necrosis factor, 
rtTNF functionalised colloidal 
gold. 
Passive A variety of histologies  
Increased maximum dose; possible 






1.3.1 Passive targeting 
Passively targeting nanocarriers were the first of the two types of targeting to appear in clinical 
trials in the 1980s and have resulted in a number of approved products appearing on the market 
for clinical use. The most well-known example of this type of targeting drug vehicle is Doxil®, 
a liposomal doxorubicin used to target refractory Karposi’s sarcoma, ovarian cancer and 
recurrent breast cancers.37,51,64 Doxil® is made up of doxorubicin loaded PEGylated liposomes, 
where the hydrophilic polymer acts as a ‘stealth’ surface coating which reduces the rapid 
clearance seen for many conventional liposomes in parallel with more effectively passive 
targeting of cancer cells.51 Due to the clinical precedent set by Doxil® there have been a large 
number of liposomal formulations that have been US Food and Drug Administration, FDA, 
approved. One of the most recent of these is Onivyde® which is a liposomal irinotecan 
formulation for the treatment of metastatic pancreatic cancer.52 Studies showed that when the 
nanoliposomal irinotecan was administered in combination with 5-FU and folinic acid there 
were significant improvements in a number of characteristics of the treatment.33,52 The survival 
of patients was extended compared to that of traditional gemcitabine-based regimens. 
Moreover the efficacy and pharmacokinetics were also improved along with providing a 
controllable safety profiles.33,52  
In addition passively targeting nanoparticles are not limited to liposomes. There are a number 
of other examples of nanocarriers, with a range of different structures and components that also 
illustrate the ability to passively target tumour cells. These nanostructures include polymeric 
nanoparticles and micelles such as PEGylated cyclodextrin nanoparticles and 
poly(ethylene glycol-co-lactide), PEG-PLA, micelles respectively.54,60 Unlike liposomes, these 
structures are restricted to the encapsulating of hydrophobic compounds drugs within 
hydrophobic cores providing the prospect of the delivery of poorly water soluble drugs to target 
sites. For example, PEG-PLA micelles have allowed for the encapsulation of a number of drug 
molecules such as AstraZeneca drug AZD2811 and docetaxel for the treatment of leukaemia, 
CRC and ovarian cancers.60,62 These vehicles have shown a reduction in drug related toxicities 
along with a number of other characteristics which reiterate the list of advantages that can be 
accessed by the utilisation of nanocarriers of various forms.60,62  
The main mechanism that aids these drug delivery vehicles to selectively target tumour sites 
without any intentional targeting moiety is the enhanced permeability and retention, EPR, 
effect caused by tumour cell’s biological composition (Figure 1.4).65–67 As tumour cells rapidly 




achieved by the angiogenesis of a new, rapidly growing, neovasculature and the engulfing of 
pre-existing blood vessels.67 This in turn results in a number of abnormalities that set tumour 
vessels apart from normal blood vasculature, for example dilated saccular channels, irregular 
diameter and an abnormal branched pattern.67,68 Included in this list of characteristics is the 
incomplete endothelial lining of the blood vessels causing the presence of pores between 0.1 
and 3 µm in diameter.69,70 This, combined with a diminished pericyte coverage, allows 
nanocarriers to leak out of tumour vasculature into the tumour bed.66 The accumulated 
nanoparticles are then retained in the tumour site due to the lack of an effective lymphatic 
drainage system§.65  
Figure 1.4 – Schematic representation of passive tissue targeting via the enhanced 
permeation and retention, EPR, effect in a site with a limited lymphatic drainage 
system.71 
                                                          
§ The complex network of lymph nodes that facilitates the removal of unwanted material from cells grow at a 
slower rate than blood vessels. This results in tumours often having an extensive blood vessel network whilst 





The EPR effect only provides approximately a 2-fold increase of accumulation of nanoparticles 
in the tumour compared to normal tissues and organs, which clear nanoparticles from 
circulation via glomerular filtration (kidneys) or the mononuclear phagocyte system, MPS.67 
Moreover there is a significant reduction in side effects as a consequence of low accumulation 
in healthy tissues equipped with non-leaky vasculature and a complete effective lymphatic 
drainage system. Therefore, exploiting the EPR effect phenomenon is key to increased efficacy, 
which is in turn facilitated by increasing circulation times for nanoparticles and preventing 
clearance through the kidneys or liver.  This highlights the significance of nanocarrier 
physicochemical characteristics such as the size of the nanoparticles, the corona of these 
entities and their shape.38,65 For instance, as seen with the examples Doxil® and Cripec®, 
passively targeting nanocarriers often have a PEGylated corona.51,62 This not only offers a 
steric stability to particles but also prevents the binding of plasma proteins, shields the surface 
charge, adds hydrophilicity to the surface and induces repulsion in particle-blood component 
interactions.49 This in turn protects the particle against opsonin interactions and reducing 
clearance by the reticuloendothelial system, RES.72 
As highlighted, the exploitation of passive targeting, particle physicochemical properties and 
the EPR effect have successfully led to a number of nanomedicines that have decreased 
cytotoxicity whilst increasing bioefficacy. Nevertheless this method of targeting has limitations 
with regards to the achievable drug concentrations in tumours and consequently the therapeutic 
efficacy and the lack of ability to categorically distinguish between healthy and tumour cells.67 
These factors can be enhanced by the implementation of active targeting to deliver drugs and 
their metabolites to a chosen site within the body. 
1.3.2 Active targeting 
Active targeting was developed to further increase the selectivity of nanoparticles to tumour 
sites by proactively exploiting a number of different characteristics associated with solid 
tumour masses. This is often achieved by the addition of covalently bonded targeting moieties, 
associated to a specific group of cells, to the corona of nanoparticles.50,73 Optionally sites that 
are actively targeting nanoparticles can give a controlled and definite response when a specified 
stimuli is applied. This can be either an internal stimuli, such as pH or a chemical change, or 
can be an external environmental change inducing a response from the nanoparticles, such as 




 There are a number of examples of targeting moieties including antibodies, dendrons and 
protein ligands (Figure 1.5) which allow for binding of the nanocarrier to the selected site with 
consequential internalisation of the receptor-ligand complex by the endocytosis/phagocytosis 
mechanism.76 This internalisation is followed by liposomal degradation of the receptor-carrier 
complex which results in drug release.76  
Figure 1.5 – Examples of targeting moieties that can be used in nanocarriers designed for 
active targeting. 
Protein targeting ligands, for instance folic acid** and iron rich transferrin††, can be used to 
decorate the corona of nanocarriers and highly selectively exploit the corresponding receptors 
that are over expressed on the surface of rapidly growing cancer cells.76 Both these ligands are 
involved in a receptor-ligand pair on the surface of the cell and result in endocytosis into the 
cell cytoplasm.76,77 They are desirable as targeting ligands due to their receptors being over-
expressed in malignant cells, along with the internalisation of each ligand through folate 
receptor, FR, or transferrin receptor, TfR, respectively.73,77 Folate, one the most extensively 
used targeting moiety, has been conjugated onto a number of particles,73 for example, 
biodegradable PEG-PLGA polymeric micelles carrying doxorubicin.77,78 These showed the 
                                                          
** Folic acid or folate is a vitamin required for the biosynthesis of purines and pyrimidines within cells.202 The 
most significant receptor for nanocarriers decorated with folate is the high-affinity phosphatidyl-inositol-linked 
folate receptor, FR, which is capable of internalising these nanocarriers and is over-expressed in tumour cells.203 
This receptor is minimally expressed in healthy cells of adults and therefore a good receptor for active targeting.73  
†† Transferrin is responsible for the transport of iron through the blood stream to cells resulting in internalisation 
at transferrin receptors.204 These receptors expression is up to a 100 x higher in malignant cells compared to 




active internalisation of the particles into the cell cytoplasm with increased cytotoxicity and 
cellular uptake compared to untargeted doxorubicin, whilst also demonstrating reduced 
cardiotoxicity indicating a differentiation between healthy and tumour cells.77,78  
Monoclonal antibodies are also well-established targeting moieties due to their high selectivity 
and binding affinity to a certain target, owing to the presence of site specific binding sites on 
each molecule.73 There are a number of antigens which are overexpressed in malignant cells 
and can be targeted by the complementary corresponding antibody. These include, but are not 
limited to, the epidermal growth factor receptor, EGFR; the human epidermal growth factor 
receptor 2, HER2; and the A33 antigen.77,79 These allow for more specific differentiation 
between cancer and healthy cells which generally generates substantial improvement in 
therapeutic efficacy compared to the passive counterparts, as seen with studies conducted by 
Domínguez-Ríos and co-workers.80 Here PLGA particles functionalised with trastuzumab an 
anti-HER2 antibody were used to actively target ovarian cancer cells for site specific delivery 
of cisplatin.80 HER2 receptors are most commonly over expressed in a number of breast and 
ovarian cancers allowing for this targeting pathway to be exploited in this group of cancers.81 
The anti-HER2 decorated nanoparticles showed an increase in cytotoxicity and cellular uptake 
in vitro, demonstrating promising pathways for increasing efficacy whilst simultaneously 
lowering side effects.80 
Not only can particles decorated with the corresponding antibodies to these receptors allow for 
the targeted delivery of anti-cancer drugs, but can also permit additional positive effects to be 
accessed. For example, antibodies that interact with the EGFR can diminish or stop cancer cell 
proliferation; combined with anti-cancer drug compounds such as cisplatin and doxorubicin, 
this can halt tumour growth or eradicate the tumour altogether.77 These features have made 
these targeting moieties a popular choice despite their complexity.79 
Whilst antibodies and protein ligands both present specific targets to interact with, dendrons 
offer the prospect to target sites by creating the opportunity to add random or zoned 
multi-functionality to the surface of nanoparticles.82 This can be achieved by two synthesis 
pathways, resulting in either dendrimers or dendron functionalised polymers including 
hyperbranched polydendrons, hyp-polydendrons.83–86 The most investigated of the two for drug 
delivery has been dendrimers, in particular those synthesised from polymers containing 
poly(amidoamine), PAMAM. PAMAM dendrimers have a large number of potential binding 




additional functionalisation for increased targeting effects. For example, a single PAMAM-
NH2 dendrimer of the fourth generation, G4, used to encapsulate 5-FU has ca. 250 potential 
bonding sites (64 1° amine surface groups, 62 3° amine internal groups and 124 amide 
groups).85 In a similar formulation, these numerous bonding sites have been exploited to aid 
PEGylation, the linking of biotin‡‡ and the conjugation of paclitaxel.57 The conjugated Biotin 
components allowed for increased cytotoxicity and cell internalisation in multicellular cancer 
spheroids compared to conjugated materials and free paclitaxel.57 Simultaneously PEG 
functionalities provided shielding of the cationic charged dendrimers to decrease toxicity.57 
The development of both passively and actively targeting nanoparticles means that there is an 
extensive library of materials and formulations that can be used to deliver poorly targeting, 
hydrophobic drug molecules to their specified site. In spite of this, further refining of this 
library along with novel additions will solve problems with existing systems as well as create 
new systems that deliver drugs that have previously failed to be encapsulated in nanocarrier 
systems. 
1.3.3 Nanostructures 
As detailed in 1.3.1 and 1.3.2 there is an extensive library of nanomaterials that can achieve 
passive or active targeting by modifying the corona. However, focus must also be given to the 
general structure of the nanomaterials used. There is a wide range of structures that can be 
formed on the nanoscale that allow for the encapsulation and/or transportation of active 
pharmaceutical ingredients such as poorly water soluble or biologically unstable drug 
molecules. These include liposomes,87 nanoemulsions,88 micelles,89 polymeric nanoparticles,90 
solid drug nanoparticles and dendrimers (summarised in Table 1.2).91,92   
                                                          
‡‡ Biotin is an essential micronutrient, more commonly known as vitamin B7 or vitamin H.205 It is required as a 
co-factor in the function of 5 biotin dependant carboxylases. This results in cancer cells over-expressing biotin to 
increase uptake to achieve rapid proliferation and growth therefore making it a prime candidate as an active 




Table 1.2-Summary of various nanostructures used for drug delivery and tumour imaging. 




SUV (< 100 nm) 
LUV (100-1000 nm) 
GUV (> 1 µm) 
MLV (> 1 µm) 
 
General overall method consists of 4 steps: 
- Formation of a monolith/thin film from organic 
solvent 
- Dispersion in aqueous media (methods can 
include mechanical and solvent dispersion 




Drug loading can be achieved by passive and active 
methods. 
 Very low toxicity  
 Able to entrap both hydrophilic 
and hydrophobic molecules 
 Often biodegradable 
 Easy modulation of size by 
synthesis 
 Modification to achieve ‘stealth’ 
properties (by PEGylation) or 
active targeting 
 Can be cleared by the RES by 
interactions with opsonins 
 High and low density lipoproteins, 
HDLs and LDLs, can decrease 
stability 
 High cost of synthesis 
 Difficult to scale synthesis  




< 100 nm 
Self-assembly and drug loading by: 
- Dialysis 
- Film casting 
 Small size and narrow distribution 
that allows for the accumulation in 
tumour tissues (EPR effect) 
 Possible to decorate the surface 
with PEG or targeting 
functionalities to improve targeting 
 Easy variation of the components  
to tune properties 
 Poor in vivo stability due to the 
dilution of the micelles in the 
blood leading to a shift below the 
CMC causing partial micelle 
dissolution 
 Interaction with blood components 
(e.g. albumin and apolipoproteins) 




10 nm-1 µm 
 These include but are not limited to : 
- Nanoprecipitation 
- Solvent evaporation  
- High-pressure Homogenisation 
- Dialysis  
- Spray drying 
 Reproducible synthesis technique 
 Easy modification of the 
components to tune the particle 
physicochemical properties; 
 Variety of polymers can be used 
 Drug retention due to diffusion in 
complex polymer matrix 
 Method of synthesis makes it hard 
to tune the size 
 Scale up can be difficult 
 Small accumulation in target tissue 
can occur 
 Only a small number of 
formulations in clinical trials 
90,95,96 
Dendrimer < 15 nm 
Convergent synthesis:  
- Synthesis from the periphery of the dendrimer 
- Number of generations is pre-determined  
- Wedges coupled to a multivalent core to 
ultimately yield a dendrimer  
Divergent synthesis: 
- Starts from the multivalent core molecule 
- Step-wise synthesis to ‘grow’ the dendrimer, 
adding generations in each synthetic cycle. 
 Reproducible synthesis 
 Monodisperse samples made  
 Easy addition of surface or 
targeting functionalities  
 Multiple ways of transporting a 
hydrophobic molecule.  
 Rapidly cleared from the blood due 
to small size – do not need to be 
biodegradable 
 Modification required to decrease 
the toxicity induced by cationic 
amine groups  
 Lengthy manufacturing with many 
repetitive steps 
 Costly 







Table 1.2 cont. -Summary of various nanostructures used for drug delivery and tumour imaging. 
Structure Typical size Typical Synthesis Advantages Disadvantages Ref 
Solid Drug 
Nanoparticles 
< 1 µm 
Top-down (suitable for thermostable compounds): 
- Nano milling/ media milling 
- High pressure homogenisation 
- Micro-fluidization 
Bottom-up: 
- Nanoprecipitation under sonication 
- Emulsion template freeze drying 
- Spray drying  
 Option for oral administration 
 Scalable synthesis techniques  
 Stability over time 
 Composed of 100 % drug  
 Sustained release profiles  
 Can allow for the decrease in 
dosing regimens 
 Limited to solid drug compounds 
 Limited knowledge on the effects 
different stabilisers play on the 
properties of the SDNs 
 Pharmacokinetic variability with 
drug release and movement around 
the body  
41,92,98–
100 
Nanoemulsions 10-100 nm  
High energy methods: 
- Emulsion Template Freeze Drying 
- Ultrasonic emulsification 
- High-pressure homogenisation  
- Micro-fluidics  
- Membrane emulsification 
Low energy methods: 
- Phase inversion temperature method 
- Spontaneous emulsification 
- Emulsion inversion point method  
 
 Option for oral administration 
 Ability to deliver multiple drugs 
simultaneously  
 Option for active targeting 
functionalities 
 Can be used for both solid and 
liquid drug compounds 
 Easily tuneable properties. 
 Thermodynamically unstable, will 
separate into two macro-phases 
over time  
 Manufacturing processes can limit 
the types of compounds used 
 Scale up could be difficult due to 







(~10 – 500nm) 
Magnetic nanoparticles such as iron oxide NPs: 
- Precipitation of salt in aqueous media 
- Polyol process, dissolution of magnetic salts 
- Degradation of metallic compounds in organic 
solvents 
Production of NPs with good crystallinity: 
- Hydrothermal synthesis (use of temperature and 
pressure) 
Metallic nanoparticles: 
- Spray/laser pyrolysis (spraying of salts into 
reactors or lasers heat precursor mixtures) 
Other methods: 
- Micro emulsions  
 Gold nanoparticles are FDA 
approved 
 Drug delivery can be used in 
conjunction with another imaging 
or treatment pathway 
 Unique properties of metallic 
nanoparticles (SPR) can allow for 
simultaneous imaging of different 
tissues 
 SPIONs in an oscillating magnetic 
field can induce controlled cell 
death 
 Carbon nanotubes and quantum 
dots are both hydrophobic and 
require polymer stabilisation 
 Drug molecules are generally 
required to be covalently attached 
with a cleavable linker 
 Some cytotoxicity can be induced 
by burst release of metallic 
nanoparticles, namely iron 
 Carbon nanotubes are cytotoxic 
and require polymer functionality 






Liposomes are by far the most researched and widely used form of nanostructure. Composed 
of a lipid bi-layer formed from amphiphilic lipid and cholesterol molecules assembled in a 
spherical fashion to produce particles of sizes between 50 and 500 nm.50,93,94 This results in 
clear segregated hydrophobic and hydrophilic domains, the hydrophobic domain is sandwiched 
between two hydrophilic layers, the outer layer stabilising the structure, with the inner layer 
creating a hydrophilic internal cavity.93 In this way the liposome is set apart from other 
nanocarriers as it has the ability to simultaneously carry both hydrophobic and hydrophilic 
compounds within the two domains (Figure 1.6). Equally their chemical composition induces 
low toxicity and immunogenicity of these carriers as their components are analogous to the 
phospholipid bi-layer of biological cells.93 Modifications can also be used to enhance the 
properties of these nanostructures, for example the conjugation of PEG to the corona of the 
liposomes prevents the binding of opsonins and therefore diminishes recognition and clearance 
by the RES. 50,105 Furthermore the easy modulation of the size, targeting mechanism and 
hydrophilic/hydrophobic character allow the liposome to maintain its status as the most studied 
and extensively used “injected” nanoscale drug-delivery system. 
Figure 1.6 – Example structure of a liposome (A) and micelle (B).106 
A similar nanostructure formed from the self-assembly of small molecule surfactants are 
micelles (Figure 1.6) which consists of a hydrophilic surface domain surrounding a 
hydrophobic environment but is void a hydrophilic inner cavity due to the lack of 




environment is capable of encapsulating poorly water-soluble drug molecules. Micelles are 
typically under 100 nm in size and their amphiphilic components are generally surfactants, 
however block co-polymers have been used, which can be easily varied to allow for the tuning 
of the characteristics of the micelles.62,93 For example, size, drug loading capabilities, drug 
retention and also drug release can be tuned by the adaptation of the micelle element’s chemical 
composition and molecular weight.62 Like liposomes, the corona can be decorated with PEG 
or targeting moieties, such as antibodies, to take advantage of both passive and active targeting 
pathways. On the other hand, these vehicles have a number of obstacles to overcome in vivo 
mainly related to the decrease in stability when the formulation is greatly diluted, below the 
critical micelle concentration, CMC§§, in the blood stream.62 Further disadvantages related to 
drug retention are being tackled by the synthesis of amphiphilic polymer drug conjugates that 
are capable of self-assembly upon reaching the CMC.62 
Another system that employs the use of polymeric species are polymeric nanoparticles 
(Figure 1.7), similarly to polymeric micelles these nanostructures consist of a hydrophobic core 
domain surrounded by a hydrophilic corona. Despite this, these structures differ from 
polymeric micelles in a number of ways including size, synthesis routes and composition. 
Commonly synthesised by nanoprecipitation, the polymer species collapse, upon desolvation, 
to form nanoparticles with a dense polymer core ranging in sizes from 10 nm to 1 µm.95 Drug 
encapsulation is achieved by dissolution in the organic solvent, containing the selected 
polymer, resulting in entrapment within the polymer core following nanoprecipitation. A 
number of biocompatible, and often biodegradable, synthetic polymers can be used to form 
these structures including PLGA and poly(2-hydroxypropyl methacrylate), pHPMA, co-
polymers which induce slower release rates of the encapsulated drug as the molecules are 
required to diffuse through the polymer.37 Additionally, these particles are commonly 
PEGylated which prevents phagocytosis and opsonisation and also induces stability under 
biological conditions.107 Furthermore there is the ability to easily vary and modify the 
components used to tailor the physicochemical properties of the particles and in turn their 
polymer-drug interactions as well as corona functionality to vary the stability and method of 
cell targeting (Figure 1.7). Despite the multitude of promising characteristics these nanocarriers 
have, there are only a small number of formulations that have made it to clinical trials with 
only one of these capable of active targeting.108 Nonetheless they still maintain their reputation 
                                                          
§§ The critical micelle concentration, CMC, is the concentration of surfactants at which micelles spontaneously 




as one of the more popular forms of nanostructure for drug delivery research and 
development.108 
Figure 1.7 – Examples of polymeric nanoparticles with varying corona functionality. 
(A) PEGylated, (B) dendrons and (C) anti-bodies.109  
Although research seems swayed towards polymer nanoparticles and liposomes there are a 
number of other structures that are also being investigated for the treatment and diagnosis of 
disease and cancer. Dendrimers offer an alternative way to transport hydrophobic drug 
molecules within their tree-like, three dimensional structures.50,93,94 The active drug molecules 
can be transported either by being covalently bonded to the surface of the dendrimer or by 
encapsulation within internal cavities.50 The synthesis of these species results in monodisperse, 
globular high molecular weight particles. The ease of surface functionality coupled with 
controlled and reproducible synthesis makes these nanostructures a promising group of drug 
vehicle.71,94 On the contrary, many successful dendrimer syntheses result in the presence of 
tertiary amine groups, which act as sites of cationic charge; modification maybe required to 
overcome the inherent toxicity of polycationic materials. This is normally achieved by the 
addition of a hydrophilic polymer to the periphery of the dendrimer.93,97  
In comparison to the nanostructures previously discussed in this section, which are all directed 
towards intravenous injection to avoid the gastrointestinal tract and the clearance issues linked 
with it, there are some nanostructures tailored to oral administration. In particular solid drug 
nanoparticles, SDNs, and nanoemulsions (Figure 1.8) which have properties tailored for oral 





Figure 1.8 – Example structures of (A) solid drug nanoparticles and (B) nanoemulsions. 
SDNs are nanoparticles made directly from poorly water-soluble drug compounds and 
stabilised by polymeric and/or surfactant species.98 Although the poorly water soluble drug is 
not contained in or attached in this case, SDNs have shown to improve the bioavailability of 
drugs, induce slow sustained release and overcome effects linked to food with oral 
administration.110–112 These in turn are linked to lower dosing regimens and lower pill burdens 
for patients due to enhanced drug absorption after oral administration.35,92 Studies on SDNs for 
the treatment of HIV have shown little effect on the immune system, suggesting that these 
nanostructures may have an advantage in terms of immunogenicity compared to some 
nanostructures addressed earlier in this section, for example dendrimers.113 Not only do these 
nanostructures offer pharmacological benefits, their manufacturing processes are scalable with 
both top-down and bottom-up routes available for their synthesis.100,114,115 SDNs have been 
shown to be able to be stored over long periods of time proving they are one of the most 
commercially viable forms of nanostructure reflected by having the most FDA approved 
nanomedicines than any other technology.116  
Nanoemulsions also allow for oral administration along with the options for topical and 
parenteral routes.88,101,102 The composition of these nanostructures are mixtures of two 
immiscible liquids, an aqueous continuous phase and a non-aqueous dispersed phase of nano-
sized droplets.50,101 The size of these nano-droplets can be tuned by using different oils to create 
the non-aqueous phase, for example soybean oil, a long chain triglyceride, has been used to 
produce large particles of around 120 nm.101 This can be combined with varying the structure 
and concentration of the stabilising polymers or surfactants as demonstrated by Hobson et al.88 




encapsulation of poorly water soluble drugs within dispersed non-aqueous droplets, can 
decrease toxicity and increase bioavailability due to sustained circulation and protect the drug 
from degradation and clearance.101 Additionally the supplementary functionalisation of the 
stabilising polymers used when forming nanoemulsions with targeting moieties can allow 
access to active targeting pathways. 101 
Lastly there are also a number of different inorganic particles (Figure 1.9) that have been 
studied as drug delivery agents, treatment and diagnostic applications of treating disease due 
to their unique properties. They also often have lower toxic side effects than organic based 
nanostructures and allow access to more imaging techniques.37 Gold nanoparticles, for 
example, have unique optical and thermal properties which, combined with the ability to tune 
a number of physical characteristics such as size and surface functionality, make them one of 
the most researched inorganic nanoparticles for disease treatment.33 There are a number of 
other particles associated with this diverse group of nanostructures which include, silver iron 
oxide and silica nanoparticles along with quantum dots and carbon nanotubes however, like 
gold, iron oxide nanoparticles are the most intensely studied.117 These particles are being 
investigated for use in targeted drug delivery and contrast enhancement agents for magnetic 
resonance imaging, MRI, due to the magnetic properties they possess.33,118 Magnetism is also 
used to treat tumours from controlled cell death with superparamagnetic iron oxide 
nanoparticles, SPIONs, in the presence of an oscillating magnetic field inducing a thermal 
effect local to the nanoparticles position.33,43,63 Metallic inorganic nanoparticles allow access 
to surface plasmon resonance, SPR; the oscillation of metal-free electrons on the surface of the 
particles.117,119 These oscillations are stimulated by interaction with light in the visible region 
and allow for ultra-sensitive imaging that can achieve clarity capable of differentiating between 
healthy cells and tumour cells.119 There is also the opportunity to functionalise these 





Figure 1.9 – Examples of inorganic nanoparticles: (A) metallic nanoparticles, (B) quantum dots 
and (C) carbon nanotubes. Not to respective scales. 
Quantum dots are biocompatible, semiconducting nanocrystals that have a multitude of 
physicochemical properties that make them an attractive alternative to other nanostructures for 
cancer treatment and detection.93,120 These include, but are not limited to, highly tuneable 
photoluminescence and multi-colour fluorescence.37 The optical properties that make quantum 
dots ideal for targeted and traceable drug delivery are dependent on their size. Each size on 
quantum dot emits a different colour when excited by the same wavelength of light.93,121,122 
This means that different tissues could be imaged simultaneously by targeted delivery of 
different sized quantum dots to these selected tissues. Despite a large number of advantages, 
these structures do have shortcomings, they are inherently hydrophobic and are highly likely 
to aggregate and have high toxicity.123,124 This can be avoided by coating the quantum dots 
with a polar species or mono/multi-layer ligand shells (usually formed from amphiphilic 
polymers).125 This also provides an opportunity for the embedding of hydrophobic drug 
molecules or contrast agents beneath the hydrophilic shells and the attachment of hydrophilic 
guest molecules and targeting agents to the periphery of the particles.37,126 In combination with 
the number of advantageous properties these structures have they prove to be a promising 
avenue for the imaging of tumour sites and aiding the drug delivery to them.   
As a final example carbon nanotubes are rolled sheets of graphene rings made from sp2 
hybridised carbon and are most well-known for near-infrared photothermal ablation therapy.37 
In this case the carbon nanotubes increase the temperature in the tumour sites and cause cell 
death. This effect can be tuned as it is dependent on the concentration of nanotubes and the 
light intensity.127,128 These structures not only possess useful optical properties but also can 
penetrate cells, have a flexible structure and are intrinsically stable.127,128 Like most of the 




induce active targeting or carry drug molecules.129 The internal cavity of carbon nanotubes can 
also serve as a carrier for hydrophobic guest molecules or plasmid DNA.129 Nonetheless these 
structure also have their problems with poor water solubility, non-biodegradability and 
cytotoxicity which all require functionalisation with polymers to avoid and improve.94 Even 
so, the advantageous characteristics and alternative therapy pathways they offer make them a 
good candidate for future drug delivery candidates in conjunction with new treatment options. 
Although there is a wide variety of nanostructures that could be selected for the application of 
drug delivery, this body of work will focus on the use of polymeric nanoparticles.  
1.4 Homo- and co-polyesters 
When designing new polymeric nanocarriers, a number of factors must be considered, one of 
which being the properties of the nanoparticle components. A review of the nanomedicine 
literature shows that polyesters account for a large proportion of the materials contributing to 
nanocarriers structures under development. These polymers are desirable as they possess a 
number of characteristics that are favourable for medicinal and biological use.  Some of these 
properties are the ability to be bio-reabsorbed, tuneable biodegradability and crystallinity.130,131 
Polyesters of varying structures have also be shown to be biocompatible, meaning they do not 
illicit any toxicity or carcinogenic effects in local tissues when placed in the body.130,132 Due 
to their biodegradation, by hydrolysis of the ester backbone, the degradation products of these 
particular polyesters can also be viewed as biocompatible as they do not interfere with tissue 









Over the past 3 decades the most popular polymers in this category have been based on lactide 
and/or glycolide diesters*** cyclic monomers, namely PLA, and PLGA (Figure 1.10). After the 
FDA approval of formulations containing PLA, the research of these polymers was accelerated 
which increased their use in clinical settings with applications such as bone scaffolding, 
biodegradable implants and tissue sutures becoming prevalent.133–135  
These polymers possess a number of characteristics, mentioned earlier, that have led to their 
implementation in the development of a number of nanomedical interventions such as 
polymeric nanoparticles. These characteristics can generally be tuned by adjusting the 
chemistry, for example adjusting the ratio of lactide to glycolide in PLGA polymers or by 
producing PLA with specific chiral conformations.36,130,136 The degradation of PLA is quite 
slow, taking around 3-5 years to completely break down under biological conditions.130 This 
can be tuned as the time taken to hydrolyse the ester backbone is dependent on numerous 
polymer properties including the molecular weight, crystallinity, morphology and stereoisomer 
content.130,137 Furthermore the degradation products of PLA and PLGA, lactic and glycolic 
acid, are both present within the body and metabolised via the Cori and Krebs cycles (Figure 
1.11) meaning they have a minimal toxicity when the polymers are broken down.36,136,138 
Further advantages over vinyl polymers are highlighted by the synthesis of the monomers 
themselves. Lactic acid, the precursor to its cyclic dimer, and the monomer lactide, can be 
produced by the fermentation of sugars.130,137,139 This offers a method of synthesis that is 
sustainable and has low environmental impact adding to the benefits of the resulting polymers. 
                                                          
*** Diesters within this text refer to the saturated cyclic ring molecules that contain 2 ester functional groups within 




Figure 1.11 –Scheme representing the degradation pathways of lactic acid via hydrolysis 
intermediates. 
The combination of these numerous desired properties has encouraged the creation of various 
nanomedical drug delivery vehicle examples based on PLA and PLGA polyesters. These 
systems are capable of encapsulating a range of molecules with a variety of molecular weights. 
Recent studies have resulted in a PLGA formulation that is capable of actively targeting 
epithelial ovarian cancer cells by the addition of an antibody to the corona of the PLGA 
nanoparticles.80 After loading the particles with the highly hydrophobic drug cisplatin, a layer 
by layer method was used to coat chitosan onto the particles.80 This consequently allowed the 
decoration of the corona with trastuzumab antibodies which resulted in greater cytotoxicity 
towards cancer cells and increased cellular uptake in vitro.80 Drug release studies showed that 
cisplatin was released quicker from the nanoparticle when the pH of the release media was 
decreased.80 This was characteristic of PLGA nanoparticles as the lower pH aids the hydrolysis 
of the polymer backbone releasing the drug molecules from the polymer network.140  
Although there are numerous examples of nanomedicines that utilise the PLGA co-polymers, 
a large number of studies can be found using PEG-PLA in the nanoparticle composition. Chen 
et al. have recently formulated a new PEG-PLA system capable of co-encapsulating two anti-
cancer drug molecules, erlotinib (an EGFR tyrosine kinase inhibitor) and fedratinib (a highly 
selective JAK2 inhibitor) for the treatment of erlotinib-resistant non-small cell lung 
cancer.141,142 The encapsulation of these drug molecules within the PEG-PLA nanoparticles 




improved drug solubility, reduction in toxicities.141,142 Moreover the ability to incorporate two 
drug molecules within the same nanoparticle can allow for complementary effects to be 
obtained in the target tumour sites.142 Interestingly in vitro release studies showed that, like 
PLGA particles, a decrease in pH led to an increased concentration of released drug after 48 
hours.141 This again is characteristic of PLA being subject to faster hydrolysis of the polyester 
backbone at acidic pH although the protonation of the amine groups in the drug molecules, 
causing them to be more hydrophilic, has also been eluded too.141  
Alternatively the almost forgotten monomer, caprolactone, has started to increasingly be seen 
in research in recent years after a boom in examination the 1970s which declined with the 
increased exploration of lactide and glycolide based polymers. Similar to the 6-membered ring 
diesters, ε-caprolactone is also biocompatible,††† bioresorbable, biodegradable and the 
monomer has potential to be made from renewable resources.131,143 Moreover its slower 
degradation rates, due to greater hydrophobicity, made it initially more popular for long acting 
depot injections, releasing drugs over longer periods such as a year.131,144 This became a very 
active research area for PCL applications, including studies of a suture material (Maxon™) 
capable of degrading slowly, before numerous reports of faster releasing and faster degrading 
biomedical devices and drug carriers based on PLA, PGA and PLGA polymers.131,145  
Nonetheless the pliability, low melting point and the ability to tune the degradation and 
crystallinity of poly(ε-caprolactone), PCL, based polymers (Figure 1.10, B) has seen a 
resurgence of interest both in the field of drug delivery and tissue engineering for this 
polymer.131 Additionally the absence of isomerism in the polymer chains, unlike PLA, allows 
for more predictability in the resulting polymers allowing characteristics like solubility and 
thermal properties to be more consistent between polymer batches.130 A further advantage is 
the ease in functionalisation of the monomer ring which therefore can provide opportunities 
for tuneable properties and targeting moieties.131,133 Finally, similar to PLA, a number of PCL 
based nanoparticle systems have been FDA approved for drug delivery.131,146 
New innovations are now being created which highlight the advantages of PCL based 
nanoparticles, although these are not in clinical trials as of yet. Paclitaxel and doxorubicin 
loaded PEG-PCL nanoparticles have shown the importance of the hydrophobic nature of the 
                                                          
††† The degradation products produced by the hydrolysis of the ester bonds in the poly(ε-caprolactone), PCL, 





PCL chains to achieving higher drug loadings than nanoparticles based on PLA and PLGA.146–
148 Paclitaxel is a more hydrophobic drug than doxorubicin and therefore interacts more 
strongly with the PCL polymer segments.146 This results in an increase in drug loading, from 
0.2 to 5.1 %, with increasing PCL block lengths, from 1,100 to 23,500 gmol-1, in contrast this 
was not seen with doxorubicin as the interactions with the polymer chains are weaker.146–148 
This highly hydrophobic nature of PCL, which can be tuned when combined with hydrophilic 
PEG,  allows for the encapsulation of a large number of drug molecules, such as ovalbumin 
and curcumin, with a range of computational LogP values‡‡‡, (-9.9 to 7.5) and a range of 
molecular weights.146 Among the drugs encapsulated are SN-38 and cyclosporin A, two active 
compounds that have been difficult to encapsulate in a number of nanocarriers.146,149,150 
Cyclosporin A, a highly insoluble immunosuppressant used to reduce risk of transplant organ 
rejection, had previously been successful encapsulated in lipid-based nanocarriers however 
these were shown to be unstable.149 In contrast, when encapsulated within PEG-PCL polymeric 
micelles concentrations of cyclosporin A comparable to those in the clinical treatment 
Sandimmune® (an ethanol and cremophor EL formulation) were achieved.149 Further studies 
on these particles showed that the release of the drug was slower for the PEG-PCL micelles 
compared to the clinical formulation, and resulted in decreased accumulation in the kidneys 
and reduced nephrotoxic effect.149,151 This was attributed to reduced drug leakage due to greater 
interactivity between the drug molecules and the PCL core, increased stability of the polymer 
micelles and the ‘stealth’ properties§§§ gained by the incorporation of a PEG corona.151 
A selection of studies have explored the encapsulation of SN-38 in PEG-PCL nanoparticles, 
which is unable to be directly administered into the body due to its pH sensitivity and poor 
water solubility (Chapter 1.2).152 To achieve encapsulation, different methods have been 
implemented which use characteristics of PCL polymers. Rychahou et al. achieved 
encapsulation of SN-38 along with a selection of other drugs by utilising a thin film hydration 
method, owing to PCL mechanical and physical properties.153 The encapsulation of these drug 
molecules improved cytotoxicity and solubility both in vitro and in vivo showing an increased 
accumulation in target tissues and a decrease in lung cancer tumours after 72 hours.153 Another 
study aiming to encapsulate SN-38 demonstrated the blending capabilities PCL polymers 
                                                          
‡‡‡ LogP is a logarithm of the partition coefficient of a molecule between n-octanol and water and is used to 
measure its hydrophobicity. The more positive the value the more hydrophobic the compound is, the molecule 
will partiction favourably into the octanol phase.207 
§§§ Stealth refers to the common property associated with a PEG corona giving the nanoparticles the ability to 





possess as pluronic F108 was used in conjunction with PEG-PCL to aid loading of SN-38 into 
the resulting nanoparticles.144,150 The combination of these polymers in various ratios was 
critical to successfully achieve high drug loading and stabilise the micelles in aqueous 
medium.150 These particles were not only able to retain the drug payload over several days but 
were also capable of combining several functions such as drug delivery and imaging shown by 
the introduction of fluorescent tags to aid drug tracking.150 
1.5 Functionalised monomers and polymers 
There are a range of unmodified monomers that can be used to create a library of homo- and 
co-polyesters, but a host of properties can be accessed by the modification of simple cyclic 
esters and diesters. The addition of functional groups to these monomers allows new properties 
to be unlocked once they have undergone polymerisation which would otherwise been unable 
to be accessed due to the lack of diversity in commercially available lactone monomers.154 
There have been a number of publications demonstrating ring opening polymerisation, ROP, 
involving multiple functionalised lactones derived from 4, 6 and 7 membered rings (Table 
1.3).155 ROP of monomers that have been functionalised with aromatic groups, amine groups 
and hydroxyl groups have produced a range of polymers.156 Chemical properties such as the 
glass transition temperature and crystallinity of these resulting polymers varies with the 
substituents on the cyclic (di)ester monomers.155 Polar functionalities such as amine and 
hydroxyl groups could increase the hydrophilicity of the polymers and allow for increased 
polymer-drug interactions when loaded into nanocarriers. In reality these require complicated 
pre- and post-polymerisation protection and de-protection procedures for successful ROP.156 
Conversely a recent study by Hao et al. has achieved the polymerisation of lactones carrying 
unprotected tertiary amine functionalities attaining polyesters with characteristics essential for 




Table 1.3 - Summary of select examples of functionalised lactone monomers, polymers and their resulting properties. 




 Thiol-ene reactions can yield macro-initiators  
 Epoxidation and sulfonation resulted in polymers capable of 








                                             
 Polymers have high crystallinity resulting in low solubility 
in organic solvents. 
 Resulting polymer hydrophobicity could be altered by 




                                        
 20 wt% included in co-polymers with PCL gives more rigid 
polymers capable of undergoing dihydroxylation to produce 
polymers with greater stability than other hydroxyl 
polyesters.  




 Gives the potential for post-polymerisation click chemistry 
with selected groups. 
 For example, functionalisation with benzophenone groups 
produce photopatternable aliphatic polymers. 
164,165 
  
 Polymers allow for modification for fluorescent dye 
attachment  
 Can also be functionalised with a peptides via click 
reactions to improve cell internalisation. 
166,167 






Table 1.3 cont. - Summary of select examples of functionalised lactone monomers, polymers and their resulting properties. 
Monomer Polymer Notable Properties of resulting polymer Ref 
 
                       
 Deprotection of this polymer can yield poly(β-malic acid). 
 The pendant carboxylic acid groups on poly(β-malic acid) 






 MRI-visible, hydrophobic co-polymers can be produced by 
the functionalisation with diethylene-triaminepentaacetic 
acid/Gd3+ complexes.  
 Possible to form organogels after click reaction 




 Potential for radical thiol-ene reactions to functionalise the 
polymer with amines and subsequently fluorescein 
isothiocyanate 
o The resulting polymers from this reaction are 
cationic and water soluble and have the 
potential for gene delivery. 




 Radio-opaque and could allow for visualisation of drug 
delivery via X-ray radioscopy 
173 
                            
 Ability to modify the groups post polymerisation so 
introduce hydroxyl groups capable of reacting further to 
achieve fluorescent dye attachment or graft co-polymers. 










Table 1.3 cont. - Summary of select examples of functionalised lactone monomers, polymers and their resulting properties. 
Monomer Polymer Notable Properties of resulting polymer Ref 
                                
 Both polyacrylates and polyesters can result from this 
monomer via atom transfer radical polymerisation or ROP 
respectively. 
 The resulting polyester is capable of intermolecular 
crosslinking, a flexible approach to small nanoparticles. 
 The polyester can also be grafted onto metallic surfaces to 




                          
 
 The resulting polymer can be deprotected to yield a 
bis(hydroxymethyl) functionalised PCL . 
 This resulting polymer is capable of self-polymerisation to 
produce hyperbranched polyesters. 
 This pendant group can also be used in the divergent growth 






 Allows the cross linking of polymer chains during 
polymerisation resulting in branched polymer architecture 




 Allows the cross linking of polymer chains during 
polymerisation resulting in branched polymer architecture 









A wide variety of monomers have been investigated in the production of polymers with the 
most variations being seen for 7-membered rings (i.e. -CL type monomers).133 The polymer 
properties accessed can in turn affect the physicochemical properties of the core of the 
nanoparticles formed from these species. These monomers can also allow for the adaptation of 
the biocompatible and biodegradable nature of the resulting polyesters which could aid their 
use as nanocarriers. For example, the incorporation of a carboxylic acid group in the polymer 
backbone, introduced by the ROP of malide dibenzyl ester followed by acid deprotection, 
achieves faster hydrolysis compared to non-functionalised PLA.181,182 Modifications to the 
ε-CL monomer ring can be introduced at 3 different positions on the lactone ring, α-, β- or γ-
positions.158 Functionalisation at the γ-position include the addition of tert-butyldimethylsilane 
groups (1), ketal functionality (2), ketones (3) or carboxylate groups (4) some of which can 
serve as protecting groups that can be removed after polymerisation to ultimately achieve 
hydroxyl groups (Figure 1.12, Table 1.3).155,183–185 Reports of β-substituted ε-caprolactones are 
significantly more rare in the literature with only a small number of publications dedicated to 
them.158 Nonetheless α-substituted ε-caprolactones have yielded numerous monomers with 
functionalities that include (5) halogenated, (6) alkyne and (7) alkene functionalities which 
allow for click and thiol-ene reactions to be undertaken post-polymerisation (Figure 1.12, Table 
1.3).158,169,171,186 Further complex adaptations can include the incorporation of an initiating 
group that can be used in sub-sequential polymerisations, for example atom transfer radical 
polymerisation (8), allowing the formation of co-polymers with various architecture which 
could further tune the physicochemical properties of the resulting materials.187 Additional 
modifications can be made to yield difunctional monomers, such as 2,2-bis(ε-caprolatone-4-
yl) and 4,4’-bioxepanyl-7,7’-dione, BOD,  which are capable of cross-linking polyester chains 





Figure 1.12 – Examples of functionalised 7-membered lactones used as monomers. 
(1) 5-((tert-butyldimethylsilyl)oxy)oxepan-2-one, (2) 5-ethylene ketal ε-caprolactone, (3) oxepane-2,5-
dione, (4) γ-tert-butyl carboxylate-ε-caprolactone, (5) α-chloro-caprolactone, (6) α-propargyl-ε-
caprolactone, (7) α-allyl-ε-caprolactone and (8) γ-(2-bromo-2-methyl propionyl)-ε-caprolactone. 
These modifications are achieved in numerous different ways and vary depending on the ring 
size and the desired functionality. These synthetic routes often arise from the adaptation of the 
methods used to synthesise the basic monomer forms. For example functionalised 4-membered 
β-lactones are yielded from either a [2+2] cycloaddition of a ketene and an aldehyde or the 
metal-based Lewis acid catalysed carbonylation of epoxides, the latter of which has been show 
to yield both cis- and trans- β-lactones.154,188–190 6-membered lactide monomers have a number 
of routes to formation and therefore have a number of routes to introduce functionality, two 
examples being dimerization of α-hydroxyl acids (which can only yield homo-bifunctional 
lactide monomers) and the condensation of α-haloacyl halides/-halocarboxylic acids and 
α-hydroxyl acids followed by lactonisation  (can yield hetero-bifunctional lactide 
monomers).154,191–193 7-membered functional lactones can also be created via lactonisation, but 
this is difficult  due to competing reactions and results in low yields.154,194 The preferred method 




oxidation of cyclic alcohols.185,195,196 This is an attractive route to monomers due to the 
diversity in both available cyclic ketones and catalysts.154 Its success has effectively yielded 
numerous monomers with varying ring functionality from ketones and halides to 
ethers.154,184,197,198 
Although many complex modifications have been made to 6 and 7 membered lactone rings to 
widely vary the properties of the polymers produced, literature seems to be lacking for the 
investigations and effects that simpler modifications might have on the resulting polyesters. 
These, unlike the monomers detailed above in Table 1.3, require less complex synthesis and 
remove the need to protect any functional groups that may take part in the reaction (e.g. 
hydroxyl, carboxylic acid and amine groups).155 Investigating smaller modifications by adding 
and varying an alkyl side chain could allow for fine tuning of properties, creating subtle 
changes to the polymers physical properties (e.g. Tg and crystallinity) that could significantly 
impact the interactions of the polymer with drug molecules. 
Comparatively for most of these functionalised monomers their controlled ROP is usually 
achieved by the use of metal based catalysts such as aluminium alkoxide or tin (II) octanoate 
(see Scheme 1) and also high reaction temperatures.155 This results in polymers that are usually 
hard to purify due to metal residue. Few reports have shown the use of organo-catalysts in the 
case of functionalised polyesters, most polymerisations of this nature utilise tin (II) 
octanoate.156 This allows for the opportunity to explore new boundaries by implementing 
organo-catalysed ROP along with the novel monomers to produce a series of polymers with 
tailored physical properties. 
1.6 Aims of the project 
The following PhD research aims to ultimately create a number of nanoparticle formulations 
centred on caprolactone-based polymers. These nanoparticle dispersions’ capability of 
encapsulating and delivering the active drug metabolite of irinotecan, SN-38 will be explored. 
Leading to this ultimate outcome this research will investigate the potential to vary the polymer 
backbone to achieve varying physicochemical properties of the resulting polymers.  
The synthesis of a number of substituted caprolactone monomers that have varying alkyl 
groups of increasing chain length (Figure 1.13) will be attempted by Baeyer-Villiger oxidation. 
The addition of these side chains is hypothesised to effect the thermal properties of the resulting 
polymers allowing the potential for the tuning of the semi-crystallinity seen with PCL. 




will allow for the creation of linear polymers with the potential to create polymers of varying 
architecture. The inclusion of a branching bis-lactone monomer BOD should allow access to a 
modified ‘Strathclyde’ approach (discussed in Chapter 2, Section 2.1.2.2) within the 
polymerisations to achieve branched architectures. Furthermore the variation of the initiator 
used in these polymerisations to include PEG is expected to result in the production of linear 
and branched block co-polymers (Figure 1.13)  
Figure 1.13- Schematic representation of aims of the project involving polymerisation to 
produce linear and branched species. 
As there are a variety of methods to form polymeric nanoparticles the library of polymers, 
resulting from the synthetic programme, will initially be studied using a rapid 
(co)nanoprecipitation method. This should allow for the testing of the hypothesis that 
composition and architecture of the polymeric species affect the characteristics and stability of 
the resulting polyester nanoparticles (Figure 1.14). Salt studies could also provide 
complementary data to further analyse the roles of architecture and PEGylation. Considering 
previous research within the Rannard group, it is hypothesised that the implementation of a 
branched architecture would result in the production of smaller nanoparticles when compared 
to polymers of linear architecture. Additionally the presence of hydrophilic PEG coronas 





Finally the ability of the nanoparticles to encapsulate guest molecules and ultimately SN-38 
must be explored to permit comparisons to similar systems within the literature (Figure 1.14). 
Development of the encapsulation method would allow for the evaluation of optimum drug 
loading potential and the stability of the resulting dispersions. The aim to create nanoparticle 
systems capable of encapsulating SN-38, possessing stability over time and decorated with a 
PEGylated corona will open up the opportunity for pharmacological studies to evaluate the rate 
of drug release, the cytotoxicity of nanoparticles with and without drug. In vitro studies 
evaluating release, toxicity and cellular uptake of nanoparticle systems should help to establish 
the viability of these systems. It is expected that the collection of results during in vitro 
investigations will enable selections for in vivo studies to be undertaken. It is hypothesised that 
the nanoparticle dispersions will induce slower release rates when compared to free SN-38 and 
the encapsulation of the drug within the polymer matrix will mitigate the offsite toxicities 
linked to SN-38 in vivo.  
Figure 1.14 – Schematic representation of the nanoprecipitation aims of this work. 
Involving the (i) nanoprecipitation of singular species, (ii) co-nanoprecipitation of two species 





1 Oxford Dictionary, Main definitions of Cancer in English, 
https://en.oxforddictionaries.com/definition/cancer, (accessed 4 February 2019). 
2 National Cancer Institute, What Is Cancer?, https://www.cancer.gov/about-
cancer/understanding/what-is-cancer, (accessed 4 February 2019). 
3 G. M. Cooper, A Cell: A Molecular Approach, Sinauer Associates, Sunderland (MA), 
2nd Ed., 2000. 
4 National Cancer Institute, NCI Dictionary of Cancer Terms - Malignancy, 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/malignancy, 
(accessed 29 July 2019). 
5 F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, CA A 
Cancer J. Clin., 2018, 68, 394–424. 
6 M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Gut, 
2017, 66, 683–691. 
7 M. Kekelidze, L. D’Errico, M. Pansini, A. Tyndall and J. Hohmann, World J. 
Gastroenterol., 2013, 19, 8502–8514. 
8 A. M. Leufkens, M. A. A. J. van den Bosch, M. S. van Leeuwen and P. D. Siersema, 
Scand. J. Gastroenterol., 2011, 46, 887–894. 
9 M. De Rosa, U. Pace, D. Rega, V. Costabile, F. Duraturo, P. Izzo and P. Delrio, Oncol. 
Rep., 2015, 34, 1087–1096. 
10 L. R. Zarour, S. Anand, K. G. Billingsley, W. H. Bisson, A. Cercek, M. F. Clarke, L. M. 
Coussens, C. E. Gast, C. B. Geltzeiler, L. Hansen, K. A. Kelley, C. D. Lopez, S. R. Rana, 
R. Ruhl, V. L. Tsikitis, G. M. Vaccaro, M. H. Wong and S. C. Mayo, Cell. Mol. 
Gastroenterol. Hepatol., 2017, 3, 163–173. 
11 W. Hohenberger, K. Weber, K. Matzel, T. Papadopoulos and S. Merkel, Color. Dis., 
2009, 11, 354–364. 
12 K. Sondenaa, P. Quirke, W. Hohenberger, K. Sugihara, H. Kobayashi, H. Kessler, G. 
Brown, V. Tudyka, A. D’Hoore, R. H. Kennedy, N. P. West, S. H. Kim, R. Heald, K. E. 
Storli, A. Nesbakken and B. Moran, Int. J. Colorectal Dis., 2014, 29, 419–428. 
13 G. P. Kanas, A. Taylor, J. N. Primrose, W. J. Langeberg, M. A. Kelsh, F. S. Mowat, D. 
D. Alexander, M. A. Choti and G. Poston, Clin Epidemiol, 2012, 4, 283–301. 
14 E. P. Misiakos, N. P. Karidis and G. Kouraklis, World J. Gastroenterol., 2011, 17, 4067–
4075. 
15 S. R. Alberts and L. D. Wagman, Oncologist, 2008, 13, 1063–1073. 
16 G. F. Gustavsson B, Carlsson G, D Machover, Petrelli N, Roth A, Schmoll HJ, Tveit 
KM, Clin. Colorectal Cancer, 2014, 14, 1–10. 
17 D. B. Longley, D. P. Harkin and P. G. Johnston, Nat Rev Cancer, 2003, 3, 330–8. 





19 R. J. Gibson and D. M. K. Keefe, Support. Care Cancer, 2006, 14, 890–900. 
20 N. Zdenkowski, S. Chen, A. van der Westhuizen and S. Ackland, Oncologist, 2012, 17, 
201–211. 
21 Y. Pommier, P. Pourquier, Y. Fan and D. Strumberg, Biochim. Biophys. Acta - Gene 
Struct. Expr., 1998, 1400, 83–106. 
22 M. Huang, H. Gao, Y. Chen, H. Zhu, Y. Cai, X. Zhang, Z. Miao, H. Jiang, J. Zhang, H. 
Shen, L. Lin, W. Lu and J. Ding, Clin. Cancer Res., 2007, 13, 1298–1307. 
23 C. Marchand, S. Antony, K. W. Kohn, M. Cushman, A. Ioanoviciu, B. L. Staker, A. B. 
Burgin, L. Stewart and Y. Pommier, Mol. Cancer Ther., 2006, 5, 287–296. 
24 G. S. Laco, PLoS One, 2011, 6, 1–7. 
25 A. Y. Chen and L. F. Liu, Annu. Rev. Pharmacol. Toxicol., 1994, 34, 191–218. 
26 Y. Hsiang, M. G. Lihou and L. F. Liu, Cancer Res., 1989, 49, 5077–5082. 
27 C. Holm, J. M. Covey, D. Kerrigan and Y. Pommier, Cancer Res., 1989, 49, 6365–6368. 
28 R. J. Gibson, J. M. Bowen, M. R. B. Inglis, A. G. Cummins and D. M. K. Keefe, J. 
Gastroenterol. Hepatol., 2003, 18, 1095–1100. 
29 A. Alimonti, A. Gelibter, I. Pavese, F. Satta, F. Cognetti, G. Ferretti, D. Rasio, A. 
Vecchione and M. Di Palma, Cancer Treat. Rev., 2004, 30, 555–562. 
30 M. Fittkau, W. Voigt, H. J. Holzhausen and H. J. Schmoll, J. Cancer Res. Clin. Oncol., 
2004, 130, 388–394. 
31 M. Ma and H. McLeod, Curr. Med. Chem., 2003, 10, 41–49. 
32 R. P. Jones, P. Sutton, R. M. D. Greensmith, A. Santoyo-Castelazo, D. F. Carr, R. 
Jenkins, C. Rowe, J. Hamlett, B. K. Park, M. Terlizzo, E. O’Grady, P. Ghaneh, S. W. 
Fenwick, H. Z. Malik, G. J. Poston and N. R. Kitteringham, Cancer Chemother. 
Pharmacol., 2013, 72, 359–368. 
33 D. Bobo, K. J. Robinson, J. Islam, K. J. Thurecht and S. R. Corrie, Pharm. Res., 2016, 
33, 2373–2387. 
34 M. Kurd, S. Sadegh Malvajerd, S. Rezaee, M. Hamidi and K. Derakhshandeh, Artif. 
cells, nanomedicine, Biotechnol., 2019, 47, 2123–2133. 
35 R. P. Bakshi, L. M. Tatham, A. C. Savage, A. K. Tripathi, G. Mlambo, M. M. Ippolito, 
E. Nenortas, S. P. Rannard, A. Owen and T. A. Shapiro, Nat. Commun., 2018, 9, 1–8. 
36 A. Kumari, S. K. Yadav and S. C. Yadav, Colloids Surfaces B Biointerfaces, 2010, 75, 
1–18. 
37 S. Senapati, A. Kumar Mahanta, S. Kumar and P. Maiti, Signal Transduct. Target. Ther., 
2018, 3, 1–19. 
38 A. Jurj, C. Braicu, L. A. Pop, C. Tomuleasa, C. D. Gherman and I. Berindan-Neagoe, 
Drug Des. Devel. Ther., 2017, 11, 2871–2890. 
39 A. R. Town, J. Taylor, K. Dawson, E. Niezabitowska, N. M. Elbaz, A. Corker, E. Garcia-




40 A. Gordillo-Galeano and C. E. Mora-Huertas, Eur. J. Pharm. Biopharm., 2018, 133, 
285–308. 
41 J. J. Hobson, A. Al-khouja, P. Curley, D. Meyers, C. Flexner, M. Siccardi, A. Owen, C. 
F. Meyers and S. P. Rannard, Nat. Commun., 2019, 10, 1–10. 
42 S. K. Libutti, G. F. Paciotti, A. A. Byrnes, H. R. Alexander, W. E. Gannon, M. Walker, 
G. D. Seidel, N. Yuldasheva and L. Tamarkin, Clin. Cancer Res., 2010, 16, 6139–6149. 
43 B. Thiesen and A. Jordan, Int. J. Hyperth., 2008, 24, 467–474. 
44 R. Berges, Eur. Urol. Suppl., 2005, 4, 20–25. 
45 J. Ford, P. Chambon, J. North, F. L. Hatton, M. Giardiello, A. Owen and S. P. Rannard, 
Macromolecules, 2015, 48, 1883–1893. 
46 K. Riehemann, S. W. Schneider, T. A. Luger, B. Godin, M. Ferrari and H. Fuchs, Angew. 
Chemie Int. Ed., 2009, 48, 872–897. 
47 G. Lövestam, H. Rauscher, G. Roebben, B. S. Klüttgen, N. Gibson, J. Putaud and H. 
Stamm, Considerations on a Definition of Nanomaterial for Regulatory Purposes, 2010. 
48 O. Dechy-Cabaret, B. Martin-Vaca and D. Bourissou, Chem. Rev., 2004, 104, 6147–
6176. 
49 V. P. Torchilin, AAPS J., 2007, 9, 128–147. 
50 H. Boulaiz, P. J. Alvarez, A. Ramirez, J. A. Marchal, J. Prados, F. Rodríguez-Serrano, 
M. Perán, C. Melguizo and A. Aranega, Int. J. Mol. Sci., 2011, 12, 3303–3321. 
51 N. D. James, R. J. Coker, D. Tomlinson, J. R. W. Harris, M. Gompels, A. J. Pinching 
and J. S. W. Stewart, Clin. Oncol., 1994, 6, 294–296. 
52 A. Wang-Gillam, C. P. Li, G. Bodoky, A. Dean, Y. S. Shan, G. Jameson, T. MacArulla, 
K. H. Lee, D. Cunningham, J. F. Blanc, R. A. Hubner, C. F. Chiu, G. Schwartsmann, J. 
T. Siveke, F. Braiteh, V. Moyo, B. Belanger, N. Dhindsa, E. Bayever, D. D. Von Hoff 
and L. T. Chen, Lancet, 2016, 387, 545–557. 
53 R. Lencioni and D. Cioni, Hepatic Oncol., 2016, 3, 193–200. 
54 X. Tian, M. Nguyen, H. P. Foote, J. M. Caster, K. C. Roche, C. G. Peters, P. Wu, L. 
Jayaraman, E. G. Garmey, J. E. Tepper, S. Eliasof and A. Z. Wang, Cancer Res., 2017, 
77, 112–122. 
55 V. Venugopal, S. Krishnan, V. R. Palanimuthu, S. Sankarankutty, J. K. Kalaimani, S. 
Karupiah, N. S. Kit and T. T. Hock, PLoS One, 2018, 13, 1–17. 
56 X. Guo, X. Kang, Y. Wang, X. Zhang, C. Li and Y. Liu, Acta Biomater., 2019, 84, 367–
377. 
57 S. V. K. Rompicharla, P. Kumari, H. Bhatt, B. Ghosh and S. Biswas, Int. J. Pharm., 
2019, 557, 329–341. 
58 M. E. Davis, Mol. Pharm., 2009, 6, 659–668. 
59 A. C. Eifler and C. S. Thaxton, Biomedical Nanotechnology: Methods and Protocols, 




60 S. Ashton, Y. H. Song, J. Nolan, E. Cadogan, J. Murray, R. Odedra, J. Foster, P. A. Hall, 
S. Low, P. Taylor, R. Ellston, U. M. Polanska, J. Wilson, C. Howes, A. Smith, R. J. A. 
Goodwin, J. G. Swales, N. Strittmatter, Z. Takáts, A. Nilsson, P. Andren, D. Trueman, 
M. Walker, C. L. Reimer, G. Troiano, D. Parsons, D. De Witt, M. Ashford, J. Hrkach, 
S. Zale, P. J. Jewsbury and S. T. Barry, Sci. Transl. Med., 2016, 8, 1–11. 
61 N. Floc’h, S. Ashton, D. Ferguson, P. Taylor, L. S. Carnevalli, A. M. Hughes, E. Harris, 
M. Hattersley, S. Wen, N. J. Curtis, J. E. Pilling, L. A. Young, K. Maratea, E. J. Pease 
and S. T. Barry, Mol. Cancer Ther., 2019, 18, 1–33. 
62 A. Varela-Moreira, Y. Shi, M. H. A. M. Fens, T. Lammers, W. E. Hennink and R. M. 
Schiffelers, Mater. Chem. Front., 2017, 1, 1485–1501. 
63 K. Maier-Hauff, F. Ulrich, D. Nestler, H. Niehoff, P. Wust, B. Thiesen, H. Orawa, V. 
Budach and A. Jordan, J. Neurooncol., 2011, 103, 317–324. 
64 D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, Nat. 
Nanotechnol., 2007, 2, 751–760. 
65 K. Greish, J. Fang, T. Inutsuka, A. Nagamitsu and H. Maeda, Clin. Pharmacokinet., 
2003, 42, 1089–1105. 
66 J. Fang, H. Nakamura and H. Maeda, Adv. Drug Deliv. Rev., 2011, 63, 136–151. 
67 Y. Nakamura, A. Mochida, P. L. Choyke and H. Kobayashi, Bioconjug. Chem., 2016, 
27, 2225–2238. 
68 H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. 
Jain and D. M. McDonald, Am. J. Pathol., 2000, 156, 1363–1380. 
69 M. K. Danquah, X. A. Zhang and R. I. Mahato, Adv. Drug Deliv. Rev., 2011, 63, 623–
639. 
70 D. M. Mcdonald, G. Thurston and P. Baluk, Microcirculation, 1999, 6, 7–22. 
71 D. Peer, J. M. Karp, S. Hong, O. C. FaroKhzad, R. Margalit and R. Langer, Nat. 
Nanotechnol., 2007, 2, 751–760. 
72 J. H. Senior, Crit. Rev. Ther. Drug Carrier Syst., 1987, 3, 123–193. 
73 R. Bazak, M. Houri, S. El Achy, S. Kamel and T. Refaat, J. Cancer Res. Clin. Oncol., 
2014, 141, 769–784. 
74 D. Le Garrec, J. Taillefer, J. E. Van Lier, V. Lenaerts and J. C. Leroux, J. Drug Target., 
2002, 10, 429–437. 
75 S. Gammas, K. Suzuki, C. Sone, Y. Sakurai, K. Kataoka and T. Okano, J. Control. 
Release, 1997, 48, 157–164. 
76 G. Pillai, Nanotechnology Toward Treating Cancer, Elsevier Inc., 2018. 
77 S. D. Steichen, M. Caldorera-Moore and N. A. Peppas, Eur. J. Pharm. Sci., 2013, 48, 
416–427. 
78 H. S. Yoo and T. G. Park, J. Control. Release, 2004, 96, 273–283. 




80 R. Domínguez-Ríos, D. R. Sánchez-Ramírez, K. Ruiz-Saray, P. E. Oceguera-Basurto, 
M. Almada, J. Juárez, A. Zepeda-Moreno, A. del Toro-Arreola, A. Topete and A. 
Daneri-Navarro, Colloids Surfaces B Biointerfaces, 2019, 178, 199–207. 
81 D. P. English, D. M. Roque and A. D. Santin, Mol. Diagnosis Ther., 2013, 17, 85–99. 
82 F. Y. Hern, A. Hill, A. Owen and S. P. Rannard, Polym. Chem., 2018, 9, 1767–1771. 
83 F. L. Hatton, L. M. Tatham, L. R. Tidbury, P. Chambon, T. He, A. Owen and S. P. 
Rannard, Chem. Sci., 2015, 6, 326–334. 
84 F. L. Hatton, P. Chambon, T. O. McDonald, A. Owen and S. P. Rannard, Chem. Sci., 
2014, 5, 1844–1853. 
85 A. Buczkowski, S. Sekowski, A. Grala, D. Palecz, K. Milowska, P. Urbaniak, T. 
Gabryelak, H. Piekarski and B. Palecz, Int. J. Pharm., 2011, 408, 266–270. 
86 K. Ulbrich, K. Holá, V. Šubr, A. Bakandritsos, J. Tuček and R. Zbořil, Chem. Rev., 
2016, 116, 5338–5431. 
87 A. Akbarzadeh, R. Rezaei-Sadabady, S. Davaran, S. W. Joo, N. Zarghami, Y. 
Hanifehpour, M. Samiei, M. Kouhi and K. Nejati-Koshki, Nanoscale Res. Lett., 2013, 
8, 1–8. 
88 J. J. Hobson, S. Edwards, R. A. Slater, P. Martin, A. Owen and S. P. Rannard, RSC Adv., 
2018, 8, 12984–12991. 
89 K. Letchford and H. Burt, Eur. J. Pharm. Biopharm., 2007, 65, 259–269. 
90 M. Rangasamy, J. Appl. Pharm. Sci., 2011, 1, 08–16. 
91 E. Abbasi, S. F. Aval, A. Akbarzadeh, M. Milani, H. T. Nasrabadi, S. W. Joo, Y. 
Hanifehpour, K. Nejati-Koshki and R. Pashaei-Asl, Nanoscale Res. Lett., 2014, 9, 1–10. 
92 A. C. Savage, L. M. Tatham, M. Siccardi, T. Scott, M. Vourvahis, A. Clark, S. P. 
Rannard and A. Owen, Eur. J. Pharm. Biopharm., 2019, 138, 30–36. 
93 J. K. Patra, G. Das, L. F. Fraceto, E. V. R. Campos, M. D. P. Rodriguez-Torres, L. S. 
Acosta-Torres, L. A. Diaz-Torres, R. Grillo, M. K. Swamy, S. Sharma, S. Habtemariam 
and H. S. Shin, J. Nanobiotechnology, 2018, 16, 1–33. 
94 D. Lombardo, M. A. Kiselev and M. T. Caccamo, J. Nanomater., 2019, 2019, 1–26. 
95 C. J. Martínez Rivas, M. Tarhini, W. Badri, K. Miladi, H. Greige-Gerges, Q. A. Nazari, 
S. A. Galindo Rodríguez, R. Á. Román, H. Fessi and A. Elaissari, Int. J. Pharm., 2017, 
532, 66–81. 
96 B. V. N. Nagavarma, H. K. S. Yadav, A. Ayaz, L. S. Vasudha and H. G. Shivakumar, 
Asian J. Pharm. Clin. Res., 2012, 5, 16–23. 
97 R. Duncan and L. Izzo, Adv. Drug Deliv. Rev., 2005, 57, 2215–2237. 
98 H. Zhang, D. Wang, R. Butler, N. L. Campbell, J. Long, B. Tan, D. J. Duncalf, A. J. 
Foster, A. Hopkinson, D. Taylor, D. Angus, A. I. Cooper and S. P. Rannard, Nat. 
Nanotechnol., 2008, 3, 506–511. 




100 S. Verma, R. Gokhale and D. J. Burgess, Int. J. Pharm., 2009, 380, 216–222. 
101 E. Sánchez-López, M. Guerra, J. Dias-Ferreira, A. Lopez-Machado, M. Ettcheto, A. 
Cano, M. Espina, A. Camins, M. L. Garcia and E. B. Souto, Nanomaterials, 2019, 9, 
821. 
102 A. Gupta, H. B. Eral, T. A. Hatton and P. S. Doyle, Soft Matter, 2016, 12, 2826–2841. 
103 N. Sharma, S. Mishra, S. Sharma, R. D. Deshpande and R. Kumar Sharma, Int. J. Drug 
Dev. Res., 2013, 5, 37–48. 
104 G. Romero and S. E. Moya, Synthesis of organic nanoparticles, 2012, vol. 4. 
105 H. Koide, T. Asai, K. Hatanaka, S. Akai, T. Ishii, E. Kenjo, T. Ishida, H. Kiwada, H. 
Tsukada and N. Oku, Int. J. Pharm., 2010, 392, 218–223. 
106 Health Products Distibutors, Liposomes, 
http://www.integratedhealth.com/supplements/liposomes.html?mode=list, (accessed 13 
March 2020). 
107 F. Masood, Mater. Sci. Eng. C, 2016, 60, 569–578. 
108 S. P. Egusquiaguirre, J. L. Pedraz, R. M. Hernández and M. Igartua, Nanotherapeutic 
Platforms for Cancer Treatment: From Preclinical Development to Clinical 
Application, Elsevier Inc., 2016. 
109 F. L. Hatton, P. Chambon, A. C. Savage and S. P. Rannard, Chem. Commun., 2016, 52, 
3915–3918. 
110 M. Siccardi, P. Martin, D. Smith, P. Curley, T. McDonald, M. Giardiello, N. Liptrott, S. 
Rannard and A. Owen, J. Interdiscip. Nanomedicine, 2016, 1, 110–123. 
111 M. Farha, E. Masson, H. Tomkinson and G. Mugundu, J. Clin. Pharmacol., 2019, 59, 
463–471. 
112 C. Tistaert, T. Heimbach, B. Xia, N. Parrott, T. S. Samant and F. Kesisoglou, J. Pharm. 
Sci., 2019, 108, 592–602. 
113 N. J. Liptrott, M. Giardiello, T. O. McDonald, S. P. Rannard and A. Owen, J. 
Nanobiotechnology, 2018, 16, 1–15. 
114 R. J. Malcolmson and J. K. Embleton, Pharm. Sci. Technol. Today, 1998, 1, 394–398. 
115 R. H. Muller and K. Peters, Int. J. Pharm., 1998, 160, 229–237. 
116 M. Giardiello, N. J. Liptrott, T. O. McDonald, D. Moss, M. Siccardi, P. Martin, D. 
Smith, R. Gurjar, S. P. Rannard and A. Owen, Nat. Commun., 2016, 7, 1–10. 
117 A. Z. Mirza and F. A. Siddiqui, Int. Nano Lett., 2014, 4, 1–7. 
118 V. Mody, R. Siwale, A. Singh and H. Mody, J. Pharm. Bioallied Sci., 2010, 2, 282. 
119 P. K. Jain, X. Huang, I. H. El-Sayed and M. A. El-Sayed, Plasmonics, 2007, 2, 107–
118. 
120 P. N. Prasad, Nanophotonics, John Wiley & Sons Inc., 2004. 
121 G. Xu, S. Zeng, B. Zhang, M. T. Swihart, K. T. Yong and P. N. Prasad, Chem. Rev., 




122 J. Liu, T. Liu, S. Nie, S. K. Lau, V. A. Varma, J. A. Petros, A. O. Osunkoya, R. A. 
Moffitt, M. Caldwell, M. D. Wang, A. N. Young, T. Krogstad and B. Leyland-Jones, 
ACS Nano, 2010, 4, 2755–2765. 
123 C. B. Murray, D. J. Norris and M. G. Bawendi, J. Am. Chem. Soc., 1993, 115, 8706–
8715. 
124 R. Bilan, I. Nabiev and A. Sukhanova, ChemBioChem, 2016, 17, 2103–2114. 
125 V. Noireaux, B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou and 
A. Libchaber, Science (80-. )., 2002, 298, 1759–1762. 
126 G. J. Halder, C. J. Kepert, B. Moubaraki, K. S. Murray and J. D. Cashion, Science (80-. 
)., 2002, 298, 1762–1765. 
127 N. Huang, H. Wang, J. Zhao, H. Lui, M. Korbelik and H. Zeng, Lasers Surg. Med., 2010, 
42, 638–648. 
128 N. Ahmed, H. Fessi and A. Elaissari, Drug Discov. Today, 2012, 17, 928–934. 
129 K. H. Son, J. H. Hong and J. W. Lee, Int. J. Nanomedicine, 2016, 11, 5163–5185. 
130 S. Farah, D. G. Anderson and R. Langer, Adv. Drug Deliv. Rev., 2016, 107, 367–392. 
131 M. A. Woodruff and D. W. Hutmacher, Prog. Polym. Sci., 2010, 35, 1217–1256. 
132 Houghton Mifflin Company, The American Heritage Medical Dictionary, Houghton 
Mifflin Company, 2007. 
133 C. K. Williams, Chem. Soc. Rev., 2007, 36, 1573–1580. 
134 J. Lunt, Polym. Degrad. Stab., 2002, 59, 145–152. 
135 U. F. and D. Administration, Inventory of Effective Food Contact Substance (FCS) 
Notifications, 
https://www.accessdata.fda.gov/scripts/fdcc/?set=FCN&id=475&sort=FCN_No&order
=DESC&startrow=1&type=basic&search=lactide, (accessed 24 July 2019). 
136 K.-T. Kim, J.-Y. Lee, D.-D. Kim, I.-S. Yoon and H.-J. Cho, Pharmaceutics, 2019, 11, 
280. 
137 K. Hamad, M. Kaseem, H. W. Yang, F. Deri and Y. G. Ko, Express Polym. Lett., 2015, 
9, 435–455. 
138 S. Sun, H. Li, J. Chen and Q. Qian, Physiology, 2017, 32, 453–463. 
139 L. W. McKeen, Plastics Used in Medical Devices, Elsevier Inc., 2013. 
140 B. S. Zolnik and D. J. Burgess, J. Control. Release, 2007, 122, 338–344. 
141 D. Chen, F. Zhang, J. Wang, H. He, S. Duan, R. Zhu, C. Chen, L. Yin and Y. Chen, 
Front. Pharmacol., 2018, 9, 1–9. 
142 A. Pardanani, C. Harrison, J. E. Cortes, F. Cervantes, R. A. Mesa, D. Milligan, T. 
Masszi, E. Mishchenko, E. Jourdan, A. M. Vannucchi, M. W. Drummond, M. Jurgutis, 
K. Kuliczkowski, E. Gheorghita, F. Passamonti, F. Neumann, A. Patki, G. Gao and A. 
Tefferi, JAMA Oncol., 2015, 1, 643–651. 




144 R. P. Brannigan and A. P. Dove, Biomater. Sci., 2017, 5, 9–21. 
145 S. A. Metz, N. Chegini and B. J. Masterson, Biomaterials, 1990, 11, 41–45. 
146 P. Grossen, D. Witzigmann, S. Sieber and J. Huwyler, J. Control. Release, 2017, 260, 
46–60. 
147 X. Shuai, T. Merdan, A. K. Schaper, F. Xi and T. Kissel, Bioconjug. Chem., 2004, 15, 
441–448. 
148 X. Shuai, H. Ai, N. Nasongkla, S. Kim and J. Gao, J. Control. Release, 2004, 98, 415–
426. 
149 H. M. Aliabadi, A. Mahmud, A. D. Sharifabadi and A. Lavasanifar, J. Control. Release, 
2005, 104, 301–311. 
150 Q. Gu, J. Z. Xing, M. Huang, C. He and J. Chen, Nanotechnology, 2012, 23, 1–10. 
151 H. M. Aliabadi, S. Elhasi, D. R. Brocks and A. Lavasanifar, J. Pharm. Sci., 2008, 97, 
1916–1925. 
152 K. K. Vangara, J. L. Liu and S. Palakurthi, Int. J. Cancer Res. Treat., 2013, 33, 2425–
2434. 
153 P. Rychahou, Y. Bae, D. Reichel, Y. Y. Zaytseva, E. Y. Lee, D. Napier, H. L. Weiss, N. 
Roller, H. Frohman, A. T. Le and B. Mark Evers, J. Control. Release, 2018, 275, 85–
91. 
154 R. Tong, Ind. Eng. Chem. Res., 2017, 56, 4207–4219. 
155 X. Lou, C. Detrembleur and R. Jérôme, Macromol. Rapid Commun., 2003, 24, 161–172. 
156 H. Seyednejad, A. H. Ghassemi, C. F. Van Nostrum, T. Vermonden and W. E. Hennink, 
J. Control. Release, 2011, 152, 168–176. 
157 J. Hao, S. Elkassih and D. J. Siegwart, Synlett, 2016, 27, 2285–2292. 
158 G. Becker and F. R. Wurm, Chem. Soc. Rev., 2018, 47, 7739–7782. 
159 C. G. Jaffredo and S. M. Guillaume, Polym. Chem., 2014, 5, 4168–4194. 
160 J. W. Kramer and G. W. Coates, Tetrahedron, 2008, 64, 6973–6978. 
161 X.-Q. Liu, Z.-C. Li, F.-S. Du and F.-M. Li, Macromol. Rapid Commun., 1999, 20, 470–
474. 
162 X.-Q. Liu, M.-X. Wang, Z.-C. Li and F.-M. Li, Macromol. Chem. Phys., 1999, 200, 
468–473. 
163 B. Parrish and T. Emrick, Macromolecules, 2004, 37, 5863–5865. 
164 B. Parrish, R. B. Breitenkamp and T. Emrick, J. Am. Chem. Soc., 2005, 127, 7404–7410. 
165 D. Chen, C. C. Chang, B. Cooper, A. Silvers, T. Emrick and R. C. Hayward, 
Biomacromolecules, 2015, 16, 3329–3335. 
166 D. E. Borchmann, R. Tarallo, S. Avendano, A. Falanga, T. P. Carberry, S. Galdiero and 
M. Weck, Macromolecules, 2015, 48, 942–949. 





168 J. Y. Ljubimova, M. Fujita, A. V. Ljubimov, V. P. Torchilin, K. L. Black and E. Holler, 
Nanomedicine, 2008, 3, 247–265. 
169 S. El Habnouni, B. Nottelet, V. Darcos, B. Porsio, L. Lemaire, F. Franconi, X. Garric 
and J. Coudane, Biomacromolecules, 2013, 14, 3626–3634. 
170 O. Jazkewitsch, A. Mondrzyk, R. Staffel and H. Ritter, Macromolecules, 2011, 44, 
1365–1371. 
171 E. M. Pelegri-O’Day, S. J. Paluck and H. D. Maynard, J. Am. Chem. Soc., 2017, 139, 
1145–1154. 
172 V. Darcos, S. Antoniacomi, C. Paniagua and J. Coudane, Polym. Chem., 2012, 3, 362–
368. 
173 S. El Habnouni, V. Darcos and J. Coudane, Macromol. Rapid Commun., 2009, 30, 165–
169. 
174 W. Dai, J. Zhu, A. Shangguan and M. Lang, Eur. Polym. J., 2009, 45, 1659–1667. 
175 E. L. Prime, Z. A. Abdul Hamid, J. J. Cooper-White and G. G. Qiao, 
Biomacromolecules, 2007, 8, 2416–2421. 
176 H. Li, R. Jéröme and P. Lecomte, Polymer (Guildf)., 2006, 47, 8406–8413. 
177 M. Trollsas, P. Lowenhielm, V. Y. Lee, M. Moller, R. D. Miller and J. L. Hedrick, 
Macromolecules, 1999, 32, 9062–9066. 
178 C. C. Lee, S. M. Grayson and J. M. J. Fréchet, J. Polym. Sci. Part A Polym. Chem., 2004, 
42, 3563–3578. 
179 N. T. Nguyen, K. J. Thurecht, S. M. Howdle and D. J. Irvine, Polym. Chem., 2014, 5, 
2997–3008. 
180 R. Palmgren, S. Karlsson and A. C. Albertsson, J. Polym. Sci. Part A Polym. Chem., 
1997, 35, 1635–1649. 
181 H. Tian, Z. Tang, X. Zhuang, X. Chen and X. Jing, Prog. Polym. Sci., 2012, 37, 237–
280. 
182 Y. Kimura, K. Shirotani, H. Yamane and T. Kitao, Macromolecules, 1988, 21, 3338–
3340. 
183 D. Tian, O. Halleux, P. Dubois, R. Jérôme, R. Sobry and G. Van den Bossche, 
Macromolecules, 1998, 31, 924–927. 
184 J. P. Latere, P. Lecomte, P. Dubois and R. Jérôme, Macromolecules, 2002, 35, 7857–
7859. 
185 M. Trollsås, V. Y. Lee, D. Mecerreyes, P. Löwenhielm, M. Möller, R. D. Miller, J. L. 
Hedrick, M. Trollsas, V. Y. Lee, D. Mecerreyes, P. Lowenhielm, M. Moller, R. D. Miller 
and J. L. Hedrick, Macromolecules, 2000, 33, 4619–4627. 





187 D. Mecerreyes, B. Atthoff, K. A. Boduch, M. Trollsa and J. L. Hedrick, 
Macromolecules, 1999, 32, 5175–5182. 
188 J. E. Wilson and G. C. Fu, Angew. Chemie - Int. Ed., 2004, 43, 6358–6360. 
189 S. G. Nelson, C. Zhu and X. Shen, J. Am. Chem. Soc., 2004, 126, 14–15. 
190 M. Mulzer and G. W. Coates, J. Org. Chem., 2014, 79, 11851–11862. 
191 W. W. Gerhardt, D. E. Noga, K. I. Hardcastle, A. J. García, D. M. Collard and M. Weck, 
Biomacromolecules, 2006, 7, 1735–1742. 
192 D. E. Noga, T. A. Petrie, A. Kumar, M. Weck, A. J. García and D. M. Collard, 
Biomacromolecules, 2008, 9, 2056–2062. 
193 R. J. Pounder and A. P. Dove, Biomacromolecules, 2010, 11, 1930–1939. 
194 C. Galli and L. Mandolini, J. Chem. Soc. Chem. Commun., 1982, 251–253. 
195 M. Renz and B. Meunier, Eur. Hournal Org. Chem., 1999, 1999, 737–750. 
196 G. J. ten Brink, I. W. C. E. Arends and R. A. Sheldon, Chem. Rev., 2004, 104, 4105–
4123. 
197 C. Detrembleur, M. Mazza, O. Halleux, P. Lecomte, D. Mecerreyes, J. L. Hedrick and 
R. Jérôme, Macromolecules, 2000, 33, 14–18. 
198 T. Mathisen, K. Masus and A. C. Albertssor, Macromolecules, 1989, 22, 3842–3846. 
199 National Cancer Institute, NCI Dictionary of Cancer Terms - Complete Remission, 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/complete-
remission, (accessed 28 May 2019). 
200 National Cancer Institute, NCI Dictionary of Cancer Terms - Remission, 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/remission, 
(accessed 28 May 2019). 
201 L. Iyer, S. Das, L. Janisch, M. Wen, J. Ramírez, T. Karrison, G. F. Fleming, E. E. Vokes, 
R. L. Schilsky and M. J. Ratain, Pharmacogenomics J., 2002, 2, 43–47. 
202 M. Talekar, J. Kendall, W. Denny and S. Garg, Anticancer. Drugs, 2011, 22, 949–962. 
203 B. Yu, H. C. Tai, W. Xue, L. J. Lee and R. J. Lee, Mol. Membr. Biol., 2010, 27, 286–
298. 
204 Z. M. Qian and P. L. Tang, BBA - Mol. Cell Res., 1995, 1269, 205–214. 
205 D. M. Mock, Biotin: Pharmacology, Pathophysiology, and Assessment of Biotin Status, 
2004. 
206 T. Tadros, Encyclopedia of Colloid and Interface Science, 2013. 
207 ScienceDirect, Lipophilicity, https://www.sciencedirect.com/topics/pharmacology-













SYNTHESIS AND CHARACTERISATION OF 
CAPROLACTONE DERIVED POLYESTERS VIA 













2.1.1 Ring opening polymerisation, ROP 
Polyesters can be synthesised from two distinct routes, involving either linear or cyclic 
monomer units; for non-cyclic monomers, such as hydroxyl-acids, step growth 
polycondensation is the route to polymers.1 The polymerisation of cyclic lactones however has 
been mainly achieved by the “controlled/living” technique of ring opening polymerisation, 
ROP, allowing for the de-cyclisation of each monomer unit as the polymerisation progresses.2–
4 Unlike other controlled polymerisations, such as atomic transfer radical polymerisation, 
ATRP, where the driving force is the enthalpy change when C=C bonds move to C-C, ROP is 
driven by the loss of ring strain also equating to a loss of enthalpy.5  
This technique is of high industrial importance contributing to the synthesis of numerous 
polymers for wide ranging applications such as polyethylene oxide, polysiloxane, Nylon-6 
(polycaprolactam) and increasingly polylactide and polyglycolide.5 Due to the industrial 
relevance of ROP, the polymers it produces, and their advantageous properties with regards to 
biological applications research into this area has increased. For example, variation of 
polymerisation conditions has allowed well-defined polyesters to be achieved under mild 
conditions. As the reaction is catalysed, through activation of either the growing polymer chain 
end or the monomer (to facilitate hydroxide attack), modified catalysis conditions have been 
highly explored. These catalysts can be categorised dependant on the properties and method of 
action of the species in question. Considering the ROP of lactones in particular there are 4 main 
routes for the reaction to proceed namely anionic, cationic, monomer activated and 
coordination-insertion mechanisms.4,6 
The most common method of ROP of ε-CL is driven by metal based catalysts, with reports of 
tin (II) octanoate regularly found in literature.4 These catalysts proceed by a 
coordination/insertion mechanism (Scheme 2.1, A), a pseudo anionic route, which allows for 
the attack of a new monomer molecule by the metal catalyst forming a hydrogen bond between 
the metal ion and the carbonyl oxygen thus initiating the reaction.7 The propagation of the 
polymerisation continues by the insertion of the monomer into the metal-oxygen bond followed 
by ring opening of the monomer to extend the polymer chain. The metal bond to the polymer 
chain end is maintained throughout the reaction only being cleaved by proton transfer in the 





Scheme 2.1 – Schematic representation of three ROP mechanisms; (A) coordination/insertion mechanism (metal catalysed), (B) electrophilic activated 
monomer mechanism (methanesulfonic acid, MSA,/trifluoromethanesulfonic acid, TfOH catalysed) and (C) nucleophilic activated monomer mechanism (N-





Although this is the most commonly used technique for the ROP of ε-CL it is not without some 
drawbacks which make it undesirable for the synthesis of polyesters bound for biological use. 
The most significant drawbacks stem from the difficult removal of the catalyst in its entirety 
leading to residual metal within the polymers coupled with the necessity for high temperatures 
that promote both inter- and intramolecular reactions, thereby broadening the polydispersity of 
resulting polymers.1,4,9 In an attempt to achieve metal free polymerisation, gain easy catalyst 
removal and lower polymerisation temperatures several research groups have investigated a 
whole host of alternatives. These include enzymes, which can prove difficult to work with 
(polymerisation, degradation and enzyme deactivation occur simultaneously) and 
organocatalysts.4 This latter group that consists of a number of molecules with advantageous 
properties over the traditional metal catalysis routes.1,5,10–12 
Organocatalysts were first reported by Nederberg et al. in 2001 using 
4-(dimethylamino)pyridine, DMAP, as catalyst for ROP of lactide.13 Since then the range of 
molecules, and combinations of such, has expanded greatly to include a wide range of 
compounds capable of ROP catalysis.11,13 Among these are thiourea amines, N-hetrocyclic 
carbenes, NHCs, organic bases and acids (Figure 2.1) many of which are commercially 
available and easily stored.1,4,5,10,11,14,15 The approach for each of these groups falls into an 
activated monomer (Scheme 2.1, B & C) or activated chain end mechanism dependant on the 











Figure 2.1 – Examples of organocatalysts that have been applied to ROP; (A) N-hetrocyclic 
carbenes, NHC, (i) free NHC examples, (ii) examples of protected NHCs; (B) (thio)urea amines, (i) 
thiourea containing both H-donor and acceptor groups within same molecule, (ii) bicomponent urea and 
base (2-tert-Butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine, BEMP) 
catalytic system; (C) organic bases, (i) 4-(dimethylamino)pyridine, DMAP, and triethylamine, TEA, (ii) 
1,8-diazabicyclo[5.4.0]undec-7-ene, DBU, and triazabicyclodecene, TBD; and (D) organic acids, (i) 
sulfonic acids, methanesulfonic acid, MSA, and trifluoromethanesulfonic acid, TfOH, (ii) carboxylic 
acid, salicyclic acid, SAA, and phosphoric acid, diphenyl phosphate, DPP, catalysts.10,15 
NHCs are highly popular due to their successful application to the polymerisation of a range 
of monomers including epoxides, siloxanes and cyclic carbonates but in particular lactide 
(Figure 2.1, A).11,16–18 First applied by Connor et al. in 2002,14 NHCs offer highly reactive 
catalysis for ROP when coupled with an alcohol initiator and have since been extensively 
studied in the catalysis of ROP.10 Despite their clear success, NHCs are seen as inaccessible to 
a large number of researchers due to being highly unstable in air and requiring inert 
atmospheres. More recently, “protected” NHCs have more frequently been applied.11 These 
compounds allow for more air stable adducts that generate a free carbene that can catalyse the 
polymerisation when triggered by a stimulus such as temperature or solvent.10,19 This group of 
molecules includes examples such as NHC-carboxylates and NHC- alcohol adducts which, 
although provide a solution to air  instability, generally have lower activity than unprotected 
NHCs due to the reliance on complete generation of the active catalyst within the reaction 
mixture.10  
Supramolecular chemistry has also been applied to the catalysis of ROP by the use of thiourea 
amines and similar molecules (Figure 2.1, B). The combination of both H-acceptors (amine 
base) and H-donors (thiourea, N-H) in the same catalyst (either joined in the same molecule or 
dual component) allows for activation of both the chain end and the monomer giving a 





and broad functional group tolerance.11,15 Recent studies have shown the rate of polymerisation 
when using bicomponent catalysts can be optimised by the selective pairing of (thio)urea and 
amine. Lin and Waymouth showed that the rate of polymerisation increased with increased 
basicity of the amine pair to a given (thio)urea and that optimum rate was reached when the 
acidity of the (thio)urea was closely matched to that of the protonated base.15 When comparing 
ureas to thioureas it was found that ureas were more active when paired with a base compared 
to the corresponding thiourea pairings. These findings gave insight into the mechanism of 
action of these catalysts showing there are 2 potential mechanisms dependant on base strength, 
however, both mechanisms result in the activation of the chain end and the monomer.15  
In a similar manner to supramolecular catalysts, base and acid catalysis allow for a more 
accessible metal free ROP than seen with NHCs with a broad spectrum of molecules that can 
be implemented. For example the first organocatalyst DMAP, a Brønsted base, is one of several 
pyridine derivatives that behave as nucleophiles that have been shown to catalyse the ROP of 
a variety of monomers such as glucose, cyclodextrin, and lactones (Figure 2.1, C).10,14,20 
Further examples of bases capable of catalysing ROP are numerous including guanidines and 
amidines such as 1,8-diazabicyclo[5.4.0]undec-7-ene, DBU, which shows high activity to 
lactide and can be used in combination with a H-bond donor to broaden the library of monomers 
that can be successfully polymerised.11,21,22 Furthermore, phosphazene bases have been shown 
to be capable of low temperature ROP as well as promote co-polymerisation with methacrylate 
monomers.4,10,11However, these catalysts seem to have limited monomer tolerability with each 
showing limitations in activity with respect to the monomer chosen.11  
Among the various acids, including carboxylic acids and phosphoric acids, that have been 
studied to catalyse ROP of lactones there is a group of strong sulfonic acids that have been 
widely investigated (Figure 2.1, D).10 This group includes methanesulfonic acid, MSA, and 
trifluoromethanesulfonic acid, TfOH, which have been shown to successfully catalyse the ROP 
of lactones in various solvents, such as dichloromethane, DCM, toluene and water.10,23 TfOH 
has been shown to successfully catalyse the polymerisation of five and six membered rings 
(butyrolactone and lactide), which have the lowest ring strain, showing the activity of this 
catalyst is related to the higher acidity. Nonetheless, weaker MSA is capable of catalysing the 
ROP of ε-caprolactone, ε-CL, more efficiently and with more control than TfOH, showing that 
the reactivity of the catalyst does not solely correlate with the strength of the acid.23 This 





deactivation of the initiating alcohol that is in direct competition with the activation of the 
monomer (Scheme 2.2).4,23  
Scheme 2.2 – Deactivation and activation of the monomer and initiating species by an 
acid catalyst (e.g. methanesulfonic acid, MSA, and trifluoromethanesulfonic acid, 
TfOH).23 
These acids have been shown to promote an activated monomer mechanism (Scheme 2.1, B) 
which can be referred to as pseudo cationic due to the generation of a positively charged species 
after protonation of the monomer.10 This is the result of the catalyst activating the monomer 
and facilitating attack of the carbonyl group by the alcohol initiator. Following the exchange 
of protons, the ring opens allowing the propagation of the polymer chain. The polymerisation 
propagates through attack of the chain end hydroxyl functionality at the carbonyl of another 
activated monomer molecule. As with all ring opening polymerisations, this can be seen as a 
“controlled/living” polymerisation where chain-extension will occur after the addition of more 
monomer after full conversion of the initial monomer feed. 
2.1.2 Variation in polymer composition and architecture 
The modification of polyesters to tune their polymer properties is not limited to the use of 
functionalised monomers and/or post-polymerisation reactions. Other strategies, applied 
during polymer synthesis, allow the resulting polymers to exhibit physicochemical properties 
that would have otherwise been unexploited. These methods can be divided into two groups; 
(1) composition - to alter the polymer backbone by the addition of co-monomers, co-
polymerisation, and (2) architecture - to vary the way the polymer chains are linked together, 
branching.  
2.1.2.1 Variation of polymer composition – co-polymerisation of polyesters 
The introduction of two or more monomers into a linear polymer chain via co-polymerisation 
may lead to a number of different structures that vary in the relative ordering of the monomers 
along each chain (Figure 2.2). The most common co-polymers seen in the application of 





(frequently PEG or poly(vinylpyrrolidone), PVP) and a hydrophobic block (any hydrophobic 
polymer including polyesters and polymethacrylates) (Figure 2.2, A).24–27 These are normally 
synthesised by sequential polymerisations, polymerisation of one monomer before the addition 
of a second monomer, yielding two separate blocks with distinct hydrophobicity. These 
structures are advantageous in the formation of nanoparticles due to various properties of the 
polymer segments that allow clear domains to be created during nanoparticle formation thus 
allowing for greater particle stability. For example, and as discussed in Chapter 1, PEG-b-PLA 
co-polymers can be used to form drug containing polymeric micelles with a hydrophobic core 
surrounded by a hydrophilic corona inducing stability within the aqueous phase.28 Among 
numerous examples, PCL has also been reported to provide the hydrophobic block within PEG 
co-polymers which have subsequently been used for the formation of polymeric nanoparticles 
or micelles.25,29,30 The polyester blocks are most commonly synthesised using metal catalysis 
and PEG macroinitiators to achieve such architecture; along with the most widely used 
Sn(Oct)2 catalyst other inorganic compounds have been utilised to catalysed the ROP of ε-CL 
from monomethoxy-PEG such as tin oxide, zinc and antimony trioxide.25,29,30 Block 
co-polymer structures that contain two hydrophobic segments have also been synthesised using 
novel catalytic approaches; using a catalyst “switch” technique that directs block segment 
synthesis from reactions containing monomer mixtures. 26,31 Wang et al. have shown that by 
utilising organocatalysts, such as MSA, that are active for ε-CL or -valerolactone but not 
lactide and the switching to a catalytic system that is only active for lactide, such as DBU, 
multi-block co-polymers can be synthesised without the need for purification between each 
block formation.31 
Figure 2.2 – Representation of the different possibilities of monomer sequence when 
altering polymer composition using co-polymerisation. (A) Block co-polymer, (B) gradient co-






Alongside block co-polymers, the most common co-polyester structure found within literature 
are statistical co-polyesters such as PLGA (Figure 2.2, D). Statistical (previously known as 
“random”) co-polymer composition relies on a one-pot synthetic approach where both 
monomers are present at the start of the polymerisation. This can result in a mixture of polymer 
compositions dependant on the ratios of the monomers used, their subsequent reactivity’s with 
respect to each other and the catalyst used. In the case of PLGA, glycolide possesses a greater 
reactivity with regards to ROP therefore it is likely that large segments of the polymer chain 
will comprise of glycolide blocks, however protocols have been explored to prevent this.32–34 
Hoye and co-workers, studied methods to control the statistical addition of lactide and 
glycolide monomers to the polymer chain during propagation.34 It was found that the 
implementation of a semi-batch polymerisation involving the continuous addition of glycolide 
to the polymerisation mixture at a rate that mitigated the increased reactivity of the monomer 
resulted in the ability to control the monomer sequence within the polymer.34  The most 
significant advantage to this method is the ease in the ability to vary polymer composition 
within the reaction allowing tailoring of the resulting polymer properties. The properties of 
PLGA can be tuned by varying the lactide to glycolide ratio in the final polymer composition. 
PLGA polymers which are rich in lactide often have more hydrophobic character than glycolide 
rich counterparts leading to slow degradation times.32,33 Nonetheless, these effects cannot be 
readily predicted from the feedstock monomer ratio within the reaction mixture; this is most 
clearly demonstrated by the disappearance of crystallinity in PLGA co-polymers despite 
poly(glycolide) being highly crystalline.32 
Alternatively, the simultaneous polymerisation of dicyano-substituted ε-CL by Pahovnik and 
co-workers yielded statistical co-polymers with ε-CL confirmed by 1H and 13C nuclear 
magnetic resonance, NMR.35 A difference in reactivity of the monomers was controlled by the 
use of a solvent system in which the more reactive monomer was only partially soluble, thereby 
minimising monomer concentration in the reaction mixture. 13C NMR also revealed that like 
to like monomer interactions were slightly more favourable which would indicate more zonal 
or gradient type co-polymerisation.35  
Although significantly less common in the literature, examples of gradient co-polymers have 
been achieved relying on the differing reactivity of the monomers inducing a composition shift 
as the polymerisation proceeds.36  The co-polymerisation of caprolactone and lactide 
highlighted that the monomer’s reactivity within the co-polymerisation differ from each other 





preferably polymerised.37 This difference in reactivity would suggest that the synthesis of 
gradient co-polymers predominate; however, due to the presence of transesterification 
reactions, statistical co-polymers are achieved.37,38 The successful synthesis of gradient co-
polymers has been achieved with -valerolactone, VL, and ε-caprolactone utilising 
organocatalysed ROP in the presence of 1,3-diethyl-4,5-dimethylimidiazol-2-ylidene.38,39 
Here, Shin et al. confirmed the gradient structure of the co-polymers by 13C NMR, indicating 
larger fractions of CL-CL and VL-VL bonds within the polymer structures and the difference 
inferred in the thermal properties of the resultant polymers.39 The study of the thermal 
properties highlighted the advantages of accessing a number of different co-polymer structures 
as the melting point of gradient co-polymers was lower than that of the block co-polymer 
analogue but higher than the statistical co-polymer.38,39 These structures are also considered a 
cheaper alternative to block co-polymers, removing the need for purification of the separate 
polymer chains before complete synthesis of the co-polymer structure.36 Combined with recent 
advances in the use of vinyl gradient co-polymers in polymeric micelles, the area of co-
polymerisation is expected to continue to grow over the coming years.36 
2.1.2.2 Variation of polymer architecture – branching of polyesters via ROP 
Variation in polymer architecture, often along with the formation of high molecular weight 
polymers, may be achieved by the linking of primary polymer chains and the creation of 
branching. The synthesis of branched polymers, and the components used within them, allows 
for the tuning of numerous physicochemical properties such as rate of degradability, lower 
viscosities and improved nanoparticle formation coupled with additional functionality that can 
be gained from the large number of chain ends.40–43 There are several routes to achieve 
branched architectures in polyesters, with both ROP and polycondensation techniques yielding 
such polymers. In all cases, the polymerisations achieve a higher number of chain ends within 
each macromolecule, and such branching generally requires more simplistic, less time 
consuming syntheses than those used for perfect dendritic branching.40,44–46 Although there is 
a significant body of literature concerning the polycondensation of monomers such as 
2-bis(methylol)propionic acid, bis-MPA, to form branched polyesters, the use of ROP allows 
for the controlled production of branched polymers using lactone monomers, such as PCL and 
PLA, with potentially high molecular weight.43,47 Several ROP methods have been reported 
that yield particular branched architectures such as graft, star, dendritic and hyperbranched 







Figure 2.3- Representation of the types of branched architectures resulting from ROP 
methods; (A) graft co-polymers, (B) star polymers, (C) dendritic polymers and (D) hyperbranched co-
polymers. 
Graft and star branched architectures commonly require the use of polymeric macroinitiators 
or post-functionalisation of polymer chains via click chemistry to achieve their unique 
structures (Figure 2.3, A & B).48 Graft co-polymers commonly are a form of branched co-
polymer that employ multifunctional macroinitiators to allow the growth of polymers from 
numerous functional sites either randomly or equally spaced along the macroinitiator polymer 
chain.43 There are three methods to achieve this architecture which have all been explored with 
ROP of cyclic lactones (Figure 2.4). For example, PLGA has been ‘grafted onto’ poly(vinyl 
alcohol), PVA, chains through the conversion of hydroxyl terminal groups to carboxylic acid 
groups which could subsequently be used to graft onto PVA polymer chains before further 





architecture has recently been explored by the grafting of PEG chains onto a co-polymer of 
caprolactone and 3,3-bis(chloromethyl)oxacyclobutane via a Janus polymerisation**** in the 
presence of propylene oxide.50 ‘Grafting from’, another common method, involves the 
polymerisation of monomers from initiating points along a polymer backbone (Figure 2.4, B). 
This has been demonstrated by Shang et al., where α-chloro-ε-CL was co-polymerised with 
ε-CL from PEG macroinitiators then reacted together to form a tri-block polymer backbone 
with pendant chlorine groups. Subsequently the ATRP of 2-(2-methoxy ethoxy)ethyl 
methacrylate and oligoethylene glycol methyl methacrylate from these pendant groups yielded 
a graft co-polymer which, following azide end-functionalisation and click-reactions with a 
cross linker, possessed the ability to form hydrogels.51 Alternatively, Kissel and co-workers 
successfully polymerised lactide and glycolide via Sn(Oct)2 catalysed ROP from OH groups 
along a PVA chain producing polymers with number averaged molecular weight, Mn, values 
between 5000 and 30,000 g mol-1; these materials were capable of being tuned for slow 
degradation using additional sulfonate modification.52 Finally, ‘grafting through’ presents an 
alternative route to branched co-polymer architectures; this strategy involves the 
(co)polymerisation of macromonomers (Figure 2.4, C), commonly short polyester chains 
functionalised by a vinyl monomer containing an hydroxyl functional group in order to 
synthesise a polymer backbone, such as N-(2-hydroxypropyl)methacrylamide.43,53 This results 
in branched architecture often referred to as ‘comb’ polymers which can self-assemble to form 
micelles and other nanostructures.43,48,53 
                                                          
**** Janus polymerisation is a variation of ROP in which anionic and cationic polymerisations are combined at the 





Figure 2.4 – Representation of the routes to achieve graft co-polymers; (A) ‘grafting onto’, 
(B) ‘grafting from’ and (C) ‘grafting through’; arrows showing propagation of polymer chain with 
addition of the, (black) first, (blue) second, (red) third and (purple) fourth, monomer in polymerisation 
sequence. 
Star polymers have a single point of branching at the centre of the structure that is surrounded 
by linear polymer chains. High molecular weight star polymers can be achieved via two routes, 
either ‘core-first’ or ‘arm-first’ (Figure 2.5).43,47,48 Core-first begins with the ROP of a lactone 
monomer initiated by a chosen polyol to give hydrophobic linear arms extending from the core 
which can then be functionalised by a hydrophilic polymer such as PEG.48 The degree of 
branching within these structures is determined by the number of alcohol groups present in the 
core polyol.48 Variation has been created with this method by both post-functionalising PCL 
chain ends and utilising macromolecules such as cyclodextrin as a core molecule.43 Conversion 
of PCL hydroxyl end groups to thiols successfully allowed the growth of 
N-(2-hydroxypropyl)methacrylamide to act as the hydrophilic block within amphiphilic star 





allow for the creation of miktoarm†††† Janus star polymers with both PCL and PEG polymers 
originated from the cyclodextrin core which was shown to prolong drug release.43,55  
Figure 2.5 – Two synthesis routes to star polymers; (A) core-first and (B) arm-first: (i) coupling 
to a singular multi-functional molecule and (ii) polymerisation of highly branched core initiated by arm 
segments; arrows showing propagation of polymer chain with addition of the, (black) first, (blue) 
second, (red) third and (purple) fourth, monomer in polymerisation sequence. 
Arm-first synthesis of star polymers often has poor coupling between the arm and core sections 
due to steric hindrance therefore it has become more common to see highly branched cross-
linked cores within star polymers made via an arm-first strategy.43,48 This route removes the 
requirement for precise reactions to a single multi-armed molecule to gain the desired star 
architecture (Figure 2.5, B i).43 MSA has been used as a catalyst in the synthesis of such 
branched structures by exploiting 4,4’-bioxepanyl-7,7’-dione, BOD, as a bis-lactone to achieve 
                                                          
†††† Miktoarm star polymers refer to star polymers that have arms of varying chemical nature, for example arms 





star co-polymers with a cross-linked core and linear PCL arms (Figure 2.6).10,56 Despite 
previous reports of such structures being synthesised using Sn(Oct)2, MSA was shown to be a 
viable catalyst for the polymerisation of both the PCL arm macroinitiators and subsequent 
cross-linked BOD core.10,56 Ren et al. explored the use of MSA in the synthesis of star co-
polymers, derived from PCL and BOD, in both one and two-pot reactions and showed that both 
methods produced polymers at faster rates and lower dispersities when compared to similar 
reactions using Sn(Oct)2.
10,56 Here, BOD is used as the sole monomer within the second 
polymerisation allowing for the synthesis of a highly cross-linked core in the star polymer to 
produce molecular weight values between 9,900 and 36,200 g mol-1.56 This method was also 
shown to produce higher star purity than polymers synthesised using traditional tin-based 
catalysts.56 
Figure 2.6 - Representation of ‘arm first’ star polymer synthesis detailed by Ren et al.; 
(A) ROP of ε-CL resulting in linear ‘arm’ macroinitiators followed by (B) ROP of BOD resulting in a 
highly branched cross linked core;56 arrows showing propagation of polymer chain with addition of the, 
(black) first, (blue) second, (red) third and (purple) fourth, monomer in polymerisation sequence. 
Dendritic-like branched architectures are common within the literature, being created via ring 
opening multi-branching polymerisation, ROMBP, also referred to as self-condensing ring 
opening polymerisation, SCROP. Based on the concept of self-condensing vinyl 
polymerisation, SCVP, latent AB2 monomers, referred to as inimers, are polymerised to give 
polymers with branched architecture and increased terminal functionality towards the 
periphery of the polymers.43–45,47,57,58 Inimers, frequently hydroxyl functionalised cyclic 
monomers, are capable of acting as both a monomer and initiating species allowing branching 
points to be created as the polymerisation progresses, and generating highly branched 
architecture from a single origin point.43,47,59 The study of this method of polymerisation 
originated with both cyclic ester monomers, namely 4-(2-hydroxyethyl)-ε-caprolactone, being 





co-workers.45,60 Considering 4-(2-hydroxyethyl)-ε-caprolactone as an example, Sn(Oct)2 
catalysed SCROP yielded polymers with Mn values between 65,000-85,000 g mol
-1 and 
analysis indicated that the structure produced consisted of three structural units (linear, 
dendritic and terminal groups) that are consistent with conventional ABn branching (Figure 
2.7).45 Since these first reports, this method has been further explored with a range of 
monomers, for example the latent AB3-like bis(hydroxymethyl)-substituted-ε-caprolactone and 
a number of different catalysts such as Lewis acids.43,47,58,61–64 Additionally, the methodology 
has been refined to enable the polymerisation of more well defined dendritic polymers with 
lower dispersity values by utilising a slow monomer addition technique.59,62,65  
Figure 2.7 – Dendritic branched polymer based on 4-(2-hydroxyethyl)-ε-caprolactone; 
indicating (i) linear, (ii) dendritic and (iii) terminal units.  
Finally, soluble hyperbranched architectures can be achieved by the implementation of a 
modified ‘Strathclyde route’. This is a one pot synthesis which is an adaptation of the 
Strathclyde method developed by Sherrington and co-workers in 2000 using free radical 
polymerisation of mono- and di-vinyl monomers in the presence of a chain transfer agent.40,46,66 
The method was subsequently referred to as the ‘modified Strathclyde method’ when it was 
applied to controlled radical polymerisation techniques such as ATRP and reversible addition-
fragmentation chain-transfer polymerisation, RAFT, where control in radical concentration 
regulated the primary chain length and number of branching points per chain to prevent 
gelation.40 The basis of this method is the statistical co-polymerisation of a bifunctional 
monomer and monofunctional monomer under standard polymerisation conditions.40,46 When 
employing the ‘modified Strathclyde method’, the polymerisation can be split into 3 separate 





polymerisations, all polymer chains grow and propagate under identical conditions and near-
identical rates. Additionally, Flory-Stockmayer theory suggests that as long as the 
incorporation of a bi-functional monomer is controlled to less than one per polymer chain, the 
product will not gel.68 Finally, at the latter stage of the polymerisation and high monomer 
conversion polymer chains start to form branched architectures through intermolecular 
reactions, leading to a high molecular weight soluble polymer. (Figure 2.8).67 
Figure 2.8 – Representation of the evoluition of branching from the application of a 
modified ‘Strathclyde route’ to hyperbranched polymers to ROP. 
Amongst other researchers, the Rannard group has shown the versatility of the ‘modified 
Strathclyde method’, implementing it in numerous radical polymerisations to yield branched 
architectures that include polymethacrylates, such as poly(butyl methacrylate) and 
poly(2-hydroxypropyl methacrylate) and poly(oligo(ethyleneglycol) methacrylate).69–73 
Furthermore this method has allowed the introduction of a new polymer architecture, 
hyperbranched polydendrons, a unique structure that combines the segmental nature of block 
co-polymers, surface functionality opportunities of dendrons and branched architecture into a 
single macromolecule.70,72,74 Consequently these polymers have then been studied in a number 
of applications that have demonstrated the advantages that can be drawn from such 
architecture.71,72 Hatton et al. showed, by the isolation of highly branched, high molecular 





be influenced significantly and the resulting nanoparticles could be tuned in size and 
stability.41,75  
Literature regarding the application of a ‘modified Strathclyde method’ to ROP, however, is 
lacking with only a few papers reporting the combination of a cyclic ester with bis-lactone. 
Bulk ROP of caprolactone with bis-lactone BOD was initially reported by Nguyen et al. 
utilising a Sn(Oct)2 catalyst which yielded polymers of molecular weights above 
30,000 g mol-1.42 Researchers showed that, unlike controlled radical polymerisations where 
molecular weight rapidly increases at ~ 70 % monomer conversion due to the linking of linear 
chains, tin catalysed ROP showed a similar behaviour at ~90 % monomer conversion.42 This 
was hypothesised to be due to the steric hindrance induced by the incorporation of BOD into 
the polymeric species. Once incorporated, the significant steric bulk of the pendant CL group 
would be likely to impede catalyst coordination, and favour activation of free mono-functional 
ε-CL; at high monomer conversions, coordination to the pendant CL rings of the BOD groups 
would encourage intermolecular reactions and subsequent branching.42  
Nonetheless, literature within this area of branched polyesters is lacking with significantly less 
publications than star, graft and dendritic architectures, inviting the exploration of avenues into 
this area of study. When coupled to the lack of investigation into the synthesis of all branched 
architecture types, in particular highly branched soluble polymers via a ‘modified Strathclyde 
routes’, organocatalysed ROP, investigation into this area could bring additional advantages. 
2.1.3 Chapter aims 
This chapter aims to lay foundations for the work to be addressed in following chapters, 
providing information in key ideas and concepts that have either been previously explored in a 
limited fashion or yet to be investigated. Given the variety of branched architectures that has 
been achieved with polyesters, yet the lack of exploration implementing a ‘modified 
Strathclyde method’, this work aims to further develop the area. Furthermore, although co-
polymers again have been widely explored, particularly with PEG, amphiphilic branched co-
polyesters within literature have only been obtained via star and graft co-polymer structures. It 
is hypothesised that, given the advantages and variety of physicochemical properties that are 
made available by a high level of branching and presence of separate hydrophobic and 
hydrophilic segments, structures achieved via a ‘modified Strathclyde method’ will be 
instrumental in future chapters. The implementation of MSA catalysed ROP, and the inclusion 





catalysed routes (Figure 2.9). Although polymerisation studies are expected to begin with ε-
caprolactone, development of a number of substituted caprolactone monomers, SCM, are 
theorised to allow for the tuning of the resulting polyester properties, such as Tg, crystallinity 
and hydrophobicity (Figure 2.9, B). Therefore this chapter ultimately aims to study the 
synthesis of a range of new branched polyesters and their resulting properties. 
Figure 2.9 – Representation of the aims of this chapter; (A) synthesis of a library of polymers 
of varying architecture based on ε-caprolactone and (B) implementation of a variety of substituted 
caprolactone monomers in these syntheses. 
 2.2 Synthesis of substituted caprolactone monomers via Baeyer-Villiger 
oxidation 
As detailed in Section 1.5, there has been an absence of studies in the literature of polymers 
made by simple modifications to the caprolactone monomer ring, and the effects these have on 
the properties of polymers that would result from their polymerisation. As mentioned 
previously, one aim of this research was to study the effects of backbone substitution, using 
various pendant groups, on the physiochemical properties of the resulting polymers. As part of 
this study, the viability of substituted monomers in the production of polymers of varying 
architecture via MSA catalysed ROP was also important to understand. The use of substituted 
monomers within branched architecture is ultimately hypothesised to yield control of 
nanoparticle formation and guest molecule encapsulation and release (Section 1.6). 
The selection of substituted caprolactone monomer structures targeted for this study was aided 
by a review of commercially available cyclic ketone precursors that may be utilised in the well-






Scheme 2.3 – Scheme representing the synthesis of substituted caprolactone monomers 
via Baeyer-Villiger oxidation.  
Four commercially available cyclic ketones were selected due to their chemical diversity and 
the potential for the substituted groups to impact the resulting polymer glass transition 
temperature and crystallinity. Two target monomers aimed to introduce straight chain methyl 
and propyl substituents, analogous to varying side-chain lengths within vinyl polymers that 
would be expected to lead to a decrease in glass transition temperature.79,80 The introduction of 
a tert-butyl substituent was also selected to increase glass transition temperature, drawing upon 
the analogy of the impact of moving from n-butyl side chains to t-butyl side chains, within 
(meth)acrylate structures; whilst the addition of an aromatic pendant group was expected to 
introduce the potential for π-π stacking between chains or between chains and guest 
molecules.79–81 In summary, the target substituted caprolactone monomers were 5-
methyloxepan-2-one, MOP, 5-propyloxepan-2-one, POP, 5-(tert-butyl)oxepan-2-one, BOP 





Figure 2.10 – Molecular structures of substituted caprolactone monomers produced from 
cyclic ketones; (A) 4-methylcyclohexanone, (B) 4-propylcyclohexanone, (C) 4-(tert-
butyl)cyclohexanone, (D) 4-phenylcyclohexanone and (E) bicyclohexanone Producing (F) 5-
methyloxepan-2-one, MOP, (G) 5-propyloxepan-2-one, POP, (H) 5-(tert-butyl)oxepan-2-one, BOP, (I) 
5-phenyloxepan-2-one, PHLOP and (J) 4,4’-bioxepanyl-7,7’-dione, BOD. 
The target monomers all possess substitution at position 5 on the ring for consistency and to 
minimise any potential for steric hindrance in the activated monomer mechanism during ROP. 
In addition to the four new substituted caprolactone monomers, a bi-functional ketone, 
bicyclohexanone, allowed the production of bis-lactone, BOD, for the synthesis of polyesters 
with branched architecture (Figure 2.10, J).  
Baeyer-Villiger oxidation allows the addition of an oxygen atom into a C-C bond adjacent to 
a C=O ketone bond, and relies upon the cleavage of a O-O bond commonly within peroxide or 
peroxy-acid reagents.76–78 When using a cyclic ketone, for example a 6-membered ring, the 
migration of the oxygen atom from the O-O bond produces a 7-membered ring ester (a lactone). 
The four substituted caprolactone monomers were readily achieved using the same method of 
Baeyer-Villiger oxidation, detailed by Nguyen et al. to achieve BOD, where a reactive peroxy-





resulting formate subsequently reacts with hydrogen peroxide to form the peroxy-acid (Scheme 
2.3, A). Upon the addition of the selected ketone, nucleophilic attack proceeds by the migration 
of oxygen from the O-O bond within the peroxy-acid into the cyclic ring yielded the desired 
lactone (Scheme 2.3, B).76–78 
Optimisation of the reported reaction conditions was achieved by extending the reaction time 
of the cyclic ketone with the peroxy-acid from 2 to 24 hours. This allowed the reaction to 
proceed to completion and considerably reduced the amount of unreacted ketone to be removed 
from the products. The equivalents of reactants used gave a 3:1 molar ratio of peroxy-acid to 
ketone for the oxygen migration step (assuming the complete reaction of all UHP), also 
promoting the production of the cyclic ester. Water was added to quench the reaction after 24 
hours, to decompose the remaining peroxy-acid to the starting formic acid and UHP, hence 
enabling safe purification in the absence of large concentrations of residual peroxy-acid. A 
simple water-chloroform extraction allowed the removal of any remaining peroxy-acid and the 
excess formic acid and UHP into the aqueous phase and the concentration of the product 
lactone with the chloroform layer. After the final washes with saturated sodium bicarbonate 
solution, thin layer chromatography, TLC, analysis showed the presence of residual formic acid 
and each starting cyclic ketone (Rf values 0 (formic acid) and between 0.46 and 0.84 (cyclic 
ketones) Section 6.3.1.1) along with the desired final products (Rf values MOP = 0.20, POP = 
0.25, BOP = 0.33, PHLOP =0.15). These impurities were removed by column chromatography 
with a solvent mixture of ethyl acetate:hexane (25:75). Achieving high purity was necessary to 
allow for accurate targeted degrees of polymerisation (via monomer mass) and, in the case of 
BOD, which had previously been used without purification by column chromatography, the 
addition of accurate equivalents to avoid gelation during ROP; removal of formic acid was also 
essential to eliminate any interference with MSA used as the polymerisation catalyst. This 
procedure was followed for all the monomers; reactions for MOP, POP, BOP and PHLOP were 
conducted on a 15 g scale (3 x 5 g scales to work safely with the peroxy-acid) which resulted 
in recovered yields of: MOP = 56.3 %, POP = 39.8 %, BOP = 63.3 % and PHLOP = 64.8 %. 
BOD synthesis was carried out on a 5 g scale and resulted in a recovered yield of 62 %.  
Analysis of all monomers was achieved by 1H NMR, 13C NMR and chemical ionisation mass 
spectrometry, MS. For all substituted caprolactone monomers, the presence of the ester group 
was confirmed by a number of hydrogen and carbon environments within the NMR spectra; 
these environments and chemical shifts correlated with caprolactone NMR spectra (Appendix, 





multiplet splitting and could be assigned to the CH2 group next to the C-O ester bond within 
the cyclic newly formed lactone ring; MOP = 4.42 - 4.12 ppm (Figure 2.11, A, proton 
environment e), POP = 4.39 – 4.10 ppm (Figure 2.12, A, proton environment e), BOP = 4.46 
– 4.05 ppm (Figure 2.13, A, proton environment e), PHLOP = 4.43 – 4.23 ppm (Figure 2.14, 
A, proton environment e) and BOD = 4.22 ppm (Figure 2.15, A, proton environment e). 
The 13C NMR further confirmed the formation of the lactone ester group with peaks at 175-
176 and 68 ppm corresponding to the C=O ester carbonyl and the CH2 next to the ester oxygen 
in correlation with caprolactone (Appendix, Figure A1 & A2); MOP = 176.06 ppm and 
68.09 ppm (Figure 2.11, B, carbon environments a and f), POP = 176.14 ppm and 68.19 ppm 
(Figure 2.12, B, carbon environments a and f), BOP = 176.28 ppm and 68.63 ppm (Figure 2.13, 
B, carbon environments a and f), PHLOP = 175.72 ppm and 68.26 ppm (Figure 2.14, B, carbon 
environments a and f) and BOD = 175.38 ppm and 68.07 ppm (Figure 2.15, B, carbon 
environments a and f). Chemical ionisation MS in all cases had peaks corresponding to both 
the protonated ions, [MH+], and ammonium adducts, [MNH4
+]; [MH+] peaks generated for 
each monomer were, MOP = 129.1 Da (Figure 2.11, C), POP = 157.1 Da (Figure 2.12, C), 
BOP = 171.1 Da (Figure 2.13, C), PHLOP = 191.1 Da (Figure 2.14, C) and BOD = 227.1 Da 
(Figure 2.15, C).  Further confirmation of successful syntheses was provided by elemental 
analysis, CHN, which showed highly comparable measurements to the calculated percentages 





Figure 2.11 – Analysis undertaken to confirm structure of 5-methyloxepan-2-one, MOP; 





Figure 2.12 – Analysis undertaken to confirm structure of 5-propyloxepan-2-one, POP; 





Figure 2.13 – Analysis undertaken to confirm structure of 5-(tert-butyl)oxepan-2-one, 






Figure 2.14 – Analysis undertaken to confirm structure of 5-phenyloxepan-2-one, 






Figure 2.15 – Analysis undertaken to confirm structure of 4,4’-bioxepanyl-7,7’-dione, 






2.3 MSA catalysed ROP of ε-caprolactone 
The investigation of lactone polymerisations commenced with a comprehensive study of MSA-
catalysed ROP of commercially available ε-CL, to investigate previously reported findings by 
Gazeau-Bureau et al. which detailed the higher activity of MSA for ε-CL than the stronger acid 
TfOH.23 Furthermore, following success reported by Nguyen et al., it was hoped that by 
exploring the possibility of utilising MSA in co-polymerisation using  a ‘modified Strathclyde 
method’ variation in architecture may be achieved.42 Finally the incorporation of 
macroinitiators in MSA-catalysed co-polymerisations, again somewhat lacking in literature, 
was hypothesised to offer further insight into the capabilities of this type of ROP and help 
define reaction conditions.  
2.3.1 Linear polymerisation of ε-caprolactone via MSA catalysed ROP 
2.3.1.1 Benzyl alcohol initiated, MSA catalysed ROP of ε-caprolactone 
Homopolymerisation of ε-CL was investigated in a series of experiments where the number 
average degree of polymerisation, DPn, was increased from 10 to 200 monomer units. The 
reactions were carried out at 50 wt% in toluene at 30 °C and were initiated with benzyl alcohol, 
BzA (Scheme 2.4).  An argon atmosphere within the reaction vessel was utilised to reduce the 
possibility of water being introduced into the reaction and acting as an initiator. Upon addition 
of the MSA catalyst, at a molar ratio of 1:1 initiator: catalyst, homogeneous clear reaction 
mixtures were observed. 
Scheme 2.4 – Benzyl alcohol initiated MSA catalysed ROP of ε-caprolactone in toluene 
at 30 °C. 
Reaction times were increased by intervals of ca. 30 minutes per additional 10 monomer units 
to allow for the reactions to proceed to completion and ranged from 15 minutes to 9 hours for 
DPn 10 to 200. Termination of the reactions was achieved by the dilution of the reaction mixture 





short basic alumina filtration to remove the catalytic system an aliquot of the resulting liquid 
was taken for NMR analysis of the crude product. 
1H NMR determined that the reactions achieved high conversion with values >99% in all cases 
except PCL200 which only reached 44 % after 9 hours (Table 2.1). Triple detection size 
exclusion chromatography, SEC, in DMF/LiBr (0.01 M), showed an increase in the number 
average, Mn, and weight average, Mw, molecular weights ranging from 4,060 and 5,540 g mol
-1 
to 8,760 and 10,630 g mol-1 (Table 2.1) respectively for PCL30 to PCL100. Although reaction 
times spanned from only 15 minutes for PCL10 to 9 hours for PCL200 the dispersity, Đ, of each 
polymer fell within the range of 1.09 to 1.36 when analysed by SEC reiterating the high amount 
of control that can be achieved with this catalyst.23 Unfortunately, as the SEC instrument 
available had columns that were unable to accurately separate very low molecular weights from 
the solvent front, PCL10 and PCL20 were unable to be analysed by SEC. These low Đ values 
indicate that there are limited transesterification reactions occurring in this set of reactions, 
which is advantageous for the targeting of branched polymers using a high concentration of 
bis-lactone monomer as described in Section 2.3.1. Furthermore, as demonstrated by Gazeau-
Bureau et al., the control of these reaction, demonstrated by low Đ  values, correlates to the 
low pKa of MSA which reduces the deactivation of the initiating BzA which is direct 





Table 2.1 - Series of MSA catalysed ROP of ε-CL, initiated by benzyl alcohol, with varied degree of polymerisation 10 to 200 monomer 
units, normalised with dn/dc value 0.06044 (calculation given in Appendix (Table A1));  






DPI by NMR 
(Initiator)d 











PCL10 0.25 >99% 12 1,480 1,250 -f 
PCL20 0.66 >99% 21 2,510 2,390 -f 
PCL30 1 >99% 33 3,870 3,530 4,060 5,540 1.36 0.76 
PCL40 1.5 >99% 41 4,790 4,670 4,680 5,650 1.21 0.82 
PCL50 2 >99% 66 7,640 5,820 6,510 7,660 1.18 0.84 
PCL60 2.5 >99% 66 7,640 6,960 6,920 7,960 1.15 0.98 
PCL80 4 >99% 99 11,410 9,240 7,560 9,720 1.29 0.69 
PCL100 5 >99% 137 15,750 11,520 8,760 10,630 1.21 0.71 
PCL200 9 44 % 110 12,670 10,150 7,150 7,770 1.09 0.92 
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples and calculated using equation 1 in Appendix, b Calculated using the equation: Mntheory = 
(DPtargeted x conv. x MrCL) + MrBzA, c Determined by triple detection SEC with a mobile phase of DMF/LiBr 0.01 M (60 °C) at 1 mL min-1, d Calculated using 
the equation; DPI = (∫4.05/2 ÷ ∫5.1/2), e Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x MrCL) + MrBzA, f insufficient light scattering for calculation but 





SEC analysis also showed monomodal chromatograms for all polymers (Figure 2.16), with high 
molecular weight shoulders beginning to appear at the highest targeted DPn values. The ability 
to accurately control the polymerisation at low targeted DPn values, using MSA catalysed ROP, 
is important to understand to allow accurate design of branched polymers and avoid gelation. 
Therefore ideal branching is more likely to occur for polymers with a targeted DPn ≤ 50 for 
each linear chain linked together to allow for control of water impurity concentrations. 
Figure 2.16 - Refractive index, RI, detector output chromatograms of linear PCLx 
polymers (x = 10-100) generated by MSA catalysed ROP. Obtained by triple detection SEC; 












2.3.1.2 Poly(ethylene glycol)2K/5K initiated MSA catalysed ROP of ε-
caprolactone 
MSA catalysed ROP using a hydrophilic macroinitiator, in this case poly(ethylene glycol), 
PEG-OH, was studied to form amphiphilic A-B block co-polymers (Scheme 2.5). Two 
PEG-OH polymers of differing molecular weight were selected to allow for the exploration of 
the effect hydrophilic block length on nanoparticle formation. Mn values of 2000 g mol
-1, 
PEG2K-OH, and 5000 g mol
-1, PEG5K-OH, were selected to allow variation in amphiphilicity 
when the target DPn of the hydrophobic PCL block was maintained at 40 monomer units. 
Similar initiating conditions to those used for linear homo-polymerisations were utilised 
(initiator: catalyst ratio - 1:1 molar equivalents), however, the reaction dilution was increased 
to 33 wt%, with respect to monomer, using toluene heated to 50 °C to enable PEG-OH to 
completely dissolve.  
Scheme 2.5 – PEG-OH initiated MSA catalysed ROP of ε-CL in toluene at 50 °C. 
As seen with the BzA initiated linear homo-polymers, 1H NMR analysis showed both PEG-b-
PCL polymerisations reached >99% conversion (Table 2.2). This indicated that the use of a 
large macroinitiator does not retard the rate of polymerisation and supports the monomer 
activated mechanism, induced by the catalyst. The propagating polymer chain is surrounded by 
activated monomer species which decreases the impact of steric hindrance that is reported in 
classic chain end activated polymerisations where, as the polymerisation progresses and 










Table 2.2 - MSA catalysed ROP of ε-CL initiated by PEG-OH with Degree of 
Polymerisation 40 monomer units.  





Mn by NMR 
(Initiator) 










e 41 6,680 6,570 5,470 6,260 1.15 0.59 
PEG5K-b-PCL40
f 42 9,790 9,570 7,540 8,400 1.12 0.70 
PEG2K-OH - -
g 
PEG5K-OH - 4,970 5,250 1.06 0.76 
Both polymers reached > 99% monomer conversion following a reaction time of 2 hours; a Determined 
by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Calculated using the equation: Mntheory = 
(DPtargeted x conv. x MrCL) + MrBzA, c Determined by triple detection SEC with a mobile phase of 
DMF/LiBr 0.01 M (60 °C) at 1 mL min-1, d Calculated using the equation; DPI = (∫4.05/2 ÷ ∫3.36/2), e 
Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x MrCL) + MrBzA/PEG-OH, e dn/dc value 0.0588 used, 
f dn/dc value 0.0605 used, g insufficient light scattering for calculation but RI chromatograms indicated 
monomodal distribution 
Triple detection SEC analysis (DMF/ 0.01 M LiBr, 60 °C) was undertaken after purification, 
following the same catalyst removal as detailed in Section 2.3.1.1, and precipitation into cold 
hexane. Good control of the polymerisation was evident from this analysis, with monomodal 
and narrow molecular weight distributions for both PEG2K-b-PCL40 and PEG5K-b-PCL40; Đ 
1.12 and 1.15 respectively (Table 2.2), indicating good initiator efficiency. Refractive index, 
RI, chromatogram comparisons between the initial macroinitiators and the A-B block co-
polymers also showed an increase in molecular weight (Figure 2.17, A & B) and extension of 
the polymer chains with the new PCL40 blocks. Additionally, comparative overlays of 
chromatograms of PEG2K-b-PCL40 and PEG5K-b-PCL40 highlights the different molecular 
weights of the final block co-polymers, derived from either the PEG2K-OH or larger PEG5K-
OH blocks (Figure 2.17, C). However there was seen to be small discrepancies between the 
between theoretical (by 1H NMR) and calculated (by SEC) Mn values with the SEC given Mn 
values being lower than expected when Mn was calculated based the initiator proton 





Figure 2.17 - Refractive index, RI, detector output chromatograms of PEGx-b-PCL40, 
obtained by MSA catalysed ROP, overlaid with the corresponding PEGx-OH 
macroinitiator; A) PEG2K-b-PCL40 (black, solid) overlaid with PEG2K-OH (blue, dashed); B) PEG5K-
b-PCL40 overlaid with PEG5K-OH (red, dashed) and C) PEG2K-b-PCL40 (blue) overlaid with PEG5K-b-





2.3.2 Mechanistic studies of linear polymerisation of ε-caprolactone via MSA 
catalysed ROP 
As MSA catalysed ROP provides a fast synthetic route to controlled polymers and given the 
favourable reaction conditions when compared to traditional metal catalysed ROP routes 
polymerisations of ε-CL were undertaken with commercial scale up in mind. Therefore 
stringent anhydrous conditions were not followed throughout the investigations detailed in this 
chapter. However the implementation of less stringent conditions can lead to a number of 
complications which could affect the success of this ROP route in a commercial setting. Firstly 
the speed of the polymerisation could be affected by the lack of strict anhydrous conditions 
which also generates potential for opportunistic initiation of polymer chains (possibly by 
water). Finally the possibility of side reactions, such as transesterification, could affect the 
controlled nature of the resultant polymers therefore mechanistic studies were undertaken to 
explore these concerns. 
2.3.2.1 Kinetic studies of linear MSA catalysed ROP of ε-caprolactone 
initiated by benzyl alcohol 
In order to fully understand the role MSA plays in the polymerisation of ε-CL detailed kinetic 
studies were conducted. These were also useful as a comparison for kinetics later performed on 
the branched PCL polymers giving insight into how the introduction of a bis-lactone monomer 
affects the kinetics of the polymerisation. This study was performed with a molar ratio of BzA: 
ε-CL set to 1:40 monomer units, therefore targeting PCL40, and was conducted in the same 
fashion as the standard linear polymerisations and left to react over 1.5 hours before 
termination. Samples were initially taken every 5 minutes after the addition of MSA for the first 
30 minutes, and then every 10 minutes until 1.5 hours was reached; the catalyst was removed 
using basic alumina as previously. The resulting crude samples were consequently analysed by 
1H NMR spectroscopy and SEC to determine the progression of monomer conversion and 
molecular weight as the reaction advanced. 
Upon the execution of initial kinetic studies, and subsequent 1H NMR analysis, it appeared that 
the basic alumina was removing excess unreacted monomer upon filtration, therefore, accurate 
monomer conversion values could not be deduced. In order to develop the best experimental 
protocol, two acid neutralisation methods applied in parallel to a limited number of time points 





Firstly, rather than passing the samples through a small basic alumina column, a small amount 
of basic alumina was instead added to each sample after first dissolving the aliquot from the 
reaction in chloroform; a simple filtration was then used to remove the solid alumina. Secondly, 
triethylamine, TEA, was dissolved in toluene and added to each sample aliquot at an equimolar 
concentration to the MSA; a simple filtration was utilised to remove the solid salt precipitate. 
The samples were analysed by 1H NMR to determine monomer conversions for each sample 
removed during the polymerisation. Importantly, monomer conversion appeared to not follow 
any consistent trend between time points when the samples were treated with basic alumina, 
but the conversion data generated from samples treated with TEA followed a clear trend during 
the polymerisation (Figure 2.18).  
Figure 2.18- Semi-log plot vs time of PCL40 synthesis drawing comparisons between acid 
neutralisation techniques for kinetic analysis studies calculated by 1H NMR in CDCl3. (A) 
TEA neutralisation (●) against basic alumina (Δ) with best fit line fitted to TEA time points excluding 
t90 as t60 = t90, r2 = 0.9952. 
This preliminary model reaction indicated that 91.5 % monomer conversion had been reached 





MSA addition up to a reaction time of 30 minutes, and additional samples taken every 5 until 
1.5 hours. Analysis of samples taken in the first 30 minutes by 1H NMR showed that the 
polymerisation had achieved 17.8 % conversion after just 3 minutes with 99 % conversion being 
surpassed at 27 minutes. Analysis of all the time points after t27 showed a consistent plateau at 
> 99 % conversion. Consequently, kinetics plots were constructed using 1H NMR analysis from 
time points t0 to t30 at which point 99.9 % conversion was indicated (Figure 2.19). The first 
order integration law was applied to the data to plot ln([M]0/[M]t) versus time (Figure 2.19, A) 
where [M]0 is the monomer concentration at t0 and [M]t is the monomer concentration at a 
specific time. In contrast to the linear relationship expected between ln([M]0/[M]t) and time, an 
upward curve trending to an increased rate with increased time was observed with a regression 
of only r2 = 0.8485 (Figure 2.19, A). Literature illustrates that the use of acid catalysts in ROP 
does in fact follow first order kinetics, particularly in the case of lactide polymerisation; 
however, the polymerisation proceeding by an activated monomer mechanism adds an extra 





Figure 2.19- Analysis for kinetic study of PCL40 synthesis completed with TEA acid 
neutralisation, between 0 to 30 minutes (when full monomer conversion reached- 
calculated by 1H NMR in CDCl3). (A) semi-log plot from 0 – 99.9 % conversion (t0 to t30) calculated 
by 1H NMR in CDCl3, (B) evolution of molecular weight with conversion calculated by 1H NMR in 
CDCl3 and RI detection SEC (DMF/LiBr 0.01 M at 1 mL min-1 w.r.t to poly(methyl methacrylate, 
PMMA, calibrants), (C) overlay of RI traces from 17.8 – 99.9 % conversion (t3 to t30) using RI detection, 





Considering first order rate equations seen for other “controlled/living” polymerisations a 
common feature is the rate dependence on the concentration of monomer and radicals where 





•]                                      Equation 2.1 
Where [M] is monomer concentration, kp is the propagation constant and [R
•] is the 
concentration of radicals.84 Therefore as the polymerisation proceeds and monomer 
concentrations decrease plotting ln([M]0/[M]t) versus time yields a linear relationship. On the 
other hand, the propagation in an activated monomer mechanism involves reactions between a 





= 𝑘[𝐻 − 𝑀+][𝑂𝐻]                                Equation 2.2 
where [H-M+] is the concentration of protonated monomer, [OH] is the concentration of OH 
groups and k is a rate constant. Moreover the concentration of protonated monomer and its 
proportionality to the overall monomer concentration is determined by the basicity of the 
unreacted monomer and the monomer units in the polymer chain.37,83,85 
The inclusion of monomer concentration, [M], in the kinetic equation of propagation required 
the derivation of the term for the concentration of protonated monomer, [H-M+]. This must 
begin with the definition of the equilibrium constants of protonation for the OH groups, KOH, 
monomer, KM, and polymer, KP: 
𝐾𝑂𝐻 =  
[𝑂𝐻2]
[𝑂𝐻][𝐻+]
                                             Equation 2.3 
where [OH2] is the concentration of water and [H
+] is the concentration of protons.  
𝐾𝑀 =  
[𝐻−𝑀+]
[𝑀][𝐻+]
                                              Equation 2.4 
𝐾𝑃 =  
[𝐻−𝑃+]
[𝑃][𝐻+]
                                              Equation 2.5 
Where [H-P+] is the concentration protonated monomer units within the polymer chain and [P] 






The total concentration of protons, [H+], is defined as: 
[𝐻+] = [𝐻 − 𝑀+] + [𝐻 − 𝑃+] + [𝑂𝐻2]                    Equation 2.6 















          Equation 2.8 
Equation 2.8 can now be simplified (Eq. 2.9) and subsequently rearranged (Eq. 2.10): 




                     Equation 2.9 
 









                         Equation 2.10 
Therefore the term [H-M+] can be represented by the equation: 
[𝐻 − 𝑀+] =  𝐵[𝑀]                                  Equation 2.11 
𝑤ℎ𝑒𝑟𝑒 𝐵 =
[𝐻+]
{[𝑀] + [𝑃] (
𝐾𝑃
𝐾𝑀





Monomer concentration, [M], can now appear in the kinetic equation of propagation adapted 








= 𝑘𝐵[𝑂𝐻]𝑡                                   Equation 2.13 
  where [M]0 is the concentration of monomer at t0 and t is time. 
After considering equations 2.2 to 2.13 it is clear that the linear relationship between 
ln([M]0/[M]t) and time is dependent on the equilibrium constants of protonation for the 
monomer, monomer units in the polymer chain and the OH groups. [OH] remains constant 
throughout the reaction and KOH/KM can be assumed to also be constant and thus disregarded 





according to the equation [M] + [P] if Cste = [M]0,  the term B can only then be considered a 
constant when the ratio KP/KM is close to 1. 
The term KP/KM is dependent on the relative basicity of the unreacted monomer and the 
monomer units in the polymer chain.37 Lactide, for example, has similar basicity in both ring 
closed and open (polymerised) forms therefore protonation can be regarded as equally 
distributed between polymer chains and unreacted monomer at any given time.37,85 In this case 
KP/KM can be assumed to be close to 1 thus generating a linear relationship between 
ln([M]0/[M]t) and time. In contrast, ε-caprolactone has a significantly higher basicity as a closed 
ring, unreacted monomer, when compared to the open polymerised counterpart.37 At the 
beginning of the polymerisation the concentration of activated monomer, [M-H+], is in 
equilibrium with the concentration of free acid, [H+], and inactivated monomer, [M], (Equation 
2.4) defining a certain concentration of activated monomer. During propagation the number of 
polyester groups (open ring polymerised monomers), [P], increases. As the acid does not bind 
well to the ester groups within the polymer chain (i.e. KP is < 1), the effective concentration 
of acid in the equilibrium that is activating unreacted monomer, [H+], increases and therefore 
the effective concentration of activated monomer, [M-H+], increases. This means that, as the 
polymerisation progresses, and the growing polymer chain is less likely to become protonated, 
the amount of activated monomer per hydroxyl chain end increases.‡‡‡‡ This increases the 
probability of reaction and therefore the rate of polymerisation (Figure 2.19, B). KP/KM can 
now be considered as < 1 producing an upward curving plot in the semi-log graph as rate 
increases with time ([M] + (KP/KM)[P]  [M]0) (Figure 2.19, A). Figure 2.20 B shows a cartoon 
representation of the reaction assuming [H+] = [H-M+] (i.e. KM = 1). However due to the 
equilibrium between the free acid and protonated monomer, KM, (Equation 2.4) and the fact KM 
would be greater than 1, this process is likely to be more complex than the one depicted this 
figure.  
A plot of Mn vs monomer conversion, using SEC analysis, generated a linear relationship 
(Figure 2.19, B), indicating control of the polymerisation. However, when plotted with both Mn 
by NMR and Mn theory vs time plots it is clear that the gradient produced with Mn by SEC was 
significantly different from these plots. Additionally, the regression line for Mn by SEC failed 
to pass through the origin of the graph. This deviation in gradient and intercept is not 
                                                          
‡‡‡‡ This also suggests that transesterification reactions are kept at a minimum when monomer is present in the 





unexpected as SEC analyses are known to be inaccurate at relatively short chain lengths and 
the single detection SEC instrument used here was only fitted with oligomer column; 
additionally single detection analysis (RI in this case) relies on poly(methyl methacrylate), 
PMMA, calibrants to calculate molecular weight values. In this case, the RI chromatograms 
(Figure 2.19, C) for the early and late time points lay on the upward and downward curve of 
the cubic plot produced by the PMMA calibrants which again leads to inaccuracies within the 
calculations of molecular weight values. Nonetheless both Mn by SEC and Mn by NMR have a 
linear relationship with conversion confirming all chains are apparently growing at a similar 
rate and suggesting control of the polymerisation.84 The data here, and the strong indication of 
polymerisation control, indicates that the formation of branched polymer architectures using 
MSA-catalysed ROP should be possible using similar considerations to those previously 





Figure 2.20- Schematic representation of the effects differing basicity of unreacted 
monomer and polymerised monomer has on the rate of polymerisation (assuming all free 
acid (1 eq. per BzA) results in a protonated monomer, KM = 1). (A) Basicity of both species 
are similar therefore KP/KM ~ 1, (B) basicity of the unreacted monomer is much greater than the 
polymerised monomer therefore KP/KM ≪ 1. Insight into the reaction given at (i) 0 % monomer 
conversion, (ii) 50 % monomer conversion and (iii) 80 % monomer conversion. (Green circles) 
protonated monomer units, (dark pink circles) polymerised monomer units, (pink circles) unreacted 






2.3.2.2 Assessment of opportunistic side reactions present in linear MSA 
catalysed ROP of ε-caprolactone 
As mentioned in Section 2.3.2 stringent anhydrous conditions were avoided for MSA catalysed 
ROP to target a polymerisation more suitable for industrial scale up. ε-CL required the most 
labour intensive drying process, frequently distilled over calcium hydride, CaH2, at 92 °C, 
which also generated problematic waste disposal. Therefore a short study was undertaken to 
assess molecular sieves as an alternative drying method mitigating both waste disposal and 
distillation difficulties. Targeting a DPn = 40 monomer units and implementing the 
polymerisation method detailed in Section 2.3.1.1 PCL polymers were generated from ε-CL 
stocks either as received, dried over CaH2 or dried over molecular sieves (Table 2.3). Reaction 
times were extended to 2.5 hours in an attempt to emphasise any differences that may occur 
between the three reactions.  
Table 2.3 - Series of MSA catalysed ROP of ε-CL (DPn = 40 monomer units), initiated by 
benzyl alcohol, exploring the effects of monomer drying methods on polymer control; 



















Ð α dn/dc 
As purchased >99 % 41 4,790 4,670 5,020 5,350 1.07 0.78 0.0776 
CaH2 
distillation 
>99 % 42 4,900 4,670 5,320 5,930 1.12 0.87 0.0703 
Molecular 
sieves 
>99 % 44 5,130 4,670 5,320 5,580 1.05 0.77 0.0723 
Polymerisations undertaken at 30 °C for 2.5 hours; a Determined by 1H NMR (CDCl3, 400 MHz) of the 
crude samples, b Calculated using the equation: Mntheory = (DPtargeted x conv. x MrCL) + MrBzA, c 
Determined by triple detection SEC with a mobile phase of THF/ 2 v/v % TEA at 1 mL min-1, d 
Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x MrCL) + MrBzA/PEG-OH. 
1H-NMR analysis revealed that all three polymerisations reached >99 % monomer conversion 
suggesting that the polymerisation rate was unaffected by the lack of anhydrous monomer. 
Furthermore triple detection SEC (THF/ 2 v/v % TEA) revealed that all three polymers possess 
Mn values close to targeted and Đ ≤ 1.12 in all cases. Therefore, as molecular sieves was thought 
to diminish the concentration of water compared to the commercially available monomer this 





As this alteration of drying method was hypothesised to affect the water content in the reaction 
mixture, in turn decreasing the possibilities of opportunistic initiation by this species, the 
monomer mass was normalised and set, and the targeted DPn was increased by systematically 
decreasing the BzA mass. Therefore it could be stipulated that the concentration of water in a 
given mass of ε-CL would increase relative to BzA concentration with increasing DPn. The 
assessment of opportunistic initiation was assessed by studying 1H-NMR and triple detection 
SEC analysis of PCL polymers, determining the DPn values generated by different treatment of 
the analysis. Studies began with BzA initiated polymerisation and later expanded to include 





Table 2.4 - Series of MSA catalysed ROP of ε-CL, initiated by benzyl alcohol and PEG-OH, with varied degree of polymerisation 10 to 200 
monomer units, with extended 1H-NMR analysis; 














% of chains 
initiated by 
initiator 










PCL10 0.25 >99% 12 12 99 1,480 1,250 -g 
PCL20 0.66 >99% 21 20 94 2,510 2,390 -g 
PCL30 1 >99% 33 29 89 3,870 3,530 4,060 5,540 1.36 0.76 
PCL40 1.5 >99% 41 39 95 4,790 4,670 4,680 5,650 1.21 0.82 
PCL50 2 >99% 66 57 86 7,640 5,820 6,510 7,660 1.18 0.84 
PCL60 2.5 >99% 66 58 88 7,640 6,960 6,920 7,960 1.15 0.98 
PCL80 4 >99% 99 71 71 11,410 9,240 7,560 9,720 1.29 0.69 
PCL100 5 >99% 137 79 58 15,750 11,520 8,760 10,630 1.21 0.71 
PCL200 9 44 % 110 55 50 12,670 10,150 7,150 7,770 1.09 0.92 
PEG2K-b-PCL40e 2 >99% 41 38 93 6,680 6,570 5,470 6,260 1.15 0.59 
PEG5K-b-PCL40f 2 >99% 42 28 68 9,790 9,570 7,540 8,400 1.12 0.70 
BzA initiated PCL polymer normalised with dn/dc value 0.06044, a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Calculated using the 
equation: Mntheory = (DPtargeted x conv. x MrCL) + MrBzA, c Determined by triple detection SEC with a mobile phase of DMF/LiBr 0.01 M (60 °C) at 1 mL min-1, 
d Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x MrCL) + MrBzA/PEG-OH, e dn/dc value 0.0588 used, f dn/dc value 0.0605 used, g insufficient light scattering 





Firstly, 1H NMR analysis was used to determine the DPn of linear PCL polymers (Table 2.4) 
and draw comparisons between the DPn values obtained from either the proton environment 
located on the CH2 immediately prior the first ester functionality of polymer chain, directly 
associated with the initiating group, DPI, (Equation 2.14, Figure 2.21, environment b) or the 
DPn derived from utilising the proton environment directly adjacent to the hydroxyl chain end 
that terminates all polymers, DPOH (Equation 2.15, Figure 2.21, environment g). A strong 
correlation between these values would represent a lack of opportunistic initiation by impurities 









= 𝐷𝑃𝐼                                        Equation 2.14 
Where ∫Polymer is the integration of the last CH2 proton environment of the monomer repeat 
unit at 4.05 ppm (Figure 2.21, environment f); nHRU is the number of protons that correspond 
to this CH2 environment of each repeat unit, defined as environment f in Figure 2.21, known to 
be 2; ∫Initiator is the integration of the CH2 environment directly before the first ester bond 
within the polymer chain at 5.1 ppm (Figure 2.21, environment b) and nHI is the number of 
protons associated this CH2 environment of the initiating species defined as environment b in 






(∫ 𝐶ℎ𝑎𝑖𝑛 𝐸𝑛𝑑 (𝑂𝐻))
𝑛𝐻𝐶𝐸
)
= 𝐷𝑃𝑂𝐻                                   Equation 2.15 
Where ∫Chain End is the integration of the CH2 proton environment, of the last repeat unit, next 
to the terminal OH of the polymer (Figure 2.21, environment g) and nHCE is the number of 
protons associated with this CH2 environment of the last repeat unit defined as environment g 






Figure 2.21 – 1H NMR (CDCl3, 400 MHz) of purified PCL40; illustrating the polymer proton 
environments (4.05 ppm) and highlighting the peaks corresponding to the environments of the benzyl 
alcohol, BzA, initiator (5.1 ppm) and the chain end (3.6 ppm). 
Firstly concentrating on BzA initiated PCL polymer (Table 2.4), comparison of the DPI and 
DPOH values calculated from the different 
1H NMR end group analyses show a good correlation 
for chain lengths below a targeted DPn of 50 monomer units. This was also reflected by a good 
correlation between the Mn by NMR (based on DPI) and the Mn by SEC and indicates that BzA 
initiation efficiency of these reactions was high at chain lengths ≤ 50 monomer units. At higher 
DPn values (PCL50 to PCL100) significant discrepancies were seen between the Mn determined 
by NMR (based on DPI) and Mn values determined by SEC; this may suggest an increase in 
water impurity being introduced into the reaction vessel with increasing DPn.
87 This would lead 
to a larger number of OH chain ends within the polymer sample than would be expected, i.e. a 
BzA: OH molar ratio of < 1. 
Therefore, to further study the potential for co-initiation by water impurities, the values 
determined by using both Eq. 2.14 and Eq. 2.15 when analysing 1H NMR spectra from purified 
polymers (Figure 2.21) were more closely considered and a clear relationship could be seen 
between DPOH, DPI, the percentage of chains initiated by BzA (Equation 2.16) and the DPn of 
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Two illustrative examples are PCL40 and PCL100 (Table 2.4); both polymers achieved high 
conversion (>99 %), which provides confidence that unreacted monomer has not been lost in 
purification. Each polymer, however, has a very different comparison of DPI and target DPn 
values with PCL40 very closely matching the target.§§§§ In comparison, DPOH calculations for 
PCL40 and PCL100 yielded values of 39 and 79 monomer units; excellent control was, therefore, 
achieved at low targeted DPn values but this much lower DPOH value for PCL100 suggests a 
higher number of hydroxyl chain ends, than expected, which may be generated by initiation by 
water impurities. A greater understanding can be determined using Eq. 2.16. 
When the NMR analysis for PCL40 was applied to Eq. 2.16, where the integration of the CH2 
proton environment of BzA (Figure 2.21, environment b), ∫Initiator, was normalised to 2 and 
the integration of the CH2 proton environment next to the terminal OH of the polymer (Figure 
2.21, environment g), ∫Chain End, was calculated as 2.11, the percentage of chains initiated by 
BzA was calculated to be 94.8 % (Table 2.4). In contrast, an identical comparison for PCL100 
led to 1H NMR calculated values for ∫Initiator and ∫Chain End of 2 and 3.48 respectively, 
generating a percentage of BzA initiated chains of 57.5 %.  
Utilising SEC for the determination of DPn is not a highly accurate technique, however, analysis 
of the SEC data allowed a DPSEC value to be derived via Eq.2.17; where MnSEC is the Mn 
generated by SEC analysis, MrI is the molecular weight of the initiator and Mrmonomer is the 




= 𝐷𝑃𝑆𝐸𝐶                                     Equation 2.17 
A good correlation was obtained between DPSEC and calculated values of DPOH throughout the 
whole polymer series (Figure 2.22), illustrating that calculating DPOH allows relatively good 
representation of the polymer sample. Clearly, at DPn values < 50 monomer units, DPI 
calculated using Eq. 2.14 correlated well to DPSEC and also acts as a good representative value. 
 
                                                          
§§§§ A high DPI value signifies that the ratio of initiator to monomer units at 99 % conversion has decreased from 
the targeted DPn ratio added at the start of the polymerisation. This can be attributed to some initiator being lost 
during purification due to a lower number of chains initiated by BzA. Therefore, although Eq. 2.14 allows the 
number of chains initiated by BzA to be determined it does not account for any chains initiated by moisture, 





Figure 2.22 – Comparison of calculated DPn values for linear PCL polymers (targeted DPn 
– 30 to 100) by both 1H NMR and SEC; (●) DPn calculated by SEC (Eq. 2.4), (●) DPn calculated 
by 1H NMR and ∫Chain End (OH) (Eq. 2.2), (●) DPn calculated by 1H NMR and ∫Initiator (Eq. 2.1). 
Studies were continued with the assessment of opportunistic initiation in the PEGx-b-PCL40 co-
polymers synthesised in Section 2.3.1.2. As the targeted DPn was 40 monomer units it was 
expected that a good correlation of PCL chain length would be seen when comparing DPI 
(calculated by 1H NMR using the PEG initiating end group) and DPSEC, as seen with the linear 
polymers, synthesised in Section 2.3.1.1. The DPI and DPSEC values for the hydrophobic PCL 
block of PEG2K-b-PCL40 and PEG5K-b-PCL40 were calculated to be 41 and 30 or 42 and 22 
monomer units respectively indicating a potential initiation by water impurities within both 
samples (Table 2.3). Additionally further analysis of the purified polymers by 1H NMR gave 
DPOH (calculated using the CH2 proton environment directly preceding the OH functionality of 
the PCL block chain end) at the values of 38 monomer units for PEG2K-b-PCL40 and 28 for 
PEG5K-b-PCL40, further suggesting the presence of water impurity in the reaction mixtures. 
This could be associated with the difficulty in removing all water impurities, when using a 
vacuum oven, from the macroinitiators prior to polymerisation resulting in a deviation from the 
expected results based on BzA initiated PCL40. However it is important to note that the 
deviation in DPn values calculated by 





mass of macroinitiator added to the polymerisation due the nominal molecular weights of 2000 
and 5000 g mol-1 for these species. Therefore greater deviation of DPI from DPSEC for PEG5K-
b-PCL40 could be the result of two possibilities; there may more water impurity entrapped 
within the longer PEG chains or greater inaccurate measurements were made during the 
preparation of this polymerisation due to the lower concentration of hydroxyl end groups in 
PEG5K-OH and mixture of chain lengths within the sample. This, in turn, could either introduce 
further water impurity to the reaction or a number of lower molecular weight species due to the 
presence shorter initiating species in the PEG5K-OH sample, which could account for the small 
artefact in the RI chromatogram of the polymer. Even so the low Đ values for both polymers 
indicates the reaction is still highly controlled with good initiator efficiency and allows for 
accurate targeting of a chosen DPn.  
The ability to synthesise well-defined linear A-B block co-polymers with good control suggests 
that progression to attempting to synthesise amphiphilic branched architectures that are key to 
the study is justified using MSA catalysis. This also points towards a ROP method capable of 
challenging traditional tin-catalysed routes to allow a library of both homo and co-polymers of 
varying architecture to be produced. 
2.3.2.3 Analysis of the potential transesterification during linear MSA 
catalysed ROP of ε-caprolactone initiated by benzyl alcohol  
Further investigations of MSA catalysed ROP were undertaken to achieve a greater 
understanding of the polymerisation before proceeding to varying initiators, architectures or 
monomer structures. The potential for transesterification within linear polymerisations was 
studied to identify side reactions that may impact the control within the polymerisation.4 This 
was achieved by repeating the linear polymerisation targeting a DPn of 40 monomer units in 
toluene at 30 °C and sampling the reaction mixture at four time points. The first of these before 
catalyst addition, t0, to determine the experimental starting ratios of each reagent; the second, 
taken at 1.5 hours, t1.5, was previously shown to allow >99 % conversion for PCL40 (Table 2.5) 
and, finally, samples were taken at 24 hours, t24, and 48 hours, t48, after the polymer had reached 
full conversion (Table 2.5). The catalyst was removed from each sample using basic alumina 
before analysis was undertaken by 1H NMR and single detection SEC, equipped with an 
oligomer column, using a conventional calibration with PMMA calibrants with a mobile phase 
of DMF/LiBr 0.01 M at 60 °C with a flow rate of 1 mL min-1. The final polymer sample was 





pure 1H NMR and SEC samples subsequently analysed using the oligomer SEC equipment 
(Table 2.5).  
Table 2.5 - Experiment to determine the presence of transesterification reactions during 
MSA catalysed ROP of ε-caprolactone with a DPn of 40 monomer units. 
 1H NMRb  SECc 
Time point Monomer conversiona 
 
Mn (g mol-1) Mw (g mol-1) Ð α 
t1.5 >99%  5,070 6,220 1.23 0.7 
t24 >99%  7,770 11,520 1.48 0.7 
t48 >99% 
 7,100 11,030 1.55 0.7 
Polymer after precipitation  7,130 10,960 1.54 0.7 
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Calculated using the equation: 
Mntheory = (DPtargeted x conv. x MCL) + MBzA = 4,670 g mol-1 for all polymers, c Determined by single 
detection SEC with a mobile phase of DMF/LiBr 0.01 M at 1 mL min-1 w.r.t to poly(methyl 
methacrylate), PMMA, calibrants. 
As the polymerisation progressed passed 1.5 hours, having reached >99 % conversion as shown 
by 1H NMR, the viscosity of the polymerisation mixture appeared to increase with sampling 
becoming more difficult at latter time points. Although, this could not confirm the specific type 
of secondary reaction occurring (e.g. transesterification), it was an important observation to 
note. The NMR spectra generated from the pure material showed no change or no additional 
proton environments when compared to the material synthesised in Section 2.3.1.1 confirming 
that the observed viscosity change was not the result of any additional material.  SEC analysis 
indicated a dramatic increase in molecular weight between samples t1.5 and t24 which was clearly 
seen by a decrease in retention time of the molecular weight distribution, generated by the RI 





Figure 2.23 – Analysis of samples (at time points t1.5, t24, t48 and after purification) 
obtained during the linear MSA catalysed ROP of ε-caprolactone over 48 hours; refractive 
index, RI, detector output chromatograms of time points of PCL40 polymerisation, analysed utilising a 
single detection SEC, equipped with an oligomer column, w.r.t PMMA calibrants; Mobile phase: DMF/ 
0.01 M LiBr at 60 °C. 
Here it is important to note that the bimodal distribution***** generated by the RI detector, for 
the sample t1.5 was due to the increased resolution of the oligomer column used with the single 
detection SEC. This is in keeping with the appearance of a shoulder of PCL polymers of 
increasing DPn (from PCL40 to PCL100) analysed with a triple detection SEC in Section 2.3.1.1 
(Figure 2.16). The higher molecular weight fraction highlighted by the second environment at 
a lower retention time also suggests that transesterification could have occurred before t1.5. This 
coupled with the Mn and Mw values of 5,070 and 6,220 g mol
-1 for t1.5 and 7,770 and 11,520 g 
mol-1 for t24 respectively indicated that inter- and intramolecular reactions were occurring once 
full conversion had been reached causing a dramatic reorganisation and broadening of the 
molecular weight distribution. There is little literature on the subject of acid catalysed 
transesterification within MSA catalysed ROP; however, it is theorised that the presence of 
MSA in the reaction mixture is critical in this phenomenon. Once the polymerisation has 
                                                          
***** The bimodal distribution observed in Figure 2.23, B was hypothesised to be a result of transesterification 
reactions occurring between 30 minutes and 1.5 hours, after full conversion was reached following the lower Đ 
of the polymer at t30 compared to t90 in Section 2.3.2.1. This was supported by the appearance of a shoulder in 





reached >99 % monomer conversion, as there are no monomer molecules left that can be 
protonated/activated by MSA. Ester groups within the PCL chain are now protonated and are, 
subsequently, more susceptible to attack by the chain end hydroxyl groups.4 Following chain 
end attack and proton transfer the chain is cleaved, liberating two new PCL chains of differing 
length (Figure 2.24, A). Not only is it possible for one chain to cleave another but at the same 
time a single chain can cleave itself subsequently forming a new polymer chain and a cyclic 
polymer chain which now does not contain an initiating molecule (BzA in this case); (Figure 
2.24, B). Furthermore, as these multiple transesterification reactions increase as time 
progresses, the dispersity of the polymer sample will increase as some chains increase in length 
during coupling and other fragments of shorter chains are formed.  
Figure 2.24- Schematic representation of transesterification reaction between linear 
polymer chains following the attack of a chain end OH resulting in; (A) two new chains of 
differing DPn when chains initiated by BzA = 100 % and (B) cyclic polymers and chain of differing DPn 
when chains initiated by BzA = 100 %. 
Finally, only a small decrease in Mn and Mw values was observed between t24 and t48 (NB this 
could be due to the error inherent to SEC analysis). This indicates no significant change of the 
molecular weight distribution after 24 hours however this does not necessarily indicate that 
transesterification reactions had stopped. Most significantly the Đ values for t1.5, t24 and t48 





progressed, from 1.23 to 1.55, which further confirms the presence of excessive 
transesterification reactions between chains (Figure 2.23).   
In light of these observations, it is important to note that ROP does allow control of the 
polymerisation, allowing the targeting of a specific DPn and producing polymers with low Đ, 
(Section 2.3.1.1) as during propagation it is likely that the reaction with cyclic monomers is the 
dominant process. At high conversion, the decreasing unreacted monomer concentrations will 
lead to an increased likelihood of intramolecular transesterification reactions as MSA is more 
likely to protonate repeat units within the polymer chain (Scheme 2.6).4 This is a well-known 
phenomenon in polyesterification and also occurs in industrial linear polymerisations 
containing di-acid and diol mixtures.4,56,87,88 Preventative measures would allow 
transesterification reactions to be kept at a minimal level and this requires additional 
understanding of the kinetics of the ROP in question to terminate the polymerisation reaction 
closest to the time full monomer conversion is reached.  
Scheme 2.6 – Example of intermolecular transesterification of PCL chains resulting after 
high monomer conversion is reached.  
2.3.2.4 Overall outlook from mechanistic studies 
The mechanistic studies of MSA catalysed ROP of ε-CL revealed that although both 
opportunistic initiation and transesterification were present to some extent these phenomena 
should not be considered a significant problem for the targeting of highly branched PCL 
material via a modified ‘Strathclyde’ method. Opportunistic initiation was shown to be low 
when DPn <50 monomer units therefore initially targeting a DPn of 40 monomer units for 
branched architecture is hypothesised to mitigate this issue As DPn increases, more chains are 





the linking of most of the polymer chains during the polymerisation to achieve branched 
architecture.  
Transesterification can also be considered as not significant for the formation of branched 
architecture via MSA catalysed ROP for several reasons. Firstly polymerisations are to be 
terminated after 1.5 hours following results gained in Section 2.3.2.1 indicating full conversion 
was reached after 30 minutes therefore transesterification is expected to be low. Furthermore 
literature regarding the implementation of a modified ‘Strathclyde’ route to branched 
architecture with various polymerisation techniques reveal that branched architecture often 
occurs at higher monomer conversion > 50 %. Therefore transesterification could possibly help 
achieve higher molecular weight structures once high monomer conversion is reached and 
ultimately not greatly affect the average primary chain length within the structure (Figure 2.25). 
Figure 2.25- Representation of transesterification within a branched polymer species; 
altering the length of the primary chain however the average DPn of all the primary chains within the 
polymer remains constant. 
2.3.3 Statistical co-polymerisation of ε-caprolactone and BOD via MSA 
catalysed ROP to achieve branched architecture 
The synthesis of branched PCL structures have been achieved in literature via a number of 
methods as discussed in Section 2.1.2.2; however, achieving branched architectures via the 
combination of a modified “Strathclyde approach” using the bis-lactone molecule BOD and 
MSA catalysed ROP, is previously unexplored. Previous work has utilised BOD and Sn(Oct)2 
catalysed ROP; most literature mechanistic reports also utilise this catalyst although MSA 
catalysed reactions in DCM have been reported to produce cross-linked star polymers (however 





advantages of MSA catalysed ROP, especially that lack of residual metal catalyst in polymers 
targeted for pharmacological use, the ability to achieve branched architecture via this route was 
explored using commercially available ε-CL as the co-monomer.  
2.3.3.1 Benzyl alcohol initiated statistical co-polymerisation of ε-caprolactone 
and BOD via MSA catalysed ROP 
Polymerisations to explore the branching polymerisations using MSA catalysed ROP of BOD 
and ε-CL (Scheme 2.7) were initially set to a DPn of 40 monomer units for the primary chain 
length††††† and sought to establish conditions leading to gelation. The gelation point was 
determined by decreasing the molar ratio of BOD: BzA until a soluble branched polymer was 
produced. Unpublished research by Blackmore et al. showed that soluble branched PCL 
polymers could be produced with a BOD: initiator molar ratio of 1:1; the polymers showed Mn 
and Mw values of 13,400 and 332,600 g mol
-1 respectively when analysed by triple detection 
SEC using a tetrahydrofuran, THF/TEA (2 v/v%) eluent and appeared to be in accordance with 
Flory-Stockmayer theory.68,89 The polymers were also of higher molecular weight than similar 
material reported by Nguyen et al. when using a Sn(Oct)2 catalysed ROP method which 
displayed gelation above a BOD: initiator molar ratio of 0.6:1.42 
Scheme 2.7 – Benzyl alcohol initiated MSA catalysed ROP of ε-CL and BOD in toluene at 
36-38 °C. 
Within the current work, a refined purification of BOD has been employed, detailed in Section 
2.2 and subsequently, a new gelation point was observed at BOD: BzA molar ratios of > 0.7:1 
within the MSA catalysed ROP targeting a primary chain length of 40 monomer units (Table 
2.6). This polymer yielded Mn and Mw values of 12,430 and 261,900 g mol
-1 respectively (Đ = 
21.1) when analysed by triple detection SEC (DMF/LiBr 0.01 M at 60 °C), corresponding to 
                                                          
††††† Primary chain length refers to the DPn of the linear portion of branched polymer architecture that would be 





an average of 56 linear primary chains linked together, on a weight average basis‡‡‡‡‡. Further 
reduction of the BOD: BzA molar ratio to 0.6:1, yielded a polymer that had a notable decrease 
in Mw and Đ to 74,650 g mol
-1 and 6.63 respectively, and a relatively small change in Mn values 
as expected. This shows the significance of BOD concentration in joining together linear 
primary chains and creating of highly branched architecture. 
 
                                                          
‡‡‡‡‡ Calculated by dividing the Mw of the branched polymer by the Mn of the corresponding linear polymer 





Table 2.6 - Series of BzA initiated MSA catalysed ROP of ε-CL with BOD with varied Degree of Polymerisation 40 to 200 monomer units 
normalised with dn/dc value 0.06044.  






DPI of primary 
chain by NMRc 
(Initiator) 





No. of primary 
chains (weight 
averaged) 
PCL40-co-BOD0.8 1.5 Gel 
PCL40-co-BOD0.75 1.5 >99% 51 
 Gel 
PCL40-co-BOD0.7 1.5 >99% 51 
 
12,430 261,900 21.1 0.35 56 
PCL40-co-BOD0.6 1.5 >99% 47 
 
11,250 74,650 6.63 0.35 16 
PCL60-co-BOD0.7 2.5 >99% 74 
 
12,380 76,740 6.20 0.35 11 
PCL80-co-BOD0.7 4 >99% 98 
 
12,050 88,570 7.35 0.35 12 
PCL100-co-BOD0.7 5 >99% 116 
 
13,500 63,900 4.73 0.36 7 
PCL200-co-BOD0.7 9 51 % 122 
 7,910 8,700 1.10 0.57 - 
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Determined by triple detection SEC with a mobile phase of DMF/LiBr 0.01 M (60 °C) at 





To explore the influence of an increased primary chain length on the molecular weight of the 
resulting polymers the targeted DPn of the primary chain was increased to 60, 80, 100 and 200 
monomer units with a fixed BOD: BzA molar ratio of 0.7:1. As seen with the linear 
polymerisations targeting long chain lengths, PCL200-co-BOD0.7 failed to reach high conversion 
after 9 hours, which indicated that the polymerisation may have a limit to the DPn that can be 
targeted or the kinetics of this particular reaction are more complicated than those targeting ≤ 
100 monomer units. Branched polymers with a targeted primary chain DPn of 60 and 80 
monomer units showed high values for both Mw and Đ; however, these results were also 
attainable for PCL40-co-BOD0.6. This, combined with SEC analysis of PCL100-co-BOD0.7 
indicating a polymer with an Mw of 63,900 g mol
-1 suggests that increased primary chain length 
decreases the overall potential for branching to occur due to a lower BOD: ε-CL molar ratio 
and increased probability of forming polymer ‘loops’. 
Confirmation of the formation of branched architectures can be achieved for each of the 
polymers produced from SEC analysis; namely, higher than targeted molecular weights, broad 
molecular weight distributions and the calculated Mark-Houwink alpha values, α. All of the 
branched polymers produced exhibited a multimodal molecular weight distribution when 






Figure 2.26 - Refractive index, RI, detector output chromatograms of PCLx-co-BODy, 
obtained by MSA catalysed ROP, overlaid with the corresponding linear PCL polymer; 





An overlay of the corresponding linear polymers within their branched analogues (Figure 2.26), 
shows a linear population within the broad distributions; this is characteristic of branched 
polymers obtained via a conventional and modified “Strathclyde” methods and can be attributed 
to the presence of BOD having little effect on the formation of primary chains (Figure 
2.19).4,90,91This has been broadly studied with the creation of branched vinyl polymer 
architectures via a modified ‘Strathclyde’ route with several concepts being published within 
the literature. Bannister et al. demonstrated the statistical nature in which double bonds react 
during the polymerisation leading to the presence of unreacted pendant vinyl groups.86 
Monomer dilution has also been shown to be related to the linear population within the polymer 
species; an increased monomer dilution within the reaction mixture increases the number of 
wasteful intramolecular reactions due to the decreased interpenetration of propagating polymer 
chains.90,91 However 1H NMR analysis of the polymers produced in this section, by MSA 
catalysed ROP, would suggest that ‘loop’ formation is minimal. Furthermore it is important to 
note that although the vinyl polymerisation studies, detailed above, provide a small indication 
of what may be occurring during ROP, they cannot be fully applied to this technique due to its 
complex nature. As shown in Section 2.3.2.3 transesterification, both inter- and intra-molecular 
(Figure 2.27), is more likely to influence the branched architecture of polymers resulting from 






                                                                     
Figure 2.27 – Example of intramolecular cyclisation reaction of a PCL chain during 
ROP of ε-CL. 
Furthermore a clear trend can be seen when comparing the α values of BzA initiated linear PCL 
to the corresponding branched species giving further confirmation of the achievement of 
branched architecture. As the Mark-Houwink equation (Equation 2.18); 
[𝜂] = 𝐾𝑀𝛼                                        Equation 2.18 
used to calculate the α values of a polymer, defines the relationship of intrinsic viscosity, [η], 
and molecular weight, M, these values can be used to determine the rigidity of a polymer and 
in turn their architecture.92 K and α are constants where α signifies the architecture of the 
polymer within a given solvent.92 
In all cases for PCL-co-BOD that reached high conversion, α values < 0.4 were observed (Table 
2.6) which corresponds to a compact branched architecture. The consistency of these values is 
remarkable and shows very similar solution behaviour of all branched PCL-co-BOD polymers 





decreasing degree of branching (branching density); however, these values may indicate 
specific solution and coiling behaviour of branched PCL-derived polymers in DMF.92  
In summary, the generation of a library of branched PCL-co-BOD polymers, with varying 
primary chain DPn and BOD:BzA molar ratios may be reliably synthesised using MSA 
catalysed ROP via a modified ‘Strathclyde method’. The promising success of this investigation 
not only provides a route to metal free branched PCL-co-BOD co-polymers, but also allows 
control of many of the structural parameters within the co-polymer which may be valuable in 
further studies.  
2.3.3.1.1 Kinetic studies of the statistical co-polymerisation of ε-CL and BOD via 
MSA catalysed ROP 
A study of the kinetics of the branched ROP polymerisations was conducted in a similar manner 
to those already described above for analogous linear polymerisations (Section 2.3.2.1). As with 
previous studies, the primary chain length was targeted at DPn = 40 monomer units and the 
polymerisation was conducted at 36 °C for a total of 1.5 hours to achieve high monomer 
conversion. Following removal of the catalyst utilising equimolar TEA, the crude samples were 
analysed by 1H NMR and triple detection SEC (DMF/LiBr 0.01 M at 60 °C). 
1H NMR analysis showed that monomer conversion at each time point did not greatly differ 
from the corresponding linear time points with the branched polymerisation having slightly 
higher conversion over time. Furthermore, the application of the first order rate law Eq. 2.17, 
as derived in Section 2.3.2.1 yielded a kinetic plot that mirrored the trend seen with PCL40 with 
an upward curve as the reaction progressed (Figure 2.28, A). This confirmed that the addition 
of BOD had very little effect on the rate of polymerisation. 
Although the modified ‘Strathclyde method’ requires only a small molar concentration of the 
bi-functional monomer, following Flory-Stockmayer theory,  the basicity of BOD has not been 
reported with respect to MSA catalyst ROP.40,68 Therefore it was not obvious that the 
incorporation of BOD would have a negligible impact on the kinetics of the reaction. As no 
discernible effect on the kinetics was seen, it is safe to assume that due to the chemical similarity 
of the seven-membered lactones of BOD and ε-CL, the basicity of  the two monomers will not 






Figure 2.28- Analysis of kinetic study of PCL40-co-BOD0.7 synthesis completed with TEA 
acid neutralisation, 0 to 30 minutes (full monomer conversion reached - calculated by 1H 
NMR in CDCl3). (A) semi-log plots from 0 – 99.8 % conversion (t0 to t30) calculated by 1H NMR in 
CDCl3 overlaid with linear PCL semi-log plot and (B) overlay of selected RI traces between 3 and 90 





Triple detection SEC (DMF/LiBr 0.01 M at 60 °C) was unable to provide accurate analysis for 
the Mn, Mw and Đ of the polymer at each time point due to the presence of the monomer within 
each chromatogram. However a visual inspection of RI chromatograms at selected time points 
indicated a broadening of the molecular weight distribution from a monomodal peak 12 minutes 
(49.7 % monomer conversion) after the reaction began to the appearance of a shoulder at full 
monomer conversion (Figure 2.28, B). The broadening of the molecular weight distributions 
continued after monomer conversion reached >99 %, between 30 and 90 minutes (Figure 2.28, 
B). Therefore it is possible that although ε-CL has surpassed 99 % conversion unreacted 
pendant BOD groups are still present leading to the increased branching of the polymer 
overtime. Furthermore this could also be an indication that transesterification, which was shown 
to be present at high monomer conversion (Section 2.3.2.3), maybe contributing a gain in 
molecular weight of the branched polymer. 
2.3.3.2 Poly(ethylene glycol)5K initiated, MSA catalysed ROP of ε-
caprolactone and BOD 
The formation of amphiphilic branched polymers was studied by the inclusion of BOD in PEG-
initiated A-B block co-polymerisations described in Section 2.3.1.2. A number of researchers 
have reported that significant circulation benefits for PEGylated nanoparticles can be derived 
from PEG chains with an Mn of 5000 g mol
-1, therefore, PEG5K-OH was selected for these 
studies after successful linear co-polymerisations (Section 2.3.1.2).  Considering the success of 
PCL40-co-BOD0.7 in Section 2.3.3.1 the same primary chain length (DPn = 40 monomer units) 
and BOD: initiator molar ratios (0.7:1) were utilised. 
As with the linear PEG5K-b-PCL40 A-B block co-polymer synthesis, the polymerisation was 
conducted at 50 °C with 33 wt% solids in toluene (based on monomer mass) and  terminated 
after 2 hours. 1H NMR studies confirmed the reactions had achieved >99 % conversion and 
triple detection SEC analysis (DMF/LiBr 0.01 M at 60 °C) of PEG5K-b-PCL40-co-BOD0.7 
showed the purified sample to have Mn, Mw and Đ values of 10,370 g mol
-1, 17,530 g mol-1 
and 1.69 respectively (Table 2.7). These values indicated that although a branched species had 
been formed the weight average number of primary chains linked together was only 2.3. This 
was most likely a result of the greater monomer dilution needed for the solubilisation of 





Table 2.7 - Series of MSA catalysed ROP of ε-CL with PEG5K-OH and BOD to achieved branched amphiphilic architecture; 












Ð dn/dc α 
No. of primary 
chains (weight 
averaged) 
PEG5K-b-PCL40 2 >99% 
 
7,540 8,400 1.12 0.0605 0.70 1 
PEG5K-b-PCL40-co-BOD0.7 2.5 >99 %  10,370 17,530 1.69 0.0585 0.36 2.3 
PEG5K-b-PCL40-co-BOD0.8 2.5 >99 %  11,860 20,410 1.73 0.0593 0.36 2.7 
PEG5K-b-PCL40-co-BOD0.9 2.5 >99 %  11,490 23,600 2.05 0.0563 0.40 3.1 
PEG5K-b-PCL40-co-BOD1 2.5 >99 %  12,410 26,590 2.14 0.0563 0.38 3.5 
PEG5K-b-PCL40-co-BOD1.2 2.5 >99 %  12,280 35,960 2.93 0.0579 0.35 4.8 
PEG5K-b-PCL40-co-BOD1.5 2.5 >99 %  Gel 
PEG5K-b-PCL80-co-BOD0.8 4 98.5 % 
 13,730 25,900 1.89 0.0597 0.37 - 
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Determined by triple detection SEC with a mobile phase of DMF/LiBr 0.01 M (60 °C) at 






The BOD: initiator molar ratio was increased in order to find the gel point and to evaluate 
whether the increase in BOD: initiator molar ratio greatly affects the Mn and Mw of the resulting 
branched polymers. As the polymers approached the gelation point, increasing Mw would be 
expected; however, the relatively dilute reaction conditions (33 wt% monomer) were suspected 
to require a significant increase in the BOD: initiator molar ratio to overcome loop formation 
and create effective cross-linking between primary chains, leading gelation. These studies 
confirmed a gel point at a BOD: initiator molar ratio of between 1.2:1 and 1.5:1; microscopic 
gelation was observed and, therefore, is was possible to dissolve the soluble fraction and 
conduct 1H NMR studies (Table 2.7). NMR showed that the primary chain length to have a DPI 
of 38 monomer units and a DPOH of 25 monomer units.. SEC analysis was unable to be 
completed.  
The polymerisations leading to soluble PEG5K-b-PCL40-co-BODx (where x = 0.8 to 1.2) were 
studied by triple detection SEC analysis (DMF/0.01 M LiBr) and showed a clear trend of 
increasing Mw and Đ with increasing BOD content (Figure 2.29). Although these species again 
are not highly branched, the trend of increasing weight average molecular weight supports the 
mechanism of a modified ‘Strathclyde’ strategy where increased intramolecular reactions may 
dominate at high dilutions, even within a ROP reaction.90,91 The inability to produce highly 
branched, high molecular weight material is probably due to the large macroinitiator creating 
steric hindrance around the polymer chains and preventing primary chains from linking as 
efficiently as when low molecular weight initiators are used. Clearly, very high molecular 
weights are formed at the gel points but these appear to be hard to control reproducibly. 
A further polymer was synthesised with the BOD: initiator molar ratio of 0.8:1 but targeting a 
DPn of 80 monomer units for the primary chains. This was studied to understand whether an 
increase in DPn of the primary chain would result in a more dramatic increase in Mn and Mw. 
However, upon SEC analysis this polymer was shown to provide materials with very similar 
molecular weight compared to the DPn 40 equivalent and increasing primary chain length does 





Figure 2.29 - Change in Mn, Mw and Đ of PEG5K-b-PCL40-co-BODx with increasing BOD 
content. 
2.4 MSA catalysed ROP of substituted caprolactone monomers 
The MSA catalysed ROP of the substituted caprolactone monomers was studied, following 
insights gained and procedures utilised during the investigation of ε-CL polymerisation 
described above. The main aim for ROP including the substituted caprolactone monomers was 
to generate a library of polymers, varying in monomer chemistry, architecture and 
amphiphilicity for further studies of drug encapsulation and release. Given the strong similarity 
of the substituted caprolactone monomers with ε-CL it was assumed that these monomers 
would have little effect on the overall kinetics of the ROP polymerisations when compared to 
ε-CL, especially as the presence of BOD appeared to show no discernible effects (Section 
2.3.3.1.1).23 Reactions times were however slightly extended to 3.5 hours to ensure reactions 









2.4.1 MSA catalysed ROP of substituted caprolactone monomers to achieve 
linear architecture 
2.4.1.1 Benzyl alcohol initiated, MSA catalysed ROP of substituted 
caprolactone monomers 
As in depth studies undertaken with the synthesis of PCL via MSA catalysed ROP highlighted 
accurate targeting of polymers with a DPn of 40 monomer units, identical polymers were 
targeted. BzA initiated polymerisations of MOP, POP and BOP were undertaken at 30 °C (in 
toluene) at 50 wt% (monomer content); polymerisation of PHLOP was performed at 48 °C at 
25 wt% in toluene (monomer content) to achieve full dissolution of the monomer. Following 
termination of the polymerisations by the addition of CHCl3 and basic alumina to quench the 
catalytic system which was removed using basic alumina filtration before crude samples were 
taken for 1H NMR analysis (Table 2.8). Polymers, which were then purified by trituration in 
hexane, were then analysed by 1H NMR and triple detection SEC (DMF/LiBr 0.01 M at 60 °C). 
Table 2.8 - MSA catalysed ROP of substituted caprolactone monomers with a targeted 
DPn of 40 monomer units initiated by BzA;  



















Ð α dn/dc 
PMOP40 >99 % 57 7,410 5,230 5,440 6,570 1.21 0.61 0.0603 
PPOP40 >99 % 46 7,290 6,360 6,810 8,180 1.20 0.67 0.0594 
PBOP40 >99 % 43 7,430 6,920 7,320 8,870 1.21 0.57 0.0678 
PPHLOP40 99 % 66 12,660 7,720 8,140 9,570 1.18 0.67 0.1692 
Polymerisations undertaken at 30 °C (MOP, POP, BOP) and 48 °C (PHLOP) for 3.5 hours; a 
Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Calculated using the equation: 
Mntheory = (DPtargeted x conv. x MrBM) + MrBzA, c Determined by triple detection SEC with a mobile phase 
of DMF/LiBr 0.01 M (60 °C) at 1 mL min-1, d Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x 
MrBM) + MrBzA/PEG-OH. 
Subsequent NMR analysis of crude reaction mixture samples showed that high conversion 
≥ 99 % was achieved in all cases, suggesting that the addition of the substitution to the lactone 





Analysis by triple detection SEC revealed that each monomer appears to polymerise with 
similar control to ε-CL with Đ values ranging from 1.18 to 1.21, with monomodal molecular 
weight distributions, indicating that any transesterification reactions were relatively limited in 
these cases. 
1H-NMR analysis of the purified polymer samples, and utilising equation 2.14 showed 
discrepancies between the calculated DPI and the targeted DPn values, with PPHLOP40 and 
PMOP40 showing significantly higher DPI values than 40 monomer units. Unfortunately, due 
to the complexity of the 1H-NMR spectra of the purified polymers and overlap of proton 
environments DPOH was unable to be calculated for these samples. The observed Mn values 
derived from triple detection SEC analysis (Table 2.8) show an excellent correlation with the 
theoretical values.  
2.4.1.2 Poly(ethylene glycol)5K initiated, MSA catalysed ROP of substituted 
caprolactone monomers 
Each of the four substituted caprolactone monomers was used to create amphiphilic A-B block 
co-polymers using MSA catalysed ROP and the PEG5K-OH marcoinitiator described in studies 
with ε-CL (Section 2.3.1.2); and the polyester block was again targeted to a DPn of 40 monomer 
units, allowing for comparisons between PEG5K-b-PCL40 and the resulting block co-polymers. 
As described in Section 2.3.1.2 and 2.4.1.1, the polymerisations were undertaken at 50 °C and 
for 3.5 hours at 33 wt% dilution (with regards to monomer), although this was reduced to 
25 wt% for polymerisations using PHLOP due to its reduced solubility. 
All four polymerisations achieved ≥ 94 % conversion (Table 2.9) with the decrease potentially 
due to increased steric hindrance from the macroinitiator. DPI values for the four polymers were 
all calculated to be lower than 40 monomer units but this was to be expected as all 4 reactions 
did not reach full monomer conversion.  As mentioned in Section 2.4.1.1 due to overlap of 










Table 2.9 – AB block co-polymers generated by PEG5K-OH initiated, MSA catalysed ROP 
of substituted caprolactone monomers with a targeted DPn of 40 monomer units; 






















96% 35 9,490 9,920 9,710 10,330 1.064 0.78 
PEG5K-b-
PPOP40 
97% 36 10,620 11,060 10,870 11,490 1.058 0.78 
PEG5K-b-
PBOP40 
94% 30 10,110 11,400 10,970 11,540 1.052 0.78 
PEG5K-b-
PPHLOP40 
98% 38 12,230 12,460 12,090 12,840 1.062 0.78 
Polymerisations undertaken at 50 °C for 3.5 hours; a Determined by 1H NMR (CDCl3, 400 MHz) of the 
crude samples (see Appendix A for equations), b Calculated using the equation: Mntheory = (DPtargeted x 
conv. x MrBM) + MrBzA, c Determined by triple detection SEC with a mobile phase of DMF/LiBr 0.01 
M (60 °C) at 1 mL min-1, d Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x MrBM) + MrBzA/PEG-OH. 
Triple detection SEC (DMF/LiBr 0.01 M at 60 °C) analysis of the four A-B block co-polymers 
showed a small peak at higher retention times (Figure 2.30) despite a clearly monomodal 
molecular weight distribution being observed for the main separate signal. The small peak at a 
retention times of 20.5-22 minutes is very similar to peaks seen within chromatograms of 
PEG5K-b-PCL40 samples (Figure 2.17, B), but does not overlay with that of the PEG5K-OH 
macroinitiator  and appears to increase for PEG5K-b-PPHLOP40 samples. Although this peak 
has not been directly identified, it may indicate opportunistic initiation by trace water as the 
resulting polymer would correspond to a linear homo-polyester and not bear the PEG5K block 
segment. Molecular weight determination excluded this additional peak to allow direct 
comparison to PEG5K-b-PCL40 (Table 2.9) and the four polymers displayed a close comparison 
with the theoretical targeted values and Đ values < 1.10. Similarly, Mn values determined by 





Figure 2.30- Refractive index, RI, detector output chromatograms of PEG5K-b-PBM40; 
PEG5K-b-PMOP40 (black), PEG5K-b-PPOP40 (green), PEG5K-b-PBOP40 (blue) and PEG5K-b-PPHLOP40 
(red). Obtained by triple detection SEC; Mobile phase: DMF/ 0.01 M LiBr at 60 °C. 
For completeness, SEC analysis was conducted with the inclusion of the lower molecular 
weight peak (Table 2.10) leading to a decrease in the calculated Mn values; however, these 
values were generally similar to the theoretical values and Đ values remained < 1.10. This could 
be a result of water impurity within this reaction which is most likely a result of the initiator 
which, although was dried overnight in a vacuum oven before use, retaining water within its 












Table 2.10 – AB block co-polymers generated by PEG5K-OH initiated, MSA catalysed 
ROP of substituted caprolactone monomers with a targeted DPn of 40 monomer units 
including secondary population;  



















96% 35 9,490 
 
8,280 8,910 1.076 26 
PEG5K-b-
PPOP40 
97% 36 10,620 
 
9,020 9,780 1.084 26 
PEG5K-b-
PBOP40 
94% 30 10,110 
 
10,020 10,570 1.055 33 
PEG5K-b-
PPHLOP40 
98% 38 12,230 
 
8,990 9,560 1.064 24 
Polymerisations undertaken at 50 °C for 3.5 hours; a Determined by 1H NMR (CDCl3, 400 MHz) of the 
crude samples, b Determined by triple detection SEC with a mobile phase of DMF/LiBr 0.01 M (60 °C) 
at 1 mL min-1, c Calculated using the equation: MnNMR = (DPI(Eq. 2.14) x MrBM) + MrBzA/PEG-OH. 
2.4.2 Statistical co-polymerisation of substituted caprolactone monomers and 
BOD via MSA catalysed ROP to achieve branched architecture 
2.4.2.1 Benzyl alcohol initiated, MSA catalysed ROP of substituted 
caprolactone monomers 
Branched polymer architectures were synthesised using the four substituted caprolactone 
monomers using approaches described in Sections 2.3.3.1 and 2.4.1.1 and, again, targeting a 
DPn = 40 monomer units for all polyester primary chains; all reactions were conducted for 3.5 
hours at 38 °C to allow for BOD dissolution, with the exception of ROP reactions containing 
PHLOP which required a higher temperature of 60 °C to aid dissolution of both the solid 
monomer and BOD. Unlike PCL-co-BOD0.7, additional toluene was required to achieve 
homogenous reaction mixtures and polymerisations were conducted at 33 wt% for MOP, POP 
and BOP, and at 25 wt% (w.r.t monomer) for PHLOP. The BOD: BzA molar ratio was initially 
set to 0.8:1 and a series of soluble polymers were synthesised, however gelation of PMOP40-
co-BOD0.8 and PPOP40-co-BOD0.8 was noticed during purification and analysis. This was also 
seen for PBOP40-co-BOD0.8 and PPHLOP40-co-BOD0.8 after short periods of storage at ambient 
temperature. All polymerisations were, therefore, conducted at a BOD: initiator ratio molar 
ratio of 0.7:1 to avoid further microscopic gelation behaviour; gelation was avoided with this 





above 99 % conversion. (Table 2.11). Primary chain length was also shown to be relatively 
controlled for the polymerisation undertaken at 38 °C with DPI values of ≤ 50 monomer units. 
However PHLOP40-co-BOD0.7 was shown to have an average primary chain length of 76 
monomer units which suggests that the higher temperature of the polymerisation may contribute 
to increased transesterification reactions preventing the accurate targeting of primary chain 
length in this case.  
Table 2.11 - Series of MSA catalysed ROP of substituted caprolactone monomers with 
BOD (0.7 molar equivalents w.r.t initiator) to achieved branched architecture;  




















PMOP40-co-BOD0.7 99 % 44 
 9,920 89,470 9.02 0.34 0.0627 16.4 
PPOP40-co-BOD0.7 >99 % 50 
 12,490 83,830 6.71 0.28 0.0564 12.3 
PBOP40-co-BOD0.7 > 99 % 43 
 13,340 78,230 5.85 0.21 0.0649 10.7 
PPHLOP40-co-
BOD0.7 
99 % 76 
 
37,110 457,910 12.34 0.38 0.1326 56.3 
Polymerisations undertaken at 38 °C (MOP, POP, BOP) and 60 °C (PHLOP) for 3.5 hours; a 
Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Determined by triple detection SEC 
with a mobile phase of DMF/LiBr 0.01 M (60 °C) at 1 mL min-1, c Calculated using the equation: MnNMR 
= (DPI(Eq. 2.14) x MrBM) + MrBzA/PEG-OH. 
As seen in Table 2.9, triple detection SEC analysis (DMF/LiBr 0.01 M at 60 °C) of the branched 
polymers indicated weight average molecular weights of > 78,000 g mol-1 with broad 
distributions (Figure 2.31), indicative of statistical branching, with α values < 0.4. Furthermore 
the weight average number of primary chains linked together for each polymer species was 
> 10. The reason for the lower branched architecture of PBOP40-co-BOD0.7 is unclear at this 
time. However characteristic multimodal chromatograms were produced for all four polymer 





Figure 2.31- Refractive index, RI, detector output chromatograms of PSCM40-co-BOD0.7; 
PMOP40-co-BOD0.7 (black), PPOP40-co-BOD0.7 (green), PBOP40-co-BOD0.7 (blue) and PPHLOP40-co-
BOD0.7 (red). Obtained by triple detection SEC; Mobile phase: DMF/ 0.01 M LiBr at 60 °C. 
2.4.2.2 Poly(ethylene glycol)5K initiated,  MSA catalysed ROP of substituted 
caprolactone monomers and BOD  
The four substituted caprolactone monomers were used to synthesise a range of branched A-B 
block co-polymers using the PEG5K-OH macroinitiator, as described in Section 2.3.3.2 and 
Section 2.4.2.1. As described earlier, when using PHLOP, a lower solids content of 25 wt% 
(w.r.t monomer) was required and a molar ratio of BOD: PEG of 0.7:1 was employed to avoid 
gelation. 
1H NMR analysis indicated that after 4 hours all four polymers had reached >97 % conversion 
(Table 2.12), and  triple detection SEC analysis was undertaken on the purified polymers using 
an DMF/ 0.01 M LiBr eluent at 60 °C. As seen above (Section 2.3.3.2), the use of the 
PEG5K-OH macrointitiator in branching polymerisations led to low levels of branching and Mw 
values <26,000 g mol-1 in all cases (Table 2.12). Dispersity values were also low (Đ <2.5), 





Table 2.12 - Series of MSA catalysed ROP of substituted caprolactone monomers with PEG5K-OH and BOD to achieved branched 
amphiphilic architecture;  





Mn (g mol-1) Mw (g mol-1) Ð dn/dc α 
No. of primary 
chains (weight 
averaged) 
PEG5K-b-PMOP40-co-BOD0.7 98 %  11,960 22,350 1.87 0.0584 0.31 2.7 
PEG5K-b-PPOP40-co-BOD0.7 99 %  12,110 19,950 1.65 0.0581 0.31 2.2 
PEG5K-b-PBOP40-co-BOD0.7 99 %  11,450 18,360 1.6 0.0662 0.30 1.8 
PEG5K-b-PPHLOP40-co-BOD0.7 98 %  15,400 25,130 1.6 0.0959 0.33 2.8 
PEG5K-b-PMOP40-co-BOD0.7
c 98 %  9,020 20,420 2.27 0.0612 0.31 2.5 
PEG5K-b-PPOP40-co-BOD0.7
 c 99 %  7,870 17,490 2.22 0.0622 0.31 1.9 
PEG5K-b-PBOP40-co-BOD0.7
c 99 %  10,500 18,350 1.75 0.0671 0.30 1.8 
PEG5K-b-PPHLOP40-co-BOD0.7
 c 98 %  12,920 21,030 1.63 0.1064 0.33 2.3 
Polymerisations undertaken at 50 °C for 4 hours a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Determined by triple detection SEC with 





Interestingly the RI molecular weight distributions revealed the same smaller peak at a 
retention time of approximately 21 mins (Figure 2.32) and may indicate the opportunistic 
initiation speculated above (Section 2.4.1.2). The inclusion of this peak in SEC analysis, again, 
resulted in the decrease in Mn and Mw values; for example, PEG5K-b-PPHLOP40-co-BOD0.7 
shown a decrease in Mw from 25,130 to 21,030 g mol
-1, when the smaller secondary population 
was included in the SEC analysis (Table 2.12). However this decrease in Mw did not greatly 
affect the number of chains linked together which remained < 3 in all 4 cases; Đ did increase, 
as expected, due the inclusion of the smaller peak. (Table 2.12). The lack of high molecular 
weight, branched polymers reflected the results seen with PEG5K-b-PCL40-co-BOD0.7 in 
Section 2.3.3.2 and may have been a result of increased dilution of these reactions or the steric 
hindrance created by bringing together large PEG chains during branching.  
Figure 2.32- Refractive index, RI, detector output chromatograms of PEG5K-b-PSCM40-
co-BOD0.7; PEG5K-b-PMOP40-co-BOD0.7 (black), PEG5K-b-PPOP40-co-BOD0.7 (green), PEG5K-b-
PBOP40-co-BOD0.7 (blue) and PEG5K-b-PPHLOP40-co-BOD0.7 (red). Obtained by triple detection SEC; 
Mobile phase: DMF/ 0.01 M LiBr at 60 °C. 
2.5 Differential scanning calorimetry, DSC 
The library of polymers containing varying architecture and chemistry were studied using 
differential scanning calorimetry, DSC, in order to understand the variation in physical 





used as indicator as to thermal properties each polymer possessed. Analysis used a heat-cool-
heat cycle from -90 to 250 °C to fully erase then capture the thermal properties of each sample 
including both glass transition temperature changes, Tg, and melting points, Tm (Table 2.13). 
Table 2.13- DSC analysis of the complete polyester library;  
Sample Tg (°C) Tm (°C) 
Peak Enthalpy 
(J/g) 
PCL40 -62 52 90 
PMOP40 ------------------ Did not run ------------------ 
PPOP40 -66 - - 
PBOP40 -23 - - 
PPHLOP40 -1 - - 
PCL40-BOD0.7 -60 48 71 
PMOP40-BOD0.7 -63 - - 
PPOP40-BOD0.7 ------------------ Did not run ------------------ 
PBOP40-BOD0.7 -20 - - 
PPHLOP40-BOD0.7 4 - - 
PEG5K-PCL40 -58 52 136 
PEG5K-PMOP40 -63 53 94 
PEG5K-PPOP40 -66 53 85 
PEG5K-PBOP40 -28.8 51 79 
PEG5K-PPHLOP40 4 49 75 
PEG5K-PCL40-BOD0.7 -61 52 112 
PEG5K-PMOP40-BOD0.7 -60 53 91 
PEG5K-PPOP40-BOD0.7 -63 52 82 
PEG5K-PBOP40-BOD0.7 -17 52 86 
PEG5K-PPHLOP40-BOD0.7 13 50 70 
PEG5K-OH 49 58 200 
Heat-cool-heat cycle in the range of -90 to 250 °C at a rate of 5 °Cmin-1. 
Initial analysis was carried out with caprolactone based polymers due to the access to literature 
values to corroborate the experimental values obtained from this study. PCL is known to be 
semi-crystalline meaning that the polymer has both amorphous and crystalline character. DSC 
analysis of the second heat cycle for both PCL40 and PCL40-co-BOD0.7 showed the presence of 
both Tg and Tm peaks at -62 °C and -60 °C and 52 °C and 48 °C respectively (Figure 2.33, 
Table 2.13). The values obtained for linear PCL40 correlated closely with literature values 
of  -60 °C and 63 °C for Tg and Tm values respectively.
4,93 The presence of Tm peaks for both 





crystalline as expected and that the branched architecture does not greatly impact the 
crystallinity of the resultant polymer although it is clearly reduced. Across all the polymers 
studied, the introduction of branching led to an increase in Tg. The impact of branching on Tg 
has been studied in the literature, and similar results were seen for different polymers. Although 
not fully understood, it has been reported that an increase in Tg values may be due to the 
restriction of segmental mobility or the increasing compactness of the structure resulting in 
more chain ends, for amorphous polymers; however , this is unlikely in the case of materials 
created by a modified ‘Strathclyde’ approach as the number of chain ends present is identical 






Figure 2.33- DSC traces generated from the second heat cycle from -80 to 75 °C, rate 





PMOP40 was unavailable for this study and therefore omitted from the table. Importantly, 
substitution of the lactone ring led to a near complete disappearance of a Tm peak in all linear 
and branched polymer samples initiated by BzA, indicating a significant disruption of the 
crystallinity of the polymers and highly amorphous structure compared to PCL (Figure 2.33, 
C). Although an impact on crystallinity was hypothesised, a complete disruption of crystallinity 
was unexpected.  
Finally, examination of all linear and branched A-B PEG-derived co-polymers revealed some 
clear trends with respect to the lactone monomer. Analysis of the PEG5K-OH macroinitiator 
confirmed that the Tm peak overlaid the Tm peak for PCL, therefore generating a Tm peak for 
all the block co-polymers regardless of monomer used or architecture (Table 2.13).  
Within both the linear and branched A-B block co-polymers Tg became more negative as the 
side group substitution lengthened from a methyl side group to a flexible alkyl propyl group. 
This indicates that the extending side chain is acting like a plasticiser, preventing the tight 
packing of polymer chains and aiding movement by increasing the free volume in the polymer. 
Conversely the inclusion of a presence of a tertiary butyl side chain led to a dramatic increase 
in Tg and substitution with a phenyl ring led to a further increase. The t-butyl group is most 
likely acting as an ‘anchor’ trapping chains together and preventing free movement therefore 
increasing the energy needed to move the polymer above its Tg.
79 The pendant benzyl group is 
likely to act in a similar fashion with the additionally capability of aromatic interactions with 
other benzyl groups only the polymer backbone decreasing the flexibility and further increasing 
the energy needed to make the polymer pliable and flexible above its Tg.
79 This behaviour 
mirrors behaviour that would be seen with vinyl polymers of varying side chain chemistry.79,80 
2.6 Conclusions 
In conclusion, the aims of this chapter were to investigate MSA catalysed ROP and its 
application in the synthesis of polyester-derived polymers of varying architecture and monomer 
chemistry. This successfully generated a library of polymer species that can be taken forward 
for future nanoparticle formation studies and drug encapsulation evaluation. More in depth 
studies with caprolactone based polymers not only set a baseline for future studies with a new 
series of substituted caprolactone monomers but also provided a valuable insight into the broad 





Kinetic experiments for linear and branched PCL highlighted the complexity of this 
polymerisation technique given that the first order kinetics of the reaction were dependant on 
protonated monomer. This highlighted the relevance of the basicity of the monomer species 
and importance of its consideration when implementing new unexplored monomer species. 
Highly stringent anhydrous conditions were avoided during these polymerisations as future 
scalability was an important consideration, given that scalable techniques would have more 
long term value and commercial relevance. Molecular weight chain end and 1H NMR analysis 
of linear PCL polymers indicated that opportunistic initiation was occurring, most likely from 
low levels of residual water within the monomer. However this does not appear to be a 
significant issue, particularly when DPn is < 50 monomer units, as the tying together of primary 
polymer chains during the statistical branching process will lead to structures that approximate 
closely to the targeted materials in the overall composition.97 Further mechanistic studies 
revealed the presence of transesterification reactions once high monomer conversion had been 
surpassed although this should not pose a problem during branched polymer synthesis. 
Moreover these transesterification reaction could in fact aid the synthesis of highly branched, 
high molecular weight material.  
Amphiphilic A-B block co-polymer synthesis with long PEG chains, that have been shown to 
be of clinical relevance, highlighted the significant effects steric hindrance proved to have on 
the successful formation of high molecular weight branched species. Nonetheless structural, 
chemical and physical property diversity within the available library of polymers, synthesised 
with the inclusion of substituted caprolactone monomers, motivates exploration of nanoparticle 
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As research exploring the application of nanostructures in biomedical and industrial 
environments increases, investigations into the formation of these particles also proliferates. 
These studies focus on a wide range of areas which include scalability, uniformity and 
transferability from a research to an industrial setting. This wide ranging research has resulted 
in the development of a variety of routes to forming nanoparticles on a number of scales. As 
detailed in Section 1.3.3, there are numerous synthetic routes to form nanoparticles of a specific 
structure. Example of these are thin film hydration for liposomes or more synthetically-
focussed routes to materials such as dendrimers via convergent or divergent synthesis, however 
these are more consistently seen in a research laboratory setting.1,2 Industrial scale formation 
of nanostructures is most commonly achieved by batch or flow reactors, for instance with the 
production of carotene nanoparticles for natural colouring and taste modulation for food and 
drink.3,4  
Focusing on the research laboratory scale, with the formation of polymeric nanoparticles in 
particular, there are numerous methods of preparation that have been developed to achieve 
uniform nanoparticle dispersions.5 Among these techniques, nanoprecipitation has become 
prevalent in literature, favoured due to its reproducibility, accessibility and easy variation in 
the production of polymeric nanoparticles.6–8 
3.1.1 Nanoparticle preparation via nanoprecipitation 
First developed in the 1980s when the process was patented, nanoprecipitation of 
macromolecules, also referred to as solvent displacement, can be defined as the rapid addition 
of a sole hydrophobic or amphiphilic polymeric species into an aqueous dispersion (Figure 
3.1).9 This triggers the collapse of the polymer chains into nuclei which grow until colloidal 
stability is reached.7,8,10,11 This simple facile technique relies on the low energy mixing of two 
solvents, here referred to as a ‘good’ solvent, capable of solubilising polymer components plus 
any drug molecules, and a ‘bad’ solvent, an anti-solvent for both the polymer and guest 
molecules, commonly water. The addition of a good solvent, containing polymer/drug 
components, to a bad solvent results in a three step process, detailed below, leading to the 
formation of nanoparticle dispersions.7 The creation of nanoparticle dispersions with narrow 
size distribution and low polydispersity requires that the nucleation and growth steps within 





The complexity of the mechanism of nanoprecipitation requires a review of small molecule 
nanoprecipitation to provide a more comprehensive view of the technique. 
Figure 3.1 – Representation of the nanoprecipitation of a branched hydrophobic polymer 
to form polymeric nanoparticles by (A) rapid addition of the miscible organic phase containing 
the polymeric species and (B) evaporation of the organic phase to yield an aqueous dispersion of 
nanoparticles. 
3.1.1.1 Principles of small molecule nanoparticles prepared via 
nanoprecipitation 
Initial nanoprecipitation techniques involved the precipitation of small molecules, such as drug 
compounds. The first step in this nanoparticle formation, the generation of supersaturation, is 
achieved upon addition of good solvent to bad solvent decreasing the overall mixed solvent 
environment’s ability to dissolve the solute (drug) (Figure 3.2).6,7,12 This means that the 
supersaturation ratio, Sr, is dependent on the concentration of the solutes within the solvent 
mixture. Sr can be defined via Equation 3.1; when solvent exchange occurs by the addition of 
a good solvent to a large volume of bad solvent, where C is mass of solute divided by the final 





                                                Equation 3.1 
𝑤ℎ𝑒𝑟𝑒 𝐶 =







Once the point at which supersaturation and a metastable§§§§§ dispersion is reached, the need to 
minimise the energy of the system and gain thermodynamic stability drives nucleation to 
occur.8 The concentration at which this arises within the good solvent/solute/bad solvent 
mixture is commonly defined as the “ouzo effect”, named after the Greek drink, defined as the 
instantaneous formation of nanoparticles without the need for surfactants.8,14 The small region 
in which nucleation can occur, also referred to as the “ouzo domain”, is dependent on both 
solute concentration and the ratio of good to bad solvent. It is only within this region that 
uniform particles with narrow particle distributions will be achieved.14,15 
Following supersaturation the formation of nanoparticles can now be divided into two 
mechanisms defined by the compounds nanoprecipitated and is dependent on the 
supersaturation of the solution:  
 if supersaturation, Sr, is low, nucleation and diffusion limited growth is dominant (more 
likely for small molecules); Nucleation-growth is considered most likely for small 
molecules where nucleation is most commonly explained by the classic model which 
states that the onset of supersaturation causes phase separation to reduce the free energy 
within the system.6,14 In the case of drug molecules the formation of nuclei is often 
achieved by crystallisation.6,7,14 The formation and subsequent growth of these nuclei 
depletes the solution supersaturation thereby lowering the free energy of the system; 
the decrease in energy only stops once the supersaturation is below the concentration 
at which nuclei spontaneously form.7 Diffusion limited growth, also known as growth 
via condensation, can then take place. This characterises the two step mechanism of the 
diffusion of solutes to the nuclei surface from the bulk, followed by the integrating the 
solute molecules to the nuclei matrix.6,7,14 
 In contrast, supersaturation is high it induces diffusion limited cluster-cluster 
aggregation, DLCA (more likely for polymers) with the collection of smaller particles 
resulting larger entities, this will be fully addressed in Section 3.1.1.2 .14,16  
 
 
                                                          
§§§§§ A state in which an energy barrier must be overcome to access a more stable thermodynamic state and is not 
a reversible process. In the case of nanoparticle formation the nucleation of the solute allows the system to 





3.1.1.2 Principles of polymeric nanoparticles prepared via nanoprecipitation 
Nanoparticle formation via the nanoprecipitation of polymer is considered to be more complex 
than small molecules however some principles addressed in Section 3.1.1.1 can be applied such 
as the formation of a supersaturated solution. First nucleation occurs by the collapse of polymer 
chains; a strong entropic effect, due to the desolvation of polymers chains by the diffusion of 
good solvent into the anti-solvent. This is followed by their congregation to form defined nuclei 
of a critical size (Figure 3.2).  
Figure 3.2 – Representation of creation of supersaturation leading to polymeric nuclei 
formation during the nanoprecipitation process; (A) polymer chains dissolved in good solvent, 
(B) addition to bad solvent creates supersaturation, polymer chains collapse to minimise energy, (C) 
congregation of polymer chains form nuclei of a critical size depleting supersaturation until nuclei 
formation stops. 
The behaviour of these nuclei can then be defined by DLCA which refers to the aggregation of 
two particles within the solution which results in the growth of a single larger particle (Figure 
3.3). This mechanism relies on a high number of nuclei which causes a high number of 
collisions between ‘clusters’ and assumes each collision results in the aggregation****** of the 
two species involved.14,16,17 The moment at which the growth phase stops for polymeric 
nanoparticles is dependent on particles gaining colloidal stability and preventing aggregates 
forming from excessive growth.  
                                                          
****** There is an alternative mechanism and mathematical description for the growth of nanoparticles via cluster-
cluster aggregation known as reaction limited cluster-cluster aggregation, RLCA. In this model clusters only 
undergo a reaction to permanently join together after a large number of collisions has occurred, taking into account 





Figure 3.3 – Representation of the growth mechanisms of nuclei to form nanoparticles, 
adapted from Lepeltier et al.14 (A & D) nucleation halted when nuclei reach critical size, (B) 
diffusion limited growth; solutes diffusing through solution and adsorbing onto the surface of the nuclei, 
(E) DLCA, aggregation of 2 particles resulting in growth of a single particle, (C & F) growth by both 
mechanisms resulting in the formation of nanoparticle dispersions. 
The mechanism of polymeric nanoparticle formation from nanoprecipitation has been studied 
further by Rannard and co-workers to gain a more detailed understanding of the roles both 
polymer species play in the formation of the nanoparticles and the definition of their resulting 
properties.18,19 Investigations by Hatton et al. showed the inclusion of just 1 wt% highly 
branched polymeric species with a hydrophobic linear dendritic hybrid during 
nanoprecipitation reduced the hydrodynamic radius and polydispersity of the particles 
compared to the nanoprecipitation of a linear dendritic hybrid alone.18 Further exploration of 
this phenomenon, by varying the components within the good solvent, increasing amounts of 
branched polymer, produced a trend of decreasing hydrodynamic radius with increased 
branched polymer concentration.18 
The colloidal stability of nanoparticles formed from nanoprecipitation can be split into two 
groups defined by the nanoparticle components. The nanoprecipitation of a solely hydrophobic 
polymer into an aqueous phase would rely on electrostatic stabilisation (Figure 3.4, A), 





describes the colloidal stability of a system to be the result of two opposite forces acting on the 
nanoparticles; attractive van der Waals forces induced by dipole-dipole moments, and repulsive 
electrostatic forces induced by an electrostatic double layer that forms around a charged 
particle.22–24 The balance of these two forces determines the stability of the colloidal system. 
When electrostatic repulsion is greater that the attractive van der Waals forces, an energy 
barrier between flocculation (the reversible joining of two particles) and aggregation 
(permanent joining of two particles) is generated, resulting in a stable system.20,24 However this 
energy barrier is subject to change if the environment in which the particles exist changes, 
specifically with respect to salt concentration. The addition of charged salt ions into the system 
results in the masking of the charged double layer around the particles, reducing their surface 
potential, and in turn the energy barrier, resulting in aggregation and instability.20  
Figure 3.4 – Representation of the different types of stabilisation induced in polymeric 
nanoparticle formation. (A) Electrostatic stabilisation induced by the adsorption of charged species 
onto the surface of the nanoparticle and (B) steric stabilisation induced by a hydrophilic corona. 
Nanoprecipitation of amphiphilic block co-polymers in an aqueous environment avoids the 
disadvantages seen with respect to electrostatically stabilised colloidal dispersions and their 
sensitivity to salt by accessing steric stabilisation (Figure 3.4, B). The hydrophilic segments of 
the polymer chains are able to extend into the solvent creating a corona around each 
nanoparticle.21 Nanoparticles within this system are also subject to van der Waals forces which 
draw the particles together, therefore when two particles approach each other the solvated 
polymer chains within the corona of each nanoparticle are forced to overlap.21,24 This overlap 
induces an excluded volume effect where the solvent molecules are forced out of the space now 
occupied by interpenetrating polymer chains increasing osmotic pressure and inducing a loss 





sufficiently dense in the corona this effect is thermodynamically unfavourable resulting in 
repulsion and a colloidally stable dispersion.21,24 
3.1.2 Nanoparticle preparation via co-nanoprecipitation 
As an adaptation of nanoprecipitation, co-nanoprecipitation (Figure 3.5), follows the same 
mechanism to form nanoparticles; however, two polymeric species of differing hydrophobicity 
can be dissolved in the organic, good solvent, phase resulting in particles that possess combined 
properties.25 This technique, developed by Ford et al, was initially studied with the 
simultaneous co-nanoprecipitation of branched pHPMA along with PEG-b-pHPMA to achieve 
sterically stabilised nanoparticles.25 These studies found that, as expected, the linear 
amphiphilic block co-polymer was incorporated into the branched architecture during the 
nanoprecipitation process forming monodispersed uniform particles without the need for 
filtration.25 This adaptation of nanoprecipitation unlocks the major advantage of tuning the 
resultant particle properties by simply varying the components and their respective ratios 
within the good solvent phase. It also unlocked new scope for tackling salt stability issues as 
well as the creation of nanoparticles with mixed surface functionality. 
Figure 3.5 – Representation of the co-nanoprecipitation of a branched hydrophobic 
polymer with an amphiphilic linear block co-polymer to form polymeric nanoparticles 
by; (A) rapid addition of the miscible organic phase containing the polymeric species and (B) 
evaporation of the organic phase to yield an aqueous dispersion of nanoparticles. 
Further studies have been completed within the Rannard group to further understand the co-
nanoprecipitation process by employing a library of polymethacrylates and varying the 





achieved by the co-nanoprecipitation of branched hydrophobic polymers with linear 
amphiphilic block co-polymers, where entrapment of the hydrophilic block within the particle 
core and the effects of polymer composition and concentration were studied. Furthermore these 
particles were subjected to dilution and salt stability studies to further expand understanding in 
this area.19 This research also successfully produced nanoparticle dispersions from the co-
nanoprecipitation of linear hydrophobic polymers with linear amphiphilic block co-polymers 
which were previously unexplored. Finally this body of work further explored the successful 
encapsulation of a number of guest molecules to understand further the capabilities of this 
technique.19  
3.1.3 Chapter aims  
This chapter aims to explore the creation of a library of polyester nanoparticles using the 
materials synthesised by MSA catalysed ROP, defined in Chapter 2. Building on the work 
previously undertaken with methacrylate-based polymers, nanoprecipitation and co-
nanoprecipitation techniques are intended to be studied in the context of polyesters. It is 
hypothesised that, as with vinyl polymers, these materials will yield a number of stable 
nanoparticle dispersions. These would then allow for further study of the stability of the 
nanoparticles produced by a series of salt studies to explore the suitability of these systems for 
use within a biological environment.  
As detailed in Section 3.1.1 the nanoprecipitation mechanism of nanoparticles can be 
influenced by the conditions applied. Therefore it is thought that the study of good solvent 
choice would provide vital insight into the effects this has on the nanoparticle physicochemical 
properties.  Direct comparisons hope to be drawn between acetone and tetrahydrofuran, THF, 
within this body of work. Expansion of (co)nanoprecipitations methods to the library of 
polymers synthesised using the four bespoke monomers detailed in Chapter 2 is hypothesised 
to help determine what role the structure of the polymer backbone plays in the physicochemical 
properties of the resultant nanoparticles. Utilising the advantageous ability to vary polymer 
components used within co-nanoprecipitation is hoped to highlight any favourable interactions 
that may be gained from the combinations of the amphiphilic block co-polymer and 
hydrophobic branched polymers explored.  
Finally, initial exploration of the encapsulation abilities of these systems will aim to investigate 
the ability to incorporate guest molecules and the combining of nanoparticle growth 





greatly in molecular structure, will provide the best insight into the effects the presence of an 
additional molecule has on the co-nanoprecipitation process. Therefore Oil red O and docetaxel 
are to be utilised in these studies and the effects they have on the physicochemical properties 
of the resulting nanoparticles, at the time of synthesis and after storage, are to be assessed by 
dynamic light scattering, DLS, characterisation.   
3.2 (Co)-Nanoprecipitation studies with poly(ε-caprolactone) based 
polymers 
3.2.1 (Co)-Nanoprecipitation studies using an acetone good solvent phase 
Preliminary investigations into the nanoprecipitation of polyesters were exclusively performed 
with a series of linear and branched PCL polymers (excluding PCL200 and PCL200-co-BOD0.7 
due low monomer conversion) and expanded to include A-B block PEG co-polymers at the 
time of co-nanoprecipitation. This allowed for the conditions of the nanoprecipitation, and 
subsequent co-nanoprecipitation, of all the polymer species to be determined. Nanoparticle 
dispersions were prepared by the method and conditions developed by Rannard and co-
workers, where the selected polymer was dissolved in a chosen good solvent, either acetone or 
THF, at an initial concentration of 5 mg mL-1, and 1 mL of the resulting solution was rapidly 
added to deionised water targeting a final concentration 1 mg mL-1 of polymer in water after 
good solvent evaporation.25 The chosen good solvent for this study was initially defined as 
acetone which had previously been shown to produce well defined nanoparticle dispersions 
with both polyester and polymethacrylate-based materials.25,26 Initial studies began with the 
analysis of the resulting unfiltered dispersions, formed from nanoprecipitation of single 
species, by DLS enabling the effects of both DPn and branched architecture on nanoparticle 





Table 3.1 – DLS characterisation of PCL nanoparticles produced by nanoprecipitation from acetone; 
Sample 
Z-Average Diameter (nm) 
Number Average Diameter 
(nm) 
PdI Zeta Potential (mV) Derived Count Rate (Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PCL10 Unstable 
PCL20 85 85 55 55 0.110 0.120 -50 -55 255270 (5) 235595 (5) 
PCL30 100 105 70 70 0.110 0.105 -55 -55 333035 (4) 328735 (5) 
PCL40 100 100 70 65 0.110 0.115 -55 -45 331440 (4) 327555 (5) 
PCL50 90 90 60 60 0.090 0.090 -60 -50 257215 (5) 247865 (5) 
PCL60 95 95a 65 70a 0.090 0.085 a -55 -50  318470 (5) 179085 (6)a 
PCL80 75 85a 50 45a 0.095 0.200 a -40 -60  136440 (6) 60305 (6)a 
PCL100 75 80 50 45 0.115 0.190 -70 -55 114970 (6) 61855 (6) 
PCL40-co-BOD0.7 75 80 50 50 0.105 0.115 -55 -55 129880 (6) 115345 (6) 
PCL40-co-BOD0.6 85 85 60 55 0.090 0.105 -50 -60 218735 (5) 188010 (5) 
PCL60-co-BOD0.7 75 70 50 45 0.110 0.130 -55 -55 90475 (6) 88745 (6) 
PCL80-co-BOD0.7 70 70 45 45 0.130 0.115 -60 -50 82555 (6) 100590 (6) 
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DLS analysis established that particles were formed in all cases, apart from PCL10, with Z-
average diameters, Dz, ranging from 75 nm to 100 nm for linear polymers and 70 nm to 85 nm 
for branched PCL (Table 3.1). The polydispersity index, PdI, of all the samples were below 
0.2, this could be considered high, particularly when compared to polymethacrylates producing 
nanoparticle with PdI of 0.09 and above.25 There was no evident correlation between the 
polymer architecture and PdI values which were comparable for samples where DPn of the 
primary polymer chain was below 80 monomer units. On the other hand, there appeared to be 
a limit to chain length when acetone was used as a good solvent with PCL10 being incapable of 
forming stable nanoparticles.  
The decreased Dz of the particles formed from PCLx-co-BODy correlated with studies carried 
out by Hatton et al. investigating the effects of high molecular weight branched material on the 
characteristics of the resulting nanoparticles.18 This research indicated that the 
nanoprecipitation of a unimolecular species, containing a number of chains linked together, 
resulted in a well-defined nucleation-growth mechanism achieved by fast nucleation. As a 
consequence of many primary polymer chains linked together, larger nuclei which exceed the 
critical radius for nanoparticle formation, form faster leading to more monodisperse and 
smaller particles.18 This is supported by the mechanistic principles of nanoprecipitation, that 
separate well-defined nucleation and growth phases results in more uniform dispersions.12–14  
Precipitation of the amphiphilic block co-polymers alone also produced successful nanoparticle 
dispersions although the diameter of these particles potentially indicated a micelle-like 
structure. This would be expected due to PEG co-polymers typically being used for the creation 
of micelle structures.27 The contrast between the PEGylated nanoparticles and hydrophobic 
PCL particles demonstrates the stability mechanisms involved in each system. It is clear that 
when PEG polymer segments are absent, electrostatic stability is the sole mechanism of 
stability as the zeta potentials are between -40 and -70 mV. Furthermore studies have shown 
that electrostatic stabilisation has characteristic zeta potentials of ± 30 mV and greater.20,21,24  
The generation of negative zeta potentials at the slipping plane between water and 
nanoparticles, specifically hydrophobic in nature, is still not fully understood with a number of 
theories being submitted as to the cause. The two most utilised theories only consider the 
presence of hydroxide and hydronium ions within the aqueous phase therefore assuming that 
no other ions take part in the creation of a negatively charged interphase.28–30 The first theory 





hydrophobic surface and thus creates the negative zeta potential characteristically seen with 
hydrophobic nanoparticles.29,30 The alternative school of thought postulates that the interface 
between water and a hydrophobic surface is protonated generating hydronium ions. This causes 
water molecules to self-rearrange to accommodate these physio-adsorbed hydronium ions 
generating a negative zeta potential. More recently, a third hypothesis has been put forward 
which considers the presence of other ions within the aqueous phase for example sodium and 
chloride ions, but in particular carbon dioxide and subsequent bicarbonate ions present due to 
carbonation of water.28,31 Investigations into this proposition firstly confirmed that bicarbonate 
ions were very good candidates for interacting with surfaces. Subsequently it was confirmed 
that bicarbonate ions have a large tendency to adsorb onto hydrophobic surfaces, particularly 
in the case of polymers.28 The extension of this study to a range of pH values highlighted that 
bicarbonate ions have a lack of competition with other ions when adsorbing to the hydrophobic 
surface at neutral pH values between 6 and 9.28 Additionally, as highlighted in Chapter 2 a 
number of carboxylic acid groups were formed during MSA catalysed ROP which would also 
contribute to the negative zeta potentials of nanoparticles formed from polymers synthesised 
in Chapter 2. 
The presence of PEG chains saw a reduction in the zeta potential to ≤ -30 mV with the extension 
of the PEG chain length from 2000 to 5000 g mol-1 resulting in a 5 mV decrease in the zeta 
potential as measured one day after formation. The reduction of the zeta potential of these 
particles is most likely due to the prevention of ion adsorption on the hydrophobic interface 
between the core and corona of the particle due to the steric hindrance of the hydrophilic PEG 
chain. Additionally the presence of these hydrophilic chains in the corona of the nanoparticles 
allows for the shielding of charge simultaneously as steric stability is imparted on the colloidal 
dispersion.21,24 Furthermore the presence of the PEG corona on in the nanoparticle structure 
and the decreased zeta potential is thought to prevent the aggregation of the particles with salt 
addition seen with electrostatically charged nanoparticles.20,24 
The benefit of both mechanisms of stability were explored by additional DLS analysis 7 days 
after initial synthesis with most of the systems synthesised producing results that are 
comparable between day 1 and day 7. Furthermore, the advantages of the branched architecture 
on the stability of the nanoparticle dispersion over time was also demonstrated with some linear 





Taking into consideration the results generated in Table 3.1 and studies performed by Hatton 
et al., further exploration of nanoparticle formation was undertaken by co-nanoprecipitation of 
PCL40-co-BOD0.7 with the amphiphilic A-B block co-polymers to achieve nanoparticles of 
reasonable size and stability.18 Sterically stabilised particles were achieved by implementing 
the co-nanoprecipitation method developed by Ford et al. in which amphiphilic di-block 
co-polymers were included at various ratios within the organic phase containing PCL40-co-
BOD0.7 and then added to deionised water. The ratio of stabilising PEGX-b-PCL40 to PCL40-co-
BOD0.7 was varied from 0 to 100 wt% for both PEG2K-b-PCL40 and PEG5K-b-PCL40 block co-
polymers whilst maintaining a total polymer concentration of 5 mg mL-1 in acetone and 
subsequently a final nanoparticle dispersion concentration of 1 mg mL-1 in the aqueous phase 
once the co-nanoprecipitation process was complete. Stable nanoparticle dispersions were 
achieved in all cases with no significant differences observed in overall hydrodynamic radii or 
stability at corresponding ratios when using increased PEG chain lengths (Figure 3.6). The only 
meaningful difference between samples prepared with different amphiphilic PEGx-b-PCL40 co-
polymers that was observed was a small increase in zeta potential to less negative values when 
PEG5K-b-PCL40 was utilised (Figure 3.6, C). Stability over 7 days was also observed 
throughout the series of nanoparticles with no significant trend witnessed over all ratios and 






Figure 3.6 – Graphical representation of changes in physicochemical characteristics of 
nanoparticles produced by co-nanoprecipitation with increasing PEGx-b-PCL40 content 





The most significant trend was seen with the sequential increase in PEGx-b-PCL40 content, 
irrespective of whether PEG2K-b-PCL40 or PEG5K-b-PCL40 was used to stabilise PCL40-co-
BOD0.7. Firstly, considering the Dz of the particles, a decrease from 75 nm and 85 nm to 30 nm 
and 25 nm was observed for PEG2K-b-PCL40 and PEG5K-b-PCL40, respectively, with increasing 
PEGx-b-PCL40 content (Figure 3.6, A). This was to be expected due to the decreasing 
concentration of the hydrophobic branched PCL40-co-BOD0.7 core-forming polymer within the 
nanoprecipitation mixture effectively increasing the concentration of amphiphilic stabilising 
block co-polymer and allowing a larger surface area (therefore, smaller particles) to be 
stabilised (Figure 3.7). Additionally Dz in all cases was equal to or below that of 
nanoprecipitated PCL40-co-BOD0.7 further correlating with results observed by Hatton et al.
18 
Figure 3.7 – Schematic representation of the nucleation-growth mechanisms, during the 
(co)-nanoprecipitation process; dependant on varying polymer architecture; (A) co-
nanoprecipitation of a hydrophobic branched polymer with an amphiphilic A-B block co-polymer 
resulting in sterically stabilised nanoparticles (with (i) nucleation and (ii) rapid growth), (B) 
nanoprecipitation of amphiphilic A-B block co-polymers resulting in the formation of micelle-like 
nanoparticles (with (i) nucleation and (iii) slow growth) and (C) nanoprecipitation of a amphiphilic 
branched A-B block co-polyester resulting in similar behaviour described in (A) (with (i) nucleation 






PdI increased with increasing PEGx-b-PCL40 content, a phenomenon seen in previous work 
undertaken with pHPMA (Figure 3.6, B).25 This may be attributed to the increasing 
concentration of amphiphilic block co-polymer diminishing the influence the branched 
architecture has on the fast nucleation step, and therefore limiting controlled nanoparticle 
formation. This was reflected by the lack of monomodal intensity-derived particle distributions 
when the percentage of PEGx-b-PCL40 was ≥75 wt%. These distributions replicated those seen 
for 100 % PEG2K-b-PCL40 and PEG5K-b-PCL40 indicating successful incorporation of PEGx-b-
PCL40 in these systems. This could be a result of the size of these nanoparticles being on the 
limit of the DLS range. 
Finally, studying the zeta potentials generated by each dispersion, increasing PEGx-b-PCL40 
content resulted in less negative zeta potentials confirming a shift towards more neutral 
particles and a predominant steric stabilisation as PEGx-b-PCL40 content increased. This was 
also expected as dense PEG-derived coronas can be formed, shielding the surface charges and, 
leading to a lower measured zeta potential (Figure 3.8).28–30 However, particles with ≤ 50 wt% 
PEGx-b-PCL40 could still be characterised as electrostatically stabilised with zeta potentials 
below -35 mV suggesting that the PEG corona is not dense enough to shield the surface and a 
mixed stabilisation mechanism may be operating (Figure 3.8).20,21,24                      
Figure 3.8 – Increasing PEGx-b-PCL40 content resulting in a shift from electrostatic 
stabilisation to steric stabilisation; (top) electrostatic stabilisation, (left) combined steric and 





3.2.1.1 Salt stability studies 
The extent of steric stabilisation imparted on each nanoparticle dispersion, with increasing 
concentrations of PEGx-b-PCL40, and the variation in length of the PEG block, was evaluated 
through the addition of salt solution utilising the two methods outlined by Ford et al.25 A study 
of salt stability, following the change in particle characteristics over seven days after a single 
20 µL addition of 0.5 M NaCl(aq) to 1 mL of each nanoparticle dispersion was undertaken 
(Table 3.2, Figure 3.9). Firstly, considering the overall stability and amount of change to 
physicochemical properties in both the PEG2K-b-PCL40 and PEG5K-b-PCL40 stabilised systems, 
PEG5K-b-PCL40 stabilised nanoparticles showed an increased resistance to salt addition. This 
was demonstrated by the smaller change in values for both Dz and PdI over the seven day 
period. Nonetheless there was a general increase in Dz values one day after addition suggesting 
that particles were beginning to aggregate.  
The clearest trend was observed by the change in zeta potential of each system over time where 
it is also important to note the behaviour of 100 wt% PCL40-co-BOD0.7 particles which showed 
an increase in the negativity of the particles (Table 3.2). It could be postulated that this is a 
result of bicarbonate and chloride ions being similar in their propensity to adsorb to a 
hydrophobic surface†††††† which could increase the amount of charge available.28 In systems 
where PEG2K-b-PCL40 and PEG5K-b-PCL40 were present, zeta potential reduced by 
approximately 50 % over the seven day period. This indicates a reduction in the finite barrier 
and repulsive electrostatic forces preventing aggregation, effectively increasing the influence 
of the attractive van der Waals forces and decreasing the distance between particles.20 This 
reduction of electrostatic stabilisation most likely due to the shielding of charge by salt ions; 
also known as ‘salting-out’, leaves each system to rely solely on the steric stabilisation imparted 
on the nanoparticles by PEG2K-b-PCL40 and PEG5K-b-PCL40. The small change in PdI and size 
over the series of nanoparticles stabilised by PEG5K-b-PCL40 highlights the advantage of a 
longer PEG chain in the corona and its role in the stabilisation of the nanoparticles. 
                                                          
†††††† This is determined by the examination of the polarizability and hydrophobicity of each ion by viscosity 
measurements and NMR analyses, as detailed by Yan et al. Bicarbonate and chloride ions are soft ions and 





Table 3.2 – DLS characterisation of nanoparticles produced by (co)-nanoprecipitation with addition of 0.5 M NaCl(aq) (20 µL);  
Sample 
Multiple 20 µL 
additions of 
0.5 M NaCl(aq) 
Single 20 µL addition of 0.5 M NaCl(aq) 




Z-Average Diameter (nm)c PdIc Zeta Potential (mV)c 
No 
Salt 







Instant 1  Day 
7       
Days 
Ratio of  
PEG2K-b-PCL40: PCL40-co-BOD0.7 
             
0:100 140 90 85 95 90 0.074 0.084 0.124 0.123 -56 -45 -74 -92 
10:90 20 75 75 75 80 0.124 0.118 0.120 0.111 -54 -27 -30 -27 
25:75 20 70 70 70 70 0.143 0.112 0.151 0.121 -43 -21 -23 -25 
50:50 20 60 55 60a 60a 0.221 0.173 0.245a 0.199a -40 -17 -13 -12 
75:25 40 45 55a 55a 50a 0.215 0.292a 0.338a 0.231a -37 -15 -13 -14 
90:10 140 40a 45a 50a 55a 0.420a 0.361a 0.463a 0.593a -36 -10 -10 -21 
100:0 >2000 30a 47a 65a 60a 0.420a 0.537a 0.658a 0.677a -32 -7 -11 -10 
Ratio of  
PEG5K-b-PCL40: PCL40-co-BOD0.7 
             
0:100 140 90 85 95 90 0.074 0.084 0.124 0.123 -56 -45 -74 -92 
10:90 20 85 80 80 80 0.130 0.122 0.128 0.124 -52 -25 -19 -11 
25:75 20 75 75 75 75 0.146 0.117 0.144 0.164 -36 -14 -12 -7 
50:50 40 70 65 75 70a 0.181 0.145 0.217 0.207a -35 -6 -5 -6 
75:25 100 55 60a 55a 60a 0.198 0.219a 0.196a 0.227a -32 -8 -6 -7 
90:10 >2000 45a 50a 50a 50a 0.332a 0.272a 0.302a 0.292a -29 -8 -5 -5 
100:0 >2000 25a 40a 45a 50a 0.324a 0.324a 0.483a 0.506a -21 -5 -8 -4 
a Multimodal distributions obtained for this measurement, b volume of 0.5 M NaCl(aq.) added until visible precipitation was observed, c DLS characterisation 





Figure 3.9 – Graphical representation of changes in physicochemical characteristics with 
single 20 µL addition of 0.5 M NaCl(aq) to 1 Ml of each nanoparticle dispersion with 






Further exploration of the stability of the nanoparticles dispersions was conducted with the 
addition of 0.5 M NaCl(aq.) solution in aliquots (20 µL) to 1 mL of each aqueous dispersion 
until visual precipitation occurred (Table 3.2). It was found that with increasing PEGx-b-PCL40 
content there was increased stability of the nanoparticles to salt addition.  Interestingly when 
salt was added to the dispersion of 100 wt% PCL40-co-BOD0.7 the nanoparticles displayed 
tolerance up to 140 µL 0.5 M NaCl(aq.). This resistance to salt combined with the large zeta 
potential value of -56 mV indicates the energy barrier between flocculation and aggregation, 
defined by DLVO theory, was greater within this system when compared to the systems 
containing PEGx-b-PCL40.
20 It is also important to note that there was a slight increase in 
stability with those particles that had PEG5K-b-PCL40 present which was to be expected due to 
the longer hydrophilic block.  
3.2.2 (Co)-Nanoprecipitation studies of PCL polymers using a THF good 
solvent phase 
The solvent used within the nanoprecipitation process can have an effect on the 
physicochemical properties of the nanoparticles formed. To explore this phenomenon the study 
detailed in Section 3.2.1 was repeated with THF acting as the good solvent, replacing acetone. 
The same series of polymers was utilised to allow for direct comparison of the data produced 
by both THF and acetone. Other parameters such as concentration of the polymer in the good 
solvent and final polymer concentration in water after solvent evaporation were fixed at 5 mg 
mL-1 and 1 mg mL-1, respectively. As seen in Section 3.2.1, initial studies began with the 
synthesis of nanoparticles by nanoprecipitation of single species to assess stability and the 
physicochemical properties of the particles produced and the unfiltered samples were analysed 











Number Average Diameter 
(nm) 
PdI Zeta Potential (mV) 
Derived Count Rate 
(Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PCL10 100 540 530 365 370 0.410 0.360 -35 -40 36575 (6) 36410 (6) 
PCL20 100 125 125 75 75 0.140 0.155 -55 -55 462355 (4) 472840 (4) 
PCL30 100 140 140 95 90 0.135 0.155 -55 -60 438790 (4) 457700 (4) 
PCL40 100 145 145 90 90 0.150 0.160 -55 -60 404735 (4) 420750 (4) 
PCL50 100 115 115 70 70 0.135 0.135 -50 -60 417525 (4) 409140 (4) 
PCL60 100 105 105 65 65 0.130 0.145 -55 -60 357560 (4) 382500 (4) 
PCL80 100 100 95 55 50 0.150 0.155 -60 -65 326555 (5) 305080 (5) 
PCL100 100 120 120 75 75 0.125 0.135 -60 -60 456435 (4) 480580 (4) 
PCL40-co-BOD0.7 100 100 100 65 65 0.115 0.110 -50 -55 382840 (4) 344320 (4) 
PCL40-co-BOD0.6 100 105 105 65 70 0.130 0.115 -55 -55 427705 (4) 447255 (4) 
PCL60-co-BOD0.7 100 140 135 100 95 0.085 0.115 -50 -55 654825 (4) 650540 (4) 
PCL80-co-BOD0.7 100 95 95 60 60 0.105 0.110 -55 -50 342630 (5) 329440 (4) 





Upon initial observation the clearest difference seen when alternating the solvent used was the 
increase in both Dz and PdI of the nanoparticles nanoprecipitated from THF compared to 
acetone (Figure 3.10). This behaviour correlates with similar studies conducted with PEG-b-
PCL and pHPMA, in which both types of polymers produced larger and less monodisperse 
samples with THF.25,26,32 This phenomenon is largely the result of solvent/water interactions, 
solvent/polymer interactions, diffusion of the solvent and polymer and viscosity of the organic 
phase. A number of researchers have explored this area and the effects of solvent choice on the 
characteristics of the resultant nanoparticles; the consensus of these studies indicate that THF 
generally leads to larger particles than acetone.26,32 Comparison between the nanoparticles 
produced from the organic solvents acetone and THF within this study indicates that viscosity 
of the organic phase should not vary significantly due to the concentration of polymer in solvent 
remaining constant.32,33 Organic solvent/polymer interactions also play a role, however, in-
depth analysis of the interactions with polymers is somewhat lacking.33 The general consensus 
regarding this particular interaction is that higher solvent/polymer affinity results in reduced 
diffusion of the organic solvent into the water phase, and a shorter timescale for the creation of 
supersaturated polymer conditions due to the proportion of bound solvent.8 As a result of this 
the nanoparticles generated using a solvent with higher solvent/polymer interactions will result 
in smaller nanoparticles which could suggest a stronger interaction between acetone and PCL 





Figure 3.10 – Graphical representation of changes in physicochemical characteristics 






The role of solvent/water interactions has been most significantly cited within literature and an 
in-depth analysis of the solvent/water interactions has been performed by Galindo-Rodriguez 
et al. highlighting the definite dependence of nanoparticle size on the solvent nature.33 Initial 
calculations were performed to determine the difference in solubility parameter, ΔSW, of a 
given solvent, S, and water, W, using equation 3.2; where d denotes the dispersion force 
component, p is the polar component and h is the hydrogen bonding component, Subscripts 
S and W describe these partial parameters for solvent and water, respectively.
33  
∆𝛿𝑆𝑊 = [(𝛿𝑑,𝑆 − 𝛿𝑑,𝑊)
2
+ (𝛿𝑝,𝑆 − 𝛿𝑝,𝑊)
2




2      Equation 3.2 
These calculations determined that the smaller the value for ΔSW, the higher the affinity of a 
given solvent for water resulting in smaller nanoparticles. Further definition of the affinity 
between water and a given solvent was undertaken by Galindo-Rodriguez et al. and Bilati et 
al. where the solvent/water interaction parameters, ΧSW, were calculated for a number of 
solvents using equation 3.3; where VS represents the molar volume of solvent, R, is the gas 







                                        Equation 3.3 
A lower value of ΧSW signifies a higher affinity for water which promotes diffusion and 
polymer chain partitioning into the aqueous phase resulting in smaller nanoparticles.33,34 The 
interaction parameters of acetone and THF are calculated to be 23.9 and 28.7 respectively‡‡‡‡‡‡ 
by Lee et al. and therefore one would expect acetone to promote greater solvent diffusion upon 
addition to water and increased polymer chain partitioning correlating with the smaller particles 
produced in Section 3.2.1 when compared to THF.26,33  
The co-nanoprecipitation study undertaken from acetone in Section 3.2.1 was replicated, 
keeping the parameters unchanged apart from using THF as the good solvent. Ratios of 
amphiphilic block co-polymer to PCL40-co-BOD0.7 were increased from 0 wt% to 100 wt% for 
both PEG2K-b-PCL40 and PEG5K-b-PCL40. Similar to the acetone model, successful, stable 
nanoparticle dispersions were achieved in all cases and similar trends could be derived from 
the plotting of DLS analysis with regards to Dz, PdI and zeta potential (Figure 3.11). On average 
                                                          
‡‡‡‡‡‡ As a matter of context these values range from 0 for water-water, 11.4 for acetonitrile-water, 11 for ethanol-
water, 18.7 for isopropyl alcohol-water and 32.5 for ethyl lactate-water. Therefore the difference between acetone 





the Dz values for all the particles were higher than those produced using acetone as the good 
solvent (Figure 3.11, A). This indicates that the introduction of the hydrophilic PEG block does 
little to affect the solvent/polymer interactions or increase the affinity of THF for the polymer 
chains as this would have resulted in smaller particles. Interestingly, although PdI was higher 
when using THF and PEGx-b-PCL40 was low; larger concentrations of PEGx-b-PCL40 resulted 
in lower PdI than similar experiments using acetone and overall a smaller range in PdI 
throughout this series was observed. 
Zeta potential, which is less reliant on the solvent interactions with water and polymer chains, 
showed a similar trend to particles generated using acetone, with less negative values observed 
with higher PEGx-b-PCL40 content. This would be expected as zeta potential relies heavily on 
the composition of the nanoparticles. The decrease in negativity of the zeta potential values 
indicates a shift from electrostatic stabilisation, where ions, whether hydroxide or bicarbonate, 
are free to adsorb on the surface of the nanoparticles, imparting negative charge and 
contribution to the double layer hence stabilising the system.21,24,28–30 Increased PEGx-b-PCL40 
content masks the surface of the nanoparticle preventing the adsorption of these ions and 
shields the charge whilst simultaneously imparting steric stability between nanoparticles 
preventing aggregation. Comparison with the results gained by co-nanoprecipitation from 
acetone, particles with increasing PEG5K-b-PCL40 content showed a greater decrease in 
negative zeta potential than those stabilised PEG2K-b-PCL40 which was expected due to the 






Figure 3.11 – Graphical representation of changes in physicochemical characteristics of 
nanoparticles produced by co-nanoprecipitation with increasing PEGx-b-PCL40 content 





Nonetheless although co-nanoprecipitation using acetone as the good solvent overall produced 
particles of smaller size and lower PdI, the results gained with THF are comparable especially 
with the inclusion of stability considerations. Additionally, reflecting on the trends determined 
from studies in both acetone and THF it is clear that a compromise must be made for favourable 
physicochemical characteristics to select a ratio of PEGx-b-PCL40: PCL40-co-BOD0.7 for future 
studies. This compromise is best gained at the ratio of 50:50 wt% of the two polymer species, 
producing small particles of < 100 nm regardless of PEG length and PdI values of 
approximately 0.2. Moreover zeta potentials <-40 mV allows access to particles that have 
combined electrostatic and steric stability. 
3.2.2.1 Salt stability studies 
Salt studies were undertaken using the two separate methods detailed in Section 3.2.1.1 to allow 
for direct comparison to similar studies completed using acetone. The first method undertaken 
required the repeat analysis of each dispersion by DLS after a single 20 µL addition of 0.5 M 
NaCl(aq) (Table 3.4, Figure 3.12). Upon comparison to nanoparticles precipitated from acetone 
the data expressed in Figure 3.12 indicated less variation in physicochemical properties when 
precipitated from THF. PdI and Dz values varied only slightly in the first 24 hours with the 
largest changes being measured on day 7 across the full series of nanoparticles which could 
indicate increased stability from these particles. The largest trend was observed when the 
change in zeta potential over time was considered (Figure 3.12, C), emulating analysis of 
particles formed from an acetone co-nanoprecipitation. Moreover particles containing 100 wt% 
PCL40-co-BOD0.7 showed the same behaviour observed in the study detailed in Section 3.2.1.1 
wherein zeta potential became more negative over time. As described in Section 3.2.1.1 this 
could be a result of bicarbonate and chloride ions having similar propensity to adsorb onto 





Table 3.4 – DLS characterisation of nanoparticles produced by nanoprecipitation (from THF) with the addition of 0.5 M NaCl(aq) (20 µL);  
Sample 
Multiple 20 µL 
additions of 
0.5 M NaCl(aq) 
Single 20 µL addition of 0.5 M NaCl(aq) 
Volume of salt 
added until 
aggregation (µL)b 
Z-Average Diameter (nm)c PdIc Zeta Potential (mV)c 
No 
Salt 







Instant 1  Day 




             
0:100 120 105 100 100 100 0.120 0.115 0.115 0.140 -55 -65 -65 -60 
10:90 20 90 85 85 85 0.130 0.095 0.120 0.105 -45 -30 -25 -25 
25:75 20 80 80 80 75 0.135 0.115 0.135 0.120 -50 -20 -15 -20 
50:50 40 75 70 70 70 0.150 0.105 0.130 0.120 -35 -10 -10 -10 
75:25 60 55 55 55 55 0.185 0.150 0.165 0.160 -40 -15 -10 -10 
90:10 > 2000 40 40 40 40 0.215 0.140 0.205 0.205 -25 -10 -10 -10 
100:0 > 2000 25 30 30 35a 0.190 0.100 0.205 0.305a -30 -10 -10 -10 
Ratio of 
PEG5K-b-PCL40: PCL40-co-BOD0.7 
             
0:100 120 105 100 100 100 0.120 0.115 0.115 0.140 -55 -65 -65 -60 
10:90 20 120 115 115 110 0.125 0.105 0.115 0.115 -45 -10 -10 -10 
25:75 20 95 95 95 95 0.135 0.115 0.145 0.150 -40 -5 -5 -5 
50:50 20 80 75 75 75 0.140 0.115 0.115 0.130 -35 -5 -5 -5 
75:25 140 75 75 75 70 0.215 0.185 0.190 0.185 -35 -5 -5 -5 
90:10 > 2000 50 50 55a 60a 0.275 0.210 0.255a 0.250a -25 -5 -5 -5 
100:0 > 2000 25a 35a 45a 50a 0.295a 0.265a 0.390a 0.490a -15 -5 -5 -5 
a Multimodal distributions obtained for this measurement, b volume of 0.5 M NaCl(aq.) added until visible precipitation was observed, c DLS characterisation 





The second salt stability study requiring multiple additions of 0.5 M NaCl(aq) (20 µL) to 1 mL 
of each aqueous dispersion, showed little difference in the stability of the dispersions to results 
gained in Section 3.2.1.1 (Table 3.4). Nanoparticles synthesised from THF did require slightly 
more salt solution to induce aggregation although this was hard to determine visually and could 
not be classed as a significant difference between the two systems. Interestingly when PEGx-
b-PCL40 was absent, nanoparticles formed from 100 wt% PCL40-co-BOD0.7 showed higher 
stability to salt requiring 120 µL of 0.5 M NaCl(aq) to be added before aggregation occurred. It 
is clear the energy barrier between flocculation and aggregation was large therefore requiring 
a significant reduction before aggregation occured.20 This is indicated by the highly negative 
zeta potential of -55 mV which would requiring a larger number of positive Na+ ions to shield 
the electronegative stability induced by the adsorption of negatively charged hydroxide or 
bicarbonate ions to the surface of the nanoparticles.28–30 Furthermore the increasing 
concentration of PEGx-b-PCL40 resulted in an increase in stability to salt addition with 90 wt% 
PEGx-b-PCL40 content requiring > 2000 µL of salt before any aggregation occurred. This 
reflects results observed in similar studies using acetone and indicates similar concentrations 








Figure 3.12 – Graphical representation of changes in physicochemical characteristics 
with the addition of 20 µL 0.5 M NaCl(aq) with increasing PEGx-b-PCL40 content (THF) 





3.3 (Co)-nanoprecipitation utilising PSCM40-co-BOD0.7 
Investigations exploring the variation of the components used within the co-nanoprecipitation 
process were conducted with the selected ratio of 50:50 wt% amphiphilic di-block co-polymer 
to hydrophobic polymer, to be implemented for all future studies. It was thought that the 
versatility of this method would allow for the determination of the effects of polyester 
backbone chemistry on nanoparticle formation.25 Following the studies carried out with PCL 
based polymers in both Sections 3.2.1 and 3.2.2, in combination with previous studies 
conducted by Hatton et al., only branched co-polymers were studied.18 Initial comparison 
between the five branched polymers (PCL40-co-BOD0.7, PMOP40-co-BOD0.7, PPOP40-co-
BOD0.7, PBOP40-co-BOD0.7 and PPHLOP40-co-BOD0.7) synthesised in Sections 2.3.3.1 and 
2.4.2.1 were undertaken with the nanoprecipitation of each polymer from THF; as this solvent 
resulted in less multimodal nanoparticle dispersions after seven days (Figure 3.13).                 
Figure 3.13 – Graphical representation of changes in physicochemical characteristics 
with different PSCM40-co-BOD0.7 polymers (○) Z-average diameter Day 1, (×) Z-average 
diameter Day 7, (□) PdI Day 1 and (×) PdI Day 7. 
DLS analysis of the unfiltered samples revealed that the backbone of the hydrophobic branched 
polymer did effect the size of the nanoparticles although other physicochemical properties of 





five samples fell below -50 mV indicating complete electrostatic stability of the systems; this 
stability was sufficient enough to prevent aggregation with little change being observed over 
7 days for all five systems.20,21,24 PdI was also consistent between nanoparticles dispersions 
indicating that the solvent/polymer interactions were not playing a significant role in the control 
of the nanoparticle formation. However due to the backbone of each polymer being very similar 
to caprolactone, regardless of monomer used, this result would be expected.  
Dz values varied significantly depending on which monomer was used within the polymer 
backbone: PPOP40-co-BOD0.7 generated the largest particles of 175 nm with the second largest 
at 155 nm produced by PBOP40-co-BOD0.7. This indicates that the bulky iso-propyl and 
tert-butyl groups present on the caprolactone ring of POP and BOP monomers and 
subsequently in the polymer backbone decrease the efficiency of the polymer chains packing 
close together upon collapse in the nucleation growth process. This prevention of the polymer 
chains’ collapse into small nuclei and well organised adsorption of further groups within the 
growth process would most likely lead to the increase in nanoparticle hydrodynamic radius. 
This hypothesis would also be expected to play a role in PPHLOP40-co-BOD0.7 nanoparticles 
however these particles had Dz values of 105 nm, only slightly larger than PCL40-co-BOD0.7. 
It can be speculated that this could be a result of π to π stacking induced by the phenyl side 
group.35 These favourable intermolecular interactions would allow for chains to move closer 
to each other resulting in a more structured organisation of the chains and most likely reducing 
the size of the resulting nanoparticles. However it is important to keep in mind the probability 
of alignment is very small particularly in coiled polymer chains. Furthermore the modification 
of the polymer backbone with the addition of pendant alkyl groups may also alter the 
solvent/polymer interactions resulting in particles of varying sizes. This suggests that although 
the polymers are largely based on caprolactone-like monomers the small shift in alkyl side 
groups could have a significant effect on nanoparticle formation. 
3.3.1 PEG-b-PCL40 stabilised PSCM40-co-BOD0.7 nanoparticles via co-
nanoprecipitation 
After an initial study of branched polyester nanoprecipitation, a co-nanoprecipitation study was 
conducted utilising PCL derived A-B block co-polymers with each of the five branched 
polyester species detail in Section 3.3. Co-nanoprecipitation studies were performed with THF 
as the good solvent for the polymer and followed the same methodology detailed in Section 





concentration of 1 mg mL-1 after solvent evaporation. DLS analysis was undertaken on 
unfiltered samples both on day 1 and day 7 to gain full understanding of both the 
physicochemical properties of the nanoparticle dispersions and their stability over time (Table 
3.5). 
The addition of PEGx-b-PCL40 regardless of PEG block length resulted in a decrease in Dz for 
all the polymers compared to nanoprecipitation of 100 wt% branched species, for example 
co-nanoprecipitation of PPOP40-co-BOD0.7 with PEG2K-b-PCL40 and PEG5K-b-PCL40 
produced particles of 95 and 110 nm respectively (Table 3.5). This significant reduction in Dz 
from 175 nm without PEGx-b-PCL40 was also observed with studies involving PEGx-b-PCL40 
and PCL40-co-BOD0.7 although this was less significant when PEG5K-b-PCL40 was used as the 
stabiliser (Table 3.5). This phenomenon is most likely caused by the additional steric 
stabilisation of the nanoparticles by the addition of a PEG corona, increasing the energy barrier 
needed to be overcome to result in aggregation.21,24 Furthermore the combined steric and 
electrostatic stabilisation, inferred by the zeta potentials of all the nanoparticles being more 
negative or equal to -30 mV, causes the particles to reach stability at a smaller size than if 
reliant on electrostatic stabilisation alone.20,21,24  
Dz values for particles stabilised by PEG5K-b-PCL40 were larger overall than particles stabilised 
by PEG2K-b-PCL40 signifying the introduction of a larger PEG corona in the structure of the 
particles. Nonetheless these values, with the exception of PPHLOP40-co-BOD0.7, were smaller 
than those seen with 100 wt% branched hydrophobic polymer. This is again attributed to the 
gain of colloidal stability at a smaller size during the growth process due to the combination of 
both electrostatic and steric stabilisation.7,14,20,21 Further consideration of Dz values of all ten 
co-nanoprecipitations highlighted the same trend observed in the absence of PEGx-b-PCL40 
with a peak in Dz being achieved with the presence of PPOP40-co-BOD0.7 and PPHLOP40-co-
BOD0.7 producing particles similar in size to the PCL40-co-BOD0.7 based dispersion regardless 











PdI Zeta Potential (mV) 
Derived Count Rate 
(Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PEG2K-b-PCL40:  
PCL40-co-BOD0.7 
50:50 75 80 45 50 0.140 0.140 -40 -30 106045 (6) 89180 (6) 
PEG2K-b-PCL40:  
PMOP40-co-BOD0.7 
50:50 85 90 50 50 0.145 0.150 -35 -40 128700 (6) 122230 (6) 
PEG2K-b-PCL40:  PPOP40-
co-BOD0.7 
50:50 95 100 50 60 0.155 0.145 -40 -40 233800 (5) 148685 (6) 
PEG2K-b-PCL40: 
PBOP40-co-BOD0.7 
50:50 90 95 50 55 0.155 0.150 -40 -40 234285 (5) 223270 (5) 
PEG2K-b-PCL40: 
PPHLOP40-co-BOD0.7 
50:50 90 95 60 55 0.140 0.140 -40 -35 273960 (5) 234040 (5) 
PEG5K-b-PCL40:  
PCL40-co-BOD0.7 
50:50  100 100 60 60 0.150 0.155 -35 -30 120300 (6) 113380 (6) 
PEG5K-b-PCL40:  
PMOP40-co-BOD0.7 
50:50 100 105 55 60 0.155 0.150 -30 -35 119150 (6) 116530 (6) 
PEG5K-b-PCL40:    
PPOP40-co-BOD0.7 
50:50 110 115 60 75 0.135 0.140 -30 -30 247535 (5) 224620 (5) 
PEG5K-b-PCL40: 
PBOP40-co-BOD0.7 
50:50 110 110 60 60 0.175 0.165 -35 -30 202280 (5) 211695 (5) 
PEG5K-b-PCL40: 
PPHLOP40-co-BOD0.7 





Figure 3.14 – Graphical representation of physicochemical characteristics from the 
co-nanoprecipitation of 50:50 wt% PEGx-b-PCL40: PSCM40-co-BOD0.7 (THF). (A) Z-





Zeta potential, as mentioned previously, would indicate that electrostatic stabilisation would 
be taking part although it is hard to determine to what extent this may be (Figure 3.14, C).20,21,24 
It could be expected that complete resistance to salt addition would not be achieved by all ten 
dispersions particularly when compared to the results of the multiple addition of salt to 
PEGx-b-PCL40: PCL40-co-BOD0.7 nanoparticles (Section 3.2.2.1). However a 50:50 wt% ratio 
of PEGx-b-PCL40: PCL40-co-BOD0.7 in nanoparticles showed little variation over 7 days with 
the addition of only 20 µL 0.5 M NaCl(aq.) solution which is promising when considering the 
nanoparticles described in this section, Section 3.3.1, and the potential application of drug 
vehicles.  
Additionally limited variation in the physicochemical properties of all the nanoparticles 
stabilised by 50 wt% PEG2K-b-PCL40 and PEG5K-b-PCL40, measured on day 7, indicated good 
stability over time. This further adds to the promising data that points to the successful use of 
these systems as vehicles for drug delivery. 
3.3.2 PEG-b-PSCM40 stabilised PSCM40-co-BOD0.7 nanoparticles via (co)-
nanoprecipitation 
A final exploration involving co-nanoprecipitation of the hydrophobic branched polyesters 
involved matching hydrophobic blocks of PEG5K block co-polymers with respect to polyester 
backbone chemistry. This enabled the study of the effects complementary hydrophobic 
polymer segments may have on the co-nanoprecipitation process. The first element of this 
examination was the nanoprecipitation of the linear PEG5K block co-polymers derived from 
each substituted caprolactone monomer, in the absence of the core-forming branched polyester, 






Figure 3.15 – Graphical representation of changes in physicochemical characteristics of 
PEG5K-b-PSCM40 nanoparticles prepared by nanoprecipitation. (○) Z-average diameter Day 
1, (×) Z-average diameter Day 7, (□) PdI Day 1 and (×) PdI Day 7. 
Upon DLS characterisation it was clear that the polymers generated particles of micelle size 
and produced multimodal size distributions and large PdI values > 0.25. Therefore the results 
gained from this study could not be used to conclusively analyse trends in size and control 
between the five nanoparticle dispersions; however, it could be deduced that the addition of 
side chain functionality within the hydrophobic segments of the co-polymers led to larger 
particles than PEG5K-b-PCL40. Zeta potentials were significantly more positive than values 
seen for the co-nanoprecipitated or 100 wt% branched hydrophobic polymer particles described 
in Sections 3.3.1 and 3.3 respectively. The zeta potential values seen in this series, all ≤ -30 
mV, indicate that the particles are most likely solely sterically stabilised by the PEG corona 
creating a barrier against aggregation.21,24 This stability was indicated by the lack of variation 
in the physicochemical properties of each dispersion over 7 days reflected significantly in 
Figure 3.15. 
The importance of matching the chemistry of the hydrophobic block of the stabilising 
amphiphilic A-B block co-polymer to the branched polyester was investigated by 





polymer was kept consistent at 50:50 wt% allowing direct comparison to the PEG5K-b-PCL40 
stabilised series. THF was also used as the good solvent within this study mitigating any effects 
imparted from organic solvent choice and allowing for direct comparison to previous work 
within this chapter.  
DLS analysis of these systems when first co-nanoprecipitated revealed the production of larger 
particles than those produced by the PEG di-block co-polymers alone (Figure 3.16). This was 
to be expected as 50 wt% of the polymer mixture was now a bulky branched polymer of high 
molecular weight. There also seemed to be a shift in the stability mechanism of the particles to 
include electrostatic stabilisation. The increased concentration of hydrophobic material during 
the nucleation-growth process skews the stabilisation to favour combined steric and 
electrostatic stabilisation.28–30 Interestingly the substitution of PEG5K-b-PCL40 for the PEG co-
polymer that is complementary to the hydrophobic branched core resulted in a reversal of the 
behaviour of the polymer with respect to size with PEG5K-b-PPOP40: PPOP40-co-BOD0.7 (50:50 
wt%) producing the smallest particles with a Dz value of 90 nm (Figure 3.16). This could 
indicate that use of complementary block co-polymers increases favourable polymer-polymer 
interactions and decreases the potential for phase separation during nanoparticles formation 
inducing favourable collapse of the polymer chains and thus producing smaller particles. This 
could also be an indication of the effects utilising a mixture of PEG5K-b-PCL40 and hydrophobic 
branched polymer had on the solvent/polymer interactions, indicating that the mixture of 
hydrophobic polymers of differing structure reduced or scrambled solvent/polymer interactions 
resulting in larger particles.8 If this were the case it would be expected that PPOP40-co-BOD0.7 
and PBOP40-co-BOD0.7 would produce the largest particles when paired with PEGx-b-PCL40 





Figure 3.16 – Graphical representation of changes in physicochemical characteristics of 
co-nanoprecipitation of complementary PEG5K-b-PSCM40: PSCM40-co-BOD0.7 (50:50 
wt%, THF) including results reprecipitated from stock solutions stored for 246 days. (A) 





As an alternative investigation with this series of nanoparticles, the stock solutions of THF 
containing the polymers were kept at ambient temperature for a number of months to explore 
the possibility of reproducing the nanoparticles after storage. 246 days after first synthesis the 
THF solutions for the polymers mixtures were re-used in co-nanoprecipitation studies, 
generating samples with a final concentration in water of 1 mg mL-1 (Figure 3.16). Analysis 
indicated that nanoparticles produced from all five solutions were largely comparable to the 
initial results achieved with fresh solutions of polymer in THF particularly when Dz was 
considered. PdI and zeta potential did deviate from initial results more significantly with PdI 
increasing to include values > 0.2 compared to values < 0.175 for freshly produced 
nanoparticles. Zeta potential again increased becoming less negative after 246 days storage 
with an average reading of -20 mV generated across the series of nanoparticles. Throughout 
these studies the same DLS apparatus and type of cuvette were used, where the measurement 
distance was fixed in order to rule out variation in the physicochemical properties of the 
nanoparticles resulting from measurement. A possible cause for the variation in parameters 
could be a result of greater solvation of the polymer over storage time or slight degradation of 
the polymers within solution due to storage at ambient temperature rather than in a colder 
environment.  
Nonetheless the secondary results from the re-precipitation 246 days after the first use of the 
stock solutions correlated well with the analysis obtained seven days after the re-precipitation. 
This indicated that although it is unclear as to the cause of varying results between the first and 
second synthesis of the nanoparticle dispersions colloidal stability was still achieved. There 
was very limited change regarding Dz, PdI and zeta potential values over the 7 day period and 
this was also reflected by limited change in derived count rate of each solution signifying no 
aggregation or sedimentation. These results provide a fascinating insight into the nanoparticle 
formation and the stability imparted on these systems again combining steric and electrostatic 
stabilisation. 
3.4 Model encapsulation via co-nanoprecipitation 
An exploration of the capabilities of the systems studied in Sections 3.2 and 3.3.1 to 
encapsulate hydrophobic guest molecules was undertaken for two different hydrophobic 
compounds namely Oil red O and an anticancer drug docetaxel (Figure 3.17). THF was used 
to dissolve the chosen polymers (50:50 wt% PEGx-b-PCL40 to PCL/SCM40-co-BOD0.7) at a 





and the guest molecule (at a test loading of 2.43 wt%); 1 mL of this solutions mixture was 
added to water targeting a final concentration of 1 mg mL-1 (1 mg polymer in 1 mL water, 
varying the weight content of guest to 2.43 wt%) after solvent evaporation.§§§§§§ 
               
Figure 3.17 -Molecular structures for guest molecules used in model encapsulation 
studies. (A) Oil Red O and (B) docetaxel. 
3.4.1 Encapsulation of Oil red O via co-nanoprecipitation 
Oil red O is a molecule used to stain lipid and fat components in biological samples, and more 
recently in latent fingerprints, due to its highly hydrophobic nature which in turn make it the 
ideal model to test nanoparticle encapsulation capabilities.36 Investigations were conducted 
with the encapsulation of Oil red O from a THF solution containing polymer and guest 
molecule. Here, PEGx-b-PCL40 was used to stabilise nanoparticles formed from each of the 
hydrophobic branched polymers with 2.43 wt% Oil red O. The ratio of PEGx-b-PCL40 to 
PCL/SCM40-co-BOD0.7 was fixed at 50:50 wt% following the results gained in Section 3.2 
aiming for a compromise between size, polydispersity and zeta potential of each dispersion. 
DLS analysis was performed on the unfiltered samples on the day of formation and 14 days 
after initial measurement to gage whether these systems also possessed stability over time 
(Figure 3.18).  
Dz values of these systems revealed the same trend observed in the absence of Oil red O with 
the particles containing 50 wt% PPOP40-co-BOD0.7 producing the largest particles when 
stabilised either by PEG2K-b-PCL40 or PEG5K-b-PCL40. This indicated that the presence of this 
guest molecule had little effect on the nucleation-growth process or that its effect was 
                                                          
§§§§§§ As these were concentrations based on the mass of only polymer in solvent (THF or water), the total solid 
concentration with 2.43 wt% guest is calculated to be 5.125 mg mL-1 in THF and 1.025 mg mL-1 in water. These 
equate to masses of 50 mg polymers and 1.25 mg guest molecule in 10 mL THF and 5 mg polymer and 0.125 mg 





negligible compared to the backbone of the hydrophobic branched polymer. Further 
consideration of the Dz values showed an overall increase in the size of the nanoparticles 
produced compared to the blank counterparts. The PdI and zeta potentials generated by each 
sample were also comparable to the corresponding blank systems. This, combined with the 
lack of aggregates within each dispersion, again reinforces the hypothesis that Oil red O 
encapsulation was successful.  
Finally, repeat DLS measurements on the samples 14 days after first synthesis, and with storage 
at ambient temperature, highlighted their stability as little variation in all physicochemical 
properties was observed. This mirrors results observed for corresponding blank particles and 
is most likely due to the combined electrostatic and steric stability imparted on the particles by 
the PEG corona and hydrophobic particle core.21,24 The results generated from this initial 
experiment were a promising step towards the ultimate goal of encapsulation of SN-38 within 
these systems. Although the drug loading capabilities with this molecule was low, the success 
at 2.43 wt% was encouraging in the fact that guest molecules had effectively no impact on the 






Figure 3.18- Graphical representation of physicochemical characteristics from the 
co-nanoprecipitation of 50:50 wt% PEGx-b-PCL40: PSCM40-co-BOD0.7 to encapsulate Oil 





3.4.2 Encapsulation of docetaxel via co-nanoprecipitation 
Although Oil red O encapsulation was successful an additional model encapsulation study with 
docetaxel was conducted to study the diversity of chemical structures that may be incorporated 
using these novel polymers. Encapsulation of docetaxel was attempted at 2.43 wt% in PEG5K-
b-PCL40: PCL/SCM40-co-BOD0.7 (50:50 wt%) systems following the success in these 
conditions with Oil red O. Following the methodology used in all previous studies 1 mL of 
THF solution containing the polymers and drug (5 mg mL-1, 5 mg polymer to 1 mL THF, 
varying the weight content of guest to 2.43 wt%) was added to 5 mL of water targeting a final 
concentration of 1 mg mL-1 (1 mg polymer in 1 mL water, varying the weight content of guest 
to 2.43wt%) after solvent evaporation. DLS analysis was performed on the unfiltered samples 
on the day of synthesis and 7 days later to study the stability of these systems and compare to 
the Oil red O containing nanodispersions (Figure 3.19).   
Each of the nanoparticle dispersions successfully encapsulated docetaxel with no precipitation 
or sedimentation evident after THF evaporation. DLS analysis revealed that, similar to the Oil 
red O study, Dz values followed the same trend as the co-nanoprecipitation of the same systems 
without drug. The PEG5K-b-PCL40: PPOP40-co-BOD0.7 (50:50 wt%) system therefore produced 
the largest particles of 100 nm. Nonetheless the diameters of all five systems were smaller than 
their blank counterparts although this does not indicate that encapsulation was unsuccessful 
especially when the appearance of each dispersion indicates no drug precipitate. The smaller 
Dz values for these systems indicate that docetaxel molecules are most likely acting as nuclei 
from which the nanoparticles can grow with well-defined, fast nucleation and growth steps.6,7 
PdI also followed a similar trend to the blank systems with the most polydisperse particles 
being produced when PMOP40-co-BOD0.7 and PBOP40-co-BOD0.7 were present in the 
hydrophobic branched core of the nanoparticles. Finally, zeta potential showed very little 
variability between all five systems and was indicative of a combination of both steric and 






Figure 3.19- Graphical representation of physicochemical characteristics from the 
co-nanoprecipitation of 50:50 wt% PEG5K-b-PCL40: PSCM40-co-BOD0.7 to encapsulate 





The stability of these systems was determined by repeated DLS characterisation seven days 
after first analysis was undertaken. Although the Oil red O systems were characterised on day 
14, docetaxel containing nanoparticles showed very little variation in all characteristics after 
the seven day period (Figure 3.19). This was particularly reinforced by the similarities between 
derived count rate on day 1 and day 7 indicating that minimal to no sedimentation or 
aggregation had occurred upon storage at ambient temperature. The lack of aggregation of the 
particles was also indicated by the lack of variation in Dz over seven days. The confirmation of 
little change within all five systems give further evidence to the successful encapsulation of 
docetaxel.  
The success of docetaxel encapsulation alongside that of Oil red O in the same systems 
generates promising evidence as to the capabilities of these systems to encapsulate hydrophobic 
guest/drug molecules. In addition, the stability of these systems over time would be beneficial 
for the use of these nanoparticle dispersions as drug delivery vehicles. The combination of the 
results gained in Section 3.4 also provides encouragement to expand encapsulation 
investigations to include SN-38 and SN-38 like drug molecules to ultimately fulfil one of the 
goals for this body of work. 
3.5 Conclusions 
In conclusion, initial exploration of co-nanoprecipitation, utilising PCL polymers indicated that 
branched architectures generated smaller nanoparticles than those of linear PCL. This trend 
regarding architecture followed previous findings from work completed by Hatton et al. and 
Flynn et al., completed with polymethacrylates and indicated that the use of polyester based 
polymers did not cause a deviation from the trend they observed.18,19 
Alternation of the organic solvent used to solvate the polymers to be nanoprecipitated, from 
acetone to THF, highlighted the role solvent played in the mechanism of formation of the 
nanoparticles. It is noted that solvent/water interactions play the greatest role in the increased 
size of nanoparticles synthesised from THF with regards to polyesters; with THF having a 
larger interaction parameter, 28.7, than acetone, 23.9, signifying a lower affinity for water and 
ultimately leading to larger particles. However the small increase in Dz and PdI in THF 
suggested that this effect was limited. Variety in size of nanoparticles produced with the 
variation of polymer backbone also indicated that solvent/polymer interactions played a role in 





Additionally the variation in polyester backbone appeared to have little effect on the successful 
nanoprecipitation of the branched polymers formed from substituted caprolactone monomers. 
Furthermore the mixed polyester backbone chemistry co-nanoprecipitation of these branched 
species with PEGx-b-PCL40 had no discernible effect. This confirms that, if necessary, each 
linear amphiphilic A-B block polymer could be successfully co-nanoprecipitated with the 
complete branched polyester library.   
Finally successful encapsulation of Oil red O and docetaxel at 2.43 wt% showed that the 
hydrophobic character of the polyester core aided the incorporation of guest molecules. 
Furthermore docetaxel containing nanoparticles possessed smaller Dz values than those without 
drug which may indicate drug molecules playing a role in nucleation.6,7 The effective 
encapsulation of both Oil red O and docetaxel, which vary greatly in structure, would imply 
that co-nanoprecipitation is a viable route to SN-38 containing nanoparticles and offers a 
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There have been several systems that have succeeded in the encapsulation of SN-38 with the 
intent for intravenous delivery to tumour sites. A number of these systems involve polyester-
based nanoparticles, such as PLGA, decorated with active targeting moieties specific to a 
selected form of cancer. For example, PEG-PCL based nanoparticles decorated with a cancer 
stem-cell-like antibody, CD133Ab, successfully encapsulated SN-38 by freeze-drying and 
dispersion and were shown to selectively target colorectal cancer cells, reducing tumour 
growth.1 SN-38 was also encapsulated in PLGA microspheres, as an example of a non-active 
targeting system, synthesised by emulsion-solvent evaporation achieving 6.89 wt% drug 
content. In vivo analysis of these systems revealed that tumour growth was significantly 
inhibited; however these microspheres were directly injected into the tumour; therefore their 
ability to target the tumour site was not assessed.2 Although these examples have shown that 
encapsulation of SN-38 is possible in a variety of systems encapsulation via co-
nanoprecipitation seems to be lacking within literature reports with only a small number of 
examples; such as work encapsulating the drug within pHPMA based nanoparticles by Ford et 
al.3 
Investigations completed in the previous chapters laid the foundation for the work to be carried 
out within this chapter with the ultimate goal of achieving the successful encapsulation of 
SN-38. The polymers produced in Chapter 2 showed both the versatility of MSA catalysed 
ROP, but more relevantly the use of novel substituted caprolactone monomers allowed the 
thermal adaptation of the resulting polymer species. Similarly, the alteration of architecture 
also allowed access to different thermal properties, although this effect was less pronounced. 
Furthermore, the application of the five mono-functional monomers, one bi-functional 
monomer and two initiators, targeting four different architectures, created a polymer library 
ideal for the exploration of nanoparticle formation and guest encapsulation. The differences in 
thermal properties and crystallinity, gained by the alteration of the polymer backbone, may 
allow the tuning of favourable interactions with SN-38 to increase the likelihood of 
encapsulation. Additionally, these interactions could also improve the encapsulation ability of 
the resulting nanoparticles, thereby increasing the drug loading achieved.   
Following methods previously outlined by Rannard and co-workers, (co)-nanoprecipitation 
from acetone and THF allowed the exploration of the influence good solvent choice and 





This defined the conditions for further studies investigating the impact of polymer architecture 
and monomer selection on the resultant physicochemical properties of the particles. The studies 
also allowed proof-of-concept encapsulation studies with Oil red O and docetaxel to confirm 
the potential for guest-host studies using drug molecules. Analysis of these systems after 
storage confirmed that the presence of a guest molecule had little effect on stability over time.  
4.1.1 Chapter aims 
This chapter aims to build on the work and insights gained in the previous chapters, mentioned 
above, and take steps towards the encapsulation and assessment of SN-38 within polyester 
nanoparticles. The encapsulation SN-38 and SN-38-derived drug molecules is expected to be 
possible but it is hypothesised that macromolecular architecture may influence the ability of 
each polymer to obtain significant drug loadings. Therefore this is expected to allow for the 
investigation of possible polymer-drug interactions. An initial target of 2.43 wt% drug loading 
is expected to allow for comparisons to Oil red O and docetaxel encapsulation and build a 
foundation to understand the impact of increased drug loading. Polymer-drug interactions and 
the consequences these have on drug encapsulation, and nanoparticle stability are also 
important to explore. Furthermore, it is postulated that the variability in thermal properties and 
crystallinity of the polymers may affect encapsulation and stability.  
Pharmacological behaviour, specifically drug release, cytotoxicity, macrophage uptake and in 
vivo pKa studies, will help to gain a complete overview of the behaviour of these nanoparticles 
within a biological setting and offer a view of future medicinal value.  
4.2 Encapsulation of SN-38-based drug molecules via co-nanoprecipitation 
The encapsulation of SN-38 and SN-38 derivatives was conducted via co-nanoprecipitation 
using both PEGx-b-PCL40 and PEG5K-b-PSCM40 stabilising hydrophobic branched polymers 
which have already been shown to successfully form stable nanoparticle systems in the absence 
of drug (Chapter 3, Section 3.2 & 3.3). Studies were conducted following the same 
methodology implemented in Chapter 3 with the addition of 1 mL THF solution, containing 
polymer and drug (5 mg mL-1 polymer concentration with varying amounts of drug) to 5 mL 
deionised water targeting a final concentration, after evaporation, of 1 mg mL-1 (polymer 






4.2.1 Encapsulation of SN-38 pentanoate, SN-38 P, via co-nanoprecipitation 
Considering that SN-38 has previously been shown to be notoriously problematic concerning 
encapsulation within literature reports,4 studies began with the encapsulation of SN-38 
pentanoate, SN-38 P, a ‘pro-drug’ like molecule based on SN -38, with a pentanoate group at 
carbon 10 (Figure 4.1, B). This was synthesised within the Rannard group by Dr A Dwyer via 
nucleophilic addition/elimination reaction between pentanoyl chloride and the phenolic group 
of the drug at room temperature for 12 hours under a nitrogen atmosphere; 
4-dimethylaminopyridine, DMAP, was used as a catalyst (nucleophilic base) and 
N,N-diisopropylethylamine, DIPEA, as a scavenger and the product was purified by silica gel 
chromatography. As this molecule has a small alkyl chain variation compared to SN-38, this 
was more desirable as a model for SN-38 than irinotecan, which has been adapted specifically 
to mitigate the insolubility of SN-38 allowing for intravenous administration (Figure 4.1, A).  
 
Figure 4.1- Molecular structures for SN-38 and SN-38 derivatives. (A) Irinotecan, (B) SN-38 
Pentanoate, SN-38 P, and (C) SN-38.    
Investigations began with a 2.43 wt% drug loading, as discussed above, maintaining the 50:50 
wt% amphiphilic block co-polymer to hydrophobic branched polymer ratio. DLS analysis was 
conducted using unfiltered samples, allowing the physicochemical properties of each 





Table 4.1 – DLS characterisation of nanoparticles produced by co-nanoprecipitation with PEGx-b-PCL40 or PEG5K-b-PSCM40  (50:50 






PdI Zeta Potential (mV) 




Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 
PEG2K-b-PCL40:  PCL40-co-BOD0.7 100 100 45 50 0.240 0.300 -25 -25 112125 (6) 171080 (5) 
PEG2K-b-PCL40:  PMOP40-co-BOD0.7 105 105 45 50 0.290 0.290 -20 -20 117225 (6) 124740 (6) 
PEG2K-b-PCL40: PPOP40-co-BOD0.7 115 115 65 65 0.165 0.160 -25 -25 324035 (5) 299575 (5) 
PEG2K-b-PCL40: PBOP40-co-BOD0.7 105 100 55 50 0.315 0.265 -25 -20 139350 (6) 204695 (5) 
PEG2K-b-PCL40: PPHLOP40-co-BOD0.7 95 90 50 50 0.185 0.190 -20 -20 303595 (5) 293575 (5) 
PEG5K-b-PCL40:  PCL40-co-BOD0.7 125 120 65 40 0.260 0.260 -20 -20 220770 (5) 224760 (5) 
PEG5K-b-PCL40:  PMOP40-co-BOD0.7 110 105 55 65 0.190 0.195 -25 -20 129950 (6) 196015 (5) 
PEG5K-b-PCL40:    PPOP40-co-BOD0.7 125 125 65 65 0.185 0.190 -25 -20 273780 (5) 266290 (5) 
PEG5K-b-PCL40: PBOP40-co-BOD0.7 110 110 40 45 0.230 0.210 -25 -20 189380 (5) 124465 (6) 
PEG5K-b-PCL40: PPHLOP40-co-BOD0.7 105 105 60 60 0.195 0.210 -20 -20 291720 (5) 305970 (5) 
PEG5K-b-PMOP40:  PMOP40-co-BOD0.7 105 100 60 60 0.210 0.170 -20 -20 120935 (6) 119985 (6) 
PEG5K-b-PPOP40:  PPOP40-co-BOD0.7 105 100 50 40 0.345 0.285 -20 -20 102740 (6) 97980 (6) 
PEG5K-b-PBOP40:  PBOP40-co-BOD0.7 110 100 40 50 0.265 0.240 -25 -20 102255 (6) 106700 (6) 





After solvent evaporation, it was immediately clear that nanoparticle formation was successful 
with no evident aggregation or precipitation. SN-38 P was assumed to be encapsulated within 
the nanoparticles due to the lack of precipitate around the glass and a lack of powder 
sedimentation. DLS characterisation confirmed the presence of nanoparticles in all cases with 
all dispersions appearing monomodal. When particles were stabilised by PEG2K-b-PCL40 Dz 
values followed the same trend with varying hydrophobic branched polymer that was observed 
in Chapter 3 (Section 3.3) with PPOP40-co-BOD0.7 based nanoparticles being the largest at 115 
nm (Figure 4.2, A, Table 4.1). The PdI values for these five samples, however, did not follow 
a trend with the values varying significantly with the hydrophobic branched polymer used 
(Figure 4.2, B). The extension of the PEG block to PEG5K-b-PCL40 resulted in larger particles, 
produced in all five cases, which was to be expected due to the larger PEG corona extending 
out into the aqueous phase increasing the hydrodynamic radius of the particles. PEG5K-b-
PCL40: PPOP40-co-BOD0.7 (50:50 wt%)  produced the largest particles of 125 nm but this was 
equalled by PEG5K-b-PCL40: PCL40-co-BOD0.7 deviating away from the trend observed with 
PEG2K-b-PCL40 stabilised particles. Furthermore, there was a decrease in the PdI values for all 
the PEG5K-b-PCL40 stabilised systems which was complemented by a decrease in variability 
between the hydrophobic branched polymers used.  
When the hydrophobic block of the stabilising amphiphilic block co-polymer was matched to 
the hydrophobic branched polymer the trend in Dz observed in Chapter 3 (Section 3.3) was 
again replicated with an increase towards BOP based polymers (Dz = 110 nm) followed by a 
decrease for PHLOP (Dz = 90 nm) (Figure 4.3). PdI became more variable for this set of four 
systems and no real trend could be deduced. Considering the zeta potentials of all the systems, 
regardless of amphiphilic PEG co-polymer used, were between -20 and -25 mV this indicated 
the combined steric and electrostatic stabilisation which had been identified in Chapter 3.  
DLS analysis 14 days after initial measurements showed more variability than had been 
detected in the equivalent systems in the absence of encapsulated guest molecules. This 
indicates the presence of sedimentation and suggests encapsulation of SN-38 P may not have 
been as successful as first thought. However, little variation in the derived count rates of all 
these systems suggests that the number of particles remains relatively constant signifying that 






Figure 4.2- Graphical representation of physicochemical characteristics from the 
co-nanoprecipitation of 50:50 wt% PEGx-b-PCL40: PSCM40-co-BOD0.7 to encapsulate 





Figure 4.3- Graphical representation of physicochemical characteristics from the 
co-nanoprecipitation of 50:50 wt% PEGx-b-SCM40: PSCM40-co-BOD0.7 to encapsulate 





To gauge the potential of these systems to achieve higher drug loading, SN-38 P content was 
increased stepwise up to 5 wt%; however, this failed to produce dispersions in which all 
SN-38 P was contained within the nanoparticles as determined by aggregated material sticking 
to the sides of each glass vial after solvent evaporation. This material had the appearance of 
SN-38 P, which indicated that although encapsulation had failed, the formation of polymeric 
nanoparticles was not affected by the increased drug content. Nonetheless this result combined 
with evidence from Oil red O encapsulation indicates that there appears to be a limit to the drug 
loading capabilities of these systems synthesised by co-nanoprecipitation. However, further 
studies with a more extensive library of hydrophobic guest molecules could expand on whether 
this limit is universal or unique to specific guest molecules. 
4.2.2 Encapsulation of SN-38 via co-nanoprecipitation 
Promising encapsulation results generated with Oil red O, docetaxel and SN-38 P prompted 
investigations using SN-38 via co-nanoprecipitation. Several studies were undertaken 
replicating conditions detailed in Section 4.2.1 and targeting a drug loading of 2.43 wt%. 
Unfortunately, although encapsulation of this drug molecule has been achieved by 
co-nanoprecipitation with pHPMA based systems, each attempt utilising the polymers 
produced in Chapter 2 failed to successfully encapsulate SN-38.3 At the time of organic solvent 
addition all nanoparticle dispersions showed no aggregation and/or solid precipitate present; 
however, after full solvent evaporation, particle dispersions had an iridescent “smoky” 
appearance thought to be the result of fine crystals of SN-38 (Additional Appendix, page 3). 
The lack of polymer precipitate would indicate that polyester nanoparticles were still obtained 
regardless of which polymer was used. Analysis of these samples by optical microscopy 
revealed the presence of spindle-like crystals which were assigned to SN-38 crystallising and 





Figure 4.4- Optical microscope images showing the presence of SN-38 crystals in the 
aqueous phase. 
4.2.2.1 Dilution studies of co-nanoprecipitation with guest molecules 
The phenomenon was further investigated with the implementation of dilution studies, a 
methodology first detailed by Ford et al. to explore the nanoprecipitation zone for pHPMA 
based polymers.5 It was theorised that the implementation of this methodology would highlight 
the behaviour of the polyester mixtures (with and without drug) in aqueous solvent 
environments and therefore indicate any behavioural differences between polyester backbone 
chemistry and drug molecule presence. Here the polymers without drug, initially chosen as 
PEG5K-b-PCL40: PCL40-co-BOD0.7 (50:50 wt%), were dissolved in THF at various 
concentrations from 1.5625 to 25 mg mL-1, maintaining a fixed final mass of polymer in 5 mL 
water of 12.5 mg after evaporation. The organic polymer solution was added to 5 mL of water 
at increasing volumes from 0.5 to 8 mL and DLS analysis was undertaken immediately after 
THF addition and after solvent evaporation. Plots of derived count rate, DCR, PdI and Dz values 
both before and after solvent evaporation against volume of THF added, allowed for the 







Figure 4.5 – DLS studies of co-nanoprecipitation of PEG5K-b-PCL40 with PCL40-co-
BOD0.7 varying the THF: 5 mL water ratios keeping a constant mass of polymer (12.5 
mg) measured before (black) and after (red) solvent evaporation; (A) derived count rate, (B) 
Z-average diameter and (C) PdI. 
The polyester-based systems studied here appear to be significantly more hydrophobic than the 
various pHPMA-derived materials studies by Ford et al., forming nanoparticles upon instant 
organic solution addition up to and including a THF: water ratio of 8:5;5 this suggests that such 





which is in stark contrast to the low concentrations of organic solvent that could be tolerated 
by pHPMA-derived nanoprecipitates. 
The DCR generated for the PEG5K-b-PCL40: PCL40-co-BOD0.7 co-nanoprecipitation at all 
volumes of THF additions indicated nanoprecipitate formation and this observation was 
mirrored in the Dz and PdI results of the nanoprecipitates with swollen nanoparticles present 
within the aqueous/solvent environment and smaller nanoparticles after solvent evaporation. 
In all instances of THF: water mixtures (from 0.5:5 to 8:5) nanoprecipitates were < 300 nm 
with PdI values between 0.050 and 0.165 which would indicate a fast nucleation step and rapid 
growth. The decrease in Dz values and increase in DCR is consistent with THF evaporation, 
causing the de-swelling of nanoparticles as trapped THF solvating polymer chains, exits the 
system. The lack of variability between PdI values before and after solvent evaporation would 
indicate that solvent evaporation does little to affect the monodispersity of the system which 
must be defined upon instant addition of the THF/polymer mixture to the aqueous phase. This 
further eludes to fast nucleation and a fast growth period with a rapid termination, as slow 
growth would most likely result in macro-precipitation with large Dz and PdI values. 
The nanoprecipitation process was also studied in the presence of SN-38 dissolved in the THF 
solutions (12.5 mg polymer mass remained constant) to study the impact of a guest molecule. 
Here, PEG5K-b-PCL40: PCL40-co-BOD0.7 and PEG5K-b-PCL40: PPOP40-co-BOD0.7 
(50:50 wt%) were both investigated to also analysed the impact of polyester chemistry on the 
nanoprecipitation outcomes; the drug content was fixed at a 2.43 wt% drug loading with respect 
to polymer. DLS analysis provided the DCR, PdI and Dz before and after evaporation which 





Figure 4.6 – DLS studies of co-nanoprecipitation of PEG5K-b-PCL40 and SN-38 with either PCL40-co-BOD0.7 or PPOP40-co-BOD0.7 varying 
the THF: 5 mL water ratios keeping a constant mass of polymer (12.5 mg) measured before (black) and after (red) solvent evaporation; 





The chemistry of the hydrophobic branched polymer backbone appeared to have minimal effect 
on the behaviour of the nanoprecipitation with both systems producing highly similar results. 
The only significant difference between the two systems was a lack of increase in DCR for the 
PEG5K-b-PCL40: PPOP40-co-BOD0.7 when 8 mL THF was added. This could indicate a change 
in the solvent/polymer interactions during the nanoprecipitation mechanism. Comparison to 
the blank PCL-based dispersions revealed that the presence of drug had little impact on the 
nanoprecipitation behaviour of each system. Nonetheless a greater increase in PdI after solvent 
evaporation was observed in the drug-containing systems. This was most likely due to drug 
crystals precipitating in the aqueous dispersions due to failed encapsulation. Combined with 
the decrease in Dz values after solvent evaporation, this reinforces the hypothesis (detailed in 
Section 4.2.2) that although encapsulation of SN-38 was unsuccessful polymeric nanoparticles 
were still formed. This would also indicate that the crystals observed in Figure 4.4 by optical 
microscopy were indeed indicative of the drug. 
Finally, studies of the SN-38 nanoprecipitation in the absence of polymer were conducted. The 
final drug mass in 5 mL water was maintained at 0.3125 mg which reflected the concentrations 
and conditions used on the presence of polymer. The same treatment of the DLS data collected 
in the presence of organic solvent allowed the comparisons to be drawn with the previous two 
studies undertaken in this way (Figure 4.7). As the drug nanoparticles were unstable in an 
aqueous environment, DLS analysis was not undertaken after solvent evaporation as the data 





Figure 4.7 – DLS studies of nanoprecipitation of SN-38 varying the THF: 5 mL water ratios keeping a constant drug mass in 5 mL water 
(0.3125 mg); (A) derived count rate, (B) Z-average diameter and (C) PdI; for (i) SN-38 alone (solvent present) and (ii) SN-38 compared with PEG5K-b-PCL40: 





Firstly, considering the DCR, when the THF volume increased above 1 mL addition, the DCR 
fell to 1980 kcps followed by values < 200 kcps indicative of a sample with very limited light 
scattering (Figure 4.7, i). This was mirrored in the Dz values which dropped dramatically when 
volumes of THF greater than 1 mL were added, and this would suggest that SN-38 is 
significantly soluble in THF/water mixtures containing low concentrations of THF. 
Comparison with the co-nanoprecipitation of PEG5K-b-PCL40: PCL40-co-BOD0.7 (50:50 wt%)  
in the absence of SN-38 markedly highlights the different behaviour of the polymers and 
SN-38, especially at relatively low volumes of THF in water. When the volume of THF added 
to water is < 2 mL, the SN-38 seems to form large structures that may be crystallites or 
aggregates. This behaviour, when combined with increased solubility of SN-38 at higher ratios 
of THF: water, explains the failure of SN-38 encapsulation via co-nanoprecipitation described 
above. 
It is hypothesised that utilising the co-nanoprecipitation method, detailed in Section 4.2.2, the 
addition of THF containing both the chosen polymer mixtures (e.g. 50:50 wt% PEG5K-b-
PCL40: PCL40-co-BOD0.7) and SN-38 results in the instantaneous formation of polyester 
nanoparticles but SN-38 remains soluble within the THF/water mixture until solvent 
evaporation results in the precipitation of drug crystals. Given this remarkable behaviour, 
similar studies were conducted to evaluate the three species already shown to undergo 
successful encapsulation in this model but in the absence of polymer, namely Oil red O, 
docetaxel and SN-38 P (Figure 4.8). As may be expected, each of the guest molecules showed 






Figure 4.8 – DLS studies of nanoprecipitation of guest molecules varying the THF: 5 mL water ratios keeping a constant drug mass in 5 
mL water (0.3125 mg); compared to SN-38 (solvent present); (A) derived count rate, (B) Z-average diameter and (C) PdI; for (i) Oil red O, (ii) 





Firstly, Oil red O showed an apparent decreased solubility in the THF: water mixtures 
compared to SN-38 with significant scattering and measurable nanoparticle diameters in 
mixtures containing up to 4-5 mL THF in water (Figure 4.8, i). This behaviour is more 
complementary to the nanoprecipitation behaviour of polyester-based nanoparticle systems, 
allowing encapsulation within polymer nanoparticles at relatively high THF concentrations. 
Docetaxel and SN-38 P both showed less significant differences when compared to SN-38, 
particularly when observing the DCR generated by each system (Figure 4.8, ii & iii). Both drug 
molecules displayed similar DCR values to the corresponding SN-38 sample, indicating 
increased solubility in the THF: water mixture when the THF volume exceeded 2 mL. This 
was also reflected in the Dz values collected for both docetaxel and SN-38 P where Dz fell 
< 10 nm when THF volumes were ≥ 5 mL. Nonetheless Dz values observed when the volume 
of THF was ≤ 2 mL for both docetaxel and SN-38 P were significantly smaller than those 
generated by SN-38 for the same volumes.  
4.3 Evaluation of nanoparticle formation via a thin film hydration method 
using novel polyesters 
The failure to encapsulate SN-38 via co-nanoprecipitation, effectively ruled out this route for 
nanoparticle formation. It was hypothesised that processes that did not contain significant THF 
concentrations would allow both the polymers and drug guest molecule to be in a similarly 
unfavourable environment upon the addition of water; the hydrophobic nature of all the 
components would promote interactions whilst minimising the energy of the system and enable 
encapsulation. The most common technique involving the removal of organic solvent before 
water addition is thin film hydration; commonly used for the formation of liposomes. Typically, 
phospholipids are deposited onto a substrate or electrode and the resulting lipid bilayer films 
are reconstituted in water; rehydration times (a few minutes to several days) are known to 
define the physicochemical properties of the resulting liposomes. Further control of liposome 
properties can be achieved utilising ultrasonication.6 
More recently polymeric nanoparticles have also been successfully synthesised by 
implementing this method with polyesters seeming popular within this research area. Zhang et 
al. produced ‘flower-like’ nanoparticles utilising PCL-PEG-PCL co-polymers to encapsulate 
doxorubicin via a thin film hydration method followed by ultrasonic dispersion. This method 
resulted in nanoparticles capable of encapsulating 8.72 wt% doxorubicin, with Dz values below 





release.7 However the technique used required a large number of steps including dissolving 
polymer and drug in separate solvents.  
Reports of a SN-38 specific study utilising thin film hydration methods to synthesise drug-
loaded PEG-PCL nanoparticles have been published but little detail was provided to describe 
sonication conditions or the drug loading capabilities of the resulting particles. Nonetheless 
these particles were shown to eliminate colorectal cancer lung metastasis in vivo.8 Following a 
review of the literature, it is also important to note that studies targeting polymeric 
nanoparticles via this route generally include a hydrophilic PEG block within the co-polymer 
to aid the hydration process.7–9 
The bespoke polyesters with varying architectures and amphiphilicity synthesised within this 
study seemed to be ideal candidates for thin film hydration evaluation, whilst considering the 
concentrations and ratios of the polymers shown in Chapter 3 to form stable nanoparticles.   
4.3.1 Thin film co-hydration using multiple polymeric species 
Development of a thin film hydration method to synthesise well-defined particles utilised the 
same systems that had been investigated for co-nanoprecipitation, i.e. a hydrophobic branched 
polymer stabilised by an amphiphilic block co-polymer. As co-nanoprecipitation studies had 
revealed that 50:50 wt% ratio (amphiphilic block co-polymer to hydrophobic branched species) 
produced nanoparticle dispersions with the all-round best physicochemical properties, this ratio 
was used again. Exploration of thin film hydration methods utilised PEG5K-b-PCL40 stabilised 
PCL40-co-BOD0.7 and PPOP40-co-BOD0.7 branched polymers in the presence and absence of 
SN-38 (2.43 wt%). Each thin film was created by the evaporation of a 5 mg mL-1 THF/polymer 
solution (0.5 mL, with or without SN-38) to dryness using rotary evaporation under vacuum, 
followed by the addition of water (2.5 mL) to hydrate the resulting thin film to target a final 
polymer concentration of 1 mg mL-1 in aqueous media. 
Hydration was studied using either vortex mixing (approximately 5 minutes followed by 
sonication) or direct sonication of each sample after water addition; in all cases sonication was 
conducted for five minutes in an ultrasonic bath. Unfortunately, each sample displayed visible 
aggregation regardless of the method of hydration used, therefore further exploration was 
conducted implementing overnight stirring of each sample after water addition to provide a 
longer rehydration period. Sonication using a Covaris focussed ultrasound instrument was also 





approach. Polymer and drug concentrations were kept consistent, targeting a final polymer 
concentration in water of 1 mg mL-1 and DLS characterisation was undertaken before and after 
sonication to determine the effects of sonication on the resulting dispersions. Samples were 
sonicated for 5 minutes when using the ultrasound bath; however, samples sonicated via the 
Covaris used a controlled and focused 70 W for 60 seconds.  
Interestingly, particles containing only PCL based polymers failed to form stable dispersions 
both with and without SN-38, whereas 50:50 wt% PEG5K-b-PCL40: PPOP40-co-BOD0.7 
mixtures produced dispersions that could be readily characterised by DLS after sonication 
(Table 4.2). DLS characterisation before sonication indicated that dispersions containing 
PCL40-co-BOD0.7 generally produced larger particles. Overall the DCR combined with the Dz 
values for each of the samples indicated the formation a small number of large particles. Once 
sonication was completed DLS characterisation of the dispersions produced by 50:50 wt% 
PEG5K-b-PCL40: PPOP40-co-BOD0.7 showed a decrease in Dz to < 400 nm and PdI to values 
below 0.6 whist the DCR increased nearly two-fold in most cases, apart from the dispersion 

















Table 4.2- DLS characterisation of nanoparticles produced by thin film co-hydration, 


























0 1610 1255 0.355 276575 (4) Ultrasound bath Unstable 
0 790 185 0.510 93880   (6) Covaris Unstable 
2.43 910 265 0.650 106680 (6) Ultrasound bath Unstable 
2.43 1060 235 0.665 82305   (6) Covaris Unstable 
PEG5K-b-PCL40: PPOP40-co-BOD0.7 
0 505 145 0.515 61945 (6) Ultrasound bath 340 95 0.460 107760 (5) 
0 615 185 0.575 79705 (5) Covaris 350 90 0.425 12035 (5) 
2.43 790 260 0.705 69620 (6) Ultrasound bath 335 105 0.525 126095 (5) 
2.43 340 85 0.430 74710 (6) Covaris 205 80 0.340 84115 (6) 
a DATA AQUIRED NOT ACCURATE - multimodal distributions obtained and data does not 
consistently meet DLS quality criteria for these measurements. 
Analysis of the particle distributions (plotted against intensity) and correlograms for PEG5K-b-
PCL40: PPOP40-co-BOD0.7 particles indicated that before sonication all four samples were 
multimodal in appearance and could not be considered as successful dispersions (Figure 4.9). 
Correlograms also displayed similar results with only one sample, PEG5K-b-PCL40: PPOP40-
co-BOD0.7 containing SN-38 (treated with the Covaris), displaying an acceptable sigmoidal 
curve. Following sonication via an ultrasound bath, samples displayed only small changes in 
the particle distribution curves which was mirrored in the correlograms (Figure 4.9, B i & ii). 
The samples treated with the Covaris showed the particle distribution curves becoming less 
multimodal and more consistent over 3 measurements (Figure 4.9, B iii & iv). Regardless of 
the method of sonication, samples containing SN-38 were more unimodal which may signify 





Figure 4.9- Size by intensity distributions (black) and correlograms (blue dashed) of 
nanoparticles generated from the co-hydration of PEG5K-b-PCL40: PPOP40-co-BOD0.7 
(50:50 wt%). (A) before sonication, (B) after sonication, (i & ii) ultra sound, (iii & iv) covaris and (i 





Although the particles formed in this study displayed physicochemical properties that were 
quite far from the desired dispersion characteristics, resembling those achievable by co-
nanoprecipitation, successful SN-38 encapsulation was thought to have been achieved. 
Furthermore, the thin film hydration and sonication approach was shown to provide benefits 
that may allow optimisation. In summary, the steps used here were: 1) evaporation of 0.5 mL 
of a THF solution containing polymer (and drug) at a polymer concentration of 5 mg mL-1 
under vacuum to produce a 2.5 mg thin polymer film; 2) reconstitution by addition of 2.5 mL 
water to achieve a final polymer concentration of 1 mg mL-1 by stirring vigorously overnight; 
3) sonication using the Covaris focused ultrasound instrument for 60 seconds at 70 W at ≤ 14 
°C (Figure 4.10). DLS characterisation was undertaken before and after sonication to fully 
assess the nanoparticle dispersions after each step. 
Figure 4.10- Schematic representation of the thin film hydration method via co-hydration 
of a thin film formed from two polymeric species and SN-38. 
The whole series of hydrophobic branched species stabilised by PEG5K-b-PCL40 at 50:50 wt% 
ratios (in the presence or absence of 2.43 wt% SN-38) was studied to evaluate the benefits of 
the different polymer chemistries. DLS characterisation before sonication revealed that 
nanoparticles containing PCL40-co-BOD0.7 and PPHLOP40-co-BOD0.7 produced the largest 
particles after hydration with both dispersions with and without SN-38 (4 samples in total) 









































PCL40-co-BOD0.7 0 820 345 0.580 250140 (5) Unstable Unstable 
PMOP40-co-BOD0.7 0 535 120 0.585 47920 (6) 220 75 0.470 62325 (6) 215 80 0.400 67940 (6) 
PPOP40-co-BOD0.7 0 330 140 0.395 99800 (6) 200 80 0.345 89505 (6) 195 85 0.310 103730 (6) 
PBOP40-co-BOD0.7 0 415 155 0.425 66725 (6) 230 75 0.310 76020 (6) 240 105 0.335 77175 (6) 
PPHLOP40-co-
BOD0.7 
0 1375 345 0.560 271505 (4) 465 185 0.390 368935 (4) 495 210 0.425 377900 (4) 
PCL40-co-BOD0.7 2.43 1080 590 0.580 174770 (5) Unstable Unstable 
PMOP40-co-BOD0.7 2.43 380 110 0.445 53735 (6) 250 45 0.455 66360 (6) 255 60 0.450 62610 (6) 
PPOP40-co-BOD0.7 2.43 350 90 0.730 40495 (6) 265 35 0.390 28280 (7) 495 65 0.510 85415 (6) 
PBOP40-co-BOD0.7 2.43 480 265 0.420 55650 (6) 275 50 0.370 74470 (6) 285 140 0.345 69775 (6) 
PPHLOP40-co-
BOD0.7 
2.43 1625 965 0.685 161490 (4) 565 300 0.355 341585 (4) 590 360 0.360 318515 (4) 






Particles produced using PMOP40-co-BOD0.7, PPOP40-co-BOD0.7 and PBOP40-co-BOD0.7, as 
the branched co-polymer component, successfully formed significantly smaller particles than 
other polymer combinations, following hydration. This could indicate that semi-crystallinity in 
the polymers impacts the nanoparticle formation via this method and it would be expected that 
both ε-CL and PHLOP-based polymers would be semi-crystalline due to polymers synthesised 
from MOP, POP and BOP each possessing side chains that would prevent the uniform stacking 
of polymer chains; PHLOP differs here due to the π-π stacking that could occur between chains 
and has the potential to interact with SN-38.10   
The size by intensity distributions for each sample, regardless of drug presence, were 
multimodal over three measurements with at least two species clearly visible. After sonication 
it was clear that both blank and 2.43 wt% SN-38 containing dispersions of PEG5K-b-PCL40: 
PCL40-co-BOD0.7 (50:50 wt%) were unsuccessful with visibly aggregation present;  
characterised as “smokiness”, emulating that seen during unsuccessful encapsulation via co-
nanoprecipitation. The rest of the series were void of drug crystals and were successfully 
characterised by DLS.  
DLS characterisation after sonication showed a progression towards a more unimodal 
distribution, particularly when drug was present, reflecting results gained in the initial studies 
for method development (Figure 4.11). Size by intensity distributions generated by all the 
dispersions without drug appeared to be less well-defined, however, this qualitative analysis 
generated by DLS could not be conclusive evidence of the role SN-38 during nanoparticle 
formation (Figure 4.11, A). All eight nanoparticle dispersions characterised by DLS after 
sonication revealed a decrease in Dz and PdI values producing particles of Dz values < 500 nm 
with SN-38 present and < 600 nm when SN-38 was absent (Table 4.3). PdI of each system was 






Figure 4.11 – Size by intensity distributions (black) and correlograms (blue dashed) of 
nanoparticles generated from the co-hydration of thin films containing PEG5K-b-PCL40  
and a branched polyester after sonication (50:50 wt%); (A) blank, (B) 2.43 wt% SN-38; (i) 





Finally, DLS characterisation was undertaken after seven days storage under ambient 
conditions to assess stability and compare with nanoparticles synthesised via co-
nanoprecipitation (Figure 4.12). The most significant changes in physicochemical properties 
were seen within pure polymer samples in the absence of drug, with Dz and PdI values 
increasing significantly, particularly for PMOP40-co-BOD0.7 containing dispersions which 
increased from 265 nm (PdI = 0.390) to 495 nm (PdI = 0.510) (Table 4.3). Overall, samples 
containing SN-38 showed less variation over seven days. 
Although monomodal particle distributions utilising this technique have yet to be achieved, the 
results gained from this study are promising and the method of nanoparticle formation 





Figure 4.12 - Graphical representation of variation in physicochemical characteristics of 
nanoparticles produced by co-hydration; stabilised by PEG5K-b-PCL40 without drug and 





4.3.2 Thin film hydration using single polymeric species 
4.3.2.1 Thin film hydration of branched amphiphilic PEG5K/polyester block 
co-polymers  
The use of the branched amphiphilic polymers in a simple binary combination with SN-38 was 
evaluated using the thin film hydration method described above. It was hypothesised that the 
branched polyester-PEG co-polymers would be ideal for this investigation, encompassing all 
the components needed for successful co-nanoprecipitation into one polymeric species. The 
branched segments of the polymers allows for the formation of an amphiphilic film, deriving 
hydrophobicity from the branched polyester and hydrophilicity from the PEG5K block 
segments, that is expected to more readily rehydrate and offer steric stability to the resulting 
nanoparticles.11 Following the methodology detailed in Section 4.3.1, initial investigations 
were undertaken both without drug and at 2.43 wt% SN-38 loading allowing comparisons to 
studies carried out in Section 4.3.1. DLS analysis was undertaken before and after sonication 
to reveal the changes that had occurred in each system (Table 4.4). 
Table 4.4- DLS characterisation of nanoparticles produced by thin film hydration of 
























CL 0 150 40 0.465 23965 (7) 45 25 0.225 7360 (8) 
MOP 0 9655 75 0.320 28340 (7) 55 30 0.155 13945 (7) 
POP 0 695 100 0.935 52700 (6) 60 40 0.085 28400 (7) 
BOP 0 9365 75 0.505 25565 (7) 55 40 0.090 31725 (7) 
PHLOP 0 875 705 0.420 48605 (6) 90 40 0.195 72360 (6) 
CL 2.43 235 75 0.520 64970 (6) 90 20 0.425 19070 (7) 
MOP 2.43 1960 170 1 28855 (7) 70 25 0.235 21715 (7) 
POP 2.43 445 165 0.790 58435 (6) 65 40 0.140 41660 (6) 
BOP 2.43 605 80 0.860 57865 (6) 70 35 0.320 40155 (6) 
PHLOP 2.43 1030 170 0.695 61970 (6) 75 40 0.230 68650 (6) 
a DATA AQUIRED NOT ACCURATE - multimodal distributions obtained and data does not 





Firstly, considering the five systems produced in the absence of drug (Table 4.4), initial 
rehydration of the thin films led to very broad multimodal distributions of the dispersed 
material. Sonication resulted in a dramatic decrease in Dz values to 45, 55, 60, 55 and 90 nm 
and PdI values reflected the more homogenous nature of the final nanoparticle dispersions 
(Table 4.4, Figure 4.13). The five nanoparticle dispersions produced in the absence of SN-38 
showed Dz values below 100 nm and PdI values of < 0.3 (Table 4.4) and unimodal intensity 
distributions after sonication (Figure 4.13). This was a remarkable result given the multimodal 
and broad distributions formed when using a 50:50 wt% mixture of a linear amphiphilic block 





Figure 4.13- Size by intensity distributions (black) and correlograms (blue dashed) of 
nanoparticles generated from thin films containing branched amphiphilic co-polymers 
after sonication (blank). (i) PEG5K-b-PCL40-co-BOD0.7, (ii) PEG5K-b-PMOP40-co-BOD0.7, (iii) 
PEG5K-b-PPOP40-co-BOD0.7, (iv) PEG5K-b-PBOP40-co-BOD0.7 and (v) PEG5K-b-PPHLOP40-co-
BOD0.7. 
The inclusion of 2.43 wt% SN-38 into the thin films, composed of amphiphilic block co-
polymers, yielded dispersions with unimodal distributions and Dz values < 100 nm; however, 
PdI values were considerably larger, than the counterparts formed without SN-38, ranging from 





be present, nonetheless these values were lower than those obtained for the samples prepared 
in the absence of drug and with branched polyester present (Section 4.3.1). Interestingly, the 
ability of the branched amphiphilic co-polymers to generate narrow, monomodal particle 
distributions was not uniformly successful, suggesting an impact of the polymer chemistry in 
the formation process. For example, PEG5K-b-PCL40-co-BOD0.7, formed stable dispersions 
both in the presence and absences of SN-3; when SN-38 was present particle distributions were 
broad and multimodal (Figure 4.14, A). However, the use of PEG5K-b-PPOP40-co-BOD0.7, 
generated drug-loaded nanoparticles with monomodal distributions and low Dz and PdI values 
(Table 4.4, Figure 4.14, B).  
Figure 4.14- Size by intensity distributions (black) and correlograms (blue dashed) of 
nanoparticles generated from thin films containing branched amphiphilic co-polymers 







The loading of SN-38 was increased incrementally to explore the capability of the approach to 
generate nanoparticles with high drug content. SN-38 was initially increased to 9.09 wt% and 
evaluated across each amphiphilic branched block co-polymer option (final polymer 
concentration in water = 0.5 mg mL-1); again, after sonication, successful drug-loaded 
nanoparticle dispersions were formed (Table 4.5). 
Table 4.5- DLS characterisation of nanoparticles produced by thin film hydration of 























CL 9.09 1005 300 0.805 111295 (6) 180 110 0.205 55970 (6) 
MOP 9.09 525 80 0.620 67565 (6) 150 45 0.270 75245 (6) 
POP 9.09 560 205 0.480 46695 (6) 105 45 0.255 48005 (6) 
BOP 9.09 445 80 0.640 58200 (6) 105 35 0.280 50045 (6) 
PHLOP 9.09 850 255 0.640 50000 (6) 100 35 0.405 52105 (6) 
a DATA AQUIRED NOT ACCURATE - multimodal distributions obtained and data does not 
consistently meet DLS quality criteria for these measurements. 
SN-38 content was increased to values of 16.6, 33, 50, and 75 wt%, each maintaining a final 
polymer concentration of 1 mg mL-1 in water. Overall, increasing SN-38 content with respect 
to polymer increased Dz regardless of the polymer used within the system (Figure 4.15, A). 
These values ranged from 45 nm in the absence of drug (PEG5K-b-PCL40-co-BOD0.7) to 240 nm 
when the resulting nanoparticles contained 75 wt% SN-38 (PEG5K-b-PPHLOP40-co-BOD0.7). 
This was not completely to be expected as it may be possible to generate a greater number of 
nanoparticles as SN-38 dominates the hydrophobic “core” but it is also possible that a degree 
of crystallisation occurs at higher drug content. PdI values did not vary considerably with 
increasing SN-38 loading, with the exception of several samples with that lower drug loadings 
(Figure 4.15, B); there was a slight increase in PdI between 16.6 and 33 wt% drug loading 





Figure 4.15- Graphical representation of physicochemical characteristics of 
nanoparticles generated via thin film hydration of PEG5K-b-PCL/SCM40-co-BOD0.7 with 
increased SN-38 content. (A) Z-average diameter, (B) PdI. 
The particle distributions observed before and after sonication reflected trends observed in 
earlier studies with a reduction in multimodality of each dispersion and subsequent, decrease 
in PdI. Monomodal particle distributions were observed for PEG5K-b-PMOP40-co-BOD0.7 and 
PEG5K-b-PPOP40-co-BOD0.7 after sonication regardless of drug content; however the other 
three polymers generated multimodal particle distributions after sonication at lower SN-38 
loadings (Figure 4.16 & 4.17). At 50 wt% SN-38, small additional peaks, or artefacts, in all 





4.17, A). SN-38 drug loadings were increased further to 95 wt% SN-38; due to the high drug 
content with respect to polymer the final polymer concentration was 0.05 mg mL-1 and SN-38 
in water was 1 mg mL-1. Surprisingly all five polymers produced stabilised nanoparticle 
dispersions with Dz values between 220-240 nm and PdI values <0.25 in all cases (Figure 4.15, 
A & B). These values followed the trend of increasing Dz with increasing drug content; 
however, this increase was not as large as may have been expected. Interestingly after 
sonication all five dispersions produced monomodal distributions with only small artefacts 
present on single measurements for PEG5K-b-PBOP40-co-BOD0.7 stabilised particles (Figure 
4.17, C).  
The overwhelming success of this technique for the hypothesised encapsulation of SN-38 
highlights the significance differing solubility of the polymer and SN-38 in THF/water 
mixtures when attempting co-nanoprecipitation earlier (Section 4.2.2). The successful 
encapsulation of SN-38 via thin film hydration benefits from the solvent-free aqueous 
rehydration and the replacement of the hydrophobic branched polyester “core” component with 
SN-38 generates a film composed purely of amphiphilic branched block co-polymer and 
various ratios of drug. The ability to include such high drug content does suggest that detailed 
studies of the structure and stability are warranted before any pharmacological evaluation 





Figure 4.16- Size by intensity distribution (black) and correlograms (blue dashed) of nanoparticles generated from thin films containing 
branched amphiphilic co-polymers after sonication ((A) 16.6 wt% and (B) 33 wt% SN-38). (i) PEG5K-b-PCL40-co-BOD0.7, (ii) PEG5K-b-PMOP40-










Figure 4.17- Size by intensity distribution (black) and correlograms (blue dashed) of nanoparticles generated from thin films containing 
branched amphiphilic co-polymers after sonication ((A to C) 50, 75 & 95 wt% SN-38). (i) PEG5K-b-PCL40-co-BOD0.7, (ii) PEG5K-b-PMOP40-co-






4.3.2.2 Stability of nanoparticles created via thin film hydration of an 
amphiphilic branched polyester co-polymer and SN-38 
Unlike aqueous nanoparticle dispersions generated via co-nanoprecipitation, thin film 
hydration offers a solid state sample format that has the potential to be stored for long periods 
of time before rehydration. Two avenues can therefore be explored to assess the stability of 
these samples: a) the stability of the dry thin film when stored and b) the stability of the aqueous 
dispersion after rehydration. It is hypothesised that the solid state storage with the thin film 
hydration approach will extend the storage time significantly when compared to those stored 
as an aqueous dispersion.  
4.3.2.2.1 Stability of dry thin films formed during the thin film hydration process 
The polymers used in this study were PEG5K-b-PMOP40-co-BOD0.7 and PEG5K-b-PPOP40-co-
BOD0.7 as both these polymers consistently produced monomodal nanoparticle dispersions 
over the whole range of drug loadings explored. SN-38 content used in this study was defined 
as 10, 30, 50 and 75 wt% to cover a large range that reflected the nanoparticles detailed in 
Section 4.3.2.1. Ten thin film samples were generated from each THF polymer/drug stock 
solution containing one of the selected polymers at each of the four drug loadings (Figure 4.18). 
The films were formed following the methodology developed in Section 4.3.1 resulting in a 
1 mg mL-1 polymer in water dispersion. Therefore, as the polymer mass remained constant 
(2.5 mg) in each thin film, the mass of SN-38 increased within the films and an increased light 
yellow colour was seen (Figure 4.18). Results were obtained over 10 time points by the 
rehydration, sonication and DLS characterisation of each film undertaken on the day of analysis 
occurring; a) every week for the first 5 time points followed by b) every 2 weeks for the last 5 
time points. 
Figure 4.18- Picture of thin films with increasing drug loading; (right) PEG5K-b-PMOP40-co-





Each sample was characterised by DLS before and after sonication; however the assessment of 
stability was substantially obtained from the variation of Dz and PdI over time after sonication 
of each thin film, rehydrated at the time of characterisation. On storage, the thin films appear 
to generate larger dispersions when rehydrated after weeks in the solid state at ambient 
temperature. The largest increase in Dz was seen with the highest SN-38 containing samples; 
when 10 wt% SN-38 was present there was a relatively small increase seen for both PEG5K-b-
PMOP40-co-BOD0.7 and PEG5K-b-PPOP40-co-BOD0.7 over the full fourteen week dry film 
storage time frame. PEG5K-b-PMOP40-co-BOD0.7 thin films did display more variability upon 
rehydration when ≥30 wt% SN-38 was present; however, Dz values seemed to plateau after 4 
weeks of dry film storage (Figure 4.19, A). This may be the result of an energy minimisation, 
such as drug crystallisation or mass transportation, occurring within the thin film during storage 
which potentially discontinues after time periods above 4 weeks. PEG5K-b-PPOP40-co-BOD0.7 
also showed an increase in variability although this was markedly less than PEG5K-b-PMOP40-
co-BOD0.7 up until 75 wt% SN-38 by which point PEG5K-b-PPOP40-co-BOD0.7 showed the 
most variability over the 14 week period (Figure 4.19, B). Nevertheless, the overall variation 
of Dz values for both polymeric species was relatively small which was encouraging, indicating 





Figure 4.19- Graphical representation of variation in Dz with increased SN-38 content in 
the nanoparticles freshly produced via thin film hydration at each time point; stored in 
the solid state over a 14 week period and rehydrated upon the specified time of 
characterisation. (A) PEG5K-b-PMOP40-co-BOD0.7, (B) PEG5K-b-PPOP40-co-BOD0.7. 
Similarly, the PdI values of each dispersion were monitored. PEG5K-b-PMOP40-co-BOD0.7 
samples showed relatively consistent PdI values within the re-dispersed samples when 
compared to PEG5K-b-PPOP40-co-BOD0.7 derived samples across all SN-38 drug loadings; 
however, a similar trend to Dz was seen when SN-38 increased to 75 wt% (Figure 4.20, A & 
B). Both polymers systems showed the largest variation in PdI at this high drug content 
although no observed values were > 0.5. There was also no specific trend of increasing PdI 





does not negatively impact the mechanism for the formation of nanoparticles. Across the 
fourteen week study of dry film stability, the PdI values for 50 wt% drug loaded dispersions 
from both polymers, were consistently the lowest generated which appears to imply a beneficial 
drug loading; however, it is not clear why this is the case. 
Figure 4.20- Graphical representation of variation in PdI with increased SN-38 content 
in the nanoparticles freshly produced via thin film hydration at each time point; stored 
in the solid state over a 14 week period and rehydrated upon the specified time of 






Although some variability was seen in both Dz and PdI of the re-dispersed samples over the 14 
weeks dry film stability study the storage of these thin films over this period did not impact the 
rehydration process and drug-loaded nanoparticles were consistently formed. Considering the 
targeted application for these nanoparticle dispersions, this would be an advantage over 
systems that must be stored in aqueous media, as liquid dispersions are notoriously difficult to 
store in ambient conditions.12 Furthermore the data collected for samples containing > 50 wt% 
SN-38 was highly encouraging as it suggests that a high drug content does not have a 
detrimental effect on the stability of the dry thin films. 
4.3.2.2.2 Stability of aqueous dispersions formed from thin film hydration 
It was also important to analyse the stability of the aqueous dispersed systems, of increasing 
drug content, to understand the time frame for use after rehydration. As with all other studies, 
the methodology for the creation, hydration and sonication of each dispersion was kept 
constant; targeting a final polymer concertation of 1 mg mL-1 in water after rehydration (with 
the exception of 95 wt% SN-38 which required a 0.05 mg mL-1 polymer concentration). 
PEG5K-b-PCL40-co-BOD0.7 was used throughout this study and SN-38 content was extended 
over a range of values, 2.43, 10, 16.6, 30, 33, 50, 75 and 95 wt%. Upon formation, by 
rehydration and sonication, DLS characterisation of the aqueous dispersion was undertaken on 
two consecutive days followed by measurements four and seven days after first analysis. This 
time frame was selected as it was assumed that in a clinical setting use 7 days after initial 
synthesis would be rare. Pictures of the dispersions taken before each measurement (Figure 
4.21) allowed the presence of any sedimentation, forming on standing, to be recorded, as each 





Figure 4.21 - Photographs of PEG5K-b-PCL40-co-BOD0.7 stabilised nanoparticles 
containing increasing amounts of SN-38 and stored for several days; (A) Day 0, (B) Day 2, 
(C) Day 4, (D) Day 7, (left to right) 2.43, 10, 16.6, 30, 33, 50, 75 and 95 wt%. 
Visual inspection of the samples indicated that sedimentation of a white/yellow powder, 
assumed to be drug, occurred two days after sonication for samples containing 75 and 95 wt% 
SN-38 (Figure 4.21, B). This was possibly due to the relatively low PEG5K-b-PCL40-co-BOD0.7 
content leading to aggregation and the larger initial particle sizes seen for these samples.13–15 
However, the turbidity of the two dispersions suggests that a large fraction of the nanoparticle 
distribution was well dispersed and sedimentation did not seem to increase significantly over 
seven days (Figure 4.21, B to D). Sedimentation was evident within samples after seven days 
of dispersion storage, except those containing 2.43 and 10 wt% SN-38 (Figure 4.21, D); DLS 
characterisation not only highlighted increasing Dz values but also the impact of drug content 





Figure 4.22- Graphical representation of the physicochemical characteristics of stored 
rehydrated dispersions containing PEG5K-b-PCL40-co-BOD0.7 with varying SN-38 





Importantly, the Dz values measured immediately after rehydration and sonication replicated 
those seen in previous studies (Section 4.3.2.1), indicating the reproducibility of the thin film 
hydration method developed here (Figure 4.22, A). PdI values were also consistent with 
previous studies of thin film hydration using PEG5K-b-PCL40-co-BOD0.7 showing the highest 
value for 2.43 wt% SN-38 at 0.435 and lower values at higher drug loadings (Figure 4.22, B). 
This implies that the drug has a favourable effect on the nanoparticle formation mechanism 
with PdI decreasing to <0.3 for all other samples (Figure 4.22, B). DCR increased with SN-38 
content; however, a decrease in the attenuator was also observed which was to be expected as 
Dz values increases and samples became more turbid (Figure 4.22, C). When considering the 
variability in all three physicochemical properties, the nanoparticle dispersions containing 75 
wt% SN-38 appear to be the least stable corresponding to the sedimentation also observed over 
the course of this study. Similarly, samples containing 50 wt% SN-38 showed greater 
variability of Dz, increasing from 195 nm to 235 nm after one day of storage.  
As SN-38 content decreased below 50 wt%, there was an increase in the apparent stability of 
the suspensions, particularly at 2.43 and 10 wt%, showing little variation in all physicochemical 
properties and corresponding with visual observations. This suggests that the observed changes 
in Dz, PdI and DCR for these samples may be due to the re-dispersion of sedimented material 
before DLS characterisation. The increased variability and therefore decrease in stability of 
samples with increasing SN-38 content overtime is possibly a result in the reduction of polymer 
content relative to drug. This reduction in polymer may diminish the inferred steric and 
electrostatic stability gained from PEG5K-b-PCL40-co-BOD0.7 therefore decreasing its ability 
to prevent sedimentation of drug crystals. 
Although these results highlight some variability on storage over 7 days, it is important to 
consider the significant long-term storage benefits of the thin film hydration method and the 
ability to hydrate and sonicate at the time of administration. However, it is encouraging to note 
that a low variability was observed over the first four days of ambient storage of 
rehydrated/sonicated samples providing a considerable timeframe for storage and 







4.3.2.3 Thin film hydration comparison using linear amphiphilic 
PEG5K/polyester block co-polymers  
Linear PEG-polyester co-polymers were also investigated as candidate material within a series 
of thin film hydration studies containing increasing SN-38 concentrations to explore whether 
the branched architecture was essential for the behaviours and benefits described above. Drug 
loading was matched to the values investigated in Section 4.3.2.1, with the exception of 33 wt% 
(30 wt% used); additionally, 10 wt% SN-38 loaded samples were also included. All 5 linear 
PEG5K block co-polymers synthesised in Chapter 2, Sections 2.3.1.2 and 2.4.1.2 were studied 
using the methodology developed in Section 4.2.1 targeting a final polymer concentration in 
water (2.5 mL) of 1 mg mL-1; with exception for 95 wt% SN-38 loaded samples which required 
a polymer concentration of 0.05 mg mL-1 and a drug concentration of 1 mg mL-1 in water 
following rehydration.   
Interestingly, rehydration of thin films composed of drug and linear amphiphilic block co-
polymer also allowed nanoparticle formation. At SN-38 loading <16.6 wt%, considerable 
variation of outcomes was observed with the different polyester chemistries; this is in stark 
contrast to samples formed from the corresponding branched species. Significantly, 
PEG5K-b-PCL40, produced much larger particles than the other linear amphiphilic block co-
polymers at <16.6 wt% drug loading (Figure 4.23, A). For example, at 2.43 wt% SN-38 
content, the observed Dz values for linear block co-polymers of PEG5K and PMOP, PPOP, 
PBOP and PPHLOP all produced nanoparticles in the range of 65 to 75 nm but the presence of 
PEG5K-b-PCL40 led to Dz = 300 nm. Once drug loading surpassed 16.6 wt% all five polymeric 
species produced particles of similar Dz values (Figure 4.23, A) possibly suggesting that the 
drug behaviour is dominating the mechanism at these values. The branched polymer 
architecture appears, therefore, to dominate the mechanism at low SN-38 content.  
When linear amphiphilic co-polymers are utilised, the observed Dz values appear to increase 
with increasing SN-38 loading, reflecting the trend observed when branched PEG/polyester 
co-polymers are used. Additionally, the measured Dz values were similar to those achieved 
with the branched species in all cases, regardless of SN-38 content; this may be an indication 
of the relatively low number of primary chains linked together within the branched co-





nanoparticle formations would not be as marked when comparing the systems detailed here 
and in Section 4.3.2.1.  
Figure 4.23- Graphical representation of physicochemical characteristics of 
nanoparticles generated via thin film hydration of PEG5K-b-PCL/SCM40 with increased 
SN-38 content. (A) Z-average diameter, (B) PdI. 
The variation in the PdI of dispersions formed using linear PEG5K/polyester amphiphilic block 
co-polymers and various SN-38 loadings did not appear to follow a clear trend although more 





PEG5K/polyester block co-polymers were used. Nonetheless both branched and linear PEG co-
polymer produced the largest variation between polymer species at 2.43 wt% SN-38; this again 
would be expected due to the higher amount of polymer in each system, therefore, determining 
the physicochemical characteristic of the nanoparticles. 
The differences between nanoparticles synthesised using branched and linear PEG co-polymers 
were very small. This could be the result of two factors, firstly the number of primary polymer 
chains linked together in the branched PEG co-polymers is < 5 in all cases therefore the effects 
of the branched architecture may be difficult to determine. Secondly the method of synthesis 
for these nanoparticles differs considerably from co-nanoprecipitation and the aggregation-
clustering mechanism is no longer operating. Therefore it is unclear whether the branched 
structure of the co-polymers offers the same benefits during the hydration of a polymeric thin 
film and if so to what extent. More in depth studies, adding small fractions of highly branched 
PEG5K/polyester block co-polymers to the polymers studied in Section 4.3.2.1 (adapted from 
those performed by Hatton et al. for nanoprecipitation) and applying the thin film hydration 
approach to these polymer mixtures would contribute to superior knowledge on this 
phenomenon.11 
4.3.3 Mechanistic studies of the thin film hydration method using an 
amphiphilic branched co-polymers and SN-38 
The remarkable range of drug loading that was achieved within the thin film hydration method 
of nanoparticle formation provided a unique opportunity to probe the mechanism in some 
detail. The magnitude of this range was made clear when comparing the polymer to drug ratios 
achieved within the aqueous dispersions; these vary from 1:0.025 mg mL-1 (2.43 wt% drug 
loading) to 1:19 mg mL-1 (95 wt% drug loading). It is clear that the nanoparticles structure 
must change dramatically across such a wide range; drug encapsulation is more likely at high 
polymer ratios and drug particle stabilisation is more likely at low polymer ratios. It was, 
therefore, hypothesised that the continuum of drug loadings must lead to a transition in 
structure to a dispersion of solid drug nanoparticles, SDN, at higher drug loadings; polymeric 
nanoparticles are assumed to form below a critical drug loading value (Figure 4.24).  
The methodology here appears to be relatively unique, as it is the only known system that 
allows both polymeric nanoparticles and SDN domains to be created by solely increasing the 





resulting nanoparticles was undertaken using a combination of techniques including; scanning 
electron microscopy, SEM, DSC and thermal analysis by structural characterisation, TASC. 
Figure 4.24 - Representation of the transition between possible structures PEG-Polyester-
BOD derived thin film dispersion result in, depending on drug loading wt%. 
4.3.3.1 SEM studies of the thin film hydration method using amphiphilic 
branched polyester co-polymers 
SEM allowed a qualitative visualisation of the thin film methodology through the study of both 
the dry thin films and dried aqueous dispersions. Samples containing increasing SN-38 content 
were studied.  
4.3.3.1.1 SEM study of dry thin films formed before thin film hydration of PEG5K-
PMOP40-BOD0.7 and SN-38 
SEM imaging of dry thin films formed using PEG5K-PMOP40-BOD0.7 at 5 mg mL
-1 in THF 
containing increasing SN-38 concentrations from 0 to 95 wt% (a thin film of 100 wt% SN-38 
was also prepared to serve as a comparison). Each sample was prepared by pipetting a small 
volume of the THF mixture onto a silicon wafer atop an SEM stub and allowing solvent 
evaporation. Although this was not fully reflective of the vacuum solvent removal used to 
synthesise the thin films in Section 4.3.2, it was thought to be the best way to achieve thin films 
suitable for imaging by SEM. Once coated with chromium, images were obtained for a total of 





Figure 4.25 – SEM images of PEG5K-b-PMOP40-co-BOD0.7 thin films containing SN-38 at differing magnifications. (A) blank, (B) 10 wt%, 





Figure 4.26 – SEM images of PEG5K-b-PMOP40-co-BOD0.7 thin films containing SN-38 at differing magnifications. (A) 50 wt%, (B) 75 wt%, 





As the drug content increased the number and clarity of crystals increased, with clear crystalline 
structures being apparent in samples with ≥ 50 wt% SN-38 (Figures 4.25 & 4.26). These 
crystalline structures in each sample were characteristically needle-like in architecture 
indicating that these structures were the result of the same chemical species. The number of 
these crystalline architectures increased with increasing drug content therefore these were 
attributed to SN-38 not the polymer; when drug content was at 10 wt%; no definitive crystal 
structures could be distinguished (Figure 4.25 B). 
Furthermore the role the polymer played during thin film formation appeared changed as drug 
loading increased and the relative amount of polymer decreased. Firstly, considering the thin 
film created without drug (Figure 4.25, A), the silicon wafer appeared to be coated in a 
complete polymer film. This was most evident when a drying artefact on the wafer was imaged 
(Figure 4.25, Aii) and a coating film seemed to be observed that conformed to the artefact. 
Further images of this sample showed that it had characteristic ‘ripples’ in the coating which 
was most likely the result of a drying effect. Similar images of the polymeric film were 
observed in samples containing 10, 20 and 30 wt% SN-38, shown by a similar ‘rippling’ effect 
in the film in each sample (Figure 4.25, B to D).  
Once SN-38 content increased above 30 wt% the polymer coating was no longer evident and 
very different images were seen at 50, 75, 95 and 100 wt% drug loading (Figure 4.26). The 
lack of a discernible polymer film capable of impacting SN-38 crystals growth, or imaging, 
would suggest that the thin film is less homogeneous at drug loadings ≥ 50 wt%. When 100 
wt% SN-38 was dried from the presence of planar, flake-like structures and needle-like crystals 
were observed (Figure 4.26, D) and these are not seen when polymer is present. This shows 
that the polymer still plays a role in the disruption of SN-38 crystallisation, even in very small 
amounts.  
This reduction in the appearance of a coherent polymer film at higher drug loadings suggests 
that the nanoparticles that are being formed upon rehydration and sonication will no longer 
resemble a polymer particle with encapsulated drug but rather a transition towards a drug 
particles that is stabilised by polymer, resembling an SDN. This transition seems to occur 





assessment and requires further investigation to confirm and refine the boundaries over which 
this structural change occurs. 
Figure 4.27 – SEM images of PEG5K-b-PMOP40-co-BOD0.7 thin films containing SN-38. 
(Pink oval) indicates where the shift in structure occurs. 
4.3.3.1.2 SEM study of filtered thin film dispersions formed via thin film hydration 
of PEG5K-PCL40-BOD0.7 and SN-38 
Studies of the morphological changes within the dispersed nanoparticles formed after 
hydration/sonication of the thin films were conducted by imaging a 0.2 µm 
polytetrafluoroethylene, PTFE, filter, after filtration of a range of samples containing different 
drug loadings. This presented an opportunity to view the product particles rather than a model 
of the initial dry thin film. Before studies commenced, it was important to have a number of 
reference images, therefore an unused PTFE filter was imaged via SEM (Figure 4.28).  Images 
of both the top (Figure 4.28, A) and bottom (Figure 4.28, B) revealed the considerable 
difference between the two sides of the filter. The top was more fibrous on the 20 to 30 µm 
scales compared to the coarse, sub-micron, spindle-like fibres of the bottom with pores of 





Figure 4.28 – SEM images of a PTFE filter, unused. (A) top face of the filter and (B) bottom 
face. 
PEG5K-b-PCL40-co-BOD0.7 was selected as the amphiphilic branched block co-polymer for this 
study as it possessed the unsubstituted monomer repeat unit and the most crystalline polymeric 
structure; possibly advantageous for SEM imaging of nanoparticles. Drug loading ranged from 
2.43, 10, 16.6, 30, 33, 50, 75 to 95 wt% to give a complete picture across the whole series of 
successful nanoparticle dispersions. Each dispersion was formed by the standard method, 










Table 4.6 – DLS characterisation of nanoparticles produced by thin film hydration of 





















2.43 95 20 0.350 17815 (7) 80 20 0.245 14570 (7) 
10 120 55 0.240 54475 (6) 110 65 0.210 45800 (6) 
16.6 145 45 0.225 202980 (5) 125 60 0.185 78550 (6) 
30 145 50 0.215 341010 (4) 130 80 0.160 218505 (5) 
33 175 80 0.215 444475 (4) 160 80 0.230 352655 (4) 
50 185 95 0.210 865905 (4) 170 100 0.180 622720 (4) 
75 265 115 0.285 1251985 (3) 250 90 0.225 564025 (4) 
95 235 95 0.220 725560 (4) 240 85 0.215 351960 (4) 
It is important to note that comparative Dz values to earlier studies using PEG5K-b-PCL40-co-
BOD0.7 in Section 4.3.2.1 were achieved, again indicating the reproducibility of this method. 
The incremental increase in Dz with increasing SN-38 content, was also seen earlier. The 
comparison of data collected before and after filtration (Figure 4.29) showed a reduction in Dz, 
PdI and DCR for each sample after filtration and confirmed the retention of larger particles on 
the filter even when Dz of the nanoparticles was < 100 nm before filtration. As expected with 
the larger particles, produced with ≥ 75 wt% SN-38, a substantial drop in DCR (Figure 4.29, 
C) was observed with only a minimal decrease in Dz, indicating the possibility of a large 
fraction of the dispersion being removed. Each filter was stored in a glass vial for several weeks 
to dry and then broken open to reveal the PTFE filter for imaging (both top and bottom faces, 





Figure 4.29 – Graphical representation of changes in physicochemical characteristics 
before and after filtration of PEG5K-b-PCL40-co-BOD0.7 dispersions containing increasing 





Figure 4.30 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 2.43 wt% SN-38. (A) top face of 











Figure 4.31 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 10 wt% SN-38. (A) top face of 









Figure 4.32 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 16.6 wt% SN-38. (A) top face of 








Figure 4.33 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 30 wt% SN-38. (A) top face of 










Figure 4.34 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 33.3 wt% SN-38. (A) top face of 
the filter and (B) bottom face; (Ai) indicating spherical nanoparticles and (Aii) indicating planar artefacts and (Bi to Biii) indicating needle-like crystals within 










Figure 4.35 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 50 wt% SN-38. (A) top face of 










Figure 4.36 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 75 wt% SN-38. (A) top face of 
the filter and (B) bottom face; (Ai & Aii) indicating needle-like crystals surrounded by spherical particles and (Bi & Bii) indicating needle-like crystals within 









Figure 4.37 – SEM images of a PTFE filter, used to filter PEG5K-b-PCL40-co-BOD0.7 dispersion containing 95 wt% SN-38. (A) top face of 











Inspection of the images of the top of the filter revealed that the nanoparticles of samples 
containing trends lower drug loadings of < 20 wt% SN-38 were spherical in shape (Figure 4.30 
to 4.32), mostly uniform in diameter with some larger particles appearing to be the result of 
coalescence in the process of drying the filter, and relatively low in number. The small number 
of particles is consistent with the majority of the sample passing through each filter and the low 
Dz and Dn of these samples. The bottom face of the filters used for dispersions containing 
< 20  wt% SN-38 appeared to show the formation of a film covering the pores in the membrane; 
this is most likely a drying effect of the polymeric material trapped at the bottom face. The 
significance of these films cannot be overlooked; each film formed on the bottom face of the 
filter for samples with < 20 wt% SN-38 showed no characteristically long and spindle-like drug 
crystals as described in Section 4.2.2.  
Samples with increased SN-38 content (> 20 wt%) displayed different behaviour, particularly 
when the bottom face of the filter was considered. The top face images for nanoparticles with 
SN-38 drug loadings of 30 and 33 wt% both contained spherical particles with small diameters; 
however, these appeared to be more polydisperse than those seen at lower SN-38 content 
(Figures 4.33 & 4.34). Additionally, a small number of planar objects were also present; which 
were previously only seen in dried solutions of SN-38. The formation of a film-like substance 
on the bottom face of the filters was seen at 30 and 33 wt% SN-38 drug loading; however, a 
small number of long, spindle-like drug crystals were also seen within this film. Images of the 
top face of filter wafers used from 50 to 95 wt% SN-38 content revealed drug crystals now 
trapped on the upper face the filter with larger film-like groups of crystals evident on all three 
samples (Figure 4.35 to 3.37). Non-spherical nanoparticles were also observed in all three 
samples (top face, Figure 4.35 to 4.37), which would indicate a more SDN-like structure. 
Additionally as the concentration of spindle-like crystals increased on the top face, the number 
of particles appeared to decrease, however, this was not quantified. The Dz of the particles 
present in dispersions containing ≥ 75 wt% SN-38 exceeding 0.2 µm would lead one to expect 
increased trapping of particles when using these filters. The bottom faces of all three filter 
samples followed a similar trend in the number of crystals observed: increasing with increasing 
SN-38 content. Also, the crystals appeared to become more well-defined, which was to be 
expected due to the lack of polymer. 
The SEM study of the PTFE filters allowed a narrowing of the range in which the transition 
from polymeric nanoparticle to SDN appears to occur. The lack of drug crystals on both the 





of drug crystals on the bottom face of the filter and more planar particles on the top face at 
30 wt% SN-38 content would indicate the structure transition occurs between these two values.  
4.3.3.2 DSC of thin films formed before thin film hydration using 
PEG5K-b-PCL40-co-BOD0.7 and SN-38 
The highlighting of a structural transition of the dispersed nanoparticles between 16.6 to 
30 wt% SN-38 content via SEM allowed a focused and quantitative evaluation within this 
range of compositions using DSC analysis. Thin film homogeneity and SN-38 crystallinity was 
expected to give added insight; hypothesising that the structure of the initial films would play 
a meaningful role in defining the dispersions produced. Therefore the DSC study was 
conducted using PEG5K-b-PCL40-co-BOD0.7 in thin films formed using methods described 
above. The dry thin films were formed inside vials before being sampled and analysed using 
DSC with a heat-cool-heat cycle between the temperatures of -90 °C and 250 °C.  
To provide comparative data, both the polymer and the drug compound were analysed 
independently (Figure 4.38). PEG5K-b-PCL40-co-BOD0.7 showed both a Tg and Tm at -55 °C 
and 51 °C respectively on the second heating cycle (Figure 4.38, A); this was consistent with 
the results obtained in Section 2.5. Peak enthalpy for the Tm of the polymer was 75.73 Jg
-1. 
SN-38 produced a sharp Tm peak during the first heating cycle at 218 °C, consistent with 
literature values (Figure 4.38, B), and a peak enthalpy of 116.65 Jg-1.16 This was the only peak 
observed in the heat-cool-heat cycle for SN-38 suggesting that decomposition may also occur 
under these conditions (i.e. no observable peak on the second heat cycle). Comparison of Tm 
peak enthalpy, of the polymer and drug, was expected to allow for an insight into the structural 





Figure 4.38- DSC analysis showing a heat-cool-heat cycle on; (A) PEG5K-b-PCL40-co-BOD0.7, 





The combined polymer/drug containing dry thin films were studied across the compositions 
generated and Tm transitions for the polymer were well-defined and the respective peak 
enthalpies decreased linearly with increasing drug concentration, as would be expected (Figure 
4.39). The slight increase from samples containing 0 to 2.5 wt% may be an anomaly however 
it could be postulated that the presence of SN-38 may encourage an increased crystallinity of 
the PEG chains within the polymer film therefore increasing the peak enthalpy when drug is 
present. 
Figure 4.39- Graphical representation of changes in peak enthalpy of Tm peaks for 
PEG5K-b-PCL40-co-BOD0.7 with increasing SN-38 content. 
As SN-38 only produced an endotherm during the first cycle of the heat-cool-heat analysis 
(Figure 4.38) in depth examination of the changes in SN-38 crystallinity, and therefore the role 
of the polymer in the thin film process, were solely focussed between 160 and 250 °C of the 
first heat cycle. When considering the full series of compositions generated an exotherm began 
to appear (approximately between 220 °C and 240 °C) at 30 wt% SN-38 drug loading and 
above. This was hypothesised to be the result of a secondary reaction (possibly oxidation or a 
reaction with the labile lactone ring) however this could also be an impurity given that this 
peak only appears within the samples containing 50 and 75 wt% SN-38 (Figure 4.40 & 4.41).  
The nine samples studied were split into two groups with a single sample, 30 wt% SN-38, being 
present in both groups. The first group, consisting of dry thin films containing 0, 2.5, 10, 20 





suggesting it was predominantly in an amorphous state (Figure 4.40). The thin film containing 
30 wt% SN-38 however did show the beginnings of an endothermic peak formation at 
approximately 220 °C (Figure 4.40, pink) which would suggest the presence of crystalline 
domains of SN-38 forming within the thin film and the decline of homogeneity. This would 
also suggest the loss of amorphous molecular drug thought to be encapsulated within a polymer 
matrix and a possible transition to a new type of crystalline drug/polymer structure, resembling 
an SDN-like particle. Such DSC behaviour has been published by Prasad and Dangi who noted 
the disappearance of clear, sharp Tm peaks characteristic of crystalline SN-38 when 
encapsulated within chitosan and Eudragit® nanoparticles.17 Further studies within the 
literature have eluded to the disappearance of Tm peaks for crystalline SN-38 when formulated 
as prodrug micelles or during ball milling.16,18,19  
Figure 4.40- DSC analysis of the first heat ramp between 160 and 250 °C for SN-38 
PEG5K-b-PCL40-co-BOD0.7 thin films between 0 and 30 wt%; (blue) 0 wt%, (green) 2.5 wt%, 
(red) 10 wt%, (brown) 20 wt% and (pink) 30 wt%. 
Investigation of the DSC thermograms for the second group of thin films, with SN-38 content 
ranging from 30, 50, 75, 95 and 100 wt%, displayed an increase of a Tm between 180 and 





sharper and more well-defined, suggesting an increase in SN-38 crystallinity within the thin 
film. 
 
Figure 4.41- DSC analysis of the first heat ramp between 160 and 250 °C for SN-38 
PEG5K-b-PCL40-co-BOD0.7 thin films between 30 and 100 wt%; (pink) 30 wt%, (blue) 50 
wt%, (green) 75 wt%, (red) 95 wt% and (brown) 100 wt%.  
Further in-depth analysis was undertaken by the measurement of peak enthalpy of the SN-38 
endotherm for each sample, however due to the minimal definition of this peak in samples 
containing low amounts of SN-38 the boundaries for this measurement were varied on a sample 
basis. All the endothermic peaks within the initial region >160 °C were included. As Tm of 
crystalline SN-38 were not highly detectable when SN-38 content was low, analysis suggested 
predominantly amorphous material was present. Plotting of peak enthalpy of both polymer 
(shown on its own in Figure 4.39) and drug vs. drug loading revealed a noticeable, and near-
linear trend for SN-38 peak enthalpy at drug loadings >20 wt% (Figure 4.42); this supports the 
proposed transition from a polymer particle encapsulating drug to SDN-like particles within 





Figure 4.42- Graphical representation of changes in peak enthalpy of both Tm peaks for 
SN-38 and PEG5K-b-PCL40-co-BOD0.7 with increasing SN-38 content; guidelines for 
gradient PEG5K-b-PCL40-co-BOD0.7 (green) and the change in gradient for SN-38 (red). 
4.3.3.3 TASC of thin films formed before thin film hydration using 
PEG5K-b-PCL40-co-BOD0.7 and SN-38 
The thermal properties of the dry thin films were also evaluated using “thermal analysis by 
structural characterisation”, TASC, a technique expected to give a more in-depth picture of the 
thermal transitions at the time of melting. Developed by M. Reading, TASC allows changes in 
the sample to be analysed as heat and humidity increase by taking a number of pictures of the 
sample.20 The TASC algorithm then quantifies the changes which are observed within a 
designated area, producing a change in gradient in the TASC output. Like DSC, the mid-point 
of these sigmoidal step changes can be used to define a Tg or Tm point within the sample being 
studied.20 This technique requires no contact with the sample and is complementary to DSC, 
providing both qualitative and quantitative results.  
Similar to other studies detailed in Section 4.3.3.2, PEG5K-b-PCL40-co-BOD0.7 was selected 
for this study and thin films were created on 16 mm circular glass microscope cover slips by 
pipetting a small amount of the THF solution and allowing the solvent to evaporate. As with 
the SEM study of the dry thin films in Section 4.3.3.1.1, this method did not fully reflect the 
formation of thin films via vacuum solvent removal, however, it offered the best compromise 





temperature to 250 °C following the determination of the Tm of SN-38 to be approximately 
218 °C by DSC analysis (Section 4.3.3.2). Each sample examined was photographed at a rate 
of two pictures per second during the heating process allowing videos to be generated for each 
(see attached USB).    
Again, comparative TASC analyses were conducted using 100 wt% PEG5K-b-PCL40-co-
BOD0.7 and 100 wt% SN-38. The thin film containing only PEG5K-b-PCL40-co-BOD0.7 proved 
challenging to analyse due to transparency, resulting in considerable noise within the TASC 
analysis (Figure 4.43). Nonetheless, it was clear from the video generated that the polymer film 
began to melt between 47 and 65 °C. Following TASC analysis of the images, a change in 
gradient at 51.1 °C signified the Tm of the polymer (Figure 4.43) which was comparable to 
DSC analysis (Tm =  51.4 °C, Section 4.3.3.2). As no other visual changes were observed in the 
thin film the changes in gradient between 800 and 1,050 seconds were considered as noise.  
Figure 4.43- TASC analysis performed on a thin film of 100 wt% PEG5K-b-PCL40-co-
BOD0.7; (A) Midpoint = 51.1 °C. 
The opaque nature of the 100 wt% SN-38 film allowed for a considerable decrease in 
background noise in the TASC analysis, allowing a defined indication of changes within the 
sample during heating. Upon visual inspection the sample began to change colour at 





transformations occurred above this temperature which may indicate different SN-38 crystal 
habits and TASC analysis supported the presence of these transitions (midpoints values = 207.4 
and 230.9 °C; Figure 4.44, A & B). Both of these values were inconsistent with the Tm of SN-38 
observed by DSC (Tm = 218.1 °C, Section 4.3.3.2) which may indicate a variation of crystal 
form. The sample appeared fully molten at 230.9 °C. Varied literature values for the melting 
point of SN-38, via DSC and melting point analysis, suggest that it is difficult to assign a 
consistent melting point, supporting the hypothesis that different crystal forms of the drug may 
exist.16,18,19,21 However the discrepancies between the DSC and TASC observations could be 
linked to the increased accuracy of the DSC which is undertaken under inert atmosphere and 
requires different sample preparation which may influence the results obtained. 
Figure 4.44- TASC analysis performed on a thin film of 100 wt% SN-38; (A) Midpoint = 
207.4 °C and (B) Midpoint = 230.9 °C. 
As the transition from drug-encapsulated polymeric nanoparticle to SDN appeared to occur 
between 10-30 wt% SN-38 by SEM and DSC investigations, thin films containing 10, 16.6 and 
30 wt% SN-38 were analysed via TASC. Analysis of the PEG5K-b-PCL40-co-BOD0.7 thin film 
containing 10 wt% SN-38 showed a clear loss of structure below 100 °C, associated with the 
melting of the polymer. A second structural change resembling the complete melting of all 
components of the film occurred above 200 °C; due to the movement of the slide during the 





observed for the polymer at 52.1 °C which was comparable to both DSC and TASC analysis 
of the blank polymer film (Figure 4.45, A). A second gradient change was observed, spanning 
from 650-1,250 seconds, with a disappearance of thin film structures, at a midpoint value of 
203.6 °C, which was assigned to SN-38 (Figure 4.45, B). It is also important to note that a 
change in colour from colourless/white to yellow was not observed in this sample. This 
broader, less defined peak for the apparent melting of SN-38, coupled with a lack of colour 
change, suggests that the crystallinity of the drug has been disrupted by the polymer and several 
forms of SN-38 may be present. The shift from crystalline to amorphous SN-38 has previously 
been noted in DSC studies within literature, indicated by a disappearance of a Tm peak at 200-
230 °C when interacting with polymers or due to a processing technique such as grinding.16,18  
Figure 4.45- TASC analysis performed on a thin film with PEG5K-b-PCL40-co-BOD0.7 and 
10 wt% SN-38; (A) Midpoint = 52.1 °C and (B) Midpoint = 203.6 °C. 
The visual assessment of the film containing 16.6 wt% SN-38 showed a total of 4 changes as 
temperature increased. This was confirmed by TASC analysis displaying four changes in 
gradient correlating to the visual transitions (Figure 4.46). The first midpoint value of 51.8 °C 
was confirmed as the polymer Tm correlating well with the values gained from previous TASC 





of 109.2 °C correlates within a change of film colour from a ‘cream’ to a dark grey, almost 
transparent film, which visually suggested the melting of another structure present although it 
is difficult to assign this (Figure 4.46, B). The sample proceeded to change to a yellow colour 
after this second transition, followed by a final melting. These last two changes were 
characterised in the TASC analysis as a broader peak with a less steep gradient and a sharper 
incline for the final transitions with midpoints values of 191.2 and 245.8 °C (Figure 4.46, C & 
D). Again this lack of definition for the melting point of SN-38 and multiple melting transitions 
within the sample suggests a disruption of the SN-38 crystallinity, potentially forming 
amorphous SN-38 or at least a number of crystal habits16,17,19 
Figure 4.46- TASC analysis performed on a thin film with PEG5K-b-PCL40-co-BOD0.7 and 
16.6 wt% SN-38; (A) Midpoint = 51.8 °C, (B) Midpoint = 109.2 °C, (C) Midpoint = 191.2 °C and 
(D) Midpoint = 245.8 °C. 
Finally, the dry thing film sample containing 30 wt% SN-38, showed areas of crystallinity 
when viewed under polarised light as indicated by the readily identified birefringent ‘Maltese 
cross’ structures within the overall image. Therefore, it was clear that the thin film was not 
homogeneous and either crystals of SN-38 of the crystallisation of PEG5K chains was present 
in the film. Visual inspection of the sample during the heating process confirmed that there 





white to grey/transparent. However, this was not consistent throughout the sample and 
resembled a melting point of the same unspecified species in the 16.6 wt% sample. The final 
change occurred over an extended period in which the sample underwent a colour change from 
white to yellow, followed by the complete melting of the sample. Due to the areas of crystalline 
drug, which only melted at high temperature, two separate TASC analyses were performed on 
the sample. The first area selected, referred to as TASC 1, was located close to the edge of the 
sample where the most significant change occurred at lower temperatures, particularly during 
the polymer melting point (Figure 4.47, i). The second area, referred to as TASC 2, focussed 
on the segment close to the Maltese crosses, as during the visual inspection it was evident less 
changes occurred in this area over the full heating cycle (Figure 4.47, ii). 
Figure 4.47 – Image defining the two areas used to complete TASC analysis; (i) TASC 1 
and (ii) TASC 2. 
TASC 1 analysis revealed three changes in gradient consistent with the visual observations 
made in the segment selected: 1) the polymer melting point at 52.2 °C, was consistent with the 
other values generated for PEG5K-b-PCL40-co-BOD0.7 during this study (Figure 4.48, A); 2) a 
change that was assigned to the melting of an unknown species, possibly SN-38 in a different 
crystal form, occurred at 113.2 °C similar to the values generated with 16.6 wt% SN-38 (Figure 
4.48, B); and 3) a long sloping gradient (Figure 4.48, C) with a midpoint value of 231.5 °C 





Figure 4.48- TASC 1 analysis performed on a thin film with PEG5K-b-PCL40-co-BOD0.7 
and 30 wt% SN-38; (A) Midpoint = 52.2 °C, (B) Midpoint = 113.2 °C and (C) Midpoint 231.5 °C 
TASC 2 analysis revealed only one change in gradient at 238.0 °C, again within the literature 
range for the Tm of SN-38 (Figure 4.49, B).
16 The gradient, in this case, was much steeper than 
previously seen in thin films of lower SN-38 content, with less broadening at lower 
temperatures. The lack of changes throughout the rest of the TASC 2 analysis indicates that 
this segment of the 30 wt% sample probably contained only one crystalline form of SN-38. 
Therefore this supports the hypothesis that this thin film is not homogeneous. This would also 
lead the suggestion that the polymer content at 30 wt% SN-38 is insufficient to dominate the 
behaviour of the film during hydration/sonication and drug encapsulated polymeric 










Figure 4.49- TASC 2 analysis performed on a thin film with PEG5K-b-PCL40-co-BOD0.7 
and 30 wt% SN-38; (A) Midpoint = 51.9 °C and (B) Midpoint = 238.0 °C. 
4.4 Pharmacological studies of SN-38 containing dispersions produced via 
thin film hydration of branched PEG5K/polyester co-polymers 
Following the suggested successful encapsulation of SN-38 via thin film hydration, the 
resultant dispersions were subjected to pharmacological studies. In vitro studies were 
performed to assess the rate of SN-38 release, the cytotoxicity of the dispersions and finally 
the cellular uptake of each dispersion across the range of polymer and drug loading options. It 
was expected that in vivo studies would be possible after this in vitro evaluation. The work in 
this section was carried out by Mr Usman Arshad under the supervision of Professor Andrew 
Owen and Professor Chris Goldring in the Department of Molecular and Clinical 
Pharmacology at the University of Liverpool. 
4.4.1 Release rate studies  
The library of nanoparticle dispersions selected for this study were based upon the branched 
PEG/polyester co-polymers that had achieved successful nanoparticle dispersions over a large 
range of drug loading values. All five branched PEG/polyester co-polymers were studied with 





be more clinically valuable. Release rate studies were conducted using a well-plate rapid 
equilibrium dialysis, RED, assay in phosphate-buffered saline, PBS, at a dilution 20 times 
below that of SN-38 in PBS. Each time measurement required removal of the entire receptor 
well contents (Figure 4.50), whilst continuing until the concentration equilibrated across the 
membrane and in the nanoparticles. In this way, a maximum drug release of 50 % of the initial 
dose added to the donor well would be seen; the assay was typically conducted over 48 hours 
with full-well measurements taken every hour for the first 8 hours, then samples at 24 hours 
and finally at 48 hours. 
Figure 4.50- Schematic representation of an RED assay; (A) nanoparticles containing drug and 





Analysis of SN-38 release from each system with varying drug content and polymer chemistry 
was compared to free SN-38 to highlight any benefits of encapsulation and nanoparticle 
formation over the 48 hour study (Figure 4.51 , Appendix C). Every sample, regardless of drug 
content, appeared to replicate free drug release after 8 hours. Despite encapsulation within a 
polymeric nanoparticle or SDN-like structure all the nanoparticle systems appeared to have 
only slightly slower rates of release than that of free SN-38.  
Figure 4.51 – Example of a release rate curve produced via RED assay for a PEG5K-b-
PCL40-co-BOD0.7 nanoparticle dispersion containing 10 wt% SN-38; (A) the first 8 hours and 





To allow for a clear visual comparison, the data was replotted using bar charts, excluding 24 
and 48 hour time points. Three charts were plotted, corresponding to various SN-38 drug 
loadings, each with free SN-38 as a comparison. Firstly 10 wt% SN-38 containing nanoparticle 
dispersions were considered which highlighted PEG5K-b-PCL40-co-BOD0.7 and PEG5K-b-
PMOP40-co-BOD0.7 as the slowest releasing nanoparticle systems (Figure 4.52) at this drug 
loading. PEG5K-b-PMOP40-co-BOD0.7 maintained a slower release than free SN-38 for 3 hours, 
whereas PEG5K-b-PCL40-co-BOD0.7 showed a retarded rate until 6 hours had elapsed although 
the concentration of drug released at 2 hours was slightly higher than free drug. 
Figure 4.52- RED assay equilibrium release rate (over 8 hours) for 10 wt% SN-38 
containing samples generated from thin film hydration of branched PEG5K/polyester AB 
block co-polymers. 
Investigations of nanoparticle dispersions containing 50 wt% SN-38 portrayed the same trend 
with the only two samples displaying retardation in drug release, when compared to free SN-
38, based on PEG5K-b-PCL40-co-BOD0.7 and PEG5K-b-PMOP40-co-BOD0.7 (Figure 4.53) 
PEG5K-b-PCL40-co-BOD0.7 showed a longer delay in SN-38 release over 8 hours compared to 
both the 10 wt% containing sample and PEG5K-b-PMOP40-co-BOD0.7. PEG5K-b-PMOP40-co-






Figure 4.53- RED assay equilibrium release rate (over 8 hours) for 50 wt% SN-38 
containing samples generated from thin film hydration of branched PEG5K/polyester AB 
block co-polymers. 
The final group of nanoparticle dispersions (75 wt% SN-38) indicated that PEG5K-b-PCL40-co-
BOD0.7 released SN-38 significantly slower than the dispersions formed using the other four 
polymers (Figure 4.54); however, PEG5K-b-PBOP40-co-BOD0.7 and PEG5K-b-PPHLOP40-co-
BOD0.7 derived dispersions now showed a slower release than free SN-38 over 5 hours (Figure 
4.54). This was significantly longer than dispersions containing either 10 or 50 wt% SN-38 
indicating possible benefits for clinical application. Given the DSC analysis of the polymers in 
Section 2.5, the altered thermal behaviour of these systems may play a part in affecting drug 
release rates. 
SN-38 dispersion derived from PEG5K-b-PCL40-co-BOD0.7 and PEG5K-b-PMOP40-co-BOD0.7 
were, therefore, selected for more in-depth pharmacological tests as it was hypothesised that 
these systems had the greatest potential for future in vivo experimentation. PEG5K-b-PCL40-co-
BOD0.7 systems at all three drug loadings and PEG5K-b-PMOP40-co-BOD0.7 containing 10 and 





Figure 4.54- RED assay equilibrium release rate (over 8 hours) for 75 wt% SN-38 
containing samples generated from thin film hydration of branched PEG5K/polyester AB 
block co-polymers. 
4.4.2 Cytotoxicity  
Nanoparticle dispersions formed using PEG5K-b-PCL40-co-BOD0.7 and PEG5K-b-PMOP40-co-
BOD0.7. PEG5K-b-PCL40-co-BOD0.7 and containing 10, 50 and 75 wt% SN-38 were all 
evaluated using cytotoxicity assays. As PEG5K-b-PMOP40-co-BOD0.7 showed slow release at 
SN-38 loadings of 10 or 50 wt%, this gave the opportunity to explore the impact of varying 
polymer structure relative to PCL. A number of cell lines were investigated, obtained from 
humans and mice; human colorectal cancer, HCT 116, murine colorectal cancer, CT 26, human 
colorectal adenocarcinoma, LoVo, and Dukes’ type C colorectal adenocarcinoma, DLD-1, 2D 
cell lines were selected. Data collected after 72 hours, once each sample had achieved half 
maximal inhibitory concertation, IC50, was plotted with a comparison to SN-38 and irinotecan 
(Figure 4.55, A). Supplementary studies using 3D spheroids created with HCT 116 and CT 26 





Figure 4.55- Cytotoxicity studies of selected samples compared to SN-38 and irinotecan; 





Overall samples showed very similar behaviour to SN-38, achieving IC50 values of similar 
magnitude, <150 nM regardless of the cell line used. IC50 values obtained from the human cell 
lines HCT 116 and LoVo offered the most comparable data to SN-38. No real trend was 
observed between the SN-38 drug loading within the nanoparticle dispersion and the IC50 
values obtained. Furthermore the structural differences between nanoparticle and SDN, 
hypothesised to occur before 30 wt% SN-38 did not appear to affect toxicity. In studies utilising 
3D spheroids all five nanoparticle dispersions had comparative toxicity to SN-38 when 
considering the HCT 116 cell line. CT 26 showed greater variability with both systems based 
on PEG5K-b-PMOP40-co-BOD0.7 indicating lower toxicity than SN-38 alone. Nonetheless these 
studies supported 2D studies indicating that encapsulation of SN-38 did little to impact the 
efficacy of the drug.  
4.4.3 Macrophage uptake  
In order for drug containing nanoparticles to have a therapeutic effect they must first avoid 
uptake and clearance from the circulatory system via macrophages, a type of white blood cell 
responsible for the removal of foreign artefacts from the body. Therefore a number of particle 
dispersions were assessed with regards to cellular accumulation in macrophages. The systems 
selected for this study were based on PEG5K-b-PCL40-co-BOD0.7 and PEG5K-b-PMOP40-co-
BOD0.7 where PEG5K-b-PCL40-co-BOD0.7 contained 10, 50 and 75 wt% SN-38 and PEG5K-b-
PMOP40-co-BOD0.7 contained 10 and 50 wt% SN-38. Free SN-38 was also studied as a control 





Figure 4.56 – Graphical representation of cellular accumulation of nanoparticles in 
macrophages.  
Overall both systems containing 10 wt% SN-38 had the lowest cellular uptake whilst increasing 
SN-38 content to 50 and 75 wt% resulted in increased cellular uptake. Nonetheless the PEG5K-
b-PCL40-co-BOD0.7 system containing 10 wt% showed the least cellular uptake and would 
therefore be expected to display the longest circulation times in vivo. The trend of increasing 
cellular uptake with increased SN-38 suggests that these systems resemble the free drug which 
would complement the expected SDN structure when SN-38 is >30 wt%. 
4.4.4 In vivo Studies 
The material selected for in vivo studies was PEG5K-b-PCL40-co-BOD0.7 containing 10 wt% 
SN-38 due to the significantly lower cellular uptake suggesting that the circulation time of the 
nanoparticles within this dispersion would be the longest of the samples tested. Before in vivo 
studies could begin an increase in drug concentration was required from 0.11 mg mL-1 in water 
to 0.44 mg mL-1 to achieve the desired dosing regimen. Unfortunately, this study failed and 







In conclusion, the exploration of SN-38 encapsulation within nanoparticles generated from the 
library of polymers available, was hypothesised to build on the successful encapsulation studies 
conducted in Chapter 3. Further successful encapsulation of SN-38 P, at 2.43 wt%, via co-
nanoprecipitation generated promising results hinting towards the potential to encapsulate SN-
38 given the small variation in molecular structure. Unfortunately, SN-38 encapsulation via 
co-nanoprecipitation was unsuccessful regardless of polymer selection.  
The implementation of a thin film hydration methodology, removing the presence of a 
THF/water mixture during nanoparticle formation, resulted in the first SN-38 containing 
nanoparticles within this body of work. Furthermore, method development showed that 
sonication of the nanoparticle dispersions was key to obtaining reproducible well-defined 
nanoparticles. The successful synthesis of nanoparticle dispersions, with SN-38 drug loadings 
between 2.43-95 wt%, highlighted the applicability of this method over a range of polymers 
and suggested a transition in nanostructure from polymeric nanoparticle to SDN, occurring 
between 16.6 and 30 wt%. 
Promising signs for clinical application were also gained when samples were studied for 
storage which highlighted the remarkable length of time thin films could be retained between 
formation and successful reconstitution in water, without a detrimental effect on nanoparticle 
formation. Furthermore, exploration of the stability of the dispersions indicated at least one full 
working day in which administration could be achieved. 
Finally, the formation of an aqueous dispersion of SN-38, with a large range of options 
regarding SN-38 drug loading a polymer backbone chemistry, does offer real potential for the 
future. Furthermore, although particles indicated slower drug release, little effect of 
encapsulation on the cytotoxicity of SN-38 and reduced macrophage uptake during 
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The overall aim of this work was to understand the capabilities of polyester nanoparticles in 
the encapsulation of SN-38. Initial areas of investigation included: the synthesis of homo- and 
co-polyesters of varying architecture via MSA catalysed ROP, the implementation of 
substituted caprolactone monomers and the effects this caused on the thermal characteristics of 
the resultant polymers. Further essential studies, required to develop understanding before the 
encapsulation of SN-38 could be attempted, were nanoparticle synthesis via rapid co-
nanoprecipitation and the consequences this method had on the ability to encapsulate guest 
molecules.  
The hypotheses laid out in Chapter 1, as well as those that were developed over the course of 
study, have been examined successfully in the subsequent chapters to generate a 
comprehensive understanding of the different scientific aspects required to progress a new 
therapy option towards patient benefit. Blank nanoprecipitation and co-nanoprecipitation 
studies were initially used to develop knowledge in the context of the polymer library, based 
on ε-CL and substituted caprolactone monomers. The MSA catalysed ROP technique provided 
a metal-free route to polymers of varying architecture, such as PEG block co-polymers and 
branched architecture, obtained using a ‘modified Strathclyde method’. The avoidance of tin-
derived catalysts is of considerable importance as the removal of metal ions from the resulting 
polymers is essential for medical applications. By using a simple acid, the study extends the 
scope of the materials that have been demonstrated to be successfully polymerised using this 
approach.   
Initial (co)nanoprecipitation studies, undertaken with PEGx-b-PCL40 and linear and branched 
PCL, revealed that a decrease in size and PdI of the nanoparticles could be obtained by the 
application of a branched species when using acetone as the good solvent. This correlated well 
with previously reported results utilising polymethacrylates and shows that polyesters appear 
to behave in a similar way.1 Co-nanoprecipitation of PCL40-co-BOD0.7 with PEGx-b-PCL40 
revealed that with increased PEGx-b-PCL40 content there was a reduction in zeta potential and 
an increase in salt stability which was key for future investigations within a biological setting. 
Due to the limited solubility of SN-38, discovered to be soluble in THF up to 4 mg mL-1, a 
study of the impact of varying the organic solvent within the nanoprecipitation process 
confirmed that larger and more disperse particles were formed, which was in line with previous 





systems, decreasing Dz and zeta potentials with increasing PEGx-b-PCL40 content correlated 
with materials generated from acetone.  
The various studies conducted here, suggested a 50:50 wt% amphiphilic block co-polymer to 
hydrophobic branched polymer ratio as the best compromise between Dz, PdI and zeta 
potentials of the resulting nanoparticles. Considering the polyester backbone variation, the 
original expectation of clear trends when progressing from MOP, POP, BOP to PHLOP 
structures was not fully observed; nanoparticle size did not seem to correlate with polymer 
chemistry but thermal characteristics varied in line with the behaviour of analogous polymers 
derived from chain-growth chemistry, such as polymethacrylates. DSC analysis indicated that 
addition of alkyl chain substituents decreased crystallinity and flexible side chains led to a 
decrease in Tg values (compared to ε-CL based polymers) as may have been expected. Equally 
expected, more rigid side chains led to an increase in Tg above that of PCL. However, when 
substitution was present, nanoprecipitation led to nanoparticles that were larger than those 
containing PCL40-co-BOD0.7, regardless of the stabilising PEG co-polymer. For example, 
PPOP40-co-BOD0.7 generated the largest particles which was most likely due to the increased 
steric hindrance in the polymer backbone; additionally studies that aimed to match the 
monomer chemistry of the hydrophobic branched polymer and the stabilising A-B block 
copolymer, showed no significant effect on the properties or stability of the resulting particles. 
Across a range of guest molecules, namely Oil red O, docetaxel and SN-38 pro-drugs, Oil red 
O and docetaxel both formed highly stable nanoparticles with CL-derived polymers and SN-38 
pro-drugs were successful using CL and substituted CL-derived A-B block co-polymers with 
no significant effect observed with the variation of amphiphilic block co-polymer. SN-38 was 
not able to be encapsulated via co-nanoprecipitation indicating a clear impact of the drug 
compound chemistry on the nanoprecipitation process. Comparisons between PCL and PPOP 
based systems and SN-38 revealed large solubility differenced and these are important to 
consider when designing successful nanoprecipitation processes. Further confirmatory studies 
using Oil red O and docetaxel supported the conclusion that failure to encapsulate SN-38 via 
co-nanoprecipitation was a result of the differing solubility of the drug and the polymer. 
In search of alternative nanoparticle formation processes, branched PEG co-polymers, and later 
linear PEG co-polymers, were identified as being able to successfully form SN-38-containing 
nanoparticles over a range of drug loadings from 2.43 to 95 wt%, using a thin film hydration 





producing the most monodisperse nanoparticle dispersions over the full range of drug loadings 
using this approach. A trend of increasing size with increasing SN-38 content was observed 
indicating that an increased amount of SN-38 was successfully stabilised by the amount of 
polymer that was present. The ability to achieve such high SN-38 content was highly 
surprising, but was rationalised as a transition from drug-containing polymer nanoparticles 
(encapsulation mechanism) through to solid drug nanoparticle dispersions (stabilisation 
mechanism), also known as SDNs. 
Various studies utilising SEM, DSC and TASC analysis were performed to attempt to define 
the transition from polymer particles to SDNs. SEM of dry films and filtrates collected from 
nanoparticle dispersions, with increasing SN-38 content, suggested the transition occurred 
between 16.6 and 30 wt% SN-38, both DSC and TASC appeared to correlate with this 
conclusion. All three techniques universally indicated that the shift from polymeric 
nanoparticle to SDN also correlated with the appearance of SN-38 within the thin film.  
Additionally, SN-38 containing thin films offer a solvent- and water-free storage option that 
may provide benefits over liquid dispersion. Dry thin films derived from PEG5K-b-PMOP40-
co-BOD0.7 and PEG5K-b-PPOP40-co-BOD0.7 and containing 10, 30, 50 and 75 wt% SN-38 were 
shown to be reconstitutable after at least 14 weeks storage under ambient conditions, with little 
variation in Dz and PdI; however greater variability was observed at SN-38 contents over 30 
wt%. In contrast, nanoparticle dispersions, based on PEG5K-b-PCL40-co-BOD0.7, with SN-38 
content ranging from 2.43 and 95 wt% showed potential storage stability over several days. 
Collectively, this presents an opportunity for a clinical candidate to be stored for several months 
in a dry state, prepared by reconstitution within a hospital pharmacy and administrated within 
a period of several days, under ambient conditions; for example, samples with ≤ 33 wt% SN-38 
were shown to be stable for four days. 
Finally, pharmacological assessments of branched PEG co-polymer systems containing 10, 50 
and 75 wt% SN-38 indicated that the modification of the polymer backbone chemistries, had 
little effect on the release rate of SN-38 from the nanoparticles in vitro; PEG5K-b-PCL40-co-
BOD0.7 generated the slowest release rates across all three SN-38 concentrations. Cytotoxicity 
studies revealed that encapsulation within a polymeric nanostructure did not have a detrimental 
effect on the potency of SN-38, demonstrating similar IC50 values to free SN-38. Cellular 





three drug concentrations when compared to free SN-38 suggesting that the nanoparticles 
would have extended circulation time within the body.  
5.2 Future work 
The completion of the work detailed within this thesis, whilst achieving SN-38 encapsulation, 
highlighted a number of areas that could be further explored. Each phase that led to the 
successful synthesis of SN-38 containing nanoparticles, from polymer synthesis to 
pharmacological assessment, provides opportunities for further study to expand the ideas 
explored within this body of work. For simplicity these shall be divided into the following 
sections;  
5.2.1 Polymer synthesis 
Evidence of transesterification reactions within PCL polymers, combined with the increase in 
molecular weight once full monomer conversion was reached, directs studies to investigate the 
optimum reaction time of the ‘modified Strathclyde method’ to produce a highly branched 
polymeric species. However, as the final polymer obtained from this method would most likely 
not possess primary chain lengths of the targeted DPn, this conversely motivates exploration of 
the optimum conditions to achieve a branched species within the time it takes to reach full 
monomer conversion. This could be applied to both homo- and co-polymers, which within this 
body of work showed a lack of highly branched architecture, and may require additional 
investigation into alternative methods for the removal of water for the reaction mixture to 
further optimise the ‘modified Strathclyde method’. 
Further studies utilising acid catalysed ROP utilising both MSA and TfOH, shown to be active 
for lactide, would also expand the boundaries of what can be achieved via this method.2 The 
successful implementation of a ‘modified Strathclyde method’ utilising BOD and both BzA 
and PEG macroinitiators in the case of PCL would suggest that further studies involving a 
range branching units, monomers such as lactide and glycolide, and macroinitiators, such as 
PVP and dendrons, could greatly expand the library of polymers synthesised by this method. 
PVP block co-polymers would provide a favourable alternative to PEG due to PVP’s extremely 
low cytotoxicity, biocompatibility and non-ionic nature, however previous work conducted in 
this area would suggest that acid catalysed ROP with PVP initiators would require in depth 





method’ would provide a route to a new class of hyperbranched polydendron in which the 
hydrophobic segments would be biodegradable. 
The synthesis of a number of statistical co-polymers based on ε-CL, MOP, POP, BOP and 
PHLOP combined with DSC characterisation would give more insight into the effects the 
extending alkyl chain of the monomer had on the resulting polymer properties and crystallinity. 
Gradually increasing the substituted caprolactone monomer content within a co-polymerisation 
with ε-CL would allow the point at which crystallinity was lost to be determined by the 
disappearance of a Tm peak. Extensive kinetic studies of the polymerisations of each substituted 
caprolactone monomer would provide invaluable insight into the effects, if any, of extending 
the alkyl side chain on the basicity of the monomer and therefore the rate of polymerisation. 
This would help to predict the sequence of monomers within statistical polymerisations.  
The creation of four substituted caprolactone monomers and BOD via Baeyer-Villiger 
oxidation shows that simple monomer synthesis can be achieved utilising a selected cyclic 
ketone and therefore the library of polymers able to be created by MSA catalysed ROP is 
extensive and not limited to commercially available monomers. Further synthesis of monomers 
with increasing variety in side chain functionality based on ε-CL, and possibly glycolide, could 
unlock an extensive range of new physicochemical properties in the resulting polymers. These 
polymers could subsequently be assessed in the formation of nanoparticles and the 
encapsulation of hydrophobic guest molecules. Furthermore, the implementation of an 
expensive library of monomers could also help to achieve more favourable pharmacological 
profiles for any drug-containing nanoparticles produced.  
5.2.2 Nanoparticle formation and encapsulation via co-nanoprecipitation  
Extensive work concerning co-nanoprecipitation has been carried out within the Rannard 
group, however, the implementation of polyesters has been limited.4–6 A wide-ranging study 
utilising: a) a number of different volatile solvents, b) a variety of polymer concentrations in 
the organic phase and c) the targeted final concentration in water, would provide a more 
complete assessment of the influence of solvent choice, concentration and polymer 
combination have on the resulting nanoparticle dispersions. Additional comparisons could then 
be drawn between polyester and polymethacrylate systems to evaluate whether any 





Co-nanoprecipitation of the library of polymers within this thesis revealed that encapsulation 
of hydrophobic guest molecules was achievable only at low concentrations. Additional studies 
with a larger range of drug molecules and a variety of co-nanoprecipitation parameters could 
result in increased drug loadings of the molecules already studied and expand the potential of 
these systems. 
Supplementary studies regarding the degradation of the polymer matrix when contained within 
a nanoparticle structure using lipase, and other enzymes found in vivo, would provide 
additional data to support or rule out the potential of these systems within a biological setting. 
This study is not limited to nanoparticles formed via co-nanoprecipitation but could also be 
extended to those formed by thin film hydration.  
5.2.3 Nanoparticle formation and encapsulation via thin film hydration  
Further assessment of the thin films created within this body of work would provide greater 
understanding of what influences the particle structure and further refine the range in which 
the transition from polymeric nanoparticle to SDN occurs. This could be achieved by X-ray 
diffraction, cryo-SEM or TEM and energy-dispersive X-ray, EDX, analysis to give a more 
complete visual representation of the location and crystallinity of SN-38.  
Given that the thin film hydration methodology provides an alternative route to nanoparticles, 
resulting in a favourable storage method shown to extend the shelf-life of these systems, the 
method could be applied to a variety of drug molecules. Furthermore the removal of organic 
solvent may also improve polymer-drug interactions with a variety of different drug molecules 
which may previously have been disregarded from study due to difficulty with encapsulation. 
Assessment of nanoparticle degradation with varying drug content would provide a valuable 
insight into any effects f the structure of the nanoparticle on the degradation rate of the polymer. 
Coupled with release studies, degradation of the nanoparticles could highlight whether the 
degradation rate of the polymer matrix had any influence on the release of the drug.  
5.2.4 Pharmacological assessment 
Assessment of SN-38 release using radio-labelled SN-38 would provide a valuable comparison 
to the RED analysis conducted within this body of work. Given that the release of SN-38 was 
only slightly slower when encapsulated within a polymeric nanostructure, radiometric analysis 
would provide greater resolution to distinguish any other effects the alteration of the polymer 





Release rate studies of a larger library of nanoparticles, both synthesised within this body of 
work and further systems that could be synthesised in future - such as dispersions based on 
more highly branched PEG co-polymers, would allow for more trends to be evaluated. For 
example, obtaining release rate data for the complete range of SN-38 concentrations achieved 
when stabilised by PEG5K-b-PCL40-co-BOD0.7 could highlight any trends associated with the 
shift from polymeric nanoparticle to SDN. This proposal could also apply to further 
pharmacological assessment such as cytotoxicity and macrophage uptake. Further assessment 
in vivo, possibly with direct injection intratumorally, would give a more complete view of the 
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Toluene (anhydrous, >99.9 %), urea hydrogen peroxide (97 %), methanesulfonic acid (≥99 %), 
benzyl alcohol (anhydrous, 99.8 %), 4-tert-butylcyclohexanone (99 %), 4-
methylcyclohexanone (99 %), 4-phenylcyclohexanone (≥98 %), 4-propylcyclohexanone (≥99 
%), N,N-triethylamine, TEA (≥ 99%), oil red O and deuterated chloroform, CDCl3, were 
purchased from Sigma Aldrich and used as received. ε-Caprolactone, ε-CL, (97 %), was also 
purchased from Sigma Aldrich and purified by distillation over calcium hydride, CaH2, or 
drying over 3 Å molecular sieves for at least 24 hours. Formic acid (≥ 98 %) and aluminium 
oxide (activated, basic, Brockmann I) were purchased from Honeywell Fluka and used as 
received. Tetrahydrofuran, THF, N,N’-dimethylformamide, DMF, acetone, acetonitrile, 
methanol, MeOH, diethyl ether, hexane, ethyl acetate and chloroform, CHCl3, all reagent grade 
were all purchased from Fischer Scientific. Docetaxel and SN-38 were purchased from 
Chemleader Biochemical. Pro-drug SN-38 pentanoate, SN-38 P, was synthesised and purified 
in the group by Dr Andrew Dwyer and used as provided (see Chapter 4).   
6.2 Instrumentation and characterisation  
6.2.1 Instrumentation 
1H and 13C-nuclear magnetic resonance, NMR, was undertaken using a Bruker Avance III HD 
NMR spectrometer operating at 400 MHz for 1H-NMR and 100 MHz for 13C-NMR. The 
samples were acquired in CDCl3, D2O or DMSO-d
6. Chemical shifts, quoted in parts per 
million, ppm, where in reference to the peak generated by trimethylsilane, TMS, at 0 ppm.  
Elemental analysis was undertaken using a Thermo FlashEA 112 series CHNSO elemental 
analyser. 
Chemical ionisation, CI, mass spectrometry was recorded using an Agilent GC/Q-TOP 7200 
instrument using ammonium CI gas.  
Triple detection size exclusion chromatography, SEC, used a Malvern Viscotek SEC Max 
equipped with a GPCmax VE2001 auto sampler, two Viscotek T6000 columns and a guard 
column. The detectors were a refractive index, RI detector (VE3580) and a 270 Dual Detector 
(light scattering and viscometer). The eluent system used was DMF containing 0.01 M LiBr at 





Single detection SEC was obtained using an Agilent 1260 Infinity II equipped with a PLgel 3 
m Mixed-E 300 x 7.5 mm column and RI detector. The eluent system was DMF containing 
0.01 M LiBr at 60 °C at a flow rate of 1 mL min-1. Calculations of Mn and Mw were determined 
using a conventional calibration method against poly(methyl methacrylate), PMMA, 
calibration standards (Mp = 850 to 27,600 g mol
-1). 
Dynamic light scattering, DLS, was undertaken with a Malvern Zetasizer Nano ZS (4 mW He-
Ne 633 nm laser) with a disposable folded cuvette, or a disposable cuvette (thin film 
nanoparticle dispersions at 25 °C. 
Differential scanning calorimetry, DSC, utilised a DSC Discovery instrument using a T4P 
calibration of samples held within Tzero pans at temperatures between -90 and 500 °C under a 
nitrogen atmosphere at a pressure of 0.1 MPa. 
Scanning electron microscopy, SEM, images were recorded using a Tescan S8000G focused 
ion beam/scanning electron microscope. After preparation of each sample on a SEM stub, 
detailed specifically in Chapter 4, each sample was sputter coating with chromium using a 
Quorum Technologies Q150T ES sputter coater for 15 seconds (120 mA). 
Thermal analysis by structural characterisation, TASC, was undertaken at the Alderley Edge 
site of AstraZeneca using Linkcam scientific TASC apparatus.  
6.2.2 Summary of characterisation 
Substituted caprolactone monomers characterisation; 
 1H-NMR, 13C-NMR, CI mass spectrometry and CHNSO analysis.  
Polymer characterisation;  
 Monomer conversion and degree of polymerisation via chain end analysis were 
calculated using 1H-NMR.  
 Number-averaged and weight-averaged molecular weights, Mn and Mw respectively, 
polydispersity, Đ, dn/dc and Mark-Houlwick value, α, were determined by triple 
detection SEC. 
 Mn and Mw values for polymer samples obtained in Sections 2.3.2.1 and 2.3.2.2 were 
determined by single detection SEC. 





Nanoparticle dispersions characterisation; 
 Measurements of Z-average diameter, number-average diameter, zeta potential, 
derived count rate and PdI were determined by DLS at 25 °C at selected time points 
after nanoparticle formation.  
 All samples, excluding those specified in Section 4.3.3.1.2 were unfiltered at the time 
of characterisation. 
 Images of nanoparticle dispersions were obtained using SEM. 
Thin film characterisation;  
 Thermal properties (Tg and Tm) of thin films were calculated using DSC. 
 Further thermal analysis was undertaken using TASC microscopy. 
 Images of thin films were obtained using SEM. 
6.3 Methods for Chapter 2 – Polymer synthesis 
6.3.1 Substituted caprolactone monomer and bis-lactone monomer synthesis 
 
Scheme 6.1 – Scheme representing the synthesis of substituted caprolactone monomers 





6.3.1.1 General Baeyer-Villiger oxidation synthesis of substituted 
caprolactone monomers 
Each monomer was synthesised on a 15 g scale by synthesising three 5 g batch reactions which 
were combined at the time of extraction/purification to reduce the risks associated with large 
amounts of peroxy-acid formation during the oxidation step. 
Urea hydrogen peroxide, UHP (3 x 3 eq.) was added to excess formic acid (3 x 100 mL) and 
stirred at room temperature for 2 hours to allow for the formation of a peroxy-acid. The solution 
was then cooled to 0 °C before the selected cyclic ketone (3 x 5 g, 1 eq.) was added over 10 
minutes. The mixture was then left stirring at 0 °C for 24 hours.  
Water (3 x 100 mL) was then added followed by combination of the 3 batch reactions before 
extraction with chloroform (4 x 300 mL). The combined organic fractions were then washed 
with sodium bicarbonate (3 x 300 mL) and dried with sodium sulfate. The solution was filtered 
and the solvent removed before characterisation with 1H NMR, 13C NMR and mass 
spectrometry. 
5-Methyloxepan-2-one, MOP (1) - The synthesis of 5-methyloxepan-2-one was carried out 
following the general Baeyer-Villiager oxidation method described above with UHP (3 x 
12.58 g, 133.7 mmol, 3 eq.) and 4-methylcyclohexanone (3 x 5 g, 44.6 mmol, 1 eq.). The crude 
clear, colourless oil was purified by liquid chromatography on silica eluting with a polarity of 
ethyl acetate:hexane (25:75) (Rf= 0.2) Yield:  9.64 g, clear, colourless oil (56.3 %).1H NMR 
(400 MHz, CDCl3) δ 4.42 – 4.12 (m, 2H), 2.73 – 2.54 (m, 2H), 1.99 – 1.83 (m, 2H), 1.84 – 
1.71 (m, 1H), 1.57 – 1.44 (m, 1H), 1.34 (dtd, J = 13.9, 11.2, 2.8 Hz, 1H), 1.00 (d, J = 6.6 Hz, 
3H).13C NMR (101 MHz, CDCl3) δ 176.06 (s), 68.09 (s), 37.25 (s), 35.26 (s), 33.21 (s), 30.78 
(s), 22.12 (s), -25.14 – -25.34 (m). (Found: C, 65.41; H, 9.47; C8H12O2 requires, C, 65.6; H, 
9.44%). 
5-Propyloxepan-2-one, POP (2) - UHP (3 x 10.06 g, 107 mmol, 3 eq.) and 4-
propylcyclohexanone (3 x 5 g, 35.6mmol, 1 eq.). The crude clear, colourless oil was purified 
by liquid chromatography on silica eluting with a polarity of ethyl acetate:hexane (25:75) (Rf= 
0.25) Yield: 6.65 g, clear, colourless oil (39.8 %). 1H NMR (400 MHz, CDCl3) δ 4.39 – 4.10 
(m, 2H), 2.75 – 2.52 (m, 2H), 2.07 – 1.86 (m, 2H), 1.69 – 1.55 (m, 1H), 1.54 – 1.41 (m, 1H), 





(s), 39.91 (s), 38.65 (s), 35.34 (s), 33.19 (s), 28.88 (s), 19.85 (s), 14.14 (s). (Found: C, 69.58; 
H, 10.34; C9H16O2 requires, C, 69.19; H, 10.32%). 
5-(tert-Butyl)oxepan-2-one, BOP (3) - UHP (3 x 9.15 g, 97.2 mmol, 3 eq.) and 
4-(tert-butyl)cyclohexanone (3 x 5 g, 32.4 mmol, 1 eq.). The crude white long crystals were 
purified by liquid chromatography on silica eluting with a polarity of ethyl acetate:hexane 
(25:75)  (Rf= 0.33) Yield: 10.49 g, white long crystals (63.3 %). 1H NMR (400 MHz, CDCl3) 
δ 4.46 – 4.05 (m, 2H), 2.80 – 2.47 (m, 2H), 2.15 – 1.95 (m, 2H), 1.60 – 1.44 (m, 1H), 1.42 – 
1.24 (m, 2H), 0.90 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 176.28 (s), 68.63 (s), 50.77 (s), 
33.46 (s), 32.99 (s), 30.35 (s), 27.45 (s), 23.78(s). (Found: C, 70.42; H, 10.67; C10H18O2 
requires, C, 70.55; H, 10.66%). 
5-Phenyloxepan-2-one, PHLOP (4) - UHP (3 x 8.1 g, 86.1 mmol, 3 eq.) and 4-
phenylcyclohexanone (3 x 5 g, 28.7 mmol, 1 eq.). The crude white crystals were purified by 
liquid chromatography on silica eluting with a polarity of ethyl acetate:hexane (25:75) (Rf= 
0.15) Yield: 10.61 g, white/cream crystals (64.8 %). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.08 
(m, 5H), 4.43 – 4.23 (m, 2H), 2.92 – 2.66 (m, 3H), 2.24 – 1.60 (m, 3H), 1.93 – 1.73 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 175.72 (s), 144.98 (s), 128.79 (s), 126.88 (s), 126.63 (s), 68.26 
(s), 47.24 (s), 36.75 (s), 33.72 (s), 30.34 (s). (Found: C, 75.58; H, 7.40; C12H14O2 requires, C, 
75.76; H, 7.42%). 
6.3.1.2 Synthesis of 4,4’-bioxepanyl-7,7’-dione, BOD 
Urea hydrogen peroxide, UHP, (15 g, 6 eq i.e. 3 eq per ketone) was added to excess formic 
acid (100 mL) and stirred for 2 hours at room temperature to allow for the formation of a 
peroxy-acid. The mixture was then placed in an ice bath before bicyclohexanone (5 g, 1 eq) 
was added over 10 minutes. This was then left stirring for 24 hours with periodic changing of 
the ice bath to control the exothermic reaction.  
Water (100 mL) was then added and the organic fraction extracted with a chloroform wash 
(4 x 100 mL). A final wash of the organic layer was performed with sodium bicarbonate (3 x 
100 mL). The organic fraction was dried over sodium sulfate for 24 hours. Finally the solution 
was filtered and the solvent removed liberating a white solid. Further purification was 
completed using liquid chromatography on silica, eluting from ethyl acetate: hexane (50:50), 
increasing to a polarity of ethyl acetate: hexane (100:0) (Rf = 0.25), white solid.1H NMR (400 





1.56 – 1.39 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 175.38 (s), 68.07 (s), 45.94 (s), 33.33 (s), 
32.27 (s), 32.04 (s), 26.00 (s), 25.79 (s). (Found: C, 63.39; H, 8.03; C12H14O2 requires, C, 63.70; 
H, 8.02%). 
6.3.2 Acid Catalysed Ring Opening Polymerisation 
6.3.2.1 Linear polymerisation of cyclic esters 
In a typical synthesis, targeting a number average degree of polymerisation, DPn= 40, a cyclic 
ester (1-4, ε-CL, 2 g) was added to the reaction vessel, under an argon atmosphere, followed 
by anhydrous toluene (50 wt% for ε-CL & 1/2, 33 wt% for 3 and 25 wt% for 4). The flask was 
transferred to an oil bath and stirred at 30 °C (48 °C for 4). Benzyl alcohol (1 eq) acting as an 
initiator and methanesulfonic acid, MSA, (1 eq) were added consecutively. The flask was then 
sealed and left stirring at 30 °C (48 °C for 4) for 1.5 hours for ε-CL (3.5 hours for monomers 
1-4). 
The resulting product was dissolved in chloroform and stirred with basic alumina before the 
catalyst was removed with a basic alumina column. A sample of the crude product was taken 
at this point for analysis by 1H-NMR in CDCl3. The solution was reduced under vacuum and 
then precipitated/triturated in cold hexane (400 mL for precipitation, 2 x ~10 mL for trituration 
(1-4)) to liberate the pure polymer. The polymer was dried overnight under vacuum at 40-50 °C 
before analysis was completed with 1H-NMR in CDCl3 and triple detection SEC in DMF/LiBr 
at 60 °C. 
6.3.2.2 Branched ring opening polymerisation of cyclic esters 
The syntheses of branched polyesters (monomers 1-4, ε-CL) were carried out following the 
procedure of linear ROP (as described in 6.3.2.1) with the addition of 4,4’-bioxepanyl-7,7’-
dione, BOD, (for example, for a initiator: BOD ratio of 1:0.7, 41.63-104.07 g) to the reaction 
vessel before the addition of anhydrous toluene (w.r.t monomer: 50 wt% for ε-CL, 33 wt% 1-
3 and 25 wt% for 4). These reactions also required an increased reaction temperature of 36 °C 
for ε-CL, 38.5 °C for 1-3 and 61 °C for 4. The ratio of initiator to BOD was varied from 1:0.8 
to 1:0.6 (for ε-CL exclusively) to determine the gelation point and follow the effects of a bis-






6.3.2.3 Determining the presence of transesterification reactions in the ring 
opening polymerisation of PCL40 
Synthesis of the linear polymer was carried out following the experimental procedures detailed 
in Section 6.3.2.1, targeting an average degree of polymerisation of 40 monomer units (4 g of 
ε-CL) and undertaken in anhydrous toluene (50 wt%). Samples were taken under an argon 
atmosphere at different time points: before MSA addition, t0, after 1.5 hours at full conversion, 
t1.5, after 24 hours, t24, and finally after 48 hours, t48. MSA was removed from the aliquots (t1.5, 
t24 and t48) by a short basic alumina column in chloroform and then analysed by 
1H-NMR in 
CDCl3 and single detection SEC in DMF/LiBr. Following completion of the experiment 
remaining polymer was purified by the procedure detailed in Section 6.3.2.1 and also analysed 
by 1H-NMR in CDCl3 and single detection SEC in DMF/LiBr. 
6.3.2.4 Kinetic Studies of the ring opening polymerisation of ε-CL and ε-CL 
with BOD 
Kinetic studies for both linear and branched polymerisations of CL were prepared in the same 
manner as detailed in Sections 6.3.2.1 and 6.3.2.2, targeting a DPn of 40 monomer units in each 
case and initiator to BOD ratio of 1:0.7 for the branched polymerisation. The scale of the 
reaction was undertaken with 3 g of ε-CL and undertaken at 50 wt% dilution in anhydrous 
toluene, w.r.t monomer. A sample (t0) was taken before MSA addition, under Ar2, to give a 
representation of each polymerisation before it commenced. MSA was then added and samples 
(ca. 0.1 mL) were taken under Ar2 over 1.5 hours. The purification and frequency of sampling 
was altered during this experiment due to purification problems, detailed in Section 2.3.2.1. In 
initial studies samples (ca. 0.1 mL) were taken every 5 minutes and purified by dissolution in 
chloroform followed by a small basic alumina column. Samples were analysed by 1H-NMR in 
CDCl3.  
For the investigation of purification method, two samples (0.1 mL) were taken at each time 
point; at 0, 27, 40, 60 and 90 minutes. Sample A for each time point was treated with basic 
alumina as detailed above whereas sample B was dissolved in toluene (1 mL) containing TEA 
(equimolar to the estimated MSA content in 0.1 mL polymer mixture).  
Following the results of this investigations both linear and branched kinetic samples were 
treated with equimolar TEA. Preparation of each experiment was again undertaken following 





each case and initiator to BOD ratio of 1:0.7 for the branched polymerisation. Initial time points 
(0.1 mL), t0, were taken before MSA addition after the polymerisation mixtures were 
completely solvated at 30 and 36 °C for the linear and branched polymerisations respectively. 
Time points were then taken every 3 minutes for the first 30 minutes and then every 5 minutes 
until 1.5 hours had elapsed and each was added to 1 mL toluene containing TEA (equimolar to 
MSA). Each sample was filtered through cotton wool and analysed by 1H-NMR in CDCl3 and 
SEC analysis in DMF/LiBr at 60 °C (single detection for PCL40 and triple detection for PCL40-
co-BOD0.7) following evaporation of the toluene solution.  
6.3.2.5 Poly(ethylene glycol) methyl ether initiated linear ring opening 
polymerisation of cyclic esters 
Before the polymerisation, poly(ethylene glycol) methyl ether, PEG-OH, (2000 g mol-1 or 5000 
g mol-1) was dried overnight in a vacuum oven at 40-50 °C. In a typical reaction targeting a 
DPn= 40 monomer units using a PEG5K-OH initiator, the chosen cyclic ester (1-4, ε-CL, 40 eq, 
2 g) and initiator (1 eq) were weighed into a round bottom flask which was then equipped with 
a magnetic stirrer bar and sealed. The flask was sparged with Ar2 for ca. 10 minutes before the 
addition of toluene (50 wt% for ε-CL & 1/2, 33 wt% for 3 and 25 wt% for 4). The flask was 
submerged in an oil bath pre-heated to 50 °C where MSA (1eq) was added following complete 
solubilisation of the initiator in the reaction mixture. The reaction mixture was left stirring for 
2 hours for ε-CL (3.75 hours for 1-4). 
The resulting polymer was dissolved in chloroform and stirred with basic alumina followed by 
catalyst removal via filtration through a basic alumina column. Here, an aliquot was taken for 
analysis by 1H-NMR in CDCl3. The filter solution was then reduced to a minimal volume 
before precipitation/trituration in cold hexane (200 mL for precipitation, 2 x ~10 mL for 
trituration (1-4)). The resulting pure polymer was dried in a vacuum oven overnight at 40-50 
°C followed by analysis by 1H-NMR (CDCl3) and SEC analysis in DMF/LiBr at 60 °C. 
6.3.2.6 Poly(ethylene glycol) initiated branched ring opening polymerisation 
of cyclic esters 
Again, the synthesis of PEG5K-OH initiated branched polyesters with monomers 1-4 and ε-CL 
were carried out following the procedure detailed in Section 6.3.2.5 targeting a DPn of 40 
monomer units with the addition of BOD (0.7 eq w.r.t 1 eq initiator) before the addition of 





studies detail in Section 2.3.3.1. Crude samples were taken for determination of monomer 
conversion by 1H-NMR in CDCl3 and pure polymers were analysed by both 
1H-NMR in CDCl3 
and SEC in DMF/LiBr at 60 °C. 
Following this analysis the ratio of BOD to initiator was increased, exclusively with ε-CL, to 
determine the gel point with the BOD to initiator ratio increments being 0.8:1, 0.9:1, 1:1, 1.2:1 
and 1.5:1. Resultant polymers were analysed with both 1H-NMR and SEC in DMF/LiBr at 
60 °C. 
6.4 Methods for Chapter 3 – Particle formation 
6.4.1 (Co)-Nanoprecipitation Studies 
6.4.1.1 Typical nanoprecipitation studies of polyesters 
In a typical nanoprecipitation study, the selected polymer was dissolved in either acetone or 
THF at a concentration of 5 mgmL-1. Each solution was left mixing overnight to ensure full 
dissolution of the polymer. The organic solvent/polymer solution (1 mL) was then quickly 
added to de-ionised water (5 mL) contained within a 14 mL vial equipped with a magnetic 
stirrer bar. The mixture was left stirring vigorously at ambient temperature for approximately 
24 hours to allow for full solvent evaporation. The resulting, unfiltered nanoparticle dispersion 
was then analysed by DLS and re-analysed after 7 or 14 days, unless otherwise specified.  
6.4.1.2 Typical co-nanoprecipitation studies of polyesters  
In a typical co-nanoprecipitation study targeting a weight fraction of 75 wt% the selected 
branched polyester (e.g. PCL40-co-BOD0.7) and 25 wt% of the chosen A-B block PEG co-
polymer (PEGx-b-PCL40), 40 mg in total was weighed out. This consisted of PCL40-co-BOD0.7 
(30 mg) and PEGx-b-PCL40 (10 mg) which was then dissolved in the selected organic solvent, 
either THF or acetone (8 mL), to a concentration of 5 mgmL-1 and mixed over ca. 24 hours to 
allow for complete dissolution. An aliquot (1 mL) of this solution was then rapidly added to 
de-ionised water (5 mL) stirring vigorously. The mixture was left at ambient temperature for 
24 hours to allow for complete evaporation of organic solvent. This resulted in an aqueous 
dispersion at a final concentration of 1 mgmL-1 which was subsequently analysed by DLS.  
This method was implemented for a number of weight fractions for a large variation of 
branched polyester to AB block co-polymer combinations (specified in Chapter 3). These 






6.4.2 Salt stability studies 
6.4.2.1 Successive addition of NaCl to nanoparticle dispersions to determine 
salt stability  
The chosen nanoparticle aqueous dispersion (1 mL), with a concentration of polymer in water 
of 1 mgmL-1 was added to a small 4 ml vial. Then, aliquots of 0.5 M NaCl (20 µL) were 
consecutively added, with agitation by vortex mixing and 30 second intervals between each 
addition (20 – 2000 µL). Additions were continued until visible aggregation could be seen or 
the 2000 µL limit was reached and the volume noted. This was a qualitative method used to 
give a visual estimate of the solutions stability to be coupled with study of stability over time 
in the addition of salt detailed in section 6.5.2.2. 
6.4.2.2 Time dependant salt stability study 
Prior to the study, 1 mL of the chosen aqueous nanoparticle dispersion (concentration of 1 
mgmL-1 polymer in water) was added to a 4 mL vial (after initial DLS characterisation). For 
the instant measurement, an aliquot of 0.5 M NaCl solution (20 µL) was added followed by 
agitation by vortex mixer followed by immediate DLS analysis. The sample was returned to 
the vial and re-analysed after 1 and 7 days of storage. The procedure was repeated for all 
co-nanoprecipitates involving PEGx-co-PCL40 as the amphiphilic component. 
6.4.3 Encapsulation of hydrophobic guest molecule via rapid co-
nanoprecipitation 
In a typical guest encapsulation study, via co-nanoprecipitation, using oil red O (2.43 wt%) 
targeting a weight fraction of 50 wt% the selected branched polyester (e.g. PCL40-co-BOD0.7) 
and 50 wt% of the chosen A-B block PEG co-polymer (PEGx-b-PCL40), oil red O was initially 
dissolved in THF (1 mgmL-1) and left to dissolve overnight. The selected PEG co-polymer (10 
mg) and branched polyester (10 mg) were dissolved in THF (3.48 mL) followed by the addition 
of the THF/oil red O mixture (0.52 mL). The resulting solutions (5 mgmL-1 w.r.t polymer) were 
left to dissolve overnight, after which, an aliquot (1 mL) was rapidly added to de-ionised water 
(5 mL) under vigorous stirring. After organic solvent evaporation, the resulting aqueous 






6.5 Methods for Chapter 4 – Encapsulation of active drug molecules 
6.5.1 Encapsulation of SN-38 P via rapid co-nanoprecipitation 
In a typical guest encapsulation study of SN-38 P (2.43 wt%), via co-nanoprecipitation, 
targeting a weight fraction of 50 wt% the selected branched polyester (e.g. PCL40-co-BOD0.7) 
and 50 wt% of the chosen A-B block PEG co-polymer (PEG5K-b-PCL40 or PEG5K-b-BM40), 
SN-38 P was initially dissolved in THF (1 mgmL-1) and left to dissolve overnight. The selected 
PEG co-polymer (25 mg) and branched polyester (25 mg) were dissolved in THF (8.75 mL) 
followed by the addition of the THF/SN-38 P mixture (1.25 mL). The resulting solutions (5 
mgmL-1 w.r.t polymer) were left to dissolve overnight, after which, an aliquot (1 mL) was 
rapidly added to de-ionised water (5 mL) under vigorous stirring. After organic solvent 
evaporation, the resulting aqueous dispersion (1 mgmL-1) was characterised by DLS. 
6.5.2 Encapsulation of SN-38 via rapid co-nanoprecipitation 
First in order to select a suitable solvent which would enable the dissolution of both the polymer 
and SN-38 solubility tests were undertaken with SN-38 in a range of solvents (Table 6.1). It 
was found that only DMSO (1 mgmL-1), THF:acetonitrile (95:5 to 50:50, 1 mgmL-1) and THF 
(4 mgmL-1) were able to dissolve SN-38. 
Table 6.1 – Solubility studies conducted with SN-38 and various solvents. 
Solvent System Dissolution? Solvent System Dissolution? 
THF: Acetonitrile 


























































 THF was selected for co-nanoprecipitation studies due to the low boiling point aiding solvent 
evaporation. In a typical co-nanoprecipitation study, targeting 2.43 wt% SN-38 loaded, 50:50 
wt% linear PEG co-polymer and branched polyester (e.g. PEG5K-b-PCL40: PCL40-co-BOD0.7) 
nanoparticles, SN-38 was first dissolved in THF (1 mgmL-1) and left to mix for > 2 hours. 50 
mg of polymer was weight out into a glass vial, consisting of PEG5K-b-PCL40 (25 mg) and 
PCL40-co-BOD0.7 (25 mg), and dissolved in THF (8.75 mL). THF/SN-38 mixture (1.25 mL) 
was then added to the same vial and the resulting solution (5 mgml-1 w.r.t polymer) was left to 
mix overnight. An aliquot (1 mL) of this solution was then rapidly added to de-ionised water 
(5 mL) under vigorous stirring and the organic solvent was left to evaporate over 24 hours 
targeting a final aqueous nanoparticle dispersion (1 mgmL-1 w.r.t polymer) containing 2.43 
wt% SN-38. This methodology was applied to various combinations of PEGx-b-PCL40 
stabilised branched polymers based on ε-CL, MOP, POP, BOP and PHLOP monomers. 
Unfortunately DLS characterisation was unable to be completed for any of these dispersion 
due to instability.  
6.5.3 Variation of concentration: dilution studies 
Studies were undertaken following methodology first published by Ford et al.1 
6.5.3.1 Varying the concentration of PEG5K-b-PCL40 and branched 
polyesters in THF with and without hydrophobic guest present 
In a typical dilution study based on a co-nanoprecipitation of 50 wt% PCL40-co-BOD0.7, 50 
wt% PEG5K-b-PCL40 and SN-38 content of 2.43 wt% final polymer content in de-ionised water 
(5 mL) was targeted to be 12.5 mg following solvent evaporation. Therefore a series of 
polymer/drug in THF solutions were made with concentrations (w.r.t polymer) between 1.5625 
and 25 mgmL-1. SN-38 content was kept constant at 2.43 wt% regardless of polymer 
concentration in THF. All solutions were left to mix overnight to allow for full polymer and 
SN-38 dissolution. Then each THF mixture (concentrations specified in Table 6.2) was rapidly 
added to de-ionised water (0.5 mL to 8 mL, Table 6.2) with vigorous stirring. DLS 
characterisation was undertaken instantaneously after solvent addition and following full THF 
evaporation; both measurements were undertaken in a quartz cuvette.  
This methodology was repeated for a 50 wt% PCL40-co-BOD0.7, to 50 wt% PEG5K-b-PCL40 
co-nanoprecipitation without SN-38 and also a 50 wt% PPOP40-co-BOD0.7 to 50 wt% 





Table 6.2 – Concentration of polymers (50:50 wt%) combined PEG co-polymer and 
branched polyester, with and without SN-38, in THF targeting a final mass in water of 
12.5 mg (w.r.t polymer) and 0.303 mg (w.r.t SN-38, 2.43 wt%). 
Entry 
Volume of THF containing 
polymer (and drug) 
( mL) 
Concentration of 
polymer in THF 
(mgmL-1) 
Concentration of 





Only polymer (50:50) 
1 0.5 25 - 5 
2 1 12.5 - 5 
3 2 6.25 - 5 
4 3 4.167 - 5 
5 4 3.125 - 5 
6 5 2.5 - 5 
7 8 1.5625 - 5 
Polymer (50:50) and SN-38 (2.43 wt%) 
1 0.5 25 0.625 5 
2 1 12.5 0.3125 5 
3 2 6.25 0.15625 5 
4 3 4.167 0.101475 5 
5 4 3.125 0.078125 5 
6 5 2.5 0.0625 5 
7 8 1.5625 0.03906 5 
 
6.5.3.2 Varying the concentration of a hydrophobic guest and trial of 
nanoparticle formation without polymer present 
This study was completed using concentrations that reflect 2.43 wt% guest loading if the 
polymer was present at a constant mass in de-ionised water (5 mL) after THF evaporation 
(detailed in section 6.5.2.1). Therefore maintain a final guest mass in water (5 mL) of 0.303 
mg after THF evaporation, with concentration of guest in THF varying from 0.03906 to 0.625 
mgmL-1 (Table 6.3).  THF/guest mixtures were mixed overnight before additions of increasing 
volume (0.5 to 8 mL, Table 6.3) to de-ionised water (5 mL). DLS characterisation was only 







Table 6.3 – Concentration of guest molecules in THF targeting a final mass in water of 
0.303 mg (2.43 wt%).  
Entry 
Volume of THF containing 
polymer (and drug) 
( mL) 
Concentration of 
polymer in THF 
(mgmL-1) 
Concentration of 





Drug or guest only (2.43 wt%) 
1 0.5 - 0.625 5 
2 1 - 0.3125 5 
3 2 - 0.15625 5 
4 3 - 0.101475 5 
5 4 - 0.078125 5 
6 5 - 0.0625 5 
7 8 - 0.03906 5 
 
6.5.4 Thin film hydration 
6.5.4.1 Typical thin film co-hydration of branched polyesters and PEG co-
polymers 
In a typical thin film hydration study targeting a weight fraction of 50 wt% branched polyester 
(e.g. PCL40-co-BOD0.7) and 50 wt% PEG5K-b-PCL40 and SN-38 content of 2.43 wt%, SN-38 
(10 mg) was initially dissolved in THF (10 mL) at a concentration of 1 mgmL-1 and left to mix 
for > 2 hours. PCL40-co-BOD0.7 (10 mg) and PEG5K-b-PCL40 (10 mg) were weighed out into a 
glass vial followed by THF (3.5 mL) and SN-38 solution in THF (0.5 mL). This was mixed 
overnight to allow for dissolution. An aliquot (0.5 mL) was then added to a new glass vial and 
the THF removed under vacuum. De-ionised water (2.5 mL) was added targeting an aqueous 
dispersion concentration of 1 mgmL-1. The method of mixing was then varied between 3 
methods, vortex mixing for ca. 5 minutes, stirring vigorously overnight and sonication directly 
after water addition. Samples that were hydrated using vortex or by direct sonication were both 
sonicated using an ultrasound bath for 5 minutes. Samples which underwent vigorous stirring 
overnight were investigated with two methods of sonication, via ultrasound bath (5 minutes) 
or via a Covaris (60 seconds, 70 W at ≤ 14 °C). DLS characterisation was undertaken before 






6.5.4.2 Typical thin film hydration of single species 
In a typical thin film hydration study targeting a drug loading of 50 wt% SN-38 in a PEG5K-b-
PMOP40-co-BOD0.7 based dispersion, PEG5K-b-PMOP40-co-BOD0.7 (25 mg) and SN-38 
(25 mg) were added to a glass vial and dissolved in THF (5 mgmL-1 w.r.t polymer). The 
solution was left to mix overnight to ensure dissolution. A small aliquot (0.5 mL) was 
transferred to another glass vial followed by removal of THF via rotary evaporation. The thin 
film was then hydrated by the addition of de-ionised water (2.5 mL) and vigorous stirring 
overnight. The resulting dispersion was then characterised by DLS before sonication was 
completed using a Covaris (60 seconds, 70 W at ≤ 14 °C). Following sonication nanoparticle 
dispersions were characterised by DLS again. 
This methodology was repeated for both linear and branched PEG co-polymer with a number 
of SN-38 drug loading values, specified in Section 4.3.2. 
6.5.5 Thin film hydration stability studies 
6.5.5.1 Stability of dry thin films 
Thin films for this stability study were synthesised using the methodology detailed in Section 
6.5.3.2 utilising either PEG5K-b-PMOP40-co-BOD0.7 or PEG5K-b-PPOP40-co-BOD0.7 and SN-
38 drug loadings of 10, 30, 50 and 75 wt% maintaining a polymer in THF concentration of 5 
mgmL-1. 10 thin films of each polymer and drug loading combination (80 in total) were created 
by the reduction of an aliquot of the polymer/drug/THF solution (0.5 mL) by rotary 
evaporation. Once the dry films were created the first time point, for each polymer and SN-38 
content combination, was hydrated to a concentration of 1 mgmL-1 by the addition of water 
(2.5 mL) with vigorous stirring overnight. Following DLS characterisation, each solution was 
transferred to a 4 mL vial and sonicated for 60 seconds at 70 W and ≤ 14 °C. Final DLS 
characterisation was then undertaken on the unfiltered aqueous dispersions.  
The other 9 time points for each polymer drug combination were stored at ambient temperature 
and were hydrated and sonicated with the method detailed above once every week for the first 
4 weeks followed by every 2 weeks for the final 10 weeks.   
6.5.4.2 Stability of nanoparticle dispersions 
Thin film dispersions for the study of stability over time were synthesised using PEG5K-b-





the methodology detailed in Section 6.5.3.2. DLS characterisation was not undertaken before 
sonication however the unfiltered samples were analysed directly after.  
The samples were stored at ambient temperature and the bottom of the vials were photographed 
before further characterisation by DLS on days 2, 4 and 7 after synthesis. Each sample was 
agitated using a vortex mixer before DLS characterisation was carried out.  
6.5.6 Mechanistic studies 
6.5.6.1 SEM 
The preparation of THF solutions containing polymer and SN-38 bound for SEM were 
prepared in the same manner as detailed in Section 6.5.3.2. For example, targeting SN-38 
content of 50 wt%, the selected polymer (25 mg), either PEG5K-b-PMOP40-co-BOD0.7 or 
PEG5K-b-PMOP40-co-BOD0.7, was weighed into a glass vial. SN-38 (25 mg) was then added 
before the mixture was dissolved in THF targeting a concentration w.r.t. polymer of 5 mgmL-
1. The solution was left to mix overnight to ensure complete polymer and drug dissolution. This 
method was repeated for all targeted drug loadings (0 to 100 wt% SN-38) used in these SEM 
studies detailed in Section 4.3.3.1. Once dissolved the THF mixtures were treated in different 
ways specific to the investigation being undertaken detailed in Sections 6.5.5.1.1 and 6.5.5.1.2. 
6.5.6.1.1 SEM of the dry thin films 
Thin films, suitable for SEM imaging, were created by the addition of a small aliquot (≤ 20 µL) 
onto a silicon wafer atop a SEM stub. THF was then allowed to evaporate overnight resulting 
in a film of PEG5K-b-PMOP40-co-BOD0.7 and SN-38. The resulting thin films was then 
analysed by SEM This was repeated for a number of different SN-38 concentrations between 
0 and 100 wt%.  
6.5.6.1.2 SEM of filtered solutions  
A aliquot of each THF solution (0.5 mL), with PEG5K-b-PCL40-co-BOD0.7 (5 mgmL
-1 w.r.t. 
polymer) and SN-38 (0-100 wt%), was added to a glass vial. THF was removed using a rotary 
evaporation to create a thin film which was hydrated with de-ionised water (2.5 mL), targeting 
a concentration of 1 mgmL-1 (w.r.t. polymer), and vigorously stirred overnight. Each solution 
was then transferred to a 4 mL glass vial and sonicated using a Covaris (60 seconds, 70 W at 
≤ 14 °C). The resulting dispersions were characterised by DLS before being passed through a 





filters left for at least 1 week. Once dry the filter wafers were removed and cut into 2 small 
squares which were stuck, one top face up and the other bottom face up, on a carbon tab atop 
a SEM stub.  
6.5.6.2 Differential scanning calorimetry of dry thin films 
In a typical DSC experiment utilising a 75 wt% SN-38 containing thin film and PEG5K-b-
PCL40-co-BOD0.7 a solution of polymer and drug in THF (5 mgmL
-1 w.r.t polymer) was first 
prepared and left to mix overnight. An aliquot (2.5 mL) was then added to a glass vial and the 
organic solvent was removed under vacuum using a rotary evaporator. Once the dry film was 
formed the solid (8 to 10 mg) was scrapped out into a Tzero crucible and sealed to allow for 
DSC analysis to be undertaken.  
This process was repeated for a range of SN-38 drug loading (0, 2.5, 10, 20, 30, 50, 75, 95 and 
100 wt%). 
6.5.6.3 Thermal analysis by structural analysis, TASC  
In a typical TASC measurement utilising a 30 wt% SN-38 loaded dry thin film created with 
PEG5K-b-PCL40-co-BOD0.7, a solution of polymer and drug was first dissolved in THF 
targeting a polymer concentration of 5 mgmL-1. After solubilisation of both solids at ambient 
temperature a small amount was pipetted onto the surface of a 16 mm circular round glass 
microscope cover slip to create the thin film. Once solvent evaporation was complete the film 
covered glass slide was placed on the heating mantel of the TASC microscope. Once the 
microscope was sufficiently focussed on a section of the sample that had clear structure the 
heating mantel was sealed and the microscope refocussed to give the best image for further 
TASC analysis on the data collected.  
Once the apparatus had been set up and focused heating rate, temperature limits and picture 
rates were defined in the LINKCAM software. The heating rate was set at 10 °Cmin-1 spanning 
a temperature range of ~ 25 °C to 250 °C to encompass the literature value of the melting point 
of SN-38. Pictures of the sample were taken at a rate of 2 per second for the duration of each 
experiment which allowed a video to be created for each sample measured as melting points 
were reached (attached DVD). Once the experiment run was completed, using the LINKCAM 
software, a video was made for each sample and TASC analysis ran on the data collected 






This process was repeated for a series of PEG5K-b-PCL40-co-BOD0.7 thin films with increased 
drug loading from 0 to 100 wt% SN-38.  
6.5.7 Pharmacological studies 
Pharmacological studies were undertaken by Usman Ashard under the supervision of Prof. 
Andrew Owen and Prof. Chris Goldring 
6.5.7.1 Rapid equilibrium dialysis, RED, SN-38 release studies 
In a typical rapid equilibrium assessing the release of SN-38 a dispersion of PEG5K-b-PCL40-
co-BOD0.7 with 50 wt% SN-38, the dispersion was first diluted with phosphate buffered saline, 
PBS, (250 ngmL-1, pH = 7.4).  A control sample of SN-38 only, dissolve in DMSO (< 1% 
volume in PBS) was also prepared. An aliquot of each sample (0.5 mL) was then added to the 
donor compartment of a RED insert (8 kDa molecular weight cut off) and PBS (1 mL) added 
to the acceptor cell. This process was repeated for a total of 11 inserts per dispersion (one for 
each time point). Inserts were then stirred via orbital shaking (100 rpm, 37 °C) for 48 hours 
and the contents of each insert was removed at the specified time point (0.5, 1, 2, 3, 4, 5, 6, 7, 
8, 24 and 48 hours). The collected aliquots were then analysed by LC-mass spectrometry to 
determine the percentage SN-38 released. 
6.5.7.2 Cytotoxicity studies  
Cytotoxicity assessment of the dispersions were undertaken in both 2-dimentional and 3-
dimentsional assays. CT26, HTH116, DLDD-1 and LoVo cell lines (2000-5000 cells per well) 
were utilised for 2D assays, seeded for 24 hours (37 °C, 5 % CO2) on 96-well plates. HCT116 
(1250 cells per well) and CT26 (1000 cells per well) were used for 3D spheroids; seeded for 5 
days on low attachment plates. Nanoparticle dispersions, free SN-38 (0.1 % DMSO) and 
irinotecan (0.1 % DMSO) were used to replace the medium of the cells with increasing 
concertation (0.5 to 400 nM, 0.01 to 100 µM for irinotecan) and the cells were left for between 
24 and 96 hours for 2D and 24 and 144 hours for 3D. Cell viability, calculated as a percentage 
of the control (0.1 % DSMO or corresponding blank nanoparticle dispersion), was measured 
using a CellTiter-Glo® Luminescent cell viability assay (λ = 570 nm). 
6.5.7.3 Macrophage uptake 
Before macrophage uptake assessment could begin, CD14+ monocytes were isolated by ficoll 





into M1 and M2 macrophages. These were then added to 6-well plates and treated with the 
selected nanoparticle dispersion (50 µM) for 24 hours. SN-38 concentration, both intra- and 
extra-cellular, was quantified with LC mass spectrometry. 
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A Chapter 2 
A.1 MSA catalysed ROP of ε-caprolactone 
Table A1 – Calculation of the average dn/dc value PCL polymers 











Total  0.6044 
Total number of values 
used 
10 


























Mn (g/mol) Mw (g/mol) Ð dn/dc α 
PCL10 0.25 >99% 12 1,480 1,250 -f 
PCL20 0.66 >99% 21 2,510 2,390 -f 
PCL30 1 >99% 33 3,870 3,530 4,210 5,740 1.36 0.0584 0.79 
PCL40 1.5 >99% 41 4,790 4,670 4,930 5,950 1.21 0.0574 0.82 
PCL50 2 >99% 66 7,640 5,820 6,650 7,830 1.18 0.0592 0.84 
PCL60 2.5 >99% 66 7,640 6,960 7,220 8,290 1.15 0.0580 0.98 
PCL80 4 >99% 99 11,410 9,240 7,870 10,120 1.29 0.0581 0.69 
PCL100 5 >99% 137 15,750 11,520 9,250 11,220 1.21 0.0573 0.71 
PCL200 9 44 % 110 12,670 10,150 7,470 8,110 1.09 0.0579 0.92  
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Calculated using the equation: Mntheory = (DPtargeted x conv. x MrCL) + MrBzA, c Determined 
by triple detection SEC with a mobile phase of DMF/LiBr 0.01 M (60 °C) at 1 mL min-1, d Calculated using the equation; DPI = (∫4.05/2 ÷ ∫5.1/2), e Calculated 





Figure A1 – 1H-NMR (CDCl3, 400 MHz) of ε-caprolactone. 





Figure A3 – 1H-NMR (CDCl3, 400 MHz) of crude PCL200; illustrating the polymer proton 
environments (4.05 ppm) and highlighting the peaks corresponding to the environments of the BzA 
initiator (5.1 ppm) and the chain end (3.6 ppm). 
𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 (%) =  (
∫ 4.05
(∫ 4.25 +  ∫ 4.05)
) × 100 
Equation for the calculation of monomer conversion for PCL polymers; where ∫4.05 = 
polymer proton environment f in Figure A3 and ∫4.25 is the monomer proton environment h in 





Figure A4 – 1H-NMR (CDCl3, 400 MHz) of purified PEG-b-PCL40; illustrating the polymer 
proton environments (4.05 ppm) and highlighting the peaks corresponding to the environments of the 





Table A3 –Kinetics of linear PCL40 over 1.5 hours sampling every 3 minutes until t30 then 






















3 17.8 % 8 1,020 920 1,630 1,630 13 1.001 
6 22.9 % 10 1,250 1,150 1,970 2,010 16 1.022 
9 37.8 % 15 1,820 1,830 2,130 2,210 18 1.037 
12 54.6 % 21 2,510 2,600 2,510 2,700 21 1.074 
15 68.8 % 27 3,190 3,250 2,890 3,160 24 1.092 
18 86.1 % 33 3,870 4,040 3,390 3,690 29 1.088 
21 95.3 % 37 4,330 4,460 3,700 4,050 31 1.095 
24 96.5 % 39 4,560 4,510 3,910 4,370 33 1.118 
27 99.8 % 39 4,560 4,660 3,940 4,430 34 1.124 
30 99.9 % 39 4,560 4,670 4,010 4,570 34 1.139 
35 99.9 % 39 4,560 4,670 4,130 4,780 35 1.158 
40 99.6 % 39 4,560 4,670 4,180 5,000 36 1.197 
45 99.6 % 39 4,560 4,670 4,220 5,080 36 1.202 
50 99.3 % 39 4,560 4,670 4,270 5,240 36 1.227 
55 99.9 % 40 4,670 4,670 4,390 5,420 38 1.236 
60 99.8 % 39 4,560 4,670 4,400 5,430 38 1.235 
65 99.6 % 39 4,560 4,670 4,500 5,600 38 1.244 
70 99.9 % 39 4,560 4,670 4,610 5,720 39 1.241 
75 99.9 % 40 4,670 4,670 4,580 5,960 39 1.303 
80 99.9 % 40 4,670 4,670 4,500 5,720 38 1.270 
85 99.7 % 40 4,670 4,670 4,640 6,070 40 1.309 
90 99.9 % 40 4,670 4,670 4,620 6,580 40 1.423 
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Calculated using the equation: 
Mntheory = (DPtargeted x conv. x MCL) + MBzA, c Determined by single detection SEC with a mobile phase 
of DMF/LiBr 0.01M at 1 mLmin-1 w.r.t to poly(methyl methacrylate), PMMA, calibrants, d Calculated 





Figure A5 – 1H-NMR (CDCl3, 400 MHz) of PCL40 at time points t1.5, t24 and t48 during 





Table A4 - Series of BzA initiated MSA catalysed ROP of ε-CL with BOD with varied Degree of Polymerisation 40 to 200 monomer units 




1H NMR SECb 
Monomer 
conversiona 
DPI by NMR 
(Initiator) 
Mn (gmol-1) 
Mw    
(gmol-1) 
Ð dn/dc α 
PCL40-co-BOD0.8 1.5 Gel 
PCL40-co-BOD0.75 1.5 >99% 51 Gel 
PCL40-co-BOD0.7 1.5 >99% 51 11,780 248,230 21.1 0.0621 0.35 
PCL40-co-BOD0.6 1.5 >99% 47 9,600 63,620 6.63 0.0654 0.35 
PCL60-co-BOD0.7 2.5 >99% 74 11,690 72,460 6.20 0.0622 0.35 
PCL80-co-BOD0.7 4 >99% 98 11,130 81,770 7.35 0.0629 0.35 
PCL100-co-BOD0.7 5 >99% 116 12,910 61,070 4.73 0.0618 0.36 
PCL200-co-BOD0.7 9 51 % 122 8,080 8,880 1.10 0.0598 0.59 






Table A5 –Kinetics of branched PCL40-co-BOD0.7 over 1.5 hours sampling every 3 
minutes until t30 then every 5 minutes normalised by dn/dc = 0.06044; 
Time (min) 
1H-NMR SECb 
Monomer conversiona Mn (g/mol) Mw (g/mol) Ð α 
No. of linear 
chains (weight 
averaged) 
3 10.3 % -c 
6 23.1 % -c 
9 37.4 % -c 
12 49.7 % -c 
15 64.6 % 2,600c 2,910c 1.12c 0.079c 0.62c 
18 83.5 % 1,860c 2,570c 1.38c 0.60c 0.55c 
21 89.5 % -c 
24 96.3 % 3,620 8,300 2.29 0.32 1.77 
27 98.2 % 6,210 9,210 1.48 0.38 1.97 
30 99.8 % 4,380 9,050 2.07 0.42 1.93 
35 >99 % 3,630 8,430 2.32 0.40 1.80 
40 >99 % 4,570 10,450 2.29 0.39 2.23 
45 - 5,240 11,890 2.27 0.40 2.54 
50 - 3,610 11,240 3.11 0.37 2.40 
55 - 5,090 12,730 2.50 0.39 2.72 
60 - 5,740 13,830 2.41 0.40 2.96 
65 - 5,660 15,150 2.68 0.38 3.24 
70 - 3,050 13,670 4.48 0.45 2.92 
75 - 5,970 17,260 2.89 0.36 3.69 
80 - 3,910 17,190 4.40 0.37 3.67 
85 - 5,310 18,880 3.56 0.37 4.03 
90 - 6,880 21,450 3.09 0.38 4.60 
a Determined by 1H NMR (CDCl3, 400 MHz) of the crude samples, b Determined by triple detection 
SEC with a mobile phase of DMF/LiBr 0.01M at 1 mLmin-1,c insufficient light scattering for calculation 






A.2 MSA catalysed ROP of substituted caprolactone monomers 
Figure A6 – 1H-NMR (CDCl3, 400 MHz) of purified MOP. 







𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 (%) =  (
∫ 4.10
(∫ 4.28 +  ∫ 4.10)
) × 100 
Equation for the calculation of monomer conversion for PMOP polymers; where ∫4.10 = 
polymer proton environment g in Figure A7 and ∫4.28 = monomer proton environment e in 
Figure A6.  
Figure A8 – 1H-NMR (CDCl3, 400 MHz) of purified POP. 





𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 (%) = (
∫ 4.10
(∫ 4.28 +  ∫ 4.10)
) × 100 
Equation for the calculation of monomer conversion for PPOP polymers; where ∫4.10 = 
polymer proton environment f in Figure A9 and ∫4.28 = monomer proton environment e in 
Figure A8. 
Figure A10 – 1H-NMR (CDCl3, 400 MHz) of purified BOP. 





𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 (%) =  (
∫ 4.08
(∫ 4.25 +  ∫ 4.08)
) × 100 
Equation for the calculation of monomer conversion for PBOP polymers; where ∫4.08 = 
polymer proton environment e in Figure A11 and ∫4.25 = monomer proton environment e in 
Figure A10. 
Figure A12 – 1H-NMR (CDCl3, 400 MHz) of purified PHLOP. 





𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 (%) =  (
(3 × ∫ 2.56)
(∫ 2.70 + (3 × ∫ 2.56))
) × 100 
Equation for the calculation of monomer conversion for PPHLOP polymers; where ∫2.56 
= polymer proton environment d in Figure A13 and ∫2.70 = monomer proton environment c in 
Figure A12. 
Figure A14 – Refractive index, RI, detector output chromatograms of; (A) PMOP40, (B) 





Figure A15 – 1H-NMR (CDCl3, 400 MHz) of purified PEG5K-b-PMOP40; 





Figure A17 – 1H-NMR (CDCl3, 400 MHz) of purified PEG5K-b-PBOP40; 





B Chapter 3 









Derived Count Rate (Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PEG2K-b-PCL40:    
PCL40-co-BOD0.7 
 
0:100 90 90 65 65 0.075 0.070 -55 -45 277760 (5) 299310 (5) 
10:90 75 75 50 45 0.125 0.125 -55 -50 72410 (6) 89040 (6) 
25:75 70 70 45 40 0.145 0.150 -45 -55 63380 (6) 21960 (7) 
50:50 60 55 25 30 0.220 0.210 -40 -45 24295 (7) 13245 (7) 
75:25 45 50 20 15 0.215 0.270 -35 -35 6160 (7) 8980 (7) 
90:10 40 50 15 15 0.420 0.390 -35 -30 4910 (8) 7080 (8) 
100:0 30 55 15 15 0.420 0.530 -30 -25 2125 (9) 3730 (8) 
PEG5K-b-PCL40:    
PCL40-co-BOD0.7 
          
0:100 90 90 65 65 0.075 0.070 -55 -45 277760 (5) 299310 (5) 
10:90 85 80 50 50 0.130 0.135 -50 -45 72120 (6) 88300 (6) 
25:75 75 75 45 50 0.145 0.125 -35 -40 43570 (6) 49735 (6) 
50:50 70 70 35 30 0.180 0.230 -35 -40 25770 (7) 18915 (7) 
75:25 55 65 25 25 0.200 0.330 -30 -30 7890 (8) 8850 (8) 
90:10 45 90 15 25 0.330 0.400 -30 -25 4255 (8) 19010 (7) 






Figure B1 – Example dynamic light scattering, DLS, average size distributions by 
intensity (black trace) and correlograms (blue dashed trace) of the nanoprecipitation of 
100 % PCL of varying architecture from acetone (Day 1); A) PCL40, B) PCL50, C) PCL60, 
D) PCL80, E) PCL100, F) PCL40-co-BOD0.7, G) PCL40-co-BOD0.6, H) PCL60-co-BOD0.7, I) PCL80-co-






Figure B2 – Example dynamic light scattering, DLS, average size distributions by 
intensity (black trace) and correlograms (blue dashed trace) of the nanoprecipitation of 
100 % PCL of varying architecture from acetone (Day 1); A) PCL40, B) PCL50, C) PCL60, 
D) PCL80, E) PCL100, F) PCL40-co-BOD0.7, G) PCL40-co-BOD0.6, H) PCL60-co-BOD0.7, I) PCL80-co-






Figure B3 – Dynamic light scattering average size distributions by intensity (black trace) 
and correlograms (blue dashed trace) of the co-nanoprecipitation of PEG-b-
PCL40:PCL40-co-BOD0.7 (acetone, Day 1). PEG2K-b-PCL40 (A-F): A) 10:90, B) 25:75, C) 50:50, 







Figure B4 – Dynamic light scattering average size distributions by intensity (black trace) 
and correlograms (blue dashed trace) of the co-nanoprecipitation of PEG-b-
PCL40:PCL40-co-BOD0.7 (acetone, Day 7). PEG2K-b-PCL40 (A-F): A) 10:90, B) 25:75, C) 50:50, 






Figure B5 – Dynamic light scattering average size distributions by intensity of dispersions 
following salt addition over time following NaCl addition (20 µL of 0.5M NaCl) to 1 mL 
dispersions formed from the co-nanoprecipitation of PEG2K-b-PCL40 and PCL40-co-
BOD0.7 (acetone): No salt (black trace), Instant (black dashed trace), 24 hour (red trace) and 7 day 






Figure B6 – Dynamic light scattering average size distributions by intensity of dispersions 
following salt addition over time following NaCl addition (20 µL of 0.5M NaCl) to 1 mL 
dispersions formed from the co-nanoprecipitation of PEG5K-b-PCL40 and PCL40-co-
BOD0.7 (acetone): No salt (black trace), Instant (black dashed trace), 24 hour (red trace) and 7 day 

















Derived Count Rate 
(Attenuator) 
Day 1 8 Months Day 1 8 Months Day 1 
8 
Months  
Day 1 8 Months Day 1 8 Months 
PEG2K-b-PCL40:    
PCL40-co-BOD0.7 
 
0:100 105 100 70 65 0.120 0.120 -55 -50 365770 (4) 354715 (4) 
10:90 90 85 55 55 0.130 0.115 -45 -40 264530 (5) 260125 (5) 
25:75 80 80 40 45 0.135 0.135 -50 -35 133145 (6) 122515 (6) 
50:50 75 75 35 40 0.150 0.155 -35 -30 87830 (6) 83170 (6) 
75:25 55 60 15 25 0.185 0.205 -40 -25 30700 (7) 30480 (7) 
90:10 40 55 10 20 0.215 0.470 -25 -20 9590 (7) 12740 (7) 
100:0 25 35 15 15 0.190 0.430 -30 -30 4960 (8) 6300 (8) 
PEG5K-b-PCL40:    
PCL40-co-BOD0.7 
          
0:100 105 100 70 65 0.120 0.120 -55 -50 365770 (4) 354715 (4) 
10:90 120 130 80 65 0.125 0.235 -45 -10 380450 (4) 278480 (5) 
25:75 95 95 55 55 0.135 0.130 -40 -30 200675 (5) 226435 (5) 
50:50 80 80 45 45 0.140 0.135 -35 -25 63700 (6) 55275 (6) 
75:25 70 75 25 30 0.215 0.220 -35 -25 27795 (7) 27360 (7) 
90:10 50 55 20 15 0.275 0.340 -25 -20 7495 (8) 7805 (8) 

















Derived Count Rate (Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PCL40-co-BOD0.7 100 100 65 65 0.115 0.110 -50 -55 382840 (4) 344320 (4) 
PMOP40-co-BOD0.7 140 140 100 95 0.095 0.125 -60 -55 623425 (4) 598305 (4) 
PPOP40-co-BOD0.7 175 175 125 125 0.115 0.115 -60 -60 42730 (4) 414365 (4) 
PBOP40-co-BOD0.7 155 155 105 110 0.120 0.120 -65 -60 539900 (4) 523355 (4) 
PPHLOP40-co-BOD0.7 105 105 75 75 0.120 0.125 -55 -50 504885 (3) 485895 (3) 
 






PdI Zeta Potential (mV) Derived Count Rate (Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PEG5K-b-PCL40 25 40 15 15 0.355 0.331 -25 -20 1845 (9) 2240 (9) 
PEG5K-b-PMOP40 35 25 15 15 0.385 0.235 -15 -15 2325 (9) 1800 (9) 
PEG5K-b-PPOP40 30 30 15 15 0.360 0.355 -15 -10 2395 (9) 2510 (9) 
PEG5K-b-PBOP40 35 35 15 20 0.410 0.390 -10 -15 1765 (9) 2300 (9) 










Table B5 - DLS characterisation of PCL/SCM40-co-BOD0.7 nanoparticles produced by co-nanoprecipitation with PEGx-b-PCL/SCM40 
(50:50 wt%) from THF; 
Sample 
Z-Average Diameter (nm) 
Number Average 
Diameter (nm) 
PdI Zeta Potential (mV) 
Derived Count Rate 
(Attenuator) 
Day 1 Re-precip Day 7 Day 1 Re-precip Day 7 Day 1 Re-precip Day 7 Day 1 Re-precip Day 7 Day 1 Re-precip Day 7 
PEG5K-b-PCL40:  
PCL40-co-BOD0.7 
105 115 115 65 70 75 0.140 0.150 0.135 -35 -30 -30 
126615 
(6) 
276055 (5) 277115 (5) 
PEG5K-b-PMOP40:  
PMOP40-co-BOD0.7 
95 95 95 55 50 35 0.170 0.175 0.170 -30 -20 -20 
115505 
(6) 
109385 (6) 8675 (6) 
PEG5K-b-PPOP40:    
PPOP40-co-BOD0.7 
90 85 85 50 35 40 0.155 0.210 0.205 -30 -20 -20 
103360 
(6) 
76000 (6) 72360 (6) 
PEG5K-b-PBOP40: 
PBOP40-co-BOD0.7 
105 90 90 60 30 40 0.150 0.225 0.215 -30 -20 -20 
217720 
(5) 
89895 (6) 70055 (6) 
PEG5K-b-PPHLOP40: 
PPHLOP40-co-BOD0.7 
100 95 95 55 45 40 0.150 0.165 0.175 -30 -25 -25 
326360 
(4) 
313160 (5) 312955 (5) 
 
Table B6 - DLS characterisation of PCL40-co-BOD0.7 nanoparticles produced by co-nanoprecipitation with PEGx-b-PCL40 (50:50 wt%) 
from acetone with oil red O; 
Sample 











Derived Count Rate 
(Attenuator) 
Day 1 Day 1 Day 1 Day 1 Day 1 
PEG2K-b-PCL40:  PCL40-co-BOD0.7 2.43 80 25 0.210 -40 88726 (6) 
PEG5K-b-PCL40:  PCL40-co-BOD0.7 2.43 85 35 0.240 -30 64305 (6) 
PEG2K-b-PCL40:  PCL40-co-BOD0.7 4.76 80 40 0.210 -30 99535 (6) 





Table B7 - DLS characterisation of PCL/SCM40-co-BOD0.7 nanoparticles produced by co-nanoprecipitation with PEG2K-b-PCL40 (50:50 









Derived Count Rate 
(Attenuator) 
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 
PEG2K-b-PCL40:  PCL40-co-
BOD0.7 
90 85 55 50 0.150 0.150 -35 -35 209940 (5) 222385 (5) 
PEG2K-b-PCL40:  PMOP40-co-
BOD0.7 
95 95 45 55 0.155 0.160 -40 -40 253405 (5) 263225 (5) 
PEG2K-b-PCL40:  PPOP40-co-
BOD0.7 
105 100 60 60 0.145 0.145 -40 -40 345115 (5) 318050 (4) 
PEG2K-b-PCL40: PBOP40-co-
BOD0.7 
95 90 50 55 0.155 0.150 -40 -30 296235 (5) 299275 (5) 
PEG2K-b-PCL40: PPHLOP40-
co-BOD0.7 















Table B8 - DLS characterisation of PCL/SCM40-co-BOD0.7 nanoparticles produced by co-nanoprecipitation with PEG5K-b-PCL40 (50:50 






PdI Zeta Potential (mV) 
Derived Count Rate 
(Attenuator) 
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 
PEG5K-b-PCL40:  
PCL40-co-BOD0.7 
100 95 55 60 0.160 0.150 -35 -30 232530 (5) 228195 (5) 
PEG5K-b-PCL40:  
PMOP40-co-BOD0.7 
105 105 65 55 0.135 0.165 -35 -25 240675 (5) 228285 (5) 
PEG5K-b-PCL40:    
PPOP40-co-BOD0.7 
120 120 65 70 0.160 0.150 -35 -30 321140 (5) 309585 (5) 
PEG5K-b-PCL40: 
PBOP40-co-BOD0.7 
110 110 65 60 0.150 0.180 -30 -25 275075 (5) 274690 (5) 
PEG5K-b-PCL40: 
PPHLOP40-co-BOD0.7 














Table B9 - DLS characterisation of PCL/SCM40-co-BOD0.7 nanoparticles produced by co-nanoprecipitation with PEGx-b-PCL40 (50:50 






PdI Zeta Potential (mV) Derived Count Rate (Attenuator) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
PEG5K-b-PCL40:  
PCL40-co-BOD0.7 
85 85 50 50 0.150 0.145 -30 -30 97190 (6) 96555 (6) 
PEG5K-b-PCL40:  
PMOP40-co-BOD0.7 
95 95 45 50 0.165 0.170 -30 -30 90640 (6) 90360 (6) 
PEG5K-b-PCL40:   
PPOP40-co-BOD0.7 
100 100 60 60 0.150 0.145 -30 -30 210315 (5) 132830 (6) 
PEG5K-b-PCL40:  
BOP40-co-BOD0.7 
95 95 50 45 0.175 0.165 -30 -30 108220 (6) 105190 (6) 
PEG5K-b-PCL40: 
PPHLOP40-co-BOD0.7 






C Chapter 4 
Table C1 - DLS characterisation of PCL40-co-BOD0.7 nanoparticles produced by co-
























0.5 195 150 0.100 244090 (5) 160 100 0.165 261085 
1 165 110 0.165 322300 (5) 115 70 0.170 352690 
2 225 185 0.125 346280 (4) 120 80 0.120 511415 
3 225 180 0.100 304380 (5) 110 65 0.130 471690 
4 225 190 0.080 250400 (5) 105 70 0.115 521790 
5 255 220 0.080 246595 (5) 120 85 0.090 634775 
8 275 245 0.050 102670 (6) 155 130 0.035 608790 
  
Table C2 - DLS characterisation of PCL40-co-BOD0.7 nanoparticles produced by co-
nanoprecipitation with PEGx-b-PCL40 (50:50 wt%) varying the concentration of polymer 






















0.5 220 150 0.235 106010 (6) 175 90 0.255 86435 (6) 
1 190 130 0.205 269765 (5) 155 85 0.325 271460 (5) 
2 235 195 0.100 377920 (4) 135 85 0.215 247700 (5) 
3 230 185 0.095 299145 (5) 135 75 0.310 252110 (4) 
4 275 245 0.060 320840 (5) 140 95 0.225 270295 (5) 
5 255 225 0.074 247720 (5) 130 90 0.245 270840 (5) 






Table C3 - DLS characterisation of PPOP40-co-BOD0.7 nanoparticles produced by co-
nanoprecipitation with PEGx-b-PCL40 (50:50 wt%) varying the concentration of polymer 






















0.5 230 135 0.240 72980 (6) 190 75 0.250 48350 (6) 
1 205 140 0.185 246200 (5) 175 95 0.325 263330 (5) 
2 270 245 0.025 374625 (4) 155 100 0.210 228280 (5) 
3 255 215 0.095 338265 (5) 140 90 0.285 338840 (4) 
4 305 265 0.065 311645 (5) 160 105 0.185 261360 (5) 
5 240 210 0.075 225625 (5) 130 85 0.245 258240 (4) 
8 305 275 0.040 82090 (6) 195 150 0.110 68740 (6) 
 
Table C4 - DLS characterisation of SN-38 (2.43 wt%) nanoprecipitated, varying the 























0.5 2180 320 1 8570 (7) - 
1 1740 110 0.920 13470 (8) - 
2 275 130 0.380 1980 (9) - 
3 90 1 0.335 190 (11) - 
4 5 1 0.430 150 (11) - 
5 5 2 0.375 170 (11) - 











Table C5 - DLS characterisation of oil red O (2.43 wt%) nanoprecipitated, varying the 























0.5 110 60 0.230 90040 (6) - 
1 260 180 0.195 74175 (6) - 
2 445 325 0.185 25450 (7) - 
3 225 205 0.060 19800 (7) - 
4 245 220 0.120 7935 (8) - 
5 200 2 0.265 1770 (9) - 
8 10 2 0.500 285 (11) - 
 
Table C6 - DLS characterisation of docetaxel (2.43 wt%) nanoprecipitated, varying the 























0.5 285 195 0.200 8210 (7) - 
1 365 115 0.245 10990 (7) - 
2 115 1 0.310 335 (11) - 
3 120 1 0.230 245 (11) - 
4 10 1 0.145 125 (11) - 
5 5 2 0.250 165 (11) - 













Table C7 - DLS characterisation of SN-38 P (2.43 wt%) nanoprecipitated, varying the 























0.5 465 340 0.325 6510 (7) - 
1 520 455 0.185 11600 (8) - 
2 190 175 0.095 1700 (9) - 
3 15 1 0.615 145 (11) - 
4 145 1 0.205 135 (11) - 
5 5 2 0.270 230 (11) - 



















Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40-co-BOD0.7 16.6 475 205 0.460 290325 (5) 185 100 0.175 331180 (5) 
PEG5K-b-PMOP40-co-BOD0.7 16.6 900 120 0.550 251035 (5) 160 70 0.245 207530 (5) 
PEG5K-b-PPOP40-co-BOD0.7 16.6 555 285 0.575 238275 (5) 185 40 0.300 353060 (4) 
PEG5K-b-PBOP40-co-BOD0.7 16.6 865 350 0.665 167825 (5) 155 35 0.270 260065 (5) 
PEG5K-b-PPHLOP40-co-BOD0.7 16.6 1280 375 0.695 170870 (5) 130 40 0.265 237490 (5) 














Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40-co-BOD0.7 33 545 295 0.465 473705 (4) 180 95 0.235 521795 (4) 
PEG5K-b-PMOP40-co-BOD0.7 33 1105 590 0.425 581815 (4) 235 180 0.175 665720 (4) 
PEG5K-b-PPOP40-co-BOD0.7 33 985 340 0.590 372675 (4) 170 85 0.290 528390 (4) 
PEG5K-b-PBOP40-co-BOD0.7 33 1305 520 0.470 434265 (4) 190 50 0.250 593615 (4) 



















Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40-co-BOD0.7 50 605 350 0.300 638270 (4) 190 95 0.230 827110 (4) 
PEG5K-b-PMOP40-co-BOD0.7 50 770 475 0.425 690965 (4) 175 110 0.200 644090 (3) 
PEG5K-b-PPOP40-co-BOD0.7 50 635 295 0.315 635990 (4) 195 90 0.220 686295 (3) 
PEG5K-b-PBOP40-co-BOD0.7 50 - - - - 180 50 0.230 678735 (3) 
PEG5K-b-PPHLOP40-co-BOD0.7 50 710 230 0.440 524510 (4) 190 75 0.265 716495 (3) 














Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40-co-BOD0.7 75 660 425 0.295 1230235 (3) 210 100 0.180 10445000 (4) 
PEG5K-b-PMOP40-co-BOD0.7 75 895 280 0.335 600860 (4) 205 130 0.190 1572120 (3) 
PEG5K-b-PPOP40-co-BOD0.7 75 965 360 0.445 833825 (3) 210 100 0.215 1629375 (3) 
PEG5K-b-PBOP40-co-BOD0.7 75 835 325 0.465 1336680 (3) 220 105 0.230 1553435 (3) 











Before Sonication After Sonication 
Dz  
(nm) 
Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40-co-BOD0.7 95 705 410 0.410 370885 (4) 220 150 0.180 806915 (4) 
PEG5K-b-PMOP40-co-BOD0.7 95 700 395 0.420 573080 (4) 220 135 0.180 743775 (4) 
PEG5K-b-PPOP40-co-BOD0.7 95 710 380 0.385 509910 (4) 225 125 0.210 740720 (3) 
PEG5K-b-PBOP40-co-BOD0.7 95 690 345 0.450 642095 (4) 235 115 0.225 740000 (3) 





Table C13- DLS characterisation of nanoparticles produced by thin film hydration over 14 weeks (storage of dry thin film) of PEG5K-b-






Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 




0 115 35 0.265 88630 (6) 100 40 0.240 81040 (6) 
1 120 25 0.260 76140 (6) 110 40 0.260 95215 (6) 
2 130 30 0.260 97285 (6) 120 40 0.300 89975 (6) 
3 135 30 0.260 92910 (6) 125 35 0.275 103775 (6) 
4 135 40 0.265 95595 (6) 130 35 0.285 108880 (6) 
6 140 30 0.265 103655 (6) 130 35 0.275 104200 (6) 
8 140 20 0.275 87535 (6) 140 40 0.290 105320 (6) 
10 145 25 0.280 91265 (6) 140 40 0.295 214710 (5) 
12 150 30 0.285 103845 (6) 125 35 0.280 102990 (6) 











Table C14- DLS characterisation of nanoparticles produced by thin film hydration over 14 weeks (storage of dry thin film) of PEG5K-b-






Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 




0 155 60 0.220 363970 (4) 160 50 0.275 570650 (4) 
1 185 55 0.240 571515 (4) 150 35 0.205 550095 (4) 
2 225 45 0.265 637310 (4) 190 60 0.255 709695 (4) 
3 175 65 0.245 547380 (4) 190 45 0.240 622045 (4) 
4 200 70 0.245 606750 (4) 190 75 0.250 698230 (4) 
6 190 65 0.250 559920 (4) 170 25 0.215 603530 (4) 
8 205 75 0.245 539150 (4) 210 60 0.370 523000 (4) 
10 195 80 0.265 592335 (4) 195 40 0.235 637265 (4) 
12 190 80 0.235 623690 (4) 185 50 0.245 621075 (4) 











Table C15- DLS characterisation of nanoparticles produced by thin film hydration over 14 weeks (storage of dry thin film) of PEG5K-b-






Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 




0 180 60 0.225 767665 (4) 215 75 0.280 632205 (3) 
1 205 70 0.220 780645 (4) 190 75 0.240 705255 (3) 
2 235 115 0.245 704125 (4) 230 85 0.250 68755 (4) 
3 295 100 0.255 661755 (4) 235 90 0.240 695045 (4) 
4 235 110 0.240 683935 (4) 230 95 0.245 749500 (4) 
6 240 120 0.250 840765 (4) 220 130 0.235 700340 (4) 
8 260 105 0.255 736865 (4) 250 75 0.260 736230 (4) 
10 260 50 0.255 788695 (4) 230 110 0.260 820770 (4) 
12 235 80 0.255 816295 (4) 225 105 0.265 693800 (4) 











Table C16- DLS characterisation of nanoparticles produced by thin film hydration over 14 weeks (storage of dry thin film) of PEG5K-b-






Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 




0 240 105 0.275 1516805 (3) 230 110 0.245 1696590 (3) 
1 245 130 0.240 1410785 (3) 255 165 0.195 450010 (4) 
2 325 125 0.415 1373315 (3) 285 140 0.250 1273535 (3) 
3 270 155 0.290 1172915 (3) 310 190 0.320 1349440 (3) 
4 290 90 0.295 1173995 (3) 305 120 0.290 1453770 (3) 
6 295 150 0.325 1108285 (3) 350 125 0.415 1630200 (3) 
8 310 150 0.330 1225360 (3) 335 150 0.365 1120890 (3) 
10 290 135 0.310 121965 (3) 305 120 0.250 1289650 (3) 
12 315 160 0.360 1133755 (3) 290 150 0.240 1299615 (3) 











Table C17- DLS characterisation of nanoparticles produced by thin film hydration over 7 days (storage of dispersion) of PEG5K-b-PCL40-





































2.43 110 25 0.435 16365 (7) 105 20 0.420 15305 (7) 105 25 0.430 17455 (7) 110 30 0.475 14490 (7) 
10 120 70 0.245 49220 (6) 120 20 0.240 49805 (6) 120 25 0.255 50645 (6) 125 35 0.235 53910 (6) 
16.6 150 55 0.225 131700 (6) 150 45 0.235 205625 (5) 175 65 0.365 212160 (5) 155 70 0.210 210440 (5) 
30 170 85 0.230 420230 (4) 175 50 0.225 403705 (4) 185 80 0.265 427390 (4) 175 105 0.215 457375 (4) 
33 185 90 0.225 547495 (4) 195 100 0.240 561165 (4) 200 105 0.250 599395 (4) 200 75 0.215 603305 (4) 
50 195 100 0.235 637210 (3) 235 120 0.340 818365 (4) 220 65 0.245 677995 (3) 230 140 0.255 697115 (3) 
75 260 105 0.195 479370 (4) 275 142 0.225 1477965 (3) 320 155 0.330 1373925 (3) 285 160 0.226 1471690 (3) 












Table C18- DLS characterisation of nanoparticles produced by thin film hydration of PEG5K-b-PCL/SCM40 without drug and with 2.43 





Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 0 840 285 0.735 55460 (6) 245 50 0.275 93975 (6) 
PEG5K-b-PMOP40 0 420 45 0.71 43515 (6) 60 30 0.210 17015 (7) 
PEG5K-b-PPOP40 0 8170 85 0.295 24485 (7) 60 40 0.090 28620 (7) 
PEG5K-b-PBOP40 0 555 140 0.925 53095 (6) 60 40 0.080 25415 (7) 
PEG5K-b-PPHLOP40 0 765 75 0.775 58685 (6) 60 45 0.060 53495 (6) 
PEG5K-b-PCL40 2.43 945 185 0.805 104225 (6) 300 145 0.365 111010 (6) 
PEG5K-b-PMOP40 2.43 345 60 0.835 51385 (6) 70 20 0.225 23375 (7) 
PEG5K-b-PPOP40 2.43 485 165 0.735 58470 (6) 65 45 0.120 42095 (6) 
PEG5K-b-PBOP40 2.43 9105 50 0.650 29515 (7) 70 40 0.210 31625 (7) 

















Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 10 480 150 0.485 96240 (6) 215 60 0.390 278555 (5) 
PEG5K-b-PMOP40 10 265 55 0.300 102860 (6) 120 35 0.250 71535 (6) 
PEG5K-b-PPOP40 10 405 160 0.600 82125 (6) 115 25 0.255 91625 (6) 
PEG5K-b-PBOP40 10 370 105 0.505 92495 (6) 110 40 0.310 76590 (6) 
PEG5K-b-PPHLOP40 10 560 150 0.910 158455 (6) 185 50 0.300 137205 (6) 
 





Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 16.6 500 155 0.485 256055 (5) 155 85 0.205 343835 (4) 
PEG5K-b-PMOP40 16.6 315 130 0.360 263100 (5) 130 35 0.235 229410 (5) 
PEG5K-b-PPOP40 16.6 435 165 0.425 127605 (6) 135 30 0.245 224500 (5)  
PEG5K-b-PBOP40 16.6 810 315 0.575 299695 (5) 160 50 0.275 345395 (5) 













Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 30 530 235 0.530 622750 (4) 170 90 0.205 660765 (4) 
PEG5K-b-PMOP40 30 385 65 0.335 459715 (4) 160 75 0.215 534475 (4) 
PEG5K-b-PPOP40 30 530 105 0.465 431820 (4) 145 55 0.200 519425 (4) 
PEG5K-b-PBOP40 30 530 105 0.430 432720 (4) 160 50 0.235 519805 (4) 
PEG5K-b-PPHLOP40 30 735 165 0.560 567485 (4) 165 40 0.270 577555 (4) 
 





Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 50 380 145 0.320 818150 (4) 185 110 0.215 670745 (3) 
PEG5K-b-PMOP40 50 400 180 0.335 794120 (4) 185 80 0.225 691205 (3) 
PEG5K-b-PPOP40 50 455 145 0.320 804440 (4) 175 50 0.205 722275 (3) 
PEG5K-b-PBOP40 50 520 310 0.395 672820 (4) 210 80 0.250 759580 (3) 













Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 75 425 250 0.295 727750 (4) 205 125 0.210 829735 (4) 
PEG5K-b-PMOP40 75 705 285 0.445 1058640 (3) 250 135 0.250 152600 (3) 
PEG5K-b-PPOP40 75 660 260 0.435 1270770 (3) 240 155 0.215 1541480 (3) 
PEG5K-b-PBOP40 75 470 170 0.370 1185435 (3) 215 120 0.205 1423180 (3) 
PEG5K-b-PPHLOP40 75 570 145 0.460 1315930 (3) 240 75 0.230 588885 (4) 
 





Before Sonication After Sonication 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
Dz  (nm) Dn (nm) PdI 
Derived Count 
Rate (kcps) 
PEG5K-b-PCL40 95 505 150 0.405 620010 (4) 225 130 0.200 794900 (4) 
PEG5K-b-PMOP40 95 670 180 0.435 491705 (4) 405 130 0.400 766590 (4) 
PEG5K-b-PPOP40 95 585 220 0.420 405560 (4) 255 175 0.200 734445 (4) 
PEG5K-b-PBOP40 95 600 245 0.450 668160 (4) 250 120 0.240 771805 (4) 






Figure C1 –Release curves generated by RED assay for PEG5K-b-PCL40-co-BOD0.7 






Figure C2 – Release curves generated by RED assay for PEG5K-b-PMOP40-co-BOD0.7 






Figure C3 – Release curves generated by RED assay for PEG5K-b-PPOP40-co-BOD0.7 






Figure C4 – Release curves generated by RED assay for PEG5K-b-PBOP40-co-BOD0.7 






Figure C5 – Release curves generated by RED assay for PEG5K-b-PPHLOP40-co-BOD0.7 
dispersions containing SN-38; (A) over 48 hours and (B) over 8 hours. 
 
